,sentence_text,e1_text,e2_text,relation_type,normalized_sentence
0,"Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.",calcium,EMCYT,mechanism,Milk milk products calcium_first rich foods drugs may impair absorption EMCYT_second .
1,"Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. ",Echistatin,contortrostatin,effect,Echistatin_first alone effect tyrosine phosphorylation T24 cells dose dependently inhibits effects contortrostatin_second added simultaneously.
2,"Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. ",Flavoridin,contortrostatin,effect,Flavoridin_first alone found effect CAS completely block contortrostatin_second induced phosphorylation protein MDA MB 435 cells.
3,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.,allopurinol,ampicillin,effect,concurrent administration allopurinol_first ampicillin_second increases substantially incidence rashes patients receiving drugs compared patients receiving ampicillin alone.
4,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.,ampicillin,allopurinol,effect,known whether potentiation ampicillin_first rashes due allopurinol_second hyperuricemia present patients.
5,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",broad-spectrum antibiotics,contraceptives,effect,common broad-spectrum antibiotics_first AUGMENTIN XR may reduce efficacy oral contraceptives_second
6,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",AUGMENTIN XR,contraceptives,effect,common broad spectrum antibiotics AUGMENTIN XR_first may reduce efficacy oral contraceptives_second
7,Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.,ROMAZICON,cyclic antidepressants,effect,Particular caution necessary using ROMAZICON_first cases mixed drug overdosage since toxic effects (such convulsions cardiac dysrhythmias) drugs taken overdose (especially cyclic antidepressants_second ) may emerge reversal benzodiazepine effect flumazenil.
8,"Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.",ROMAZICON,benzodiazepine,effect,Although ROMAZICON_first exerts slight intrinsic anticonvulsant effect abrupt suppression protective effect benzodiazepine_second agonist give rise convulsions epileptic patients.
9,ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.,ROMAZICON,benzodiazepines,effect,ROMAZICON_first blocks central effects benzodiazepines_second competitive interaction receptor level.
10,"The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.",zopiclone,ROMAZICON,effect,effects nonbenzodiazepine agonists benzodiazepine receptors zopiclone_first triazolopyridazines others also blocked ROMAZICON_second .
11,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,antiarrhythmics,advise,Caution advised TRISENOX_first coadministered medications prolong QT interval (e.g. certain antiarrhythmics_second thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B).
12,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,thioridazine,advise,Caution advised TRISENOX_first coadministered medications prolong QT interval (e.g. certain antiarrhythmics thioridazine_second ) lead electrolyte abnormalities (such diuretics amphotericin B).
13,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,diuretics,advise,Caution advised TRISENOX_first coadministered medications prolong QT interval (e.g. certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such diuretics_second amphotericin B).
14,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,amphotericin B,advise,Caution advised TRISENOX_first coadministered medications prolong QT interval (e.g. certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B_second ).
15,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,Intrathecal injection naloxone_first doses 0.4 40 micrograms caused dose related blockade inhibition tail flick response induced intraventricular injection beta-endorphin_second high dose naloxone (40 micrograms) completely blocked tail flick inhibition induced intraventricular beta endorphin (16 micrograms).
16,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,Intrathecal injection naloxone doses 0.4 40 micrograms caused dose related blockade inhibition tail flick response induced intraventricular injection beta endorphin high dose naloxone_first (40 micrograms) completely blocked tail flick inhibition induced intraventricular beta-endorphin_second (16 micrograms).
17,"On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ",naloxone,morphine,effect,hand intrathecal naloxone_first (12 120 micrograms) weak effect tail flick inhibition induced intraventricular morphine_second (40 micrograms).
18,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,beta-endorphin,effect,Intraventricular injection naloxone_first doses 1.2 12 micrograms equally antagonized dose dependent manner tail flick inhibition induced intraventricular beta-endorphin_second morphine.
19,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,morphine,effect,Intraventricular injection naloxone_first doses 1.2 12 micrograms equally antagonized dose dependent manner tail flick inhibition induced intraventricular beta endorphin morphine_second .
20,Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.,steroids,aspirin,effect,Rarely salicylate toxicity may occur patients discontinue steroids_first concurrent high dose aspirin_second therapy.
21,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",Barbiturates,fludrocortisone acetate,mechanism,Barbiturates_first phenytoin rifampin increased metabolic clearance fludrocortisone acetate_second induction hepatic enzymes.
22,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",phenytoin,fludrocortisone acetate,mechanism,Barbiturates phenytoin_first rifampin increased metabolic clearance fludrocortisone acetate_second induction hepatic enzymes.
23,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",rifampin,fludrocortisone acetate,mechanism,Barbiturates phenytoin rifampin_first increased metabolic clearance fludrocortisone acetate_second induction hepatic enzymes.
24,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",Oxytocin,dinoprost,effect,Oxytocin_first oxytocics (concurrent use dinoprost_second may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
25,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",oxytocics,dinoprost,effect,Oxytocin oxytocics_first (concurrent use dinoprost_second may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
26,Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.,acetaminophen,Isoniazid,effect,Acetaminophen: report severe acetaminophen_first toxicity reported patient receiving Isoniazid_second .
27,It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.,isoniazid,acetaminophen,effect,believed toxicity may resulted previously unrecognized interaction isoniazid_first acetaminophen_second molecular basis interaction proposed.
28,"Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.",isoniazid,acetaminophen,mechanism,Furthermore proposed isoniazid_first resulted induction P 450IIE1 patients liver turn resulted greater proportion ingested acetaminophen_second converted toxic metabolites.
29,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Isoniazid,carbamazepine,mechanism,Carbamazepine: Isoniazid_first known slow metabolism carbamazepine_second increase serum levels Carbamazepine levels determined prior concurrent administration isoniazid signs symptoms carbamazepine toxicity monitored closely appropriate dosage adjustment anticonvulsant made.
30,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Carbamazepine,isoniazid,advise,Carbamazepine: Isoniazid known slow metabolism carbamazepine increase serum levels Carbamazepine_first levels determined prior concurrent administration isoniazid_second signs symptoms carbamazepine toxicity monitored closely appropriate dosage adjustment anticonvulsant made.
31,Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.,Ketoconazole,Isoniazid,int,Ketoconazole: Potential interaction Ketoconazole_first Isoniazid_second may exist.
32,Phenytoin: Isoniazid may increase serum levels of phenytoin.,Isoniazid,phenytoin,mechanism,Phenytoin: Isoniazid_first may increase serum levels phenytoin_second .
33,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.",isoniazid,theophylline,mechanism,Therophylline: recent study shown concomitan administration isoniazid_first theophylline_second may cause elevated plasma levels theophylline instances slight decrease elimination isoniazid.
34,Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.,valproate,isoniazid,mechanism,Valproate: recent case study shown possible increase plasma level valproate_first co administered isoniazid_second .
35,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.",isoniazid,valproate,advise,Plasma valproate concentration monitored isoniazid_first valproate_second co administered appropriate dosage adjustments valproate made.
36,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,aminoglycosides,advise,Co administration MYOBLOC_first aminoglycosides_second agents interfering neuromuscular transmission (e.g. curare like compounds) performed caution effect toxin may potentiated.
37,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,curare-like compounds,advise,Co administration MYOBLOC_first aminoglycosides agents interfering neuromuscular transmission (e.g. curare-like compounds_second ) performed caution effect toxin may potentiated.
38,"Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.",bosentan,Ortho-Novum,mechanism,Hormonal Contraceptives Including Oral Injectable Transdermal Implantable Contraceptives: interaction study demonstrated co administration bosentan_first oral hormonal contraceptive Ortho-Novum_second produced average decreases norethindrone ethinyl estradiol levels 14% 31% respectively.
39,"Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.",hormonal contraceptives,TRACLEER,effect,Therefore hormonal contraceptives_first including oral injectable transdermal implantable forms may reliable TRACLEER_second co administered.
40,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.,bosentan,cyclosporine A,mechanism,Steady state bosentan_first plasma concentrations 3 4 fold higher absence cyclosporine A_second .
41,The concomitant administration of bosentan and cyclosporine A is contraindicated.,bosentan,cyclosporine A,advise,concomitant administration bosentan_first cyclosporine A_second contraindicated.
42,Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.,bosentan,cyclosporine A,mechanism,Co administration bosentan_first decreased plasma concentrations cyclosporine A_second (a CYP3A4 substrate) approximately 50%.
43,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.,tacrolimus,bosentan,mechanism,Co administration tacrolimus_first bosentan_second resulted markedly increased plasma concentrations bosentan animals.
44,Caution should be exercised if tacrolimus and bosentan are used together.,tacrolimus,bosentan,advise,Caution exercised tacrolimus_first bosentan_second used together.
45,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.",TRACLEER,glyburide,advise,Therefore concomitant administration TRACLEER_first glyburide_second contraindicated alternative hypoglycemic agents considered.
46,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.,bosentan,glyburide,mechanism,Co administration bosentan_first decreased plasma concentrations glyburide_second approximately 40%.
47,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.,Bosentan,hypoglycemic agents,mechanism,Bosentan_first also expected reduce plasma concentrations oral hypoglycemic agents_second predominantly metabolized CYP2C9 CYP3A4.
48,"Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",bosentan,ketoconazole,mechanism,Ketoconazole: Co administration bosentan_first 125 mg b.i.d. ketoconazole_second potent CYP3A4 inhibitor increased plasma concentrations bosentan approximately 2 fold.
49,"Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",bosentan,simvastatin,mechanism,Simvastatin Statins: Co administration bosentan_first decreased plasma concentrations simvastatin_second (a CYP3A4 substrate) active hydroxy acid metabolite approximately 50%.
50,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,statins,mechanism,Bosentan_first also expected reduce plasma concentrations statins_second significant metabolism CYP3A4 lovastatin atorvastatin.
51,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,lovastatin,mechanism,Bosentan_first also expected reduce plasma concentrations statins significant metabolism CYP3A4 lovastatin_second atorvastatin.
52,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,atorvastatin,mechanism,Bosentan_first also expected reduce plasma concentrations statins significant metabolism CYP3A4 lovastatin atorvastatin_second .
53,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.,statins,TRACLEER,advise,Patients using CYP3A4 metabolized statins_first cholesterol levels monitored TRACLEER_second initiated see whether statin dose needs adjustment.
54,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,S-warfarin,mechanism,Warfarin: Co administration bosentan_first 500 mg b.i.d. 6 days decreased plasma concentrations S-warfarin_second (a CYP2C9 substrate) R warfarin (a CYP3A4 substrate) 29 38% respectively.
55,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,R-warfarin,mechanism,Warfarin: Co administration bosentan_first 500 mg b.i.d. 6 days decreased plasma concentrations warfarin (a CYP2C9 substrate) R-warfarin_second (a CYP3A4 substrate) 29 38% respectively.
56,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,orphenadrine,int,Therefore potential exists drug interaction WELLBUTRIN_first drugs affect CYP2B6 isoenzyme (e.g. orphenadrine_second cyclophosphamide).
57,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,cyclophosphamide,int,Therefore potential exists drug interaction WELLBUTRIN_first drugs affect CYP2B6 isoenzyme (e.g. orphenadrine cyclophosphamide_second ).
58,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,carbamazepine,mechanism,systematically studied certain drugs may induce metabolism bupropion_first (e.g. carbamazepine_second phenobarbital phenytoin).
59,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenobarbital,mechanism,systematically studied certain drugs may induce metabolism bupropion_first (e.g. carbamazepine phenobarbital_second phenytoin).
60,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenytoin,mechanism,systematically studied certain drugs may induce metabolism bupropion_first (e.g. carbamazepine phenobarbital phenytoin_second ).
61,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,mechanism,study 15 male subjects (ages 19 35 years) extensive metabolizers CYP2D6 isoenzyme daily doses bupropion_first given 150 mg twice daily followed single dose 50 mg desipramine_second increased Cmax AUC t1/2 desipramine average approximately 2 5 2 fold respectively.
62,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants_second (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
63,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline_second imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
64,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine_second desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
65,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine_second paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
66,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine_second fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
67,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine_second sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
68,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline_second ) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
69,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antipsychotics,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics_second (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
70,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol_second risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
71,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone_second thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
72,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine_second ) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
73,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,beta-blockers,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta-blockers_second (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
74,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol_second ) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
75,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,Type 1C antiarrhythmics,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics_second (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
76,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone_second flecainide) approached caution initiated lower end dose range concomitant medication.
77,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,advise,Therefore co administration bupropion_first drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide_second ) approached caution initiated lower end dose range concomitant medication.
78,MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .,bupropion,phenelzine,effect,MAO Inhibitors: Studies animals demonstrate acute toxicity bupropion_first enhanced MAO inhibitor phenelzine_second .
79,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,levodopa,effect,Levodopa Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving bupropion_first concurrently either levodopa_second amantadine.
80,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,amantadine,effect,Levodopa Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving bupropion_first concurrently either levodopa amantadine_second .
81,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,levodopa,advise,Administration WELLBUTRIN_first Tablets patients receiving either levodopa_second amantadine concurrently undertaken caution using small initial doses small gradual dose increases.
82,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,amantadine,advise,Administration WELLBUTRIN_first Tablets patients receiving either levodopa amantadine_second concurrently undertaken caution using small initial doses small gradual dose increases.
83,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antipsychotics,advise,Drugs Lower Seizure Threshold: Concurrent administration WELLBUTRIN_first agents (e.g. antipsychotics_second antidepressants theophylline systemic steroids etc.) lower seizure threshold undertaken extreme caution.
84,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antidepressants,advise,Drugs Lower Seizure Threshold: Concurrent administration WELLBUTRIN_first agents (e.g. antipsychotics antidepressants_second theophylline systemic steroids etc.) lower seizure threshold undertaken extreme caution.
85,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,advise,Drugs Lower Seizure Threshold: Concurrent administration WELLBUTRIN_first agents (e.g. antipsychotics antidepressants theophylline_second systemic steroids etc.) lower seizure threshold undertaken extreme caution.
86,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,steroids,advise,Drugs Lower Seizure Threshold: Concurrent administration WELLBUTRIN_first agents (e.g. antipsychotics antidepressants theophylline systemic steroids_second etc.) lower seizure threshold undertaken extreme caution.
87,"Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.",alcohol,WELLBUTRIN,effect,Alcohol: post marketing experience rare reports adverse neuropsychiatric events reduced alcohol tolerance patients drinking alcohol_first treatment WELLBUTRIN_second .
88,The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS),alcohol,WELLBUTRIN,advise,consumption alcohol_first treatment WELLBUTRIN_second minimized avoided (also see href= bupropz_od.htm#CI CONTRAINDICATIONS)
89,Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.,TNF antagonist,ORENCIA,effect,Concurrent administration TNF antagonist_first ORENCIA_second associated increased risk serious infections significant additional efficacy use TNF antagonists alone.
90,Concurrent therapy with ORENCIA and TNF antagonists is not recommended.,ORENCIA,TNF antagonists,advise,Concurrent therapy ORENCIA_first TNF antagonists_second recommended.
91,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.",ORENCIA,anakinra,advise,insufficient experience assess safety efficacy ORENCIA_first administered concurrently anakinra_second therefore use recommended.
92,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,cholestyramine,leflunomide,mechanism,Cholestyramine Charcoal Administration cholestyramine_first activated charcoal patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite leflunomide_second ) concentration .
93,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,activated charcoal,leflunomide,mechanism,Cholestyramine Charcoal Administration cholestyramine activated charcoal_first patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite leflunomide_second ) concentration .
94,"In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.",ARAVA,methotrexate,effect,small (n=30) combination study ARAVA_first methotrexate_second 2 3 fold elevation liver enzymes seen 5 30 patients.
95,"Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.",ARAVA,rifampin,mechanism,Rifampin: Following concomitant administration single dose ARAVA_first subjects receiving multiple doses rifampin_second M1 peak levels increased (~40%) seen ARAVA given alone.
96,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.",ARAVA,rifampin,advise,potential ARAVA levels continue increase multiple dosing caution used patients receiving ARAVA_first rifampin_second .
97,Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.,ARAVA,warfarin,effect,Warfarin: Increased INR (International Normalized Ratio) ARAVA_first warfarin_second co administered rarely reported.
98,Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.,dobutamine,b-blocking drug,effect,Animal studies indicate dobutamine_first may ineffective patient recently received b-blocking drug_second .
99,"Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",dobutamine,nitroprusside,effect,Preliminary studies indicate concomitant use dobutamine_first nitroprusside_second results higher cardiac output usually lower pulmonary wedge pressure either drug used alone.
100,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,dicumarol,advise,Therefore heparin sodium_first given dicumarol_second warfarin sodium period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained.
101,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,warfarin sodium,advise,Therefore heparin sodium_first given dicumarol warfarin sodium_second period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained.
102,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",acetylsalicylic acid,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid_first dextran phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
103,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dextran,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran_first phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
104,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",phenylbutazone,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone_first ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
105,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",ibuprofen,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen_first indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
106,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",indomethacin,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin_first dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
107,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dipyridamole,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole_first hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
108,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",hydroxychloroquine,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine_first others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium_second .
109,The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.,heparin,antithrombin III,effect,anticoagulant effect heparin_first enhanced concurrent treatment antithrombin III_second (human) patients hereditary antithrombin III deficiency.
110,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).",heparin,antithrombin III,advise,Thus order avoid bleeding reduced dosage heparin_first recommended treatment antithrombin III_second (human).
111,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",Digitalis,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis_first tetracyclines nicotine antihistamines may partially counteract anticoagulant action heparin sodium_second .
112,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",tetracyclines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines_first nicotine antihistamines may partially counteract anticoagulant action heparin sodium_second .
113,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",nicotine,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines nicotine_first antihistamines may partially counteract anticoagulant action heparin sodium_second .
114,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",antihistamines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines nicotine antihistamines_first may partially counteract anticoagulant action heparin sodium_second .
115,Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.,tricyclic antidepressants,cimetidine,mechanism,Steady state serum concentrations tricyclic antidepressants_first reported fluctuate significantly cimetidine_second either added deleted drug regimen.
116,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.",tricyclic antidepressants,cimetidine,effect,Serious anticholinergic symptoms (severe dry mouth urinary retention blurred vision) associated elevations serum levels tricyclic antidepressants_first cimetidine_second added drug regimen.
117,"In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.",tricyclic antidepressants,cimetidine,mechanism,addition higher expected steady state serum concentrations tricyclic antidepressants_first observed therapy initiated patients already taking cimetidine_second .
118,"In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.",cimetidine,tricyclic antidepressants,mechanism,well controlled patients undergoing concurrent therapy cimetidine_first decrease steady state serum concentrations tricyclic antidepressants_second may occur cime tidine therapy discontinued.
119,The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.,tricyclic antidepressants,cimetidine,effect,therapeutic efficacy tricyclic antidepressants_first may compromised patients cimetidine_second discontinued.
120,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",antidepressants,fluoxetine hydrochloride,mechanism,greater 2 fold increases previously stable plasma levels antidepressants_first including nortriptyline fluoxetine hydrochloride_second administered combination agents.
121,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",nortriptyline,fluoxetine hydrochloride,mechanism,greater 2 fold increases previously stable plasma levels antidepressants including nortriptyline_first fluoxetine hydrochloride_second administered combination agents.
122,Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.,reserpine,tricyclic antidepressant,effect,Administration reserpine_first therapy tricyclic antidepressant_second shown produce stimulating effect depressed patients.
123,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,anticholinergic drugs,advise,Close supervision careful adjustment dosage required nortriptyline hydrochloride_first used anticholinergic drugs_second sympathomimetic drugs.
124,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,sympathomimetic drugs,advise,Close supervision careful adjustment dosage required nortriptyline hydrochloride_first used anticholinergic drugs sympathomimetic drugs_second .
125,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,antidepressants,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants_second phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
126,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,phenothiazines,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines_second carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
127,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,carbamazepine,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine_second Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
128,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,Type 1C antiarrhythmics,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics_second (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
129,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,propafenone,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone_second flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
130,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,flecainide,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide_second encainide) inhibit enzyme (eg quinidine) approached caution.
131,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,encainide,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide_second ) inhibit enzyme (eg quinidine) approached caution.
132,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,quinidine,advise,Therefore co administration tricyclic antidepressants_first drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine_second ) approached caution.
133,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,CNS depressants,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants_second (alcohol barbiturates opiates sedatives anesthetics) considered.
134,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,alcohol,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants (alcohol_second barbiturates opiates sedatives anesthetics) considered.
135,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,barbiturates,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants (alcohol barbiturates_second opiates sedatives anesthetics) considered.
136,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,opiates,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates_second sedatives anesthetics) considered.
137,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,sedatives,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives_second anesthetics) considered.
138,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,anesthetics,advise,Although specific drug interaction studies conducted ALPHAGAN P_first possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics_second ) considered.
139,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.,Tricyclic antidepressants,clonidine,effect,Tricyclic antidepressants_first reported blunt hypotensive effect systemic clonidine_second .It known whether concurrent use agents ALPHAGAN P humans lead resulting interference IOP lowering effect.
140,"Interactions of cobalt and iron in absorption and retention.
",cobalt,iron,mechanism,Interactions cobalt_first iron_second absorption retention.
141,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional iron_first significantly inhibited absorption cobalt_second dietary cobalt treatments.
142,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional iron_first significantly inhibited absorption cobalt dietary cobalt_second treatments.
143,The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ,Fe,cobalt,mechanism,lower rate absorption groups receiving 446 mg Fe_first instead 48 mg Fe per kg diet resulted decreased renal excretion cobalt_second .
144,"Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ",iron,cobalt,mechanism,Consequently effect iron_first retention cobalt_second lower absorption.
145,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ketoconazole,advise,daily dose ENABLEX_first exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole_second itraconazole ritonavir nelfinavir clarithromycin nefazadone) .
146,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,itraconazole,advise,daily dose ENABLEX_first exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole_second ritonavir nelfinavir clarithromycin nefazadone) .
147,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ritonavir,advise,daily dose ENABLEX_first exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole ritonavir_second nelfinavir clarithromycin nefazadone) .
148,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,nelfinavir,advise,daily dose ENABLEX_first exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole ritonavir nelfinavir_second clarithromycin nefazadone) .
149,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,clarithromycin,advise,daily dose ENABLEX_first exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole ritonavir nelfinavir clarithromycin_second nefazadone) .
150,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,flecainide,advise,Caution taken ENABLEX_first used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide_second thioridazine tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
151,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,thioridazine,advise,Caution taken ENABLEX_first used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide thioridazine_second tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
152,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,tricyclic antidepressants,advise,Caution taken ENABLEX_first used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide thioridazine tricyclic antidepressants_second (see CLINICAL PHARMACOLOGY).
153,"The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.",ENABLEX,anticholinergic agents,effect,concomitant use ENABLEX_first anticholinergic agents_second may increase frequency and/or severity dry mouth constipation blurred vision anticholinergic pharmacological effects.
154,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.,ETHYOL,antihypertensive medications,advise,Special consideration given administration ETHYOL_first patients receiving antihypertensive medications_second drugs could cause potentiate hypotension.
155,Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.,Tiagabine,valproate,mechanism,Valproate: Tiagabine_first causes slight decrease (about 10%) steady state valproate_second concentrations.
156,Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.,tiagabine,carbamazepine,mechanism,Effects Antiepilepsy Drugs (AEDs) GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate tiagabine_first clearance 60% greater patients taking carbamazepine_second without enzyme inducing AEDs.
157,Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.,tiagabine,phenytoin,mechanism,Phenytoin: Population pharmacokinetic analyses indicate tiagabine_first clearance 60% greater patients taking phenytoin_second without enzyme inducing AEDs.
158,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,phenobarbital,mechanism,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate tiagabine_first clearance 60% greater patients taking phenobarbital_second (primidone) without enzyme inducing AEDs.
159,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,primidone,mechanism,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate tiagabine_first clearance 60% greater patients taking phenobarbital (primidone_second ) without enzyme inducing AEDs.
160,"Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.",valproate,tiagabine,mechanism,Valproate: addition tiagabine patients taking valproate chronically effect tiagabine pharmacokinetics valproate_first significantly decreased tiagabine_second binding vitro 96.3 94.8% resulted increase approximately 40% free tiagabine concentration.
161,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",ethanol,tiagabine,advise,possible additive effects drugs may depress nervous system ethanol_first triazolam used cautiously combination tiagabine_second .
162,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",triazolam,tiagabine,advise,possible additive effects drugs may depress nervous system ethanol triazolam_first used cautiously combination tiagabine_second .
163,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Acetaminophen,int,Sulfapyridine_first may interact following: Acetaminophen_second (e.g. Tylenol) (with long term high dose use)
164,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Tylenol,int,Sulfapyridine_first may interact following: Acetaminophen (e.g. Tylenol_second ) (with long term high dose use)
165,"- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics",antidiabetics,sulfapyridine,effect,Antidiabetics oral (diabetes medicine take mouth) Use oral antidiabetics_first sulfapyridine_second may increase chance side effects affecting blood and/or side effects oral antidiabetics
166,"- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate",methotrexate,sulfapyridine,effect,Methotrexate (e.g. Mexate) Use methotrexate_first sulfapyridine_second may increase chance side effects affecting liver and/or side effects methotrexate
167,"- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",methyldopa,sulfapyridine,effect,Methyldopa (e.g. Aldomet) Use methyldopa_first sulfapyridine_second may increase chance side effects affecting liver and/or blood
168,"- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",phenytoin,sulfapyridine,effect,Phenytoin (e.g. Dilantin) Use phenytoin_first sulfapyridine_second may increase chance side effects affecting liver and/or side effects phenytoin
169,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.,theophylline,quinolones,mechanism,Elevated plasma levels theophylline_first reported concomitant use quinolones_second .
170,There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.,theophylline,quinolone,effect,reports theophylline related side effects patients concomitant theophylline_first quinolone_second therapy.
171,Quinolones have also been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,Quinolones_first also shown interfere metabolism caffeine_second .
172,"Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.",cinoxacin,caffeine,advise,Although interaction reported cinoxacin caution exercised cinoxacin_first given concomitantly caffeine_second containing products.
173,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",Antacids,quinolones,mechanism,Antacids_first sucralfate substantially interfere absorption quinolones_second resulting low urine levels.
174,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",sucralfate,quinolones,mechanism,Antacids sucralfate_first substantially interfere absorption quinolones_second resulting low urine levels.
175,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,iron,mechanism,Also concomitant administration quinolones_first products containing iron_second multivitamins containing zinc Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
176,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,zinc,mechanism,Also concomitant administration quinolones_first products containing iron multivitamins containing zinc_second Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
177,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,Videx,mechanism,Also concomitant administration quinolones_first products containing iron multivitamins containing zinc Videx_second (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
178,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,didanosine,mechanism,Also concomitant administration quinolones_first products containing iron multivitamins containing zinc Videx (didanosine_second ) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
179,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,anticoagulants,effect,Quinolones_first including cinoxacin may enhance effects oral anticoagulants_second warfarin derivatives.
180,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,warfarin,effect,Quinolones_first including cinoxacin may enhance effects oral anticoagulants warfarin_second derivatives.
181,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,anticoagulants,effect,Quinolones including cinoxacin_first may enhance effects oral anticoagulants_second warfarin derivatives.
182,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,warfarin,effect,Quinolones including cinoxacin_first may enhance effects oral anticoagulants warfarin_second derivatives.
183,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,nonsteroidal anti-inflammatory drug,effect,Seizures reported patients taking another quinolone class antimicrobial_first nonsteroidal anti-inflammatory drug_second fenbufen concurrently.
184,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,fenbufen,effect,Seizures reported patients taking another quinolone class antimicrobial_first nonsteroidal anti inflammatory drug fenbufen_second concurrently.
185,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.,cinoxacin,nonsteroidal anti-inflammatory agents,advise,Physicians provided information increase awareness potential serious interactions cinoxacin_first certain nonsteroidal anti-inflammatory agents_second administered concomitantly.
186,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated cyclosporine serum levels reported concomitant use quinolones_first cyclosporine_second .
187,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,aluminum,mechanism,Administration quinolones_first antacids containing aluminum_second magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
188,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,magnesium,mechanism,Administration quinolones_first antacids containing aluminum magnesium_second calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
189,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,calcium,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium_second sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
190,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,sucralfate,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate_second metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
191,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron_second multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
192,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,multivitamins,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins_second containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
193,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron_second zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
194,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,zinc,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc_second formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
195,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,VIDEX,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX_second (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
196,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,didanosine,mechanism,Administration quinolones_first antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine_second ) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
197,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,caffeine,mechanism,Caffeine Theobromine Grepafloxacin_first like quinolones may inhibit metabolism caffeine_second theobromine.
198,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,theobromine,mechanism,Caffeine Theobromine Grepafloxacin_first like quinolones may inhibit metabolism caffeine theobromine_second .
199,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,caffeine,mechanism,Caffeine Theobromine Grepafloxacin like quinolones_first may inhibit metabolism caffeine_second theobromine.
200,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,theobromine,mechanism,Caffeine Theobromine Grepafloxacin like quinolones_first may inhibit metabolism caffeine theobromine_second .
201,Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.,Grepafloxacin,theophylline,mechanism,Theophylline: Grepafloxacin_first competitive inhibitor metabolism theophylline_second .
202,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.,grepafloxacin,theophylline,mechanism,Serum theophylline concentrations increase grepafloxacin_first initiated patient maintained theophylline_second .
203,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,advise,initiating multi day course grepafloxacin patient maintained theophylline theophylline_first maintenance dose halved period concurrent use grepafloxacin_second monitoring serum theophylline concentrations initiated guide dosage adjustments.
204,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolones,warfarin,effect,However quinolones_first reported enhance effects warfarin_second derivatives prothrombin time suitable anticoagulation test monitored closely quinolone antimicrobial administered warfarin derivatives.
205,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance effects warfarin derivatives prothrombin time suitable anticoagulation test monitored closely quinolone antimicrobial_first administered warfarin_second derivatives.
206,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,mechanism,Drugs Metabolized Cytochrome P450 Enzymes drug interaction study evaluating effect grepafloxacin theophylline indicates grepafloxacin_first inhibits theophylline_second metabolism mediated CYP1A2.
207,"In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.",quinolones,cyclosporine,mechanism,addition quinolones_first reported decrease CYP3A4 mediated metabolism cyclosporine_second .
208,Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.,nonsteroidal anti inflammatory drug,quinolone,effect,Nonsteroidal Anti inflammatory Drugs (NSAIDs): concomitant administration nonsteroidal anti inflammatory drug_first quinolone_second may increase risks CNS stimulation convulsions.
209,"Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.",quinolones,antidiabetic agent,effect,Antidiabetic Agents: Disturbances blood glucose including hyperglycemia hypoglycemia reported patients treated concomitantly quinolones_first antidiabetic agent_second .
210,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,anticholinergics,effect,concurrent use Robinul_first Injection anticholinergics_second medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
211,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,phenothiazines,effect,concurrent use Robinul_first Injection anticholinergics medications anticholinergic activity phenothiazines_second antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
212,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,antiparkinson drugs,effect,concurrent use Robinul_first Injection anticholinergics medications anticholinergic activity phenothiazines antiparkinson drugs_second tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
213,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,tricyclic antidepressants,effect,concurrent use Robinul_first Injection anticholinergics medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants_second may intensify antimuscarinic effects may result increase anticholinergic side effects.
214,Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.,Robinul,potassium chloride,mechanism,Concomitant administration Robinul_first Injection potassium chloride_second wax matrix may increase severity potassium chloride induced gastrointestinal lesions result slower gastrointestinal transit time.
215,"When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.",beta-adrenergic receptor blocking agents,Anesthetics,int,administered concurrently following drugs may interact beta-adrenergic receptor blocking agents_first : Anesthetics_second general: exaggeration hypotension induced general anesthetics.
216,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.,theophylline,quinolone,mechanism,Elevated plasma levels theophylline_first reported concomitant quinolone_second use.
217,There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.,quinolones,theophylline,effect,reports theophylline related side effects patients concomitant therapy quinolones_first theophylline_second .
218,Quinolones have been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,Quinolones_first shown interfere metabolism caffeine_second .
219,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",Quinolones,warfarin,effect,Quinolones_first including nalidixic acid may enhance effects oral anticoagulant warfarin_second derivatives.
220,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",nalidixic acid,warfarin,effect,Quinolones including nalidixic acid_first may enhance effects oral anticoagulant warfarin_second derivatives.
221,Nitrofurantoin interferes with the therapeutic action of nalidixic acid.,Nitrofurantoin,nalidixic acid,effect,Nitrofurantoin_first interferes therapeutic action nalidixic acid_second .
222,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Videx,quinolones,mechanism,Videx_first (Didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones_second resulting systemic levels considerably lower desired.
223,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Didanosine,quinolones,mechanism,Videx (Didanosine_first ) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones_second resulting systemic levels considerably lower desired.
224,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated serum levels cyclosporine reported concomitant use quinolones_first cyclosporine_second .
225,"Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",cephalexin,metformin,mechanism,Metformin: healthy subjects given single 500 mg doses cephalexin_first metformin_second plasma metformin mean cmax AUC increased average 34% 24% respectively metformin mean renal clearance decreased 14%.
226,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.",cephalexin,metformin,mechanism,Although observed study adverse effects could potentially arise co administration cephalexin_first metformin_second inhibition tubular secretion via organic cationic transporter systems.
227,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.",cephalexin,metformin,advise,Accordingly careful patient monitoring dose adjustment metformin recommended patients concomitantly taking cephalexin_first metformin_second .
228,"Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.",cephalexin,probenecid,mechanism,Probenecid: b lactams renal excretion cephalexin_first inhibited probenecid_second .
229,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Monoamine oxidase inhibitors,int,Drug Interactions: Flupenthixol_first may interact drugs like Monoamine oxidase inhibitors_second (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
230,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,MAOI,int,Drug Interactions: Flupenthixol_first may interact drugs like Monoamine oxidase inhibitors (MAOI_second ): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
231,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",MAOI,flupenthixol,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI_first could theoretically affect flupenthixol_second pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
232,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Ethanol,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol_first Ethanol_second cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
233,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Tricyclic antidepressants,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol_first increases effect Tricyclic antidepressants_second
234,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",Curariform muscle relaxants,Coly-Mycin M,effect,Curariform muscle relaxants_first (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
235,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",tubocurarine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine_first ) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
236,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",succinylcholine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine_first gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
237,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",gallamine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine_first decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
238,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",decamethonium,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium_first sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
239,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",sodium citrate,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate_first potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M_second Parenteral.
240,Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.,Sodium cephalothin,Coly-Mycin M,effect,Sodium cephalothin_first may enhance nephrotoxicity Coly-Mycin M_second Parenteral.
241,The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.,sodium cephalothin,Coly-Mycin M,advise,concomitant use sodium cephalothin_first Coly-Mycin M_second Parenteral avoided.
242,"Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.",diuretics,PRINIVIL,effect,Hypotension Patients Diuretic Therapy: Patients diuretics_first especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy PRINIVIL_second .
243,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.,diuretic,PRINIVIL,effect,possibility hypotensive effects PRINIVIL minimized either discontinuing diuretic_first increasing salt intake prior initiation treatment PRINIVIL_second .
244,"If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.",diuretic,PRINIVIL,advise,necessary continue diuretic_first initiate therapy PRINIVIL_second dose 5 mg daily provide close medical supervision initial dose blood pressure stabilized.
245,"When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.",diuretic,PRINIVIL,effect,diuretic_first added therapy patient receiving PRINIVIL_second additional antihypertensive effect usually observed.
246,Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.,ACE inhibitor,diuretic,advise,Studies ACE inhibitors combination diuretics indicate dose ACE inhibitor_first reduced given diuretic_second .
247,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.",non-steroidal anti-inflammatory drugs,lisinopril,effect,Non steroidal Anti inflammatory Agents: patients compromised renal function treated non-steroidal anti-inflammatory drugs_first co administration lisinopril_second may result deterioration renal function.
248,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,ACE inhibitors,effect,Reports suggest NSAIDs_first may diminish antihypertensive effect ACE inhibitors_second including lisinopril.
249,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,lisinopril,effect,Reports suggest NSAIDs_first may diminish antihypertensive effect ACE inhibitors including lisinopril_second .
250,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking NSAIDs_first concomitantly ACE inhibitors_second .
251,Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.,PRINIVIL,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: PRINIVIL_first attenuates potassium loss caused thiazide-type diuretics_second .
252,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium-sparing diuretics,effect,Use PRINIVIL_first potassium-sparing diuretics_second (e.g. spironolactone triamterene amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
253,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,spironolactone,effect,Use PRINIVIL_first potassium sparing diuretics (e.g. spironolactone_second triamterene amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
254,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,triamterene,effect,Use PRINIVIL_first potassium sparing diuretics (e.g. spironolactone triamterene_second amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
255,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,amiloride,effect,Use PRINIVIL_first potassium sparing diuretics (e.g. spironolactone triamterene amiloride_second ) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
256,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium,effect,Use PRINIVIL_first potassium sparing diuretics (e.g. spironolactone triamterene amiloride) potassium_second supplements potassium containing salt substitutes may lead significant increases serum potassium.
257,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: Lithium toxicity reported patients receiving lithium_first concomitantly drugs cause elimination sodium including ACE inhibitors_second .
258,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.,lithium,ACE inhibitor,effect,Lithium toxicity usually reversible upon discontinuation lithium_first ACE inhibitor_second .
259,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.,PRINIVIL,lithium,advise,recommended serum lithium levels monitored frequently PRINIVIL_first administered concomitantly lithium_second .
260,The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.,butalbital,monoamine oxidase (MAO) inhibitors,effect,CNS effects butalbital_first may enhanced monoamine oxidase (MAO) inhibitors_second .
261,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,narcotic analgesic,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesic_second alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
262,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,alcohol,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol_second general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
263,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,anesthetics,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics_second tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
264,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,tranquilizers,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers_second chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
265,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,chlordiazepoxide,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide_second sedative hypnotics CNS depressants causing increased CNS depression.
266,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,sedative-hypnotics,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics_second CNS depressants causing increased CNS depression.
267,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,CNS depressants,effect,Butalbital_first acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants_second causing increased CNS depression.
268,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,narcotic analgesic,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesic_second alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
269,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,alcohol,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol_second general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
270,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,anesthetics,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics_second tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
271,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,tranquilizers,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers_second chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
272,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,chlordiazepoxide,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide_second sedative hypnotics CNS depressants causing increased CNS depression.
273,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,sedative-hypnotics,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics_second CNS depressants causing increased CNS depression.
274,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,CNS depressants,effect,Butalbital acetaminophen_first caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants_second causing increased CNS depression.
275,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,narcotic analgesic,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesic_second alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
276,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,alcohol,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol_second general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
277,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,anesthetics,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol general anesthetics_second tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
278,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,tranquilizers,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers_second chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
279,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,chlordiazepoxide,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide_second sedative hypnotics CNS depressants causing increased CNS depression.
280,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,sedative-hypnotics,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics_second CNS depressants causing increased CNS depression.
281,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,CNS depressants,effect,Butalbital acetaminophen caffeine_first may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants_second causing increased CNS depression.
282,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,azithromycin,effect,Buforin II_first may active inhibiting Cryptosporidium parvum growth vitro upon combination either azithromycin_second minocycline.
283,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,minocycline,effect,Buforin II_first may active inhibiting Cryptosporidium parvum growth vitro upon combination either azithromycin minocycline_second .
284,"CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.",Sonata,ethanol,effect,CNS Active Drugs Ethanol: Sonata_first 10 mg potentiated CNS impairing effects ethanol_second 0.75 g/kg balance testing reaction time 1 hour ethanol administration digit symbol substitution test (DSST) symbol copying test variability component divided attention test 2.5 hours ethanol administration.
285,Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,imipramine,effect,Imipramine: Coadministration single doses Sonata_first 20 mg imipramine_second 75 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration.
286,Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,thioridazine,effect,Thioridazine: Coadministration single doses Sonata_first 20 mg thioridazine_second 50 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration.
287,"Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.",zaleplon,promethazine,mechanism,Promethazine: Coadministration single dose zaleplon_first promethazine_second (10 25 mg respectively) resulted 15% decrease maximal plasma concentrations zaleplon change area plasma concentration time curve.
288,"Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.",rifampin,zaleplon,mechanism,Multiple dose administration potent CYP3A4 inducer rifampin_first (600 mg every 24 hours q24h 14 days) however reduced zaleplon_second Cmax AUC approximately 80%.
289,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.",zaleplon,erythromycin,mechanism,Coadministration single oral doses zaleplon_first erythromycin_second (10 mg 800 mg respectively) strong selective CYP3A4 inhibitor produced 34% increase zaleplons maximal plasma concentrations 20% increase area plasma concentration time curve.
290,Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.,ketoconazole,zaleplon,mechanism,strong selective CYP3A4 inhibitors ketoconazole_first also expected increase exposure zaleplon_second .
291,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.",Cimetidine,zaleplon,mechanism,Drugs Inhibit Aldehyde Oxidase CYP3A4 Cimetidine: Cimetidine_first inhibits aldehyde oxidase (in vitro) CYP3A4 (in vitro vivo) primary secondary enzymes respectively responsible zaleplon_second metabolism.
292,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.,Sonata,cimetidine,mechanism,Concomitant administration Sonata_first (10 mg) cimetidine_second (800 mg) produced 85% increase mean Cmax AUC zaleplon.
293,"A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",INSPRA,ketoconazole,mechanism,pharmacokinetic study evaluating administration single dose INSPRA_first 100 mg ketoconazole_second 200 mg BID potent inhibitor CYP3A4 pathway showed 1.7 fold increase Cmax eplerenone 5.4 fold increase AUC eplerenone.
294,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,erythromycin,mechanism,Administration eplerenone_first CYP3A4 inhibitors (e.g. erythromycin_second 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
295,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,verapamil,mechanism,Administration eplerenone_first CYP3A4 inhibitors (e.g. erythromycin 500 mg BID verapamil_second 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
296,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,mechanism,Administration eplerenone_first CYP3A4 inhibitors (e.g. erythromycin 500 mg BID verapamil 240 mg QD saquinavir_second 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
297,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,fluconazole,mechanism,Administration eplerenone_first CYP3A4 inhibitors (e.g. erythromycin 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID fluconazole_second 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
298,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,ACE inhibitors,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension) clinical studies patients hypertension addition INSPRA_first 50 100 mg ACE inhibitors_second angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09 0.13 mEq/L).
299,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,angiotensin II receptor antagonists,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension) clinical studies patients hypertension addition INSPRA_first 50 100 mg ACE inhibitors angiotensin II receptor antagonists_second increased mean serum potassium slightly (about 0.09 0.13 mEq/L).
300,In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.,INSPRA,enalapril,effect,study diabetics microalbuminuria INSPRA_first 200 mg combined ACE inhibitor enalapril_second 10 mg increased frequency hyperkalemia (serum potassium 5.5 mEq/L) 17% enalapril alone 38%.
301,Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.,INSPRA,lithium,advise,Serum lithium levels monitored frequently INSPRA_first administered concomitantly lithium_second .
302,The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.,potassium-sparing antihypertensives,NSAIDs,effect,administration potassium-sparing antihypertensives_first NSAIDs_second shown reduce antihypertensive effect patients result severe hyperkalemia patients impaired renal function.
303,"Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",INSPRA,NSAIDs,advise,Therefore INSPRA_first NSAIDs_second used concomitantly patients observed determine whether desired effect blood pressure obtained.
304,Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.,Aminoglutethimide,corticosteroids,effect,Aminoglutethimide: Aminoglutethimide_first may diminish adrenal suppression corticosteroids_second .
305,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,amphotericin B,advise,Amphotericin B injection potassium depleting agents: corticosteroids_first administered concomitantly potassium depleting agents (e.g. amphotericin B_second diuretics) patients observed closely development hypokalemia.
306,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,diuretics,advise,Amphotericin B injection potassium depleting agents: corticosteroids_first administered concomitantly potassium depleting agents (e.g. amphotericin B diuretics_second ) patients observed closely development hypokalemia.
307,"In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.",amphotericin B,hydrocortisone,effect,addition cases reported concomitant use amphotericin B_first hydrocortisone_second followed cardiac enlargement congestive heart failure.
308,Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.,Macrolide antibiotics,corticosteroid,mechanism,Antibiotics: Macrolide antibiotics_first reported cause significant decrease corticosteroid_second clearance.
309,Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.,anticholinesterase agents,corticosteroids,effect,Anticholinesterases: Concomitant use anticholinesterase agents_first corticosteroids_second may produce severe weakness patients myasthenia gravis.
310,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.",anticholinesterase agents,corticosteroid,advise,possible anticholinesterase agents_first withdrawn least 24 hours initiating corticosteroid_second therapy.
311,"Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",corticosteroids,warfarin,effect,Anticoagulants oral: Co administration corticosteroids_first warfarin_second usually results inhibition response warfarin although conflicting reports.
312,"Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.",corticosteroids,antidiabetic agents,effect,Antidiabetics: corticosteroids_first may increase blood glucose concentrations dosage adjustments antidiabetic agents_second may required.
313,Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.,Cholestyramine,corticosteroids,mechanism,Cholestyramine: Cholestyramine_first may increase clearance corticosteroids_second .
314,Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.,cyclosporine,corticosteroids,effect,Cyclosporine: Increased activity cyclosporine_first corticosteroids_second may occur two used concurrently.
315,"Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.",Ephedrine,corticosteroids,mechanism,Ephedrine: Ephedrine_first may enhance metabolic clearance corticosteroids_second resulting decreased blood levels lessened physiologic activity thus requiring increase corticosteroid dosage.
316,"Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.",Estrogens,corticosteroids,mechanism,Estrogens including oral contraceptives: Estrogens_first may decrease hepatic metabolism certain corticosteroids_second thereby increasing effect.
317,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",barbiturates,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates_first phenytoin carbamazepine rifampin) may enhance metabolism corticosteroids_second require dosage corticosteroid increased.
318,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",phenytoin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates phenytoin_first carbamazepine rifampin) may enhance metabolism corticosteroids_second require dosage corticosteroid increased.
319,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",carbamazepine,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates phenytoin carbamazepine_first rifampin) may enhance metabolism corticosteroids_second require dosage corticosteroid increased.
320,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",rifampin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates phenytoin carbamazepine rifampin_first ) may enhance metabolism corticosteroids_second require dosage corticosteroid increased.
321,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",ketoconazole,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. ketoconazole_first macrolide antibiotics erythromycin) potential result increased plasma concentrations corticosteroids_second .
322,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",macrolide antibiotics,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. ketoconazole macrolide antibiotics_first erythromycin) potential result increased plasma concentrations corticosteroids_second .
323,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",erythromycin,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. ketoconazole macrolide antibiotics erythromycin_first ) potential result increased plasma concentrations corticosteroids_second .
324,"Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",Ketoconazole,corticosteroids,mechanism,Ketoconazole: Ketoconazole_first reported decrease metabolism certain corticosteroids_second 60% leading increased risk corticosteroid side effects.
325,"In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.",ketoconazole,corticosteroid,effect,addition ketoconazole_first alone inhibit adrenal corticosteroid_second synthesis may cause adrenal insufficiency corticosteroid withdrawal.
326,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,aspirin,corticosteroids,effect,Nonsteroidal anti inflammatory agents (NSAIDS): Concomitant use aspirin_first (or nonsteroidal antiinflammatory agents) corticosteroids_second increases risk gastrointestinal side effects.
327,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,nonsteroidal antiinflammatory agents,corticosteroids,effect,Nonsteroidal anti inflammatory agents (NSAIDS): Concomitant use aspirin (or nonsteroidal antiinflammatory agents_first ) corticosteroids_second increases risk gastrointestinal side effects.
328,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.,Aspirin,corticosteroids,advise,Aspirin_first used cautiously conjunction corticosteroids_second hypoprothrombinemia.
329,The clearance of salicylates may be increased with concurrent use of corticosteroids.,salicylates,corticosteroids,mechanism,clearance salicylates_first may increased concurrent use corticosteroids_second .
330,"Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,mechanism,Phenytoin: post marketing experience reports increases decreases phenytoin_first levels dexamethasone_second co administration leading alterations seizure control.
331,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,live vaccines,effect,Vaccines: Patients corticosteroid_first therapy may exhibit diminished response toxoids live inactivated live vaccines_second due inhibition antibody response.
332,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,inactivated vaccines,effect,Vaccines: Patients corticosteroid_first therapy may exhibit diminished response toxoids live inactivated vaccines_second due inhibition antibody response.
333,Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.,Corticosteroids,live attenuated vaccines,effect,Corticosteroids_first may also potentiate replication organisms contained live attenuated vaccines_second .
334,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.,vaccines,corticosteroid,advise,Routine administration vaccines_first toxoids deferred corticosteroid_second therapy discontinued possible.
335,Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.,temazepam,ethanol,mechanism,Acid catalyzed ethanolysis temazepam_first anhydrous aqueous ethanol_second solutions.
336,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ",temazepam,ethanol,mechanism,addition pharmacological interaction report describes novel chemical reaction temazepam_first (a benzodiazepine) ethanol_second acidic conditions similar found vivo resulting 3 ethoxylated product.
337,"The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ",alcohol,"3-hydroxy-1,4-benzodiazepine",mechanism,"results raise possibility ethanolysis reaction may occur stomach people consume alcohol_first 3-hydroxy-1,4-benzodiazepine_second regular basis."
338,"Enhanced theophylline clearance secondary to phenytoin therapy.
",theophylline,phenytoin,mechanism,Enhanced theophylline_first clearance secondary phenytoin_second therapy.
339,This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ,theophylline,phenytoin,mechanism,report describes two cases theophylline_first clearance accelerated markedly concomitant phenytoin_second administration.
340,"With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.",phenytoin,theophylline,effect,combined use clinicians aware phenytoin_first added potential reexacerbation pulmonary symptomatology due lowered serum theophylline_second concentrations.
341,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,CENTRAL NERVOUS SYSTEM DEPRESSANTS,effect,POTENTIATING ACTION HYDROXYZINE_first MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS_second NARCOTICS NON NARCOTIC ANALGESICS BARBITURATES.
342,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NARCOTICS,effect,POTENTIATING ACTION HYDROXYZINE_first MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS NARCOTICS_second NON NARCOTIC ANALGESICS BARBITURATES.
343,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NON-NARCOTIC ANALGESICS,effect,POTENTIATING ACTION HYDROXYZINE_first MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS NARCOTICS NON-NARCOTIC ANALGESICS_second BARBITURATES.
344,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,BARBITURATES,effect,POTENTIATING ACTION HYDROXYZINE_first MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS NARCOTICS NON NARCOTIC ANALGESICS BARBITURATES_second .
345,Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.,central nervous system depressants,hydroxyzine,advise,Therefore central nervous system depressants_first administered concomitantly hydroxyzine_second dosage reduced.
346,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",Amantadine,clidinium,effect,Amantadine_first tricyclic antidepressants MAOIs may increase anticholinergic effect clidinium_second .
347,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",tricyclic antidepressants,clidinium,effect,Amantadine tricyclic antidepressants_first MAOIs may increase anticholinergic effect clidinium_second .
348,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",MAOIs,clidinium,effect,Amantadine tricyclic antidepressants MAOIs_first may increase anticholinergic effect clidinium_second .
349,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,phenothiazines,effect,Clidinium_first may decrease effect phenothiazines_second levodopa ketoconazole.
350,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,levodopa,effect,Clidinium_first may decrease effect phenothiazines levodopa_second ketoconazole.
351,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,ketoconazole,effect,Clidinium_first may decrease effect phenothiazines levodopa ketoconazole_second .
352,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration oxyphenbutazone_first androgens_second may result elevated serum levels oxyphenbutazone.
353,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,diabetic patients metabolic effects androgens_first may decrease blood glucose therefore insulin_second requirements.
354,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,anticonvulsant,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations felodipine_first considerably lower epileptic patients long term anticonvulsant_second therapy (eg phenytoin carbamazepine phenobarbital) healthy volunteers.
355,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenytoin,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations felodipine_first considerably lower epileptic patients long term anticonvulsant therapy (eg phenytoin_second carbamazepine phenobarbital) healthy volunteers.
356,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,carbamazepine,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations felodipine_first considerably lower epileptic patients long term anticonvulsant therapy (eg phenytoin carbamazepine_second phenobarbital) healthy volunteers.
357,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenobarbital,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations felodipine_first considerably lower epileptic patients long term anticonvulsant therapy (eg phenytoin carbamazepine phenobarbital_second ) healthy volunteers.
358,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",NSAIDs,aspirin,advise,Aspirin: NSAIDs_first concomitant administration Ponstel aspirin_second generally recommended potential increased adverse effects.
359,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",Ponstel,aspirin,advise,Aspirin: NSAIDs concomitant administration Ponstel_first aspirin_second generally recommended potential increased adverse effects.
360,Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.,NSAIDs,methotrexate,mechanism,Methotrexate: NSAIDs_first reported competitively inhibit methotrexate_second accumulation rabbit kidney slices.
361,Caution should be used when NSAIDs are administered concomitantly with methotrexate.,NSAIDs,methotrexate,advise,Caution used NSAIDs_first administered concomitantly methotrexate_second .
362,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.,NSAIDs,ACE inhibitors,effect,ACE inhibitors: Reports suggest NSAIDs_first may diminish antihypertensive effect ACE inhibitors_second .
363,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking NSAIDs_first concomitantly ACE inhibitors_second .
364,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide_second thiazides patients.
365,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide thiazides_second patients.
366,"During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,advise,concomitant therapy Ponstel_first furosemide_second patient observed closely signs renal failure well assure diuretic efficacy.
367,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: NSAIDs_first produced elevation plasma lithium_second levels reduction renal lithium clearance.
368,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: NSAIDs_first produced elevation plasma lithium levels reduction renal lithium_second clearance.
369,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,advise,Thus NSAIDs_first lithium_second administered concurrently subjects observed carefully signs lithium toxicity.
370,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: effects warfarin_first NSAIDs_second GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone.
371,"Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.",magnesium hydroxide,mefenamic acid,mechanism,Antacids: single dose study (n=6) ingestion antacid containing 1.7 gram magnesium hydroxide_first 500 mg mefenamic acid_second increased Cmax AUC mefenamic acid 125% 36% respectively. number compounds inhibitors CYP2C9 including fluconazole lovastatin trimethoprim.
372,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,warfarin,effect,Oral Anticoagulants: normal volunteers concomitant administration diflunisal_first warfarin_second acenocoumarol phenprocoumon resulted prolongation prothrombin time.
373,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,acenocoumarol,effect,Oral Anticoagulants: normal volunteers concomitant administration diflunisal_first warfarin acenocoumarol_second phenprocoumon resulted prolongation prothrombin time.
374,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,phenprocoumon,effect,Oral Anticoagulants: normal volunteers concomitant administration diflunisal_first warfarin acenocoumarol phenprocoumon_second resulted prolongation prothrombin time.
375,This may occur because diflunisal competitively displaces coumarins from protein binding sites.,diflunisal,coumarins,mechanism,may occur diflunisal_first competitively displaces coumarins_second protein binding sites.
376,"Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.",diflunisal,anticoagulants,advise,Accordingly diflunisal_first administered oral anticoagulants_second prothrombin time closely monitored several days concomitant drug administration.
377,"Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.",diflunisal,hydrochlorothiazide,mechanism,Hydrochlorothiazide: normal volunteers concomitant administration diflunisal_first hydrochlorothiazide_second resulted significantly increased plasma levels hydrochlorothiazide.
378,Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.,Diflunisal,hydrochlorothiazide,effect,Diflunisal_first decreased hyperuricemic effect hydrochlorothiazide_second .
379,Diflunisal decreased the hyperuricemic effect of furosemide.,Diflunisal,furosemide,effect,Diflunisal_first decreased hyperuricemic effect furosemide_second .
380,Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.,antacids,diflunisal,mechanism,Antacids: Concomitant administration antacids_first may reduce plasma levels diflunisal_second .
381,"Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.",diflunisal,acetaminophen,mechanism,Acetaminophen: normal volunteers concomitant administration diflunisal_first acetaminophen_second resulted approximate 50% increase plasma levels acetaminophen.
382,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.",diflunisal,acetaminophen,advise,Since acetaminophen high doses associated hepatotoxicity concomitant administration diflunisal_first acetaminophen_second used cautiously careful monitoring patients.
383,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",diflunisal,acetaminophen,effect,Concomitant administration diflunisal_first acetaminophen_second dogs rats approximately 2 times recommended maximum human therapeutic dose (40 52 mg/kg/day diflunisal/acetaminophen) resulted greater gastrointestinal toxicity either drug administered alone.
384,Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.,diflunisal,methotrexate,advise,Methotrexate: Caution used diflunisal_first administered concomitantly methotrexate_second .
385,Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,Nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,Nonsteroidal anti-inflammatory drugs_first reported decrease tubular secretion methotrexate_second potentiate toxicity.
386,"Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",nonsteroial anti-inflammatory drugs,cyclosporine,mechanism,Cyclosporine: Administration nonsteroial anti-inflammatory drugs_first concomitantly cyclosporine_second associated increase cyclosporine induced toxicity possibly due decreased synthesis renal prostacyclin.
387,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,NSAIDs_first used caution patients taking cyclosporine_second renal function carefully monitored.
388,Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.,diflunisal,indomethacin,mechanism,Nonsteroidal Anti Inflammatory Drugs: administration diflunisal_first normal volunteers receiving indomethacin_second decreased renal clearance significantly increased plasma levels indomethacin.
389,In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.,indomethacin,diflunisal,effect,patients combined use indomethacin_first diflunisal_second associated fatal gastrointestinal hemorrhage.
390,"Therefore, indomethacin and diflunisal should not be used concomitantly.",indomethacin,diflunisal,advise,Therefore indomethacin_first diflunisal_second used concomitantly.
391,"The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",diflunisal,NSAIDs,effect,concomitant use diflunisal_first tablets NSAIDs_second recommended due increased possibility gastrointestinal toxicity little increase efficacy.
392,"Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.",diflunisal,aspirin,mechanism,Aspirin: normal volunteers small decrease diflunisal levels observed multiple doses diflunisal_first aspirin_second administered concomitantly.
393,Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.,diflunisal,sulindac,mechanism,Sulindac: concomitant administration diflunisal_first sulindac_second normal volunteers resulted lowering plasma levels active sulindac sulfide metabolite approximately one third.
394,"Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",diflunisal,naproxen,mechanism,Naproxen: concomitant administration diflunisal_first naproxen_second normal volunteers effect plasma levels naproxen significantly decreased urinary excretion naproxen glucuronide metabolite.
395,Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.,Lincomycin,neuromuscular blocking agents,effect,Lincomycin_first shown neuromuscular blocking properties may enhance action neuromuscular blocking agents_second .
396,Antagonism between lincomycin and erythromycin in vitro has been demonstrated.,lincomycin,erythromycin,effect,Antagonism lincomycin_first erythromycin_second vitro demonstrated.
397,"Rifampin and warfarin: a drug interaction.
",Rifampin,warfarin,int,Rifampin_first warfarin_second : drug interaction.
398,The drug interaction between warfarin and rifampin is not well known. ,warfarin,rifampin,int,drug interaction warfarin_first rifampin_second well known.
399,Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ,Rifampin,warfarin,mechanism,Rifampin_first reported increase warfarin_second requirements human subjects ingesting agents simultaneously.
400,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ,rifampin,warfarin,mechanism,concomitant administration rifampin_first warfarin_second resulted need unusually high maintenance dose warfarin (20 mg per day) order produce therapeutic effect.
401,Withdrawal of rifampin decreased the warfarin requirement by 50%. ,rifampin,warfarin,mechanism,Withdrawal rifampin_first decreased warfarin_second requirement 50%.
402,"This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ",rifampin,warfarin,mechanism,effect may mediated ability rifampin_first induce microsomal enzymes thus catabolism warfarin_second .
403,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,warfarin,effect,effect rifampin_first warfarin_second requirement patient appeared maximal 5 7 days initiation rifampin extended similar length time rifampin withdrawal.
404,Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.,amantadine,central nervous system stimulants,advise,Careful observation required amantadine_first administered concurrently central nervous system stimulants_second .
405,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",Zarontin,antiepileptic drugs,int,Since Zarontin_first (ethosuximide) may interact concurrently administered antiepileptic drugs_second periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid reported increase decrease ethosuximide levels).
406,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,antiepileptic drugs,int,Since Zarontin (ethosuximide_first ) may interact concurrently administered antiepileptic drugs_second periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid reported increase decrease ethosuximide levels).
407,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,phenytoin,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg ethosuximide_first may elevate phenytoin_second serum levels valproic acid reported increase decrease ethosuximide levels).
408,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",valproic acid,ethosuximide,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid_first reported increase decrease ethosuximide_second levels).
409,Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.,NIMBEX,succinylcholine,effect,Administration 0.1 mg/kg (2 x ED95) NIMBEX_first 10% 95% recovery following intubating dose succinylcholine_second (1 mg/kg) produced 95% neuromuscular block.
410,The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.,NIMBEX,succinylcholine,effect,time onset maximum block following NIMBEX_first approximately 2 minutes faster prior administration succinylcholine_second .
411,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.,succinylcholine,NIMBEX,effect,Infusion requirements NIMBEX patients administered succinylcholine_first prior infusions NIMBEX_second comparable slightly greater succinylcholine administered.
412,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,Isoflurane_first enflurane administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX_second decrease required infusion rate NIMBEX.
413,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,Isoflurane_first enflurane administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate NIMBEX_second .
414,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane enflurane_first administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX_second decrease required infusion rate NIMBEX.
415,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane enflurane_first administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate NIMBEX_second .
416,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered nitrous oxide_first /oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX_second decrease required infusion rate NIMBEX.
417,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered nitrous oxide_first /oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate NIMBEX_second .
418,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",enflurane,NIMBEX,advise,long surgical procedures enflurane_first isoflurane anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates NIMBEX_second may necessary.
419,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",isoflurane,NIMBEX,advise,long surgical procedures enflurane isoflurane_first anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates NIMBEX_second may necessary.
420,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,NIMBEX,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX_second include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
421,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,antibiotics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics_second (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
422,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,aminoglycosides,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides_second tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
423,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,tetracyclines,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines_second bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
424,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,bacitracin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin_second polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
425,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,polymyxins,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins_second lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
426,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lincomycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin_second clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
427,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,clindamycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin_second colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
428,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,colistin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin_second sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
429,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,sodium colistemethate,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate_second ) magnesium salts lithium local anesthetics procainamide quinidine.
430,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,magnesium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium_second salts lithium local anesthetics procainamide quinidine.
431,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lithium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium_second local anesthetics procainamide quinidine.
432,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,anesthetics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics_second procainamide quinidine.
433,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,procainamide,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide_second quinidine.
434,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,quinidine,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents_first NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine_second .
435,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,antibiotics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics_second (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
436,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,aminoglycosides,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides_second tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
437,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,tetracyclines,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines_second bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
438,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,bacitracin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin_second polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
439,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,polymyxins,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins_second lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
440,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lincomycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin_second clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
441,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,clindamycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin_second colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
442,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,colistin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin_second sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
443,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,sodium colistemethate,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate_second ) magnesium salts lithium local anesthetics procainamide quinidine.
444,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,magnesium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium_second salts lithium local anesthetics procainamide quinidine.
445,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lithium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium_second local anesthetics procainamide quinidine.
446,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,anesthetics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics_second procainamide quinidine.
447,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,procainamide,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide_second quinidine.
448,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,quinidine,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine_second .
449,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,phenytoin,effect,Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents_first demonstrated patients chronically administered phenytoin_second carbamazepine.
450,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,carbamazepine,effect,Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents_first demonstrated patients chronically administered phenytoin carbamazepine_second .
451,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,effect,effects chronic phenytoin_first carbamazepine therapy action NIMBEX_second unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
452,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",carbamazepine,NIMBEX,effect,effects chronic phenytoin carbamazepine_first therapy action NIMBEX_second unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
453,Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.,Starlix,tolbutamide,mechanism,Starlix_first potential inhibitor CYP2C9 isoenzyme vivo indicated ability inhibit vitro metabolism tolbutamide_second .
454,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents_first (NSAIDs) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix_second oral antidiabetic drugs.
455,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents_first (NSAIDs) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs_second .
456,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs_first ) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix_second oral antidiabetic drugs.
457,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs_first ) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs_second .
458,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates_first monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix_second oral antidiabetic drugs.
459,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates_first monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs_second .
460,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors_first non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix_second oral antidiabetic drugs.
461,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors_first non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs_second .
462,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents_first may potentiate hypoglycemic action Starlix_second oral antidiabetic drugs.
463,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents_first may potentiate hypoglycemic action Starlix oral antidiabetic drugs_second .
464,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,Starlix,effect,Certain drugs including thiazides_first corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action Starlix_second oral antidiabetic drugs.
465,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,antidiabetic drugs,effect,Certain drugs including thiazides_first corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs_second .
466,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,Starlix,effect,Certain drugs including thiazides corticosteroids_first thyroid products sympathomimetics may reduce hypoglycemic action Starlix_second oral antidiabetic drugs.
467,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids_first thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs_second .
468,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,Starlix,effect,Certain drugs including thiazides corticosteroids thyroid products_first sympathomimetics may reduce hypoglycemic action Starlix_second oral antidiabetic drugs.
469,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids thyroid products_first sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs_second .
470,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,Starlix,effect,Certain drugs including thiazides corticosteroids thyroid products sympathomimetics_first may reduce hypoglycemic action Starlix_second oral antidiabetic drugs.
471,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids thyroid products sympathomimetics_first may reduce hypoglycemic action Starlix oral antidiabetic drugs_second .
472,Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.,dexamethasone,albendazole,mechanism,Dexamethasone: Steady state trough concentrations albendazole sulfoxide 56% higher 8 mg dexamethasone_first coadministered dose albendazole_second (15 mg/kg/day) eight neurocysticercosis patients.
473,"Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",praziquantel,albendazole sulfoxide,mechanism,Praziquantel: fed state praziquantel_first (40 mg/kg) increased mean maximum plasma concentration area curve albendazole sulfoxide_second 50% healthy subjects (n=10) compared separate group subjects (n=6) given albendazole alone.
474,Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).,Albendazole sulfoxide,cimetidine,mechanism,Cimetidine: Albendazole sulfoxide_first concentrations bile cystic fluid increased (about 2 fold) hydatid cyst patients treated cimetidine_second (10 mg/kg/day) (n=7) compared albendazole (20 mg/kg/day) alone (n=12).
475,"Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",duloxetine,fluvoxamine,mechanism,Inhibitors CYP1A2: Concomitant use duloxetine_first fluvoxamine_second inhibitor CYP1A2 results approximately 6 fold increase AUC 2.5 fold increase Cmax duloxetine.
476,"Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",Paroxetine,duloxetine,mechanism,Paroxetine_first (20 mg QD) increased concentration duloxetine_second (40 mg QD) 60% greater degrees inhibition expected higher doses paroxetine.
477,"When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",duloxetine,desipramine,mechanism,duloxetine_first administered (at dose 60 mg BID) conjunction single 50 mg dose desipramine_second CYP2D6 substrate AUC desipramine increased 3 fold.
478,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,antidepressants,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants_second (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
479,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,tricyclic antidepressants,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants_second [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
480,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,TCAs,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs_second ] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
481,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,nortriptyline,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline_second amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
482,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,amitriptyline,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline_second imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
483,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,imipramine,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine_second ) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
484,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,phenothiazines,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines_second Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
485,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,Type 1C antiarrhythmics,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics_second (e.g. propafenone flecainide) approached caution.
486,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,propafenone,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone_second flecainide) approached caution.
487,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,flecainide,advise,Therefore co administration Duloxetine_first drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide_second ) approached caution.
488,Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.,TCA,Duloxetine,advise,Plasma TCA concentrations may need monitored dose TCA may need reduced TCA_first co administered Duloxetine_second .
489,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.",Duloxetine,thioridazine,advise,risk serious ventricular arrhythmias sudden death potentially associated elevated plasma levels thioridazine Duloxetine_first thioridazine_second co administered.
490,Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.,naproxen sodium,Neurontin,mechanism,Naproxen: Coadministration (N=18) naproxen sodium_first capsules (250 mg) Neurontin_second (125 mg) appears increase amount gabapentin absorbed 12% 15%.
491,Hydrocodone increases gabapentin AUC values by 14%.,Hydrocodone,gabapentin,mechanism,Hydrocodone_first increases gabapentin_second AUC values 14%.
492,"Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.",morphine,Neurontin,mechanism,Morphine: literature article reported 60 mg controlled release morphine_first capsule administered 2 hours prior 600 mg Neurontin_second capsule (N=12) mean gabapentin AUC increased 44% compared gabapentin administered without morphine.
493,Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.,cimetidine,gabapentin,mechanism,Cimetidine: presence cimetidine_first 300 mg QID (N=12) mean apparent oral clearance gabapentin_second fell 14% creatinine clearance fell 10%.
494,"Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.",cimetidine,gabapentin,mechanism,Thus cimetidine_first appeared alter renal excretion gabapentin_second creatinine endogenous marker renal function.
495,This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.,gabapentin,cimetidine,mechanism,small decrease excretion gabapentin_first cimetidine_second expected clinical importance.
496,The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;,norethindrone,gabapentin,mechanism,Cmax norethindrone_first 13% higher coadministered gabapentin_second ;
497,Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.,Maalox,gabapentin,mechanism,Antacid (Maalox ): Maalox_first reduced bioavailability gabapentin_second (N=16) 20%.
498,This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.,gabapentin,Maalox,mechanism,decrease bioavailability 5% gabapentin_first administered 2 hours Maalox_second .
499,It is recommended that gabapentin be taken at least 2 hours following Maalox administration.,gabapentin,Maalox,advise,recommended gabapentin_first taken least 2 hours following Maalox_second administration.
500,"Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",Zalcitabine,ZDV,effect,Zalcitabine_first also significant effect intracellular phosphorylation ZDV_second shown vitro peripheral blood mononuclear cells two cell lines (U937 Molt 4).
501,"Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.",lamivudine,zalcitabine,effect,Lamivudine: vitro studies peripheral blood mononuclear cells U937 Molt 4 cells revealed lamivudine_first significantly inhibited zalcitabine_second phosphorylation dose dependent manner.
502,Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);,Zalcitabine,lamivudine,effect,Zalcitabine_first inhibited lamivudine_second phosphorylation high concentration ratios (10 100);
503,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",zalcitabine,lamivudine,effect,vitro studies suggest concomitant administration zalcitabine_first lamivudine_second humans may result sub therapeutic concentrations active phosphorylated zalcitabine may lead decreased antiretroviral effect zalcitabine.
504,Concomitant use of zalcitabine and lamivudine is not recommended.,zalcitabine,lamivudine,advise,Concomitant use zalcitabine_first lamivudine_second recommended.
505,Concomitant use of HIVID with didanosine is not recommended.,HIVID,didanosine,advise,Concomitant use HIVID_first didanosine_second recommended.
506,Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.,pentamidine,HIVID,effect,Death due fulminant pancreatitis possibly related intravenous pentamidine_first HIVID_second reported.
507,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.",pentamidine,HIVID,advise,intravenous pentamidine_first required treat Pneumocystis carinii pneumonia treatment HIVID_second interrupted.
508,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin_first foscarnet aminoglycosides may increase risk developing peripheral neuropathy HIVID_second associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
509,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin_first foscarnet aminoglycosides may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance zalcitabine_second (thereby raising systemic exposure).
510,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet_first aminoglycosides may increase risk developing peripheral neuropathy HIVID_second associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
511,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet_first aminoglycosides may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance zalcitabine_second (thereby raising systemic exposure).
512,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet aminoglycosides_first may increase risk developing peripheral neuropathy HIVID_second associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
513,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet aminoglycosides_first may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance zalcitabine_second (thereby raising systemic exposure).
514,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",probenecid,zalcitabine,mechanism,Probenecid Cimetidine: Concomitant administration probenecid_first cimetidine decreases elimination zalcitabine_second likely inhibition renal tubular secretion zalcitabine.
515,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",cimetidine,zalcitabine,mechanism,Probenecid Cimetidine: Concomitant administration probenecid cimetidine_first decreases elimination zalcitabine_second likely inhibition renal tubular secretion zalcitabine.
516,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,magnesium,advise,clinical significance reduction known hence zalcitabine_first recommended ingested simultaneously magnesium_second /aluminum containing antacids.
517,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,aluminum,advise,clinical significance reduction known hence zalcitabine_first recommended ingested simultaneously magnesium/aluminum_second containing antacids.
518,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,antacids,advise,clinical significance reduction known hence zalcitabine_first recommended ingested simultaneously magnesium/aluminum containing antacids_second .
519,Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.,zalcitabine,metoclopramide,mechanism,Metoclopramide: Bioavailability mildly reduced (approximately 10%) zalcitabine_first metoclopramide_second coadministered.
520,Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.,Doxorubicin,zalcitabine,effect,Doxorubicin: Doxorubicin_first caused decrease zalcitabine_second phosphorylation ( 50% inhibition total phosphate formation) U937/Molt 4 cells.
521,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",Gastrointestinal acidifying agents,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents_first (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption amphetamines_second .
522,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",guanethidine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine_first reserpine glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption amphetamines_second .
523,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",reserpine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine_first glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption amphetamines_second .
524,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",glutamic acid HCl,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl_first ascorbic acid fruit juices etc.) lower absorption amphetamines_second .
525,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",ascorbic acid,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl ascorbic acid_first fruit juices etc.) lower absorption amphetamines_second .
526,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",Urinary acidifying agents,amphetamine,mechanism,Urinary acidifying agents_first (ammonium chloride sodium acid phosphate etc.) increase concentration ionized species amphetamine_second molecule thereby increasing urinary excretion.
527,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride_first sodium acid phosphate etc.) increase concentration ionized species amphetamine_second molecule thereby increasing urinary excretion.
528,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride sodium acid phosphate_first etc.) increase concentration ionized species amphetamine_second molecule thereby increasing urinary excretion.
529,Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers: Adrenergic blockers_first inhibited amphetamines_second .
530,"Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.",sodium bicarbonate,amphetamines,mechanism,Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate_first etc.) increase absorption amphetamines_second .
531,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",acetazolamide,amphetamine,mechanism,Urinary alkalinizing agents (acetazolamide_first thiazides) increase concentration non ionized species amphetamine_second molecule thereby decreasing urinary excretion.
532,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,mechanism,Urinary alkalinizing agents (acetazolamide thiazides_first ) increase concentration non ionized species amphetamine_second molecule thereby decreasing urinary excretion.
533,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,tricyclic,effect,Antidepressants tricyclic: Amphetamines_first may enhance activity tricyclic_second sympathomimetic agents;
534,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic: Amphetamines_first may enhance activity tricyclic sympathomimetic agents_second ;
535,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,d-amphetamine_first desipramine_second protriptyline possibly tricyclics cause striking sustained increases concentration amphetamine brain;
536,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,d-amphetamine_first desipramine protriptyline_second possibly tricyclics cause striking sustained increases concentration amphetamine brain;
537,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,d-amphetamine_first desipramine protriptyline possibly tricyclics_second cause striking sustained increases concentration amphetamine brain;
538,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors: MAOI antidepressants_first well metabolite furazolidone slow amphetamine_second metabolism.
539,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors: MAOI antidepressants well metabolite furazolidone_first slow amphetamine_second metabolism.
540,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: Amphetamines_first may counteract sedative effect antihistamines_second .
541,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: Amphetamines_first may antagonize hypotensive effects antihypertensives_second .
542,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: Chlorpromazine_first blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects amphetamines_second used treat amphetamine poisoning.
543,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: Amphetamines_first may delay intestinal absorption ethosuximide_second .
544,"Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: Haloperidol_first blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects amphetamines_second .
545,Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: stimulatory effects amphetamines_first may inhibited lithium carbonate_second .
546,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: Amphetamines_first potentiate analgesic effect meperidine_second .
547,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.",amphetamines,acidifying agents,mechanism,Methenamine therapy: Urinary excretion amphetamines_first increased efficacy reduced acidifying agents_second used methenamine therapy.
548,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: Amphetamines_first enhance adrenergic effect norepinephrine_second .
549,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: Amphetamines_first may delay intestinal absorption phenobarbital_second ;
550,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: Amphetamines_first may delay intestinal absorption phenytoin_second ;
551,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: cases propoxyphene_first overdosage amphetamine_second CNS stimulation potentiated fatal convulsions occur.
552,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: Amphetamines_first inhibit hypotensive effect veratrum alkaloids_second .
553,Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.,Amphetamines,corticosteroid,,Drug/Laboratory Test Interactions: Amphetamines_first cause significant elevation plasma corticosteroid_second levels.
554,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.,erythromycin,loratadine,mechanism,Plasma concentrations (AUC 0 24 hrs) erythromycin_first decreased 15% coadministration loratadine_second relative observed erythromycin alone.
555,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.",AED,oxcarbazepine,mechanism,addition several AED_first cytochrome P450 inducers decrease plasma concentrations oxcarbazepine_second MHD.
556,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.",phenytoin,Trileptal,mechanism,1 nc denotes mean change less 10% 2 Pediatrics 3 Mean increase adults high Trileptal doses vivo plasma levels phenytoin_first increased 40% Trileptal_second given doses 1200 mg/day.
557,"Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.",Trileptal,phenytoin,advise,Therefore using doses Trileptal_first greater 1200 mg/day adjunctive therapy decrease dose phenytoin_second may required.
558,"The increase of phenobarbital level, however, is small (15%) when given with Trileptal.",phenobarbital,Trileptal,mechanism,increase phenobarbital_first level however small (15%) given Trileptal_second .
559,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).",Trileptal,contraceptive,mechanism,Hormonal contraceptives Co administration Trileptal_first oral contraceptive_second shown influence plasma concentrations two hormonal components ethinylestradiol (EE) levonorgestrel (LNG).
560,"Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.",Trileptal,hormonal contraceptives,effect,Therefore concurrent use Trileptal_first hormonal contraceptives_second may render contraceptives less effective.
561,"Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].",Trileptal,felodipine,mechanism,Calcium Antagonists: repeated co administration Trileptal_first AUC felodipine_second lowered 28% [90% CI: 20 33].
562,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.,thiazide diuretics,dihydrotachysterol,effect,Administration thiazide diuretics_first hypoparathyroid patients concurrently treated dihydrotachysterol_second may cause hypercalcemia.
563,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,alcohol,effect,Lofexidine_first may enhance CNS depressive effects alcohol_second barbiturates sedatives
564,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,barbiturates,effect,Lofexidine_first may enhance CNS depressive effects alcohol barbiturates_second sedatives
565,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,sedatives,effect,Lofexidine_first may enhance CNS depressive effects alcohol barbiturates sedatives_second
566,- Lofexidine may enhance the effects of anti-hypertensive drug therapy,Lofexidine,anti-hypertensive drug,effect,Lofexidine_first may enhance effects anti-hypertensive drug_second therapy
567,- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.,tricyclic antidepressants,lofexidine,effect,Concomitant use tricyclic antidepressants_first may reduce efficacy lofexidine_second .
568,"Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.",cefditoren pivoxil,antacids,advise,Although clinical significance known recommended cefditoren pivoxil_first taken concomitantly antacids_second .
569,"H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",famotidine,cefditoren pivoxil,mechanism,H2 Receptor Antagonists: Co administration single dose intravenously administered famotidine_first (20 mg) reduced oral absorption single 400 mg dose cefditoren pivoxil_second administered following meal evidenced 27% decrease mean Cmax 22% decrease mean AUC.
570,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",b-lactam antibiotics,cefditoren pivoxil,mechanism,Probenecid: b-lactam antibiotics_first co administration probenecid cefditoren pivoxil_second resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half life.
571,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",probenecid,cefditoren pivoxil,mechanism,Probenecid: b lactam antibiotics co administration probenecid_first cefditoren pivoxil_second resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half life.
572,"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
",glycine,glutamate,effect,Interaction glycine_first glutamate_second development spontaneous motility chick embryos.
573,The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ,glycine,glutamate,effect,successive application glycine_first (5 10 mg/kg egg weight (e.w.) glutamate_second (15 mg/kg e.w.) 10 min interval significantly increased activation spontaneous motility 17 day old chick embryos comparison effect glutamate alone.
574,Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.,Ocupress,beta-adrenergic blocking agent,advise,Ocupress_first used caution patients receiving beta-adrenergic blocking agent_second orally potential additive effects systemic beta blockade.
575,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended beta-blocker_first administered patients receiving catecholamine depleting drugs reserpine_second possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension.
576,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",calcium channel blockers,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers_first dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
577,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",dapsone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone_first disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
578,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",disopyramide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide_first quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
579,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine_first amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
580,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",amiodarone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone_first quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
581,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinidine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine_first warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
582,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",warfarin,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin_first tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
583,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",tacrolimus,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus_first cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
584,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",cyclosporine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine_first ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
585,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",ergot derivatives,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives_first pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
586,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",pimozide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide_first carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
587,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",carbamazepine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine_first fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
588,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",fentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl_first alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
589,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alfentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl_first alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
590,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alprazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam_first triazolam) may elevated plasma concentrations coadministered saquinavir_second ;
591,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",triazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam_first ) may elevated plasma concentrations coadministered saquinavir_second ;
592,"Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,advise,Since INVIRASE_first coadministered ritonavir_second ritonavir label reviewed additional drugs coadministered.
593,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenobarbital,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital_first phenytoin dexamethasone carbamazepine) may result decreased plasma levels saquinavir_second .
594,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenytoin,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin_first dexamethasone carbamazepine) may result decreased plasma levels saquinavir_second .
595,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",dexamethasone,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin dexamethasone_first carbamazepine) may result decreased plasma levels saquinavir_second .
596,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",carbamazepine,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin dexamethasone carbamazepine_first ) may result decreased plasma levels saquinavir_second .
597,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,antibiotics,effect,vitro mixing aminoglycoside_first beta lactamtype antibiotics_second (penicillins cephalosporins) may result significant mutual inactivation.
598,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,penicillins,effect,vitro mixing aminoglycoside_first beta lactamtype antibiotics (penicillins_second cephalosporins) may result significant mutual inactivation.
599,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,cephalosporins,effect,vitro mixing aminoglycoside_first beta lactamtype antibiotics (penicillins cephalosporins_second ) may result significant mutual inactivation.
600,"Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.",aminoglycoside,penicillin,mechanism,Even aminoglycoside_first penicillin_second type drug administered separately different routes reduction aminoglycoside serum half life serum levels reported patients impaired renal function patients normal renal function.
601,Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.,acitretin,ethanol,mechanism,Ethanol:Clinical evidence shown etretinate formed concurrent ingestion acitretin_first ethanol_second .
602,"Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",acitretin,glibenclamide,effect,Glibenclamide: study 7 healthy male volunteers acitretin_first treatment potentiated blood glucose lowering effect glibenclamide_second (a sulfonylurea similar chlorpropamide) 3 7 subjects.
603,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.",acitretin,progestin,effect,However established acitretin_first interferes contraceptive effect microdosed progestin_second minipill preparations.
604,Microdosed minipill progestin preparations are not recommended for use with Soriatane.,progestin,Soriatane,advise,Microdosed minipill progestin_first preparations recommended use Soriatane_second .
605,Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.,methotrexate,etretinate,effect,Methotrexate: increased risk hepatitis reported result combined use methotrexate_first etretinate_second .
606,"Consequently, the combination of methotrexate with acitretin is also contraindicated.",methotrexate,acitretin,advise,Consequently combination methotrexate_first acitretin_second also contraindicated.
607,"Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",acitretin,phenytoin,mechanism,Phenytoin: acitretin_first given concurrently phenytoin_second protein binding phenytoin may reduced.
608,"Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.",acitretin,tetracyclines,effect,Tetracyclines: Since acitretin_first tetracyclines_second cause increased intracranial pressure combined use contraindicated.
609,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,vitamin A,acitretin,advise,Vitamin oral retinoids: Concomitant administration vitamin A_first and/or oral retinoids acitretin_second must avoided risk hypervitaminosis A.
610,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,retinoids,acitretin,advise,Vitamin oral retinoids: Concomitant administration vitamin and/or oral retinoids_first acitretin_second must avoided risk hypervitaminosis A.
611,Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.,Cerubidine,doxorubicin,effect,Use Cerubidine_first patient previously received doxorubicin_second increases risk cardiotoxicity.
612,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.,Cerubidine,doxorubicin,advise,Cerubidine_first used patients previously received recommended maximum cumulative doses doxorubicin_second Cerubidine.
613,Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.,Cyclophosphamide,Cerubidine,effect,Cyclophosphamide_first used concurrently Cerubidine_second may also result increased cardiotoxicity.
614,"However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",Argatroban,warfarin,effect,However concomitant use Argatroban_first warfarin_second (5 7.5 mg initial oral dose followed 2.5 6 mg/day orally 6 10 days) results prolongation prothrombin time (PT) International Normalized Ratio (INR).
615,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,antiplatelet agents,effect,Co administration: Concomitant use Argatroban_first antiplatelet agents_second thrombolytics anticoagulants may increase risk bleeding.
616,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,thrombolytics,effect,Co administration: Concomitant use Argatroban_first antiplatelet agents thrombolytics_second anticoagulants may increase risk bleeding.
617,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,anticoagulants,effect,Co administration: Concomitant use Argatroban_first antiplatelet agents thrombolytics anticoagulants_second may increase risk bleeding.
618,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest NSAIDs_first may diminish antihypertensive effect Angiotensin Converting Enzyme (ACE) inhibitors_second .
619,"In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.",VIOXX,benazepril,effect,patients mild moderate hypertension administration 25 mg daily VIOXX_first ACE inhibitor benazepril_second 10 40 mg 4 weeks associated average increase mean arterial pressure 3 mm Hg compared ACE inhibitor alone.
620,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.,VIOXX,ACE inhibitors,advise,interaction given consideration patients taking VIOXX_first concomitantly ACE inhibitors_second .
621,"Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.",aspirin,VIOXX,effect,Aspirin: Concomitant administration low dose aspirin_first VIOXX_second may result increased rate GI ulceration complications compared use VIOXX alone.
622,"Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",cimetidine,rofecoxib,mechanism,Cimetidine: Co administration high doses cimetidine_first [800 mg twice daily] increased Cmax rofecoxib_second 21% AUC0 120hr 23% t1/2 15%.
623,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide_second thiazides patients.
624,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide thiazides_second patients.
625,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: NSAIDs_first produced elevation plasma lithium_second levels reduction renal lithium clearance.
626,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",VIOXX,lithium,advise,Thus VIOXX_first lithium_second administered concurrently subjects observed carefully signs lithium toxicity.
627,"At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.",VIOXX,methotrexate,mechanism,higher recommended doses VIOXX_first 75 mg administered daily 10 days increased plasma concentrations 23% measured AUC0 24hr patients receiving methotrexate_second 7.5 15 mg/week rheumatoid arthritis.
628,"At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",methotrexate,rofecoxib,mechanism,24 hours postdose similar proportion patients treated methotrexate alone (94%) subsequently treated methotrexate_first co administered 75 mg rofecoxib_second (88%) methotrexate plasma concentrations measurable limit (5 ng/mL).
629,Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.,VIOXX,methotrexate,advise,Standard monitoring methotrexate related toxicity continued VIOXX_first methotrexate_second administered concomitantly.
630,"Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.",VIOXX,rifampin,mechanism,Rifampin: Co administration VIOXX_first rifampin_second 600 mg daily potent inducer hepatic metabolism produced approximate 50% decrease rofecoxib plasma concentrations.
631,"Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",VIOXX,theophylline,mechanism,Theophylline VIOXX_first 12.5 25 50 mg administered daily 7 days increased plasma theophylline_second concentrations (AUC(0 )) 38 60% healthy subjects administered single 300 mg dose theophylline.
632,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.,VIOXX,theophylline,advise,Adequate monitoring theophylline plasma concentrations considered therapy VIOXX_first initiated changed patients receiving theophylline_second .
633,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.",VIOXX,warfarin,advise,Warfarin: Anticoagulant activity monitored particularly first days initiating changing VIOXX_first therapy patients receiving warfarin_second similar agents since patients increased risk bleeding complications.
634,"In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.",warfarin,rofecoxib,effect,single multiple dose studies healthy subjects receiving warfarin_first rofecoxib_second prothrombin time (measured INR) increased approximately 8% 11%.
635,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.",VIOXX,warfarin,effect,post marketing experience bleeding events reported predominantly elderly association increases prothrombin time patients receiving VIOXX_first concurrently warfarin_second .
636,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,phenothiazines,advise,DOSTINEX_first administered concurrently D2 antagonists phenothiazines_second butyrophenones thioxanthines metoclopramide.
637,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,butyrophenones,advise,DOSTINEX_first administered concurrently D2 antagonists phenothiazines butyrophenones_second thioxanthines metoclopramide.
638,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,thioxanthines,advise,DOSTINEX_first administered concurrently D2 antagonists phenothiazines butyrophenones thioxanthines_second metoclopramide.
639,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,metoclopramide,advise,DOSTINEX_first administered concurrently D2 antagonists phenothiazines butyrophenones thioxanthines metoclopramide_second .
640,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",lansoprazole,theophylline,mechanism,lansoprazole_first administered concomitantly theophylline_second (CYP1A2 CYP3A) minor increase (10%) clearance theophylline seen.
641,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,advise,Nonetheless individual patients may require additional titration theophylline_first dosage lansoprazole_second started stopped ensure clinically effective blood levels.
642,"In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",proton pump inhibitors,sucralfate,mechanism,single dose crossover study examining lansoprazole 30 mg omeprazole 20 mg administered alone concomitantly sucralfate 1 gram absorption proton pump inhibitors_first delayed bioavailability reduced 17% 16% respectively administered concomitantly sucralfate_second .
643,"Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.",proton pump inhibitors,sucralfate,advise,Therefore proton pump inhibitors_first taken least 30 minutes prior sucralfate_second .
644,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ketoconazole,mechanism,therefore theoretically possible lansoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole_second ampicillin esters iron salts digoxin).
645,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ampicillin,mechanism,therefore theoretically possible lansoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole ampicillin_second esters iron salts digoxin).
646,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,iron,mechanism,therefore theoretically possible lansoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole ampicillin esters iron_second salts digoxin).
647,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,digoxin,mechanism,therefore theoretically possible lansoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole ampicillin esters iron salts digoxin_second ).
648,"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
",Fluvoxamine,tolbutamide,mechanism,Fluvoxamine_first inhibits CYP2C9 catalyzed biotransformation tolbutamide_second .
649,"RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ",fluvoxamine,tolbutamide,mechanism,RESULTS: treatment fluvoxamine_first statistically significant decrease median total clearance tolbutamide_second 845 mL/h 688 mL/h among volunteers received 75 mg/d.
650,"In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. ",(-)-NANM,morphine,effect,species (-)-NANM_first (+) NANM antagonized rate decreasing effects morphine_second FI FR responding.
651,"In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ",(-)-NANM,naloxone,effect,monkeys effects (-)-NANM_first (+) NANM PCP antagonized naloxone_second ;
652,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,(-)-NANM,effect,doses naloxone_first required antagonize effects (-)-NANM_second 100 times higher required antagonize effects morphine.
653,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,morphine,effect,doses naloxone_first required antagonize effects ( ) NANM 100 times higher required antagonize effects morphine_second .
654,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,(+)-NANM,effect,Haloperidol_first reduced eliminated increases FI responding produced intermediate doses either (+)-NANM_second PCP pigeons antagonize decreases FI FR responding produced high doses PCP either stereoisomer NANM.
655,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,PCP,effect,Haloperidol_first reduced eliminated increases FI responding produced intermediate doses either (+) NANM PCP_second pigeons antagonize decreases FI FR responding produced high doses PCP either stereoisomer NANM.
656,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,Phenurone,advise,Considerable caution exercised PEGANONE_first administered concurrently Phenurone_second (phenacemide) since paranoid symptoms reported therapy combination.
657,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,phenacemide,advise,Considerable caution exercised PEGANONE_first administered concurrently Phenurone (phenacemide_second ) since paranoid symptoms reported therapy combination.
658,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,phenytoin,int,two way interaction hydantoin antiepileptic_first phenytoin_second coumarin anticoagulants suggested.
659,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,coumarin anticoagulant,int,two way interaction hydantoin antiepileptic_first phenytoin coumarin anticoagulant_second suggested.
660,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin,mechanism,Presumably phenytoin_first acts stimulator coumarin_second metabolism reported cause decreased serum levels coumarin anticoagulants increased prothrombin proconvertin concentrations.
661,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin anticoagulants,mechanism,Presumably phenytoin_first acts stimulator coumarin metabolism reported cause decreased serum levels coumarin anticoagulants_second increased prothrombin proconvertin concentrations.
662,"Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.",coumarin anticoagulants,phenytoin,mechanism,Conversely coumarin anticoagulants_first reported increase serum levels prolong serum half life phenytoin_second inhibiting metabolism.
663,Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.,PEGANONE,coumarin anticoagulants,advise,Caution therefore advised administering PEGANONE_first patients receiving coumarin anticoagulants_second .
664,Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.,warfarin-type anticoagulant,griseofulvin,advise,Patients warfarin-type anticoagulant_first therapy may require dosage adjustment anticoagulant griseofulvin_second therapy.
665,Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.,barbiturates,griseofulvin,effect,Concomitant use barbiturates_first usually depresses griseofulvin_second activity may necessitate raising dosage.
666,The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.,griseofulvin,contraceptives,effect,concomitant administration griseofulvin_first reported reduce efficacy oral contraceptives_second increase incidence breakthrough bleeding.
667,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acetaminophen,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen_second acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
668,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acyclovir,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir_second angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
669,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,angiotensin-converting enzyme inhibitors,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin-converting enzyme inhibitors_second aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
670,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,aminosalicylic acid,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid_second barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
671,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,barbiturates,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates_second benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
672,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,benzodiazepines,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines_second bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
673,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,bumetanide,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide_second clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
674,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,clofibrate,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate_second methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
675,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,methotrexate,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate_second famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
676,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,famotidine,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine_second furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
677,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,furosemide,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide_second nonsteroidal anti inflammatory agents theophylline zidovudine).
678,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,nonsteroidal anti-inflammatory,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory_second agents theophylline zidovudine).
679,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,theophylline,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline_second zidovudine).
680,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,zidovudine,mechanism,Probenecid : Probenecid_first known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine_second ).
681,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.,Zidovudine,probenecid,advise,Zidovudine_first either temporarily discontinued decreased 50% coadministered probenecid_second day VISTIDE infusion.
682,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,aminoglycosides,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides_second (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
683,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,tobramycin,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin_second gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
684,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,gentamicin,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin_second amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
685,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amikacin,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin_second ) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
686,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amphotericin B,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B_second foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
687,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,foscarnet,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet_second intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
688,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,pentamidine,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine_second vancomycin non steroidal anti inflammatory agents] contraindicated.
689,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,vancomycin,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin_second non steroidal anti inflammatory agents] contraindicated.
690,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,non-steroidal anti-inflammatory agents,advise,Nephrotoxic agents : Concomitant administration VISTIDE_first agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents_second ] contraindicated.
691,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.",UROXATRAL,alpha-blockers,advise,However interactions may expected UROXATRAL_first used combination alpha-blockers_second .
692,Dimenhydrinate may decrease emetic response to apomorphine.,Dimenhydrinate,apomorphine,effect,Dimenhydrinate_first may decrease emetic response apomorphine_second .
693,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: Cholestyramine_first reported reduce intestinal absorption fat soluble vitamins_second ;
694,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin_first phenobarbital affect plasma concentrations vitamin may reduce endogenous plasma levels calcitriol_second /ergocalcitriol accelerating metabolism.
695,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin phenobarbital_first affect plasma concentrations vitamin may reduce endogenous plasma levels calcitriol_second /ergocalcitriol accelerating metabolism.
696,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration thiazides_first vitamin D_second causes hypercalcemia.
697,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D_first dosage must determined care patients undergoing treatment digitalis_second hypercalcemia patients may precipitate cardiac arrhythmias.
698,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: Ketoconazole_first may inhibit synthetic catabolic enzymes vitamin D_second .
699,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: relationship functional antagonism exists vitamin analogues_first promote calcium absorption corticosteroids_second inhibit calcium absorption.
700,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: Magnesium_first containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
701,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium containing preparations (eg antacids_first ) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
702,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,ERGAMISOL,alcohol,effect,ERGAMISOL_first (levamisole hydrochloride) reported produce ANTABUSE like side effects given concomitantly alcohol_second .
703,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,levamisole hydrochloride,alcohol,effect,ERGAMISOL (levamisole hydrochloride_first ) reported produce ANTABUSE like side effects given concomitantly alcohol_second .
704,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",levamisole,warfarin sodium,advise,reports prolongation prothrombin time beyond therapeutic range patients taking concurrent levamisole_first warfarin sodium_second suggested prothrombin time monitored carefully dose warfarin sodium coumarin like drugs adjusted accordingly patients taking drugs.
705,"The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ",GL,antibiotics,effect,antimicrobial combinations GL_first four antibiotics_second resulted additive effect instances synergism two instances antagonism two instances.
706,Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.,GL,cefazolin,effect,Synergism observed GL_first combined cefazolin_second Bacillus subtilis Klebsiella oxytoca.
707,Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.,azathioprine,allopurinol,mechanism,Use Allopurinol: principal pathway detoxification azathioprine_first inhibited allopurinol_second .
708,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",azathioprine,allopurinol,advise,Patients receiving azathioprine_first allopurinol_second concomitantly dose reduction azathioprine approximately 1/3 1/4 usual dose.
709,Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.,angiotensin converting enzyme inhibitors,azathioprine,effect,Use Angiotensln Converting Enzyme Inhibitors: use angiotensin converting enzyme inhibitors_first control hypertension patients azathioprine_second reported induce severe leukopenia.
710,"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
",diltiazem,sirolimus,mechanism,Pharmacokinetic interaction single oral doses diltiazem_first sirolimus_second healthy volunteers.
711,"RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",sirolimus,diltiazem,mechanism,RESULTS: geometric mean (90% confidence interval) whole blood sirolimus_first area plasma concentration time curve increased 60% (35% 90%) 736 1178 ng x h/mL maximum concentration increased 43% (14% 81%) 67 96 ng/mL diltiazem_second coadministration whereas mean elimination half life sirolimus decreased slightly 79 67 hours.
712,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ",sirolimus,diltiazem,mechanism,Apparent oral clearance volume distribution sirolimus decreased 38% 45% respectively sirolimus_first given diltiazem_second .
713,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",diltiazem,sirolimus,mechanism,CONCLUSIONS: Single dose diltiazem_first coadministration leads higher sirolimus_second exposure presumably inhibition first pass metabolism sirolimus.
714,"Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,diltiazem,advise,pronounced intersubject variability extent sirolimus_first diltiazem_second interaction whole blood sirolimus concentrations monitored closely patients treated two drugs.
715,Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ,InsP(3),RR,effect,Administering InsP(3)_first together RR_second (100 500 microM) inhibited InsP(3) induced responses (both Ca(2+) current responses) dose dependent fashion.
716,Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. ,RR,InsP(3),effect,Pretreatment megakaryocytes extracellular RR_first (50 microM) also inhibited InsP(3)_second induced responses.
717,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",psychotropic medications,LEXAPRO,advise,Alcohol Although LEXAPRO potentiate cognitive motor effects alcohol clinical trial psychotropic medications_first use alcohol patients taking LEXAPRO_second recommended.
718,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",alcohol,LEXAPRO,advise,Alcohol Although LEXAPRO potentiate cognitive motor effects alcohol clinical trial psychotropic medications use alcohol_first patients taking LEXAPRO_second recommended.
719,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,NSAID,effect,Epidemiological studies case control cohort design demonstrated association use psychotropic drugs_first interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use NSAID_second aspirin potentiated risk bleeding.
720,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,aspirin,effect,Epidemiological studies case control cohort design demonstrated association use psychotropic drugs_first interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use NSAID aspirin_second potentiated risk bleeding.
721,"Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",citalopram,cimetidine,mechanism,Cimetidine subjects received 21 days 40 mg/day racemic citalopram_first combined administration 400 mg/day cimetidine_second 8 days resulted increase citalopram AUC Cmax 43% 39% respectively.
722,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",lithium,escitalopram,effect,lithium_first may enhance serotonergic effects escitalopram_second caution exercised LEXAPRO lithium coadministered.
723,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",LEXAPRO,lithium,advise,lithium may enhance serotonergic effects escitalopram caution exercised LEXAPRO_first lithium_second coadministered.
724,"Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",pimozide,citalopram,effect,Pimozide Celexa controlled study single dose pimozide_first 2 mg co administered racemic citalopram_second 40 mg given daily 11 days associated mean increase QTc values approximately 10 msec compared pimozide given alone.
725,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",selective serotonin reuptake inhibitor,sumatriptan,effect,Sumatriptan rare postmarketing reports describing patients weakness hyperreflexia incoordination following use selective serotonin reuptake inhibitor_first (SSRI) sumatriptan_second .
726,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",SSRI,sumatriptan,effect,Sumatriptan rare postmarketing reports describing patients weakness hyperreflexia incoordination following use selective serotonin reuptake inhibitor (SSRI_first ) sumatriptan_second .
727,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,SSRI,advise,concomitant treatment sumatriptan_first SSRI_second (e.g. fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
728,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine_second fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
729,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine fluvoxamine_second paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
730,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine fluvoxamine paroxetine_second sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
731,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine fluvoxamine paroxetine sertraline_second citalopram escitalopram) clinically warranted appropriate observation patient advised.
732,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine fluvoxamine paroxetine sertraline citalopram_second escitalopram) clinically warranted appropriate observation patient advised.
733,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,advise,concomitant treatment sumatriptan_first SSRI (e.g. fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram_second ) clinically warranted appropriate observation patient advised.
734,"Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.",carbamazepine,escitalopram,mechanism,Although trough citalopram plasma levels unaffected given enzyme inducing properties carbamazepine possibility carbamazepine_first might increase clearance escitalopram_second considered two drugs coadministered.
735,"Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",citalopram,ketoconazole,mechanism,Ketoconazole Combined administration racemic citalopram_first (40 mg) ketoconazole_second (200 mg) decreased Cmax AUC ketoconazole 21% 10% respectively significantly affect pharmacokinetics citalopram.
736,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.",escitalopram,desipramine,mechanism,However limited vivo data suggesting modest CYP2D6 inhibitory effect escitalopram i.e. coadministration escitalopram_first (20 mg/day 21 days) tricyclic antidepressant desipramine_second (single dose 50 mg) substrate CYP2D6 resulted 40% increase Cmax 100% increase AUC desipramine.
737,Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).,LEXAPRO,metoprolol,mechanism,Metoprolol Administration 20 mg/day LEXAPRO_first 21 days healthy volunteers resulted 50% increase Cmax 82% increase AUC beta adrenergic blocker metoprolol_second (given single dose 100 mg).
738,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,citalopram,advise,Concomitant Administration Racemic Citalopram Citalopram Since escitalopram_first active isomer racemic citalopram_second (Celexa) two agents coadministered.
739,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,Celexa,advise,Concomitant Administration Racemic Citalopram Citalopram Since escitalopram_first active isomer racemic citalopram (Celexa_second ) two agents coadministered.
740,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.",EXTRANEAL,insulin,advise,However appropriate monitoring blood glucose performed initiating EXTRANEAL_first diabetic patients insulin_second dosage adjusted needed.
741,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,hypotensive drugs,effect,hypotensive effect sodium nitroprusside_first augmented hypotensive drugs_second including ganglionic blocking agents negative inotropic agents inhaled anesthetics.
742,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,ganglionic blocking agents,effect,hypotensive effect sodium nitroprusside_first augmented hypotensive drugs including ganglionic blocking agents_second negative inotropic agents inhaled anesthetics.
743,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,anesthetics,effect,hypotensive effect sodium nitroprusside_first augmented hypotensive drugs including ganglionic blocking agents negative inotropic agents inhaled anesthetics_second .
744,CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.,eszopiclone,ethanol,effect,CNS Active Drugs Ethanol additive effect psychomotor performance seen coadministration eszopiclone_first ethanol_second 0.70 g/kg 4 hours ethanol administration.
745,Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.,eszopiclone,olanzapine,effect,Olanzapine: Coadministration eszopiclone_first 3 mg olanzapine_second 10 mg produced decrease DSST scores.
746,"The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.",eszopiclone,ketoconazole,mechanism,AUC eszopiclone_first increased 2.2 fold coadministration ketoconazole_second potent inhibitor CYP3A4 400 mg daily 5 days.
747,"Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.",zopiclone,rifampicin,mechanism,Drugs Induce CYP3A4 (Rifampicin) Racemic zopiclone_first exposure decreased 80% concomitant useof rifampicin_second potent inducer CYP3A4.
748,Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.,sympathomimetic agents,FORADIL,effect,Concomitant administration sympathomimetic agents_first may potentiate undesirable effects FORADIL_second .
749,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,monoamine oxidase inhibitors,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: FORADIL_first administered extreme caution patients treated monoamine oxidase inhibitors_second tricyclic antidepressants action formoterol cardiovascular system may potentiated agents.
750,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,tricyclic antidepressants,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: FORADIL_first administered extreme caution patients treated monoamine oxidase inhibitors tricyclic antidepressants_second action formoterol cardiovascular system may potentiated agents.
751,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",xanthine derivatives,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives_first steroids diuretics may potentiate possible hypokalemic effect beta2-agonists._second
752,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",steroids,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives steroids_first diuretics may potentiate possible hypokalemic effect beta2-agonists._second
753,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",diuretics,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives steroids diuretics_first may potentiate possible hypokalemic effect beta2-agonists._second
754,"During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.",TAMBOCOR,digoxin,mechanism,administration multiple oral doses TAMBOCOR_first healthy subjects stabilized maintenance dose digoxin_second 13% 19% increase plasma digoxin levels occurred six hours postdose.
755,"In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.",TAMBOCOR,propranolol,mechanism,study involving healthy subjects receiving TAMBOCOR_first propranolol_second concurrently plasma flecainide levels increased 20% propranolol levels increased 30% compared control values.
756,The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.,TAMBOCOR,propranolol,effect,effects concomitant administration TAMBOCOR_first propranolol_second PR interval less additive.
757,"Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.",beta blockers,flecainide,effect,Nevertheless possibility additive negative inotropic effects beta blockers_first flecainide_second recognized.
758,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenytoin,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin_first phenobarbital carbamazepine ) indicate 30% increase rate flecainide_second elimination.
759,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenobarbital,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin phenobarbital_first carbamazepine ) indicate 30% increase rate flecainide_second elimination.
760,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",carbamazepine,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin phenobarbital carbamazepine_first ) indicate 30% increase rate flecainide_second elimination.
761,"In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.",cimetidine,flecainide,mechanism,healthy subjects receiving cimetidine_first (1 gm daily) one week plasma flecainide_second levels increased 30% half life increased 10%.
762,"When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.",amiodarone,flecainide,mechanism,amiodarone_first added flecainide_second therapy plasma flecainide levels may increase two fold patients flecainide dosage reduced.
763,"Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;",quinidine,flecainide,mechanism,Drugs inhibit cytochrome P450IID6 quinidine_first might increase plasma concentrations flecainide_second patients chronic flecainide therapy;
764,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",disopyramide,TAMBOCOR,advise,drugs negative inotropic properties effects coadministration TAMBOCOR unknown neither disopyramide_first verapamil administered concurrently TAMBOCOR_second unless judgment physician benefits combination outweigh risks.
765,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",verapamil,TAMBOCOR,advise,drugs negative inotropic properties effects coadministration TAMBOCOR unknown neither disopyramide verapamil_first administered concurrently TAMBOCOR_second unless judgment physician benefits combination outweigh risks.
766,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",D.H.E. 45,peripheral vasoconstrictors,effect,Vasoconstrictors: D.H.E. 45_first (dihydroergotamine mesylate) Injection USP used peripheral vasoconstrictors_second combination may cause synergistic elevation blood pressure.
767,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",dihydroergotamine mesylate,peripheral vasoconstrictors,effect,Vasoconstrictors: D.H.E. 45 (dihydroergotamine mesylate_first ) Injection USP used peripheral vasoconstrictors_second combination may cause synergistic elevation blood pressure.
768,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,D.H.E. 45,effect,Sumatriptan: Sumatriptan_first reported cause coronary artery vasospasm effect could additive D.H.E. 45_second (dihydroergotamine mesylate) Injection USP.
769,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,effect,Sumatriptan: Sumatriptan_first reported cause coronary artery vasospasm effect could additive D.H.E. 45 (dihydroergotamine mesylate_second ) Injection USP.
770,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,advise,Sumatriptan_first D.H.E. 45_second (dihydroergotamine mesylate) Injection USP taken within 24 hours other..
771,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,advise,Sumatriptan_first D.H.E. 45 (dihydroergotamine mesylate_second ) Injection USP taken within 24 hours other..
772,"Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",propranolol,ergotamine,effect,Beta Blockers: Although results clinical study indicate safe problem associated administration D.H.E. 45 (dihydroergotamine mesylate) Injection USP subjects already receiving propranolol reports propranolol_first may potentiate vasoconstrictive action ergotamine_second blocking vasodilating property epinephrine.
773,"Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.",Nicotine,ergot,effect,Nicotine: Nicotine_first may provoke vasoconstriction patients predisposing greater ischemic response ergot_second therapy.
774,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",ergot alkaloid class,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents ergot alkaloid class_first D.H.E. 45 (dihydroergotamine mesylate) Injection USP member shown interact antibiotics macrolide class_second resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
775,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",D.H.E. 45,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents ergot alkaloid class D.H.E. 45_first (dihydroergotamine mesylate) Injection USP member shown interact antibiotics macrolide class_second resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
776,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",dihydroergotamine mesylate,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents ergot alkaloid class D.H.E. 45 (dihydroergotamine mesylate_first ) Injection USP member shown interact antibiotics macrolide class_second resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
777,Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.,ergotamine,antibiotics,effect,Vasospastic reactions reported therapeutic doses ergotamine_first containing drugs co administered antibiotics_second .
778,"SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.",5-HT1 agonists,SSRIs,effect,SSRIs: Weakness hyperreflexia incoordination reported rarely 5-HT1 agonists_first co administered SSRIs_second (e. g.
779,"In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ",ouabain,PTX,effect,presence ouabain_first (10( 5) M) PTX_second (10( 8) M) failed cause first contraction;
780,"When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ",ouabain,phentolamine,effect,ouabain_first applied muscle presence phentolamine_second first second contractile responses PTX abolished.
781,Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. ,ouabain,PTX,effect,Exposure muscle ouabain_first (10( 5) M) markedly increased PTX_second induced release.
782,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).",Kineret,etanercept,effect,study patients active RA treated 24 weeks concurrent Kineret_first etanercept_second therapy 7% rate serious infections observed higher observed etanercept alone (0%).
783,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).,Kineret,etanercept,effect,Two percent patients treated concurrently Kineret_first etanercept_second developed neutropenia (ANC 1 x 109/L).
784,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antiarrhythmics,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics_second : amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
785,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,amiodarone,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone_second quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
786,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,quinidine,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine_second Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
787,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antihistamines,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines_second : astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
788,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,astemizole,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole_second terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
789,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,terfenadine,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine_second Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
790,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,ergot derivatives,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives_second Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
791,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antimycobacterial agents,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents_second : rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
792,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,rifampin,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin_second Benzodiazepines midazolam triazolam GI motility agents: cisapride
793,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Benzodiazepines,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines_second midazolam triazolam GI motility agents: cisapride
794,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,midazolam,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam_second triazolam GI motility agents: cisapride
795,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,triazolam,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam_second GI motility agents: cisapride
796,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,cisapride,advise,Drugs Coadministered VIRACEPT_first Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride_second
797,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,Antimycobacterial agents,advise,Drugs Require Dose Reduction Coadminstered VIRACEPT_first Antimycobacterial agents_second : rifabutin
798,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,rifabutin,advise,Drugs Require Dose Reduction Coadminstered VIRACEPT_first Antimycobacterial agents: rifabutin_second
799,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.",VIRACEPT,terfenadine,advise,therefore VIRACEPT_first administered concurrently terfenadine_second potential serious and/or life threatening cardiac arrhythmias.
800,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.",VIRACEPT,astemizole,advise,similar interaction likely VIRACEPT_first also administered concurrently astemizole_second .
801,Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.,indinavir,VIRACEPT,mechanism,Indinavir: Coadministration indinavir_first VIRACEPT_second resulted 83% increase nelfinavir plasma AUC 51% increase indinavir plasma A.C.
802,Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.,ritonavir,VIRACEPT,mechanism,Ritonavir: Coadministration ritonavir_first VIRACEPT_second resulted 152% increase nelfinavir plasma AUC little change ritonavir plasma A.C.
803,Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.,saquinavir,VIRACEPT,mechanism,Saquinavir: Coadministration saquinavir_first (using experimental soft gelatin capsule formulation saquinavir 1200mg) VIRACEPT_second resulted 18% increase nelfinavir plasma AUC 4 fold increase saquinavir plasma A.C.
804,Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.,ketoconazole,VIRACEPT,mechanism,Ketoconazole: Coadministration ketoconazole_first VIRACEPT_second resulted 35% increase nelfinavir plasma A.C.
805,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.",nelfinavir,didanosine,advise,therefore nelfinavir_first administered (with food) one hour two hours didanosine_second .
806,A dose adjustment is not needed when zidovudine is administered with VIRACEPT.,zidovudine,VIRACEPT,advise,dose adjustment needed zidovudine_first administered VIRACEPT_second .
807,Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.,rifabutin,VIRACEPT,mechanism,Rifabutin: Coadministration rifabutin_first VIRACEPT_second resulted 32% decrease nelfinavir plasma AUC 207% increase rifabutin plasma A.C.
808,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.,rifabutin,VIRACEPT,advise,recommended dose rifabutin_first reduced one half usual dose administered VIRACEPT_second .
809,Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.,rifampin,VIRACEPT,mechanism,Rifampin: Coadministration rifampin_first VIRACEPT_second resulted 82% decrease nelfinavir plasma A.C.
810,VIRACEPT and rifampin should not be coadministered.,VIRACEPT,rifampin,advise,VIRACEPT_first rifampin_second coadministered.
811,Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.,VIRACEPT,OVCON-35,mechanism,Ethinyl Estradiol Norethindrone: Coadministration VIRACEPT_first OVCON-35_second resulted 47% decrease ethinyl estradiol 18% decrease norethindrone plasma concentrations.
812,Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.,rauwolfia alkaloid,MAO inhibitors,effect,Taking rauwolfia alkaloid_first taking within 2 weeks taking MAO inhibitors_second may increase risk central nervous system depression may cause severe high blood pressure reaction.
813,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.,ELSPAR,methotrexate,effect,Tissue culture animal studies indicate ELSPAR_first diminish abolish effect methotrexate_second malignant cells.14 effect methotrexate activity persists long plasma asparagine levels suppressed.
814,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.",methotrexate,ELSPAR,advise,results would seem dictate clinical use methotrexate_first ELSPAR_second period following ELSPAR therapy plasma asparagine levels normal.
815,"Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",MONUROL,metoclopramide,mechanism,Metoclopramide: coadministered MONUROL_first metoclopramide_second drug increases gastrointestinal motility lowers serum concentration urinary excretion fosfomycin.
816,"Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.",Vitamin D3,arsenate,mechanism,Vitamin D3_first administration rachitic chicks effective significantly elevating duodenal arsenate_second absorption acting primarily enhance serosal transport.
817,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,acetaminophen,int,Etonogestrel_first may interact following medications: acetaminophen_second (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
818,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tylenol,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol_second ) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
819,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antibiotics,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics_second ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
820,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,ampicillin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin_second tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
821,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,tetracycline,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline_second anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
822,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,anticonvulsants,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants_second (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
823,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Dilantin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin_second Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
824,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Phenobarbital,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital_second Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
825,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tegretol,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol_second Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
826,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Trileptal,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal_second Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
827,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Topamax,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax_second Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
828,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Felbatol,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol_second ) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
829,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antifungals,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals_second (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
830,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Gris-PEG,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG_second Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
831,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Nizoral,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral_second Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
832,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sporanox,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox_second ) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
833,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,atorvastatin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin_second (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
834,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Lipitor,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor_second ) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
835,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,clofibrate,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate_second (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
836,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Atromid-S,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S_second ) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
837,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,cyclosporine,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine_second (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
838,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Neoral,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral_second Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
839,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sandimmune,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune_second ) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
840,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,protease inhibitors,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors_second (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
841,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Agenerase,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase_second Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
842,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Crixivan,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan_second Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
843,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Fortovase,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase_second Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
844,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Invirase,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase_second Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
845,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kaletra,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra_second Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
846,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Norvir,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir_second Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
847,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Viracept,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept_second ) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
848,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,morphine,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine_second (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
849,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Astramorph,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph_second Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
850,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kadian,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian_second MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
851,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,MS Contin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin_second ) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
852,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,phenylbutazone,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone_second prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
853,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,prednisolone,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone_second (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
854,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Prelone,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone_second ) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
855,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifadin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin_second (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
856,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifampin,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin_second ) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
857,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,temazepam,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam_second theophylline (Theo Dur) vitamin C.
858,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,theophylline,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline_second (Theo Dur) vitamin C.
859,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Theo-Dur,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo-Dur_second ) vitamin C.
860,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,vitamin C,int,Etonogestrel_first may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C_second .
861,"For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.",vitamin K antagonists,nilutamide,advise,example vitamin K antagonists_first administered concomitantly nilutamide_second prothrombin time carefully monitored necessary dosage vitamin K antagonists reduced.
862,Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.,L-glutamine,human growth hormone,mechanism,Human growth hormone Concomitant use L-glutamine_first human growth hormone_second may enhance nutrient absorption severe short bowel syndrome.
863,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.,L-glutamine,indomethacin,effect,Indomethacin Concomitant use L-glutamine_first indomethacin_second may ameliorate increased intestinal permeability caused indomethacin.
864,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.,methotrexate,L-glutamine,effect,Methotrexate one report methotrexate_first may decrease possible effectiveness supplemental L-glutamine_second chemotherapy induced mucositis.
865,"In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.",methotrexate,L-glutamine,effect,another report nine patients breast cancer reported decreased symptoms methotrexate_first related toxicity given supplemental L-glutamine_second dose 0.5 gram/kilogram/day.
866,"Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.",L-glutamine,paclitaxel,effect,Paclitaxel one report L-glutamine_first dose 10 grams three times daily given 24 hours receiving paclitaxel_second appeared prevent development myalgia arthralgia adverse reactions paclitaxel.
867,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,ketoconazole,mechanism,However co administration fexofenadine hydrochloride_first either ketoconazole_second erythromycin led increased plasma concentrations fexofenadine.
868,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,erythromycin,mechanism,However co administration fexofenadine hydrochloride_first either ketoconazole erythromycin_second led increased plasma concentrations fexofenadine.
869,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,ketoconazole,fexofenadine,mechanism,studies indicate ketoconazole_first erythromycin co administration enhances fexofenadine_second gastrointestinal absorption.
870,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,erythromycin,fexofenadine,mechanism,studies indicate ketoconazole erythromycin_first co administration enhances fexofenadine_second gastrointestinal absorption.
871,"This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.",ketoconazole,fexofenadine,mechanism,observed increase bioavailability fexofenadine may due transport related effects p glycoprotein. vivo animal studies also suggest addition enhancing absorption ketoconazole_first decreases fexofenadine_second gastrointestinal secretion erythromycin may also decrease biliary excretion.
872,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,aluminum,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride_first (2 x 60 mg capsule) within 15 minutes aluminum_second magnesium containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
873,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,magnesium,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride_first (2 x 60 mg capsule) within 15 minutes aluminum magnesium_second containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
874,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,antacid,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride_first (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing antacid_second (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
875,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,Maalox,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride_first (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing antacid (Maalox_second ) decreased fexofenadine AUC 41% cmax 43%.
876,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,aluminum,advise,ALLEGRA_first taken closely time aluminum_second magnesium containing antacids.
877,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,magnesium,advise,ALLEGRA_first taken closely time aluminum magnesium_second containing antacids.
878,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",narcotic analgesic,DILAUDID,effect,Patients receiving narcotic analgesic_first general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
879,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",anesthetics,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics_first phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
880,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",phenothiazines,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines_first tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
881,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tranquilizers,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers_first sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
882,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",sedative-hypnotics,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics_first tricyclic antidepressants CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
883,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tricyclic antidepressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants_first CNS depressants (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
884,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",CNS depressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants_first (including alcohol) concomitantly DILAUDID_second may exhibit additive CNS depression.
885,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",alcohol,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol_first ) concomitantly DILAUDID_second may exhibit additive CNS depression.
886,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,aspirin,advise,taking glimepiride_first tell doctor taking following medicines: aspirin_second another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
887,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salicylate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate_second magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
888,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium/choline salicylate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate_second (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
889,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Trilisate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate_second ) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
890,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salsalate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate_second (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
891,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Disalcid,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid_second others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
892,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,choline salicylate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate_second (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
893,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Arthropan,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan_second ) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
894,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium salicylate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate_second (Magan) bismuth subsalicylate (Pepto Bismol);
895,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Magan,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan_second ) bismuth subsalicylate (Pepto Bismol);
896,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,bismuth subsalicylate,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate_second (Pepto Bismol);
897,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Pepto-Bismol,advise,taking glimepiride_first tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol_second );
898,HEMABATE may augment the activity of other oxytocic agents.,HEMABATE,oxytocic agents,effect,HEMABATE_first may augment activity oxytocic agents_second .
899,"Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.",Furosemide,aminoglycoside antibiotics,effect,Furosemide_first may increase ototoxic potential aminoglycoside antibiotics_second especially presence impaired renal function.
900,Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,advise,Furosemide_first used concomitantly ethacrynic acid_second possibility ototoxicity.
901,"Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.",salicylates,furosemide,effect,Patients receiving high doses salicylates_first concomitantly furosemide_second rheumatic disease may experience salicylate toxicity lower doses competitive renal excretory sites.
902,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,tubocurarine,effect,Furosemide_first tendency antagonize skeletal muscle relaxing effect tubocurarine_second may potentiate action succinylcholine.
903,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,succinylcholine,effect,Furosemide_first tendency antagonize skeletal muscle relaxing effect tubocurarine may potentiate action succinylcholine_second .
904,Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,Lithium_first generally given diuretics_second reduce lithiums renal clearance add high risk lithium toxicity.
905,Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.,Furosemide,antihypertensive drugs,effect,Furosemide_first may add potentiate therapeutic effect antihypertensive drugs_second .
906,Furosemide may decrease arterial responsiveness to norepinephrine.,Furosemide,norepinephrine,effect,Furosemide_first may decrease arterial responsiveness norepinephrine_second .
907,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.,sucralfate,furosemide,effect,Tablets Simultaneous administration sucralfate_first furosemide_second tablets may reduce natriuretic antihypertensive effects furosemide.
908,The intake of furosemide and sucralfate should be separated by at least two hours.,furosemide,sucralfate,advise,intake furosemide_first sucralfate_second separated least two hours.
909,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",furosemide,acetylsalicylic acid,effect,Tablets Injection Oral Solution One study six subjects demonstrated combination furosemide_first acetylsalicylic acid_second temporarily reduced creatinine clearance patients chronic renal insufficiency.
910,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.",furosemide,NSAIDs,effect,case reports patients developed increased BUN serum creatinine serum potassium levels weight gain furosemide_first used conjunction NSAIDs_second .
911,Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.,indomethacin,furosemide,effect,Literature reports indicate coadministration indomethacin_first may reduce natriuretic antihypertensive effects furosemide_second patients inhibiting prostaglandin synthesis.
912,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.,indomethacin,furosemide,advise,Patients receiving indomethacin_first furosemide_second observed closely determine desired diuretic and/or antihypertensive effect furosemide achieved.
913,Warfarin: Meclofenamate sodium enhances the effect of warfarin.,Warfarin,Meclofenamate sodium,effect,Warfarin_first : Meclofenamate sodium_second enhances effect warfarin.
914,"Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",meclofenamate sodium,warfarin,advise,Therefore meclofenamate sodium_first given patient receiving warfarin_second dosage warfarin reduced prevent excessive prolongation prothrombin time.
915,"Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.",aspirin,meclofenamate sodium,mechanism,Aspirin: Concurrent administration aspirin_first may lower meclofenamate sodium_second plasma levels possibly competing protein binding sites.
916,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration oxyphenbutazone_first androgens_second may result elevated serum levels oxyphenbutazone.
917,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,diabetic patients metabolic effects androgens_first may decrease blood glucose therefore insulin_second requirements.
918,"This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ",phenytoin,quetiapine,mechanism,study demonstrated potent cytochrome P450 enzyme inducer phenytoin_first indeed marked effect metabolism quetiapine_second resulting 5 fold increase clearance administered concomitantly patients DSM IV diagnosed schizophrenia schizoaffective disorder bipolar disorder.
919,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",Chloramphenicol,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol_first erythromycins sulfonamides tetracyclines may interfere bactericidal effect penicillins_second .
920,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",erythromycins,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins_first sulfonamides tetracyclines may interfere bactericidal effect penicillins_second .
921,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",sulfonamides,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins sulfonamides_first tetracyclines may interfere bactericidal effect penicillins_second .
922,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",tetracyclines,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins sulfonamides tetracyclines_first may interfere bactericidal effect penicillins_second .
923,Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.,Probenecid,ampicillin,mechanism,Probenecid_first : May decrease renal tubular secretion ampicillin_second resulting increased blood levels and/or ampicillin toxicity.
924,"Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.",bepridil hydrochloride,digoxin,mechanism,Digoxin: controlled studies healthy volunteers bepridil hydrochloride_first either effect (one study) associated modest increases 30% (two studies) steady state serum digoxin_second concentrations.
925,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,Anti-arrhythmics,bepridil hydrochloride,effect,Anti-arrhythmics_first tricyclic anti depressants could exaggerate prolongation QT interval observed bepridil hydrochloride_second .
926,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,tricyclic anti-depressants,bepridil hydrochloride,effect,Anti arrhythmics tricyclic anti-depressants_first could exaggerate prolongation QT interval observed bepridil hydrochloride_second .
927,Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.,Cardiac glycosides,bepridil hydrochloride,effect,Cardiac glycosides_first could exaggerate depression AV nodal conduction observed bepridil hydrochloride_second .
928,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,Tetracycline_first bacteriostatic antibiotic may antagonize bactericidal effect penicillin_second concurrent use drugs avoided.
929,The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. ,DCG-IV,PCP,effect,effects DCG-IV_first strong completely depressed PCP_second induced hyperlocomotion.
930,"Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary",hydroxyurea,uricosuric medication,effect,Since hydroxyurea_first may raise serum uric acid level dosage adjustment uricosuric medication_second may necessary
931,Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.,probenecid,penciclovir,mechanism,Concurrent use probenecid_first drugs significantly eliminated active renal tubular secretion may result increased plasma concentrations penciclovir_second .
932,Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.,aminoglycoside antibiotics,cephalosporin antibiotics,effect,Nephrotoxicity reported following concomitant administration aminoglycoside antibiotics_first cephalosporin antibiotics_second .
933,Concomitant administration of probenecid doubled the AUC for cefprozil.,probenecid,cefprozil,mechanism,Concomitant administration probenecid_first doubled AUC cefprozil_second .
934,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",Diphenoxylate HCl,MAO inhibitors,int,Diphenoxylate HCl_first atropine sulfate may interact MAO inhibitors_second studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day.
935,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",atropine sulfate,MAO inhibitors,int,Diphenoxylate HCl atropine sulfate_first may interact MAO inhibitors_second studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day.
936,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressant,effect,report case adolescent altered consciousness caused carbamazepine_first overdose positive tricyclic antidepressant_second level alert clinicians cross reactivity carbamazepine toxicology screen tricyclic antidepressants.
937,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressants,advise,report case adolescent altered consciousness caused carbamazepine overdose positive tricyclic antidepressant level alert clinicians cross reactivity carbamazepine_first toxicology screen tricyclic antidepressants_second .
938,"Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.",Exjade,aluminum,advise,Although deferasirox lower affinity aluminum iron Exjade_first taken aluminum_second containing antacid preparations.
939,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenylbutazone,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone_second warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
940,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,warfarin,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin_second thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
941,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thiazide diuretics,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics_second (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
942,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,propranolol,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol_second (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
943,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,tetracycline,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline_second penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
944,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,penicillin G,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G_second phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
945,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenobarbital,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital_second thyroid thyroxine preparations estrogens progestins digitalis.
946,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thyroxine,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine_second preparations estrogens progestins digitalis.
947,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,estrogens,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens_second progestins digitalis.
948,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,progestins,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins_second digitalis.
949,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,digitalis,mechanism,Cholestyramine_first resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis_second .
950,"Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.",cholestyramine,digitalis,mechanism,Cholestyramine resin may interfere pharmacokinetics drugs undergo enterohepatic circulation discontinuance cholestyramine_first resin could pose hazard health potentially toxic drug digitalis_second filtrated maintenance level patient taking cholestyramine resin.
951,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,Acetazolamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide_second azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
952,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,azole antifungals,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals_second cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
953,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,cimetidine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine_second clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
954,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,clarithromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin_second (1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
955,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,dalfopristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin_second danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
956,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,danazol,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol_second delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
957,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,delavirdine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine_second diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
958,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,diltiazem,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem_second erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
959,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,erythromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin_second (1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
960,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluoxetine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine_second fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
961,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluvoxamine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine_second grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
962,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,isoniazid,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid_second itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
963,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,itraconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole_second ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
964,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,ketoconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole_second loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
965,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,loratadine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine_second nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
966,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nefazodone,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone_second niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
967,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,niacinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide_second nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
968,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nicotinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide_second protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
969,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,protease inhibitors,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors_second propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
970,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,propoxyphene,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene_second quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
971,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine_second quinupristin troleandomycin valproate(1) verapamil zileuton.
972,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinupristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin_second troleandomycin valproate(1) verapamil zileuton.
973,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,troleandomycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin_second valproate(1) verapamil zileuton.
974,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,valproate,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate_second (1) verapamil zileuton.
975,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,verapamil,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil_second zileuton.
976,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,zileuton,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels EQUETROTM_first following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton_second .
977,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Cisplatin,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin_second doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
978,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,doxorubicin HCL,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL_second felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
979,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,felbamate,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate_second rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
980,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,rifampin,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin_second phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
981,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,phenobarbital,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital_second Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
982,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin_second (2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
983,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,primidone,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone_second methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
984,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,methsuximide,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide_second theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
985,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,theophylline,mechanism,Agents CYP inducers found expected decrease plasma levels EQUETROTM_first following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline_second Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
986,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Acetaminophen,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen_second alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
987,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,alprazolam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam_second amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
988,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,amitriptyline,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline_second bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
989,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,bupropion,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion_second buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
990,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,buspirone,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone_second citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
991,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,citalopram,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram_second clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
992,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clobazam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam_second clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
993,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clonazepam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam_second clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
994,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clozapine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine_second cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
995,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,cyclosporin,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin_second delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
996,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,delavirdine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine_second desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
997,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,desipramine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine_second diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
998,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,diazepam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam_second dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
999,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,dicumarol,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol_second doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1000,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,doxycycline,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline_second ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1001,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ethosuximide,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide_second felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1002,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felbamate,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate_second felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1003,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felodipine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine_second glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1004,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,glucocorticoids,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids_second haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1005,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,haloperidol,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol_second itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1006,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,itraconazole,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole_second lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1007,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lamotrigine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine_second levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1008,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,levothyroxine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine_second lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1009,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lorazepam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam_second methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1010,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,methadone,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone_second midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1011,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,midazolam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam_second mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1012,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,mirtazapine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine_second nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1013,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,nortriptyline,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline_second olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1014,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,olanzapine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine_second oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1015,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,contraceptives,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives_second (3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1016,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,oxcarbazepine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine_second Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1017,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Phenytoin,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin_second (4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1018,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,praziquantel,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel_second protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1019,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,protease inhibitors,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors_second quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1020,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,quetiapine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine_second risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1021,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,risperidone,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone_second theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1022,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,theophylline,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline_second topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1023,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,topiramate,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate_second tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1024,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tiagabine,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine_second tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1025,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tramadol,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol_second triazolam valproate warfarin(5) ziprasidone zonisamide.
1026,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,triazolam,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam_second valproate warfarin(5) ziprasidone zonisamide.
1027,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,valproate,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate_second warfarin(5) ziprasidone zonisamide.
1028,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,warfarin,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin_second (5) ziprasidone zonisamide.
1029,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ziprasidone,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone_second zonisamide.
1030,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,zonisamide,mechanism,Agents found expected decreased plasma levels presence EQUETROTM_first due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide_second .
1031,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Clomipramine HCl,mechanism,Agents Increased Levels Presence Carbamazepine: EQUETROTM_first increases plasma levels following agents: Clomipramine HCl_second Phenytoin(6) primidone Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1032,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents Increased Levels Presence Carbamazepine: EQUETROTM_first increases plasma levels following agents: Clomipramine HCl Phenytoin_second (6) primidone Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1033,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,primidone,mechanism,Agents Increased Levels Presence Carbamazepine: EQUETROTM_first increases plasma levels following agents: Clomipramine HCl Phenytoin(6) primidone_second Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1034,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.,carbamazepine,lithium,effect,Pharmacological/Pharmacodynamic Interactions Carbamazepine Concomitant administration carbamazepine_first lithium_second may increase risk neurotoxic side effects.
1035,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",anti-malarial drugs,carbamazepine,effect,Additionally anti-malarial drugs_first chloroquine mefloquine may antagonize activity carbamazepine_second .
1036,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",chloroquine,carbamazepine,effect,Additionally anti malarial drugs chloroquine_first mefloquine may antagonize activity carbamazepine_second .
1037,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",mefloquine,carbamazepine,effect,Additionally anti malarial drugs chloroquine mefloquine_first may antagonize activity carbamazepine_second .
1038,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,centrally acting drugs,advise,primary CNS effect caution used EQUETROTM_first taken centrally acting drugs_second alcohol.
1039,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,alcohol,advise,primary CNS effect caution used EQUETROTM_first taken centrally acting drugs alcohol_second .
1040,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,monoamine oxidase inhibitors,effect,patients receiving another serotonin reuptake inhibitor drug_first combination monoamine oxidase inhibitors_second (MAOI) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma.
1041,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,MAOI,effect,patients receiving another serotonin reuptake inhibitor drug_first combination monoamine oxidase inhibitors (MAOI_second ) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma.
1042,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOIs,advise,Therefore recommended Fluvoxamine_first Tablets used combination MAOIs_second within 14 days discontinuing treatment MAOI.
1043,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOI,advise,Therefore recommended Fluvoxamine_first Tablets used combination MAOIs within 14 days discontinuing treatment MAOI_second .
1044,"After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.",Fluvoxamine,MAOI,advise,stopping Fluvoxamine_first Tablets least 2 weeks allowed starting MAOI_second .
1045,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",Terfenadine,ketoconazole,mechanism,Terfenadine_first astemizole cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated ketoconazole_second potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1046,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",astemizole,ketoconazole,mechanism,Terfenadine astemizole_first cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated ketoconazole_second potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1047,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",cisapride,ketoconazole,mechanism,Terfenadine astemizole cisapride_first metabolized cytochrome P450IIIA4 isozyme demonstrated ketoconazole_second potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1048,"Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.",fluvoxamine,alprazolam,int,Although definitively demonstrated fluvoxamine potent IIIA4 inhibitor likely given substantial interaction fluvoxamine_first alprazolam_second .
1049,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,terbinafine,advise,Consequently recommended fluvoxamine_first used combination either terbinafine_second astemizole cisapride.
1050,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,astemizole,advise,Consequently recommended fluvoxamine_first used combination either terbinafine astemizole_second cisapride.
1051,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,cisapride,advise,Consequently recommended fluvoxamine_first used combination either terbinafine astemizole cisapride_second .
1052,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",Benzodiazepines,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines_first metabolized hepatic oxidation (e.g. alprazolam midazolam triazolam elc.) used caution clearance drugs likely reduced fluvoxamine_second .
1053,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",alprazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. alprazolam_first midazolam triazolam elc.) used caution clearance drugs likely reduced fluvoxamine_second .
1054,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",midazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. alprazolam midazolam_first triazolam elc.) used caution clearance drugs likely reduced fluvoxamine_second .
1055,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",triazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. alprazolam midazolam triazolam_first elc.) used caution clearance drugs likely reduced fluvoxamine_second .
1056,"Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",fluvoxamine maleate,alprazolam,mechanism,Alprazolam: fluvoxamine maleate_first (100 mg qd) alprazolam_second (1 mg q.d. co administered steady state plasma concentration pharmacokinetics parameters (AUC Cmax T1/2 ) alprazolam approximately twice observed alprazolam administered alone;
1057,"This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",alprazolam,Fluvoxamine,advise,interaction investigated using higher doses fluvoxamine may pronounced 300 mg daily dose co administered particularly since fluvoxamine exhibits non linear pharmacokinetics dosage range 100 300 mg. alprazolam_first co administered Fluvoxamine_second Tablets initial alprazolam dosage least halved titration lowest effective dose recommended.
1058,Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.,Fluvoxamine,diazepam,advise,Diazepam: co administration Fluvoxamine_first Tablets diazepam_second generally advisable.
1059,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,diazepam,mechanism,fluvoxamine_first reduces clearance diazepam_second active metabolite N desmethyldiazepam strong likelihood substantial accumulation species chronic co administration.
1060,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,N-desmethyldiazepam,mechanism,fluvoxamine_first reduces clearance diazepam active metabolite N-desmethyldiazepam_second strong likelihood substantial accumulation species chronic co administration.
1061,Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.,fluvoxamine,diazepam,advise,Evidence supporting conclusion inadvisable co administer fluvoxamine_first diazepam_second derived study healthy volunteers taking 150 mg/day fluvoxamine administered single oral dose 10 mg diazepam.
1062,"Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.",alprazolam,fluvoxamine,effect,Moreover noted alprazolam_first effect fluvoxamine_second may even pronounced administered higher doses.
1063,"Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.",diazepam,fluvoxamine,advise,Accordingly diazepam_first fluvoxamine_second ordinarily co administered.
1064,"Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",theophylline,fluvoxamine maleate,advise,Therefore theophylline_first co administered fluvoxamine maleate_second dose reduced one third usual daily maintenance dose plasma concentrations theophylline monitored.
1065,"Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.",fluvoxamine maleate,warfarin,mechanism,Warfarin: fluvoxamine maleate_first (50 mg tid) administered concomitantly warfarin_second two weeks warfarin plasma concentrations increased 98% prothrombin times prolonged.
1066,Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.,anticoagulants,Fluvoxamine,advise,Thus patients receiving oral anticoagulants_first Fluvoxamine_second Tablets prothrombin time monitored anticoagulant dose adjusted accordingly.
1067,"Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).",nitazoxanide,warfarin,mechanism,Therefore caution used administering nitazoxanide_first concurrently highly plasma protein bound drugs narrow therapeutic indices competition binding sites may occur (e.g. warfarin_second ).
1068,"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agent,effect,Catecholamine depleting drugs (eg reserpine_first ) may additive effect given beta-blocking agent_second s.
1069,Calcium channel blockers may also have an additive effect when given with TENORMIN .,Calcium channel blockers,TENORMIN,effect,Calcium channel blockers_first may also additive effect given TENORMIN_second .
1070,Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.,Beta blockers,clonidine,effect,Beta blockers_first may exacerbate rebound hypertension follow withdrawal clonidine_second .
1071,"If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.",beta blocker,clonidine,advise,two drugs coadministered beta blocker_first withdrawn several days gradual withdrawal clonidine_second .
1072,"If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.",beta blockers,clonidine,advise,replacing clonidine beta blocker therapy introduction beta blockers_first delayed several days clonidine_second administration stopped.
1073,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.",indomethacin,beta blockers,effect,Concomitant use prostaglandin synthase inhibiting drugs eg indomethacin_first may decrease hypotensive effects beta blockers_second .
1074,Amiodarone is known to raise serum digoxin levels. ,Amiodarone,digoxin,mechanism,Amiodarone_first known raise serum digoxin_second levels.
1075,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ",amiodarone,digoxin,mechanism,amiodarone_first administration systemic clearance digoxin_second reduced 234 +/ 72 ml/min (mean +/ standard deviation) 172 +/ 33 ml/min (p less 0.01).
1076,These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.,digoxin,amiodarone,mechanism,alterations digoxin_first pharmacokinetics produced amiodarone_second explain increase serum digoxin level observed drug combination used clinically.
1077,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,Physostigmine_first pretreatment augmented depressant effect alcohol_second early components P1 N1 attenuating alcohol's influence components P2 P3.
1078,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,Physostigmine_first pretreatment augmented depressant effect alcohol early components P1 N1 attenuating alcohol_second 's influence components P2 P3.
1079,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,aspirin,int,Interactions may occur EPA_first supplements aspirin_second non steroidal anti inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba).
1080,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,non-steroidal anti-inflammatory drugs,int,Interactions may occur EPA_first supplements aspirin non-steroidal anti-inflammatory drugs_second herbs garlic (Allium sativum) ginkgo (Ginkgo biloba).
1081,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,ginkgo,int,Interactions may occur EPA_first supplements aspirin non steroidal anti inflammatory drugs herbs garlic (Allium sativum) ginkgo_second (Ginkgo biloba).
1082,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,Ginkgo biloba,int,Interactions may occur EPA_first supplements aspirin non steroidal anti inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba_second ).
1083,"When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.",amphotericin B,Antineoplastic agents,effect,administered concurrently following drugs may interact amphotericin B_first : Antineoplastic agents_second : may enhance potential renal toxicity bronchospasm hypotension.
1084,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticosteroids,amphotericin B,effect,Corticosteroids_first Corticotropin (ACTH): may potentiate amphotericin B_second induced hypokalemia may predispose patient cardiac dysfunction.
1085,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticotropin,amphotericin B,effect,Corticosteroids Corticotropin_first (ACTH): may potentiate amphotericin B_second induced hypokalemia may predispose patient cardiac dysfunction.
1086,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,ACTH,amphotericin B,effect,Corticosteroids Corticotropin (ACTH_first ): may potentiate amphotericin B_second induced hypokalemia may predispose patient cardiac dysfunction.
1087,Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.,amphotericin B,digitalis,effect,Digitalis glycosides: amphotericin B_first induced hypokalemia may potentiate digitalis_second toxicity.
1088,"Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.",amphotericin B,flucytosine,effect,Flucytosine: synergistic relationship amphotericin B_first reported concomitant use may increase toxicity flucytosine_second possibly increasing cellular uptake and/or impairing renal excretion.
1089,"Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.",imidazoles,amphotericin B,effect,Imidazoles (e. g. ketoconazole miconazole clotrimazole fluconazole etc.): vitro animal studies combination amphotericin B imidazoles suggest imidazoles_first may induce fungal resistance amphotericin B_second .
1090,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,skeletal muscle relaxants,effect,Skeletal muscle relaxants: amphotericin B_first induced hypokalemia may enhance curariform effect skeletal muscle relaxants_second (e.g. tubocurarine).
1091,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,tubocurarine,effect,Skeletal muscle relaxants: amphotericin B_first induced hypokalemia may enhance curariform effect skeletal muscle relaxants (e.g. tubocurarine_second ).
1092,Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.,amphotericin B,leukocyte transfusions,effect,Leukocyte transfusions: acute pulmonary toxicity reported patients receiving intravenous amphotericin B_first leukocyte transfusions_second .
1093,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,iron,mechanism,absorption lymecycline_first may affected simultaneous administration indigestion remedies iron_second zinc supplements.
1094,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,zinc,mechanism,absorption lymecycline_first may affected simultaneous administration indigestion remedies iron zinc_second supplements.
1095,Oral contraceptives may be less effective while you are taking lymecycline.,contraceptives,lymecycline,effect,Oral contraceptives_first may less effective taking lymecycline_second .
1096,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,diuretics,effect,Additional reductions blood pressure may occur FLOLAN_first administered diuretics_second antihypertensive agents vasodilators.
1097,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,antihypertensive agents,effect,Additional reductions blood pressure may occur FLOLAN_first administered diuretics antihypertensive agents_second vasodilators.
1098,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,vasodilators,effect,Additional reductions blood pressure may occur FLOLAN_first administered diuretics antihypertensive agents vasodilators_second .
1099,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",antiplatelet agents,FLOLAN,effect,antiplatelet agents_first anticoagulants used concomitantly potential FLOLAN_second increase risk bleeding.
1100,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",anticoagulants,FLOLAN,effect,antiplatelet agents anticoagulants_first used concomitantly potential FLOLAN_second increase risk bleeding.
1101,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,mechanism,clinical trials FLOLAN used digoxin diuretics anticoagulants oral vasodilators supplemental oxygen.In pharmacokinetic substudy patients congestive heart failure receiving furosemide_first digoxin therapy FLOLAN_second initiated apparent oral clearance values furosemide (n = 23) digoxin (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87.
1102,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,FLOLAN,mechanism,clinical trials FLOLAN used digoxin diuretics anticoagulants oral vasodilators supplemental oxygen.In pharmacokinetic substudy patients congestive heart failure receiving furosemide digoxin_first therapy FLOLAN_second initiated apparent oral clearance values furosemide (n = 23) digoxin (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87.
1103,"However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.",digoxin,FLOLAN,mechanism,However patients digoxin_first may show elevations digoxin concentrations initiation therapy FLOLAN_second may clinically significant patients prone digoxin toxicity.
1104,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.,L-arginine,cyclosporin,effect,Cyclosporine L-arginine_first may counteract antinaturetic effect cyclosporin_second .
1105,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.,L-arginine,ibuprofen,mechanism,Ibuprofen L-arginine_first may increase absorption ibuprofen_second taken concomitantly.
1106,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.,L-arginine,nitrates,effect,Organic nitrates L-arginine_first supplements theoretically may potentiate effects organic nitrates_second taken concomitantly.
1107,"Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.",L-arginine,sildenafil citrate,effect,Sildenafil citrate Theoretically L-arginine_first supplements taken concomitantly sildenafil citrate_second may potentiate effects drug.
1108,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergotamine,AXERT,advise,theoretical basis effects may additive use ergotamine_first containing ergot type medications (like dihydroergotamine methysergide) AXERT_second within 24 hours avoided.
1109,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergot-type medications,AXERT,advise,theoretical basis effects may additive use ergotamine containing ergot-type medications_first (like dihydroergotamine methysergide) AXERT_second within 24 hours avoided.
1110,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",dihydroergotamine,AXERT,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine_first methysergide) AXERT_second within 24 hours avoided.
1111,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",methysergide,AXERT,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine methysergide_first ) AXERT_second within 24 hours avoided.
1112,Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.,moclobemide,almotriptan,mechanism,Monoamine Oxidase Inhibitors: Coadministration moclobemide_first resulted 27% decrease almotriptan_second clearance increase Cmax approximately 6%.
1113,Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.,5-HT1B/1D agonists,AXERT,advise,5 HT1B/1D Agonists Concomitant use 5-HT1B/1D agonists_first within 24 hours treatment AXERT_second contraindicated.
1114,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs_first (e.g. fluoxetine fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
1115,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine_first fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
1116,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine fluvoxamine_first paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
1117,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine fluvoxamine paroxetine_first sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
1118,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine fluvoxamine paroxetine sertraline_first ) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
1119,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.",AXERT,SSRI,advise,concomitant treatment AXERT_first SSRI_second clinically warranted appropriate observation patient advised.
1120,Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.,almotriptan,verapamil,mechanism,Verapamil: Coadministration almotriptan_first verapamil_second resulted 24% increase plasma concentrations almotriptan.
1121,Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.,almotriptan,ketoconazole,mechanism,Coadministration almotriptan_first potent CYP3A4 inhibitor ketoconazole_second (400 mg q.d. 3 days) resulted approximately 60% increase area plasma concentration time curve maximal plasma concentrations almotriptan.
1122,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",itraconazole,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. itraconazole_first ritonavir erythromycin) studied increased exposures almotriptan may expected almotriptan_second used concomitantly medications.
1123,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",ritonavir,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. itraconazole ritonavir_first erythromycin) studied increased exposures almotriptan may expected almotriptan_second used concomitantly medications.
1124,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",erythromycin,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. itraconazole ritonavir erythromycin_first ) studied increased exposures almotriptan may expected almotriptan_second used concomitantly medications.
1125,Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.,Lamivudine,zalcitabine,effect,Lamivudine_first zalcitabine_second may inhibit intracellular phosphorylation one another.
1126,"Therefore, use of lamivudine in combination with zalcitabine is not recommended",lamivudine,zalcitabine,advise,Therefore use lamivudine_first combination zalcitabine_second recommended
1127,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenobarbital,effect,Folic acid_first large amounts may counteract antiepileptic effect phenobarbital_second phenytoin primidone increase frequency seizures susceptible pediatric patients.
1128,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenytoin,effect,Folic acid_first large amounts may counteract antiepileptic effect phenobarbital phenytoin_second primidone increase frequency seizures susceptible pediatric patients.
1129,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,primidone,effect,Folic acid_first large amounts may counteract antiepileptic effect phenobarbital phenytoin primidone_second increase frequency seizures susceptible pediatric patients.
1130,"However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.",leucovorin,methotrexate,effect,However high doses leucovorin_first may reduce efficacy intrathecally administered methotrexate_second .
1131,Leucovorin may enhance the toxicity of 5-fluorouracil.,Leucovorin,5-fluorouracil,effect,Leucovorin_first may enhance toxicity 5-fluorouracil_second .
1132,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.",Ketoconazole,terfenadine,mechanism,following drug interactions identified involving NIZORAL Tablets drugs metabolized cytochrome P450 3A4 enzyme system: Ketoconazole_first tablets inhibit metabolism terfenadine_second resulting increased plasma concentration terfenadine delay elimination acid metabolite.
1133,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.",ketoconazole,astemizole,effect,Pharmacokinetic data indicate oral ketoconazole_first inhibits metabolism astemizole_second resulting elevated plasma levels astemizole active metabolite desmethylastemizole may prolong QT intervals.
1134,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.,astemizole,ketoconazole,advise,Coadministration astemizole_first ketoconazole_second tablets therefore contraindicated.
1135,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral ketoconazole_first potently inhibits metabolism cisapride_second resulting mean eight fold increase AUC cisapride.
1136,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral ketoconazole_first cisapride_second result prolongation QT interval ECG.
1137,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.,ketoconazole,cisapride,advise,Therefore concomitant administration ketoconazole_first tablets cisapride_second contraindicated.
1138,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,cyclosporine,mechanism,Ketoconazole_first tablets may alter metabolism cyclosporine_second tacrolimus methylprednisolone resulting elevated plasma concentrations latter drugs.
1139,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,tacrolimus,mechanism,Ketoconazole_first tablets may alter metabolism cyclosporine tacrolimus_second methylprednisolone resulting elevated plasma concentrations latter drugs.
1140,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,methylprednisolone,mechanism,Ketoconazole_first tablets may alter metabolism cyclosporine tacrolimus methylprednisolone_second resulting elevated plasma concentrations latter drugs.
1141,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,midazolam,mechanism,Coadministration NIZORAL_first Tablets midazolam_second triazolam resulted elevated plasma concentrations latter two drugs.
1142,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,triazolam,mechanism,Coadministration NIZORAL_first Tablets midazolam triazolam_second resulted elevated plasma concentrations latter two drugs.
1143,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.",digoxin,ketoconazole,advise,therefore advisable monitor digoxin_first concentrations patients receiving ketoconazole_second .
1144,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",imidazole compounds,coumarin,effect,taken orally imidazole compounds_first like ketoconazole may enhance anticoagulant effect coumarin_second like drugs.
1145,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",ketoconazole,coumarin,effect,taken orally imidazole compounds like ketoconazole_first may enhance anticoagulant effect coumarin_second like drugs.
1146,"In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.",imidazole drugs,coumarin drugs,advise,simultaneous treatment imidazole drugs_first coumarin drugs_second anticoagulant effect carefully titrated monitored.
1147,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.",miconazole,hypoglycemic agents,effect,severe hypoglycemia reported patients concomitantly receiving oral miconazole_first (an imidazole) oral hypoglycemic agents_second potential interaction involving latter agents used concomitantly ketoconazole tablets (an imidazole) ruled out.
1148,Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.,ketoconazole,phenytoin,mechanism,Concomitant administration ketoconazole_first tablets phenytoin_second may alter metabolism one drugs.
1149,It is suggested to monitor both ketoconazole and phenytoin.,ketoconazole,phenytoin,advise,suggested monitor ketoconazole_first phenytoin_second .
1150,Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.,rifampin,ketoconazole,mechanism,Concomitant administration rifampin_first ketoconazole_second tablets reduces blood levels latter.
1151,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,INH,ketoconazole,mechanism,INH_first (Isoniazid) also reported affect ketoconazole_second concentrations adversely.
1152,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,Isoniazid,ketoconazole,mechanism,INH (Isoniazid_first ) also reported affect ketoconazole_second concentrations adversely.
1153,"After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.",ketoconazole,loratadine,mechanism,coadministration 200 mg oral ketoconazole_first twice daily one 20 mg dose loratadine_second 11 subjects AUC Cmax loratadine averaged 302% ( 142 S.D.) 251% ( 68 S.D.) respectively obtained co treatment placebo.
1154,"Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.",cephalosporins,aminoglycosides,effect,Although occurrence reported Cefizox nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycosides_second .
1155,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
1156,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
1157,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
1158,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
1159,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
1160,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
1161,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,troleandomycin,corticosteroids,mechanism,Drugs troleandomycin_first ketoconazole may inhibit metabolism corticosteroids_second thus decrease clearance.
1162,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,ketoconazole,corticosteroids,mechanism,Drugs troleandomycin ketoconazole_first may inhibit metabolism corticosteroids_second thus decrease clearance.
1163,Corticosteroids may increase the clearance of chronic high dose aspirin.,Corticosteroids,aspirin,effect,Corticosteroids_first may increase clearance chronic high dose aspirin_second .
1164,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.,salicylate,corticosteroid,effect,could lead decreased salicylate serum levels increase risk salicylate_first toxicity corticosteroid_second withdrawn.
1165,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.,Aspirin,cortico-steroids,advise,Aspirin_first used cautiously conjunction cortico-steroids_second patients suffering hypopro thrombinemia.
1166,The effect of corticosteroids on oral anticoagulants is variable.,corticosteroids,anticoagulants,effect,effect corticosteroids_first oral anticoagulants_second variable.
1167,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.,anticoagulants,corticosteroids,effect,reports enhanced well diminished effects anticoagulants_first given concurrently corticosteroids_second .
1168,Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.,acetaminophen,caffeine,effect,Increased hepatotoxicity acetaminophen_first concomitant administration caffeine_second rat.
1169,Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.,acetaminophen,caffeine,effect,Careful observations hepatotoxicity suggested acetaminophen_first prescribed caffeine_second .
1170,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,aminoglycosides,advise,Co administration BOTOX_first aminoglycosides_second agents interfering neuromuscular transmission (e.g. curare like compounds) performed caution effect toxin may potentiated.
1171,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,curare-like compounds,advise,Co administration BOTOX_first aminoglycosides agents interfering neuromuscular transmission (e.g. curare-like compounds_second ) performed caution effect toxin may potentiated.
1172,Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.,botulinum toxin,botulinum toxin,effect,Excessive neuromuscular weakness may exacerbated administration another botulinum toxin_first prior resolution effects previously administered botulinum toxin_second .
1173,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.,Fluvoxamine,alosetron,mechanism,Fluvoxamine_first increased mean alosetron_second plasma concentrations (AUC) approximately 6 fold prolonged half life approximately 3 fold.
1174,Concomitant administration of alosetron and fluvoxamine is contraindicated.,alosetron,fluvoxamine,advise,Concomitant administration alosetron_first fluvoxamine_second contraindicated.
1175,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,quinolone antibiotics,advise,Concomitant administration alosetron_first moderate CYP1A2 inhibitors including quinolone antibiotics_second cimetidine evaluated avoided unless clinically necessary similar potential drug interactions.
1176,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,cimetidine,advise,Concomitant administration alosetron_first moderate CYP1A2 inhibitors including quinolone antibiotics cimetidine_second evaluated avoided unless clinically necessary similar potential drug interactions.
1177,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.,Ketoconazole,alosetron,mechanism,Ketoconazole_first increased mean alosetron_second plasma concentrations (AUC) 29%.
1178,Caution should be used when alosetron and ketoconazole are administered concomitantly.,alosetron,ketoconazole,advise,Caution used alosetron_first ketoconazole_second administered concomitantly.
1179,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,clarithromycin,advise,Coadministration alosetron_first strong CYP3A4 inhibitors clarithromycin_second telithromycin protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1180,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,advise,Coadministration alosetron_first strong CYP3A4 inhibitors clarithromycin telithromycin_second protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1181,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,protease inhibitors,advise,Coadministration alosetron_first strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors_second voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1182,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,voriconazole,advise,Coadministration alosetron_first strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors voriconazole_second itraconazole evaluated undertaken caution similar potential drug interactions.
1183,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,itraconazole,advise,Coadministration alosetron_first strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors voriconazole itraconazole_second evaluated undertaken caution similar potential drug interactions.
1184,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,isoniazid,effect,Although studied alosetron_first inhibition N acetyltransferase may clinically relevant consequences drugs isoniazid_second procainamide hydralazine.
1185,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,procainamide,effect,Although studied alosetron_first inhibition N acetyltransferase may clinically relevant consequences drugs isoniazid procainamide_second hydralazine.
1186,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,hydralazine,effect,Although studied alosetron_first inhibition N acetyltransferase may clinically relevant consequences drugs isoniazid procainamide hydralazine_second .
1187,Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.,Dipyridamole,adenosine,mechanism,Adenosine: Dipyridamole_first reported increase plasma levels cardiovascular effects adenosine_second .
1188,"Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.",Dipyridamole,cholinesterase inhibitors,effect,Cholinesterase Inhibitors: Dipyridamole_first may counteract anticholinesterase effect cholinesterase inhibitors_second thereby potentially aggravating myasthenia gravis.
1189,"Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.",ipratropium bromide,anticholinergic medications,effect,Anticholinergic agents: Although ipratropium bromide_first minimally absorbed systemic circulation potential additive interaction concomitantly used anticholinergic medications_second .
1190,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.,ATROVENT,anticholinergic,advise,Caution therefore advised coadministration ATROVENT_first Inhalation Aerosol anticholinergic_second containing drugs.
1191,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,verografine,mechanism,[The effect cimetidine renal excretion verografin iodamide dogs] intravenous injection cimetidine_first dose 20 mg/kg enhanced verografine_second iodamide excretion chronic canine experiments.
1192,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,iodamide,mechanism,[The effect cimetidine renal excretion verografin iodamide dogs] intravenous injection cimetidine_first dose 20 mg/kg enhanced verografine iodamide_second excretion chronic canine experiments.
1193,"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
",Misonidazole,CCNU,effect,Misonidazole_first protects mouse tumour normal tissues toxicity oral CCNU_second .
1194,Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ,Misonidazole,CCNU,effect,Misonidazole_first reduced antitumour activity oral CCNU_second dose modifying factors (DMF) 0.58 0.71.
1195,Misonidazole has a complex effect on oral CCNU pharmacokinetics. ,Misonidazole,CCNU,mechanism,Misonidazole_first complex effect oral CCNU_second pharmacokinetics.
1196,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ,CCNU,misonidazole,mechanism,propose pharmacokinetic changes underlying mechanism reduction oral CCNU_first cytotoxicity misonidazole_second .
1197,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.",lithium,HALDOL,effect,encephalopathic syndrome (characterized weakness lethargy fever tremulousness confusion extrapyramidal symptoms leukocytosis elevated serum enzymes BUN FBS) followed irreversible brain damage occurred patients treated lithium_first plus HALDOL_second .
1198,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,CNS depressants,effect,antipsychotic agents_first noted HALDOL may capable potentiating CNS depressants_second anesthetics opiates alcohol.
1199,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,anesthetics,effect,antipsychotic agents_first noted HALDOL may capable potentiating CNS depressants anesthetics_second opiates alcohol.
1200,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,opiates,effect,antipsychotic agents_first noted HALDOL may capable potentiating CNS depressants anesthetics opiates_second alcohol.
1201,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,alcohol,effect,antipsychotic agents_first noted HALDOL may capable potentiating CNS depressants anesthetics opiates alcohol_second .
1202,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,CNS depressants,effect,antipsychotic agents noted HALDOL_first may capable potentiating CNS depressants_second anesthetics opiates alcohol.
1203,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,anesthetics,effect,antipsychotic agents noted HALDOL_first may capable potentiating CNS depressants anesthetics_second opiates alcohol.
1204,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,opiates,effect,antipsychotic agents noted HALDOL_first may capable potentiating CNS depressants anesthetics opiates_second alcohol.
1205,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,alcohol,effect,antipsychotic agents noted HALDOL_first may capable potentiating CNS depressants anesthetics opiates alcohol_second .
1206,"In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,rifampin,mechanism,study 12 schizophrenic patients coadministered oral haloperidol_first rifampin_second plasma haloperidol levels decreased mean 70% mean scores Brief Psychiatric Rating Scale increased baseline.
1207,"In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.",rifampin,haloperidol,mechanism,5 schizophrenic patients treated oral haloperidol rifampin discontinuation rifampin_first produced mean 3.3 fold increase haloperidol_second concentrations.
1208,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.",rifampin,haloperidol,advise,Thus careful monitoring clinical status warranted rifampin_first administered discontinued haloperidol_second treated patients.
1209,apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.,diphenidol,apomorphine,effect,apomorphine prior ingestion diphenidol_first may decrease emetic response apomorphine_second treatment poisoning.
1210,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",doxazosin,cimetidine,mechanism,placebo controlled trial normal volunteers administration single 1 mg dose doxazosin_first day 1 four day regimen oral cimetidine_second (400 mg twice daily) resulted 10% increase mean AUC doxazosin (p=0.006) slight statistically significant increase mean Cmax mean half life doxazosin.
1211,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors_first prolong intensify anticholinergic effects antihistamines_second .
1212,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,alcohol,effect,Antihistamines_first may additive effects alcohol_second CNS depressants e.g. hypnotics sedatives tranquilizers antianxiety agents.
1213,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,CNS depressants,effect,Antihistamines_first may additive effects alcohol CNS depressants_second e.g. hypnotics sedatives tranquilizers antianxiety agents.
1214,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,hypnotics,effect,Antihistamines_first may additive effects alcohol CNS depressants e.g. hypnotics_second sedatives tranquilizers antianxiety agents.
1215,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,sedatives,effect,Antihistamines_first may additive effects alcohol CNS depressants e.g. hypnotics sedatives_second tranquilizers antianxiety agents.
1216,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,tranquilizers,effect,Antihistamines_first may additive effects alcohol CNS depressants e.g. hypnotics sedatives tranquilizers_second antianxiety agents.
1217,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,antianxiety agents,effect,Antihistamines_first may additive effects alcohol CNS depressants e.g. hypnotics sedatives tranquilizers antianxiety agents_second .
1218,The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.,cromolyn sodium,isoproterenol,effect,addition 540 mg/kg/day cromolyn sodium_first (approximately 340 times maximum recommended daily inhalation dose adults mg/m2 basis) 2.7 mg/kg/day isoproterenol_second (approximately 7 times maximum recommended daily inhalation dose adults mg/m2 basis) appears increased incidence resorptions malformations.
1219,Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.,naltrexone,Acamprosate,mechanism,Co administration naltrexone_first Acamprosate_second produced 25% increase AUC 33% increase Cmax acamprosate.
1220,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.",Acamprosate,antidepressants,effect,Patients taking Acamprosate_first concomitantly antidepressants_second commonly reported weight gain weight loss compared patients taking either medication alone.
1221,All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.,vasopressors,monoamine oxidase (MAO) inhibitors,advise,vasopressors_first used cautiously patients taking monoamine oxidase (MAO) inhibitors_second .
1222,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,sympathomimetic drugs,advise,Epinephrine_first administered concomitantly sympathomimetic drugs_second (such isoproterenol) possible additive effects increased toxicity.
1223,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,isoproterenol,advise,Epinephrine_first administered concomitantly sympathomimetic drugs (such isoproterenol_second ) possible additive effects increased toxicity.
1224,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,cyclopropane,effect,Administration epinephrine_first patients receiving cyclopropane_second halogenated hydrocarbon general anesthetics halothane sensitize myocardium may induce cardiac arrhythmia..
1225,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halogenated hydrocarbon general anesthetics,effect,Administration epinephrine_first patients receiving cyclopropane halogenated hydrocarbon general anesthetics_second halothane sensitize myocardium may induce cardiac arrhythmia..
1226,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halothane,effect,Administration epinephrine_first patients receiving cyclopropane halogenated hydrocarbon general anesthetics halothane_second sensitize myocardium may induce cardiac arrhythmia..
1227,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,digitalis,advise,Epinephrine_first also used cautiously drugs (e.g. digitalis_second glycosides) sensitize myocardium actions sympathomimetic drugs.
1228,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,glycosides,advise,Epinephrine_first also used cautiously drugs (e.g. digitalis glycosides_second ) sensitize myocardium actions sympathomimetic drugs.
1229,Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.,Diuretic agents,epinephrine,effect,Diuretic agents_first may decrease vascular response pressor drugs epinephrine_second .
1230,Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.,Epinephrine,guanethidine,effect,Epinephrine_first may antagonize neuron blockade produced guanethidine_second resulting decreased antihypertensive effect requiring increased dosage latter.
1231,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.",CANCIDAS,tacrolimus,mechanism,CANCIDAS_first reduced blood AUC0 12 tacrolimus_second approximately 20% peak blood concentration (Cmax) 16% 12 hour blood concentration (C12hr) 26% healthy subjects tacrolimus (2 doses 0.1 mg/kg 12 hours apart) administered 10th day CANCIDAS 70 mg daily compared results control period tacrolimus administered alone.
1232,"In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.",cyclosporine,caspofungin,mechanism,two clinical studies cyclosporine_first (one 4 mg/kg dose two 3 mg/kg doses) increased AUC caspofungin_second approximately 35%.
1233,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.,CANCIDAS,cyclosporine,effect,transient increases liver ALT AST CANCIDAS_first cyclosporine_second co administered.
1234,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.,rifampin,caspofungin,mechanism,drug drug interaction study rifampin_first healthy volunteers shown 30% decrease caspofungin_second trough concentrations.
1235,Patients on rifampin should receive 70 mg of CANCIDAS daily.,rifampin,CANCIDAS,advise,Patients rifampin_first receive 70 mg CANCIDAS_second daily.
1236,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",efavirenz,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz_first nevirapine phenytoin dexamethasone carbamazepine) CANCIDAS_second may result clinically meaningful reductions caspofungin concentrations.
1237,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",nevirapine,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine_first phenytoin dexamethasone carbamazepine) CANCIDAS_second may result clinically meaningful reductions caspofungin concentrations.
1238,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",phenytoin,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine phenytoin_first dexamethasone carbamazepine) CANCIDAS_second may result clinically meaningful reductions caspofungin concentrations.
1239,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",dexamethasone,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine phenytoin dexamethasone_first carbamazepine) CANCIDAS_second may result clinically meaningful reductions caspofungin concentrations.
1240,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",carbamazepine,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine phenytoin dexamethasone carbamazepine_first ) CANCIDAS_second may result clinically meaningful reductions caspofungin concentrations.
1241,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,efavirenz,advise,CANCIDAS_first co administered inducers drug clearance efavirenz_second nevirapine phenytoin dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1242,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,nevirapine,advise,CANCIDAS_first co administered inducers drug clearance efavirenz nevirapine_second phenytoin dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1243,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,phenytoin,advise,CANCIDAS_first co administered inducers drug clearance efavirenz nevirapine phenytoin_second dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1244,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,dexamethasone,advise,CANCIDAS_first co administered inducers drug clearance efavirenz nevirapine phenytoin dexamethasone_second carbamazepine use daily dose 70 mg CANCIDAS considered
1245,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,carbamazepine,advise,CANCIDAS_first co administered inducers drug clearance efavirenz nevirapine phenytoin dexamethasone carbamazepine_second use daily dose 70 mg CANCIDAS considered
1246,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycoside antibiotics_second .
1247,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,Corticotropin_first may accentuate electrolyte loss associated diuretic_second therapy.
1248,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,barbiturates,effect,Tablets: benzodiazepines_first including lorazepam produce CNS depressant effects administered medications barbiturates_second alcohol.
1249,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,alcohol,effect,Tablets: benzodiazepines_first including lorazepam produce CNS depressant effects administered medications barbiturates alcohol_second .
1250,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,barbiturates,effect,Tablets: benzodiazepines including lorazepam_first produce CNS depressant effects administered medications barbiturates_second alcohol.
1251,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,alcohol,effect,Tablets: benzodiazepines including lorazepam_first produce CNS depressant effects administered medications barbiturates alcohol_second .
1252,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,ethyl alcohol,effect,Injection: Lorazepam_first injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol_second phenothiazines barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1253,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,phenothiazines,effect,Injection: Lorazepam_first injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines_second barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1254,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,barbiturates,effect,Injection: Lorazepam_first injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates_second MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1255,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,MAO inhibitors,effect,Injection: Lorazepam_first injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors_second antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1256,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,antidepressants,effect,Injection: Lorazepam_first injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants_second .When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1257,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,ethyl alcohol,effect,Injection: Lorazepam injection like injectable benzodiazepines_first produces depression central nervous system administered ethyl alcohol_second phenothiazines barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1258,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,phenothiazines,effect,Injection: Lorazepam injection like injectable benzodiazepines_first produces depression central nervous system administered ethyl alcohol phenothiazines_second barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1259,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,barbiturates,effect,Injection: Lorazepam injection like injectable benzodiazepines_first produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates_second MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1260,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,MAO inhibitors,effect,Injection: Lorazepam injection like injectable benzodiazepines_first produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors_second antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1261,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,antidepressants,effect,Injection: Lorazepam injection like injectable benzodiazepines_first produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants_second .When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1262,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",scopolamine,lorazepam,effect,Injection: Lorazepam injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants.When scopolamine_first used concomitantly injectable lorazepam_second increased incidence sedation hallucinations irrational behavior observed.
1263,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.,Femara,tamoxifen,mechanism,(See CLINICAL PHARMACOLOGY) Coadministration Femara_first tamoxifen_second 20 mg daily resulted reduction letrozole plasma levels 38% average.
1264,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,narcotic analgesics,effect,Codeine_first combination narcotic analgesics_second general anesthetics phenothiazines tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1265,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,anesthetics,effect,Codeine_first combination narcotic analgesics general anesthetics_second phenothiazines tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1266,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,phenothiazines,effect,Codeine_first combination narcotic analgesics general anesthetics phenothiazines_second tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1267,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,tranquilizers,effect,Codeine_first combination narcotic analgesics general anesthetics phenothiazines tranquilizers_second sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1268,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,sedative-hypnotics,effect,Codeine_first combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics_second CNS depressants (including alcohol) additive depressant effects.
1269,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,CNS depressants,effect,Codeine_first combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics CNS depressants_second (including alcohol) additive depressant effects.
1270,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,alcohol,effect,Codeine_first combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics CNS depressants (including alcohol_second ) additive depressant effects.
1271,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,Antabuse,advise,Isocarboxazid_first administered caution patients receiving Antabuse_second (disulfiram Wyeth Ayerst Laboratories).
1272,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,disulfiram,advise,Isocarboxazid_first administered caution patients receiving Antabuse (disulfiram_second Wyeth Ayerst Laboratories).
1273,"In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.",MAO inhibitor,disulfiram,effect,single study rats given high intraperitoneal doses MAO inhibitor_first plus disulfiram_second experienced severe toxicity including convulsions death.
1274,Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.,Isocarboxazid,psychotropic agents,advise,Concomitant use Isocarboxazid_first psychotropic agents_second generally recommended possible potentiating effects.
1275,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,anesthetics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration PRECEDEX_first anesthetics_second sedatives hypnotics opioids likely lead enhancement effects.
1276,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,sedatives,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration PRECEDEX_first anesthetics sedatives_second hypnotics opioids likely lead enhancement effects.
1277,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,hypnotics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration PRECEDEX_first anesthetics sedatives hypnotics_second opioids likely lead enhancement effects.
1278,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,opioids,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration PRECEDEX_first anesthetics sedatives hypnotics opioids_second likely lead enhancement effects.
1279,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,anesthetic,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage PRECEDEX_first concomitant anesthetic_second sedative hypnotic opioid may required.
1280,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,sedative,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage PRECEDEX_first concomitant anesthetic sedative_second hypnotic opioid may required.
1281,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,hypnotic,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage PRECEDEX_first concomitant anesthetic sedative hypnotic_second opioid may required.
1282,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,opioid,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage PRECEDEX_first concomitant anesthetic sedative hypnotic opioid_second may required.
1283,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,Digoxin,Adenocard,effect,Digoxin_first verapamil use may rarely associated ventricular fibrillation combined Adenocard_second .
1284,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,verapamil,Adenocard,effect,Digoxin verapamil_first use may rarely associated ventricular fibrillation combined Adenocard_second .
1285,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.,Adenocard,digitalis,effect,use Adenocard_first patients receiving digitalis_second may rarely associated ventricular fibrillation.
1286,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,methylxanthines,effect,effects adenosine_first antagonized methylxanthines_second caffeine theophylline.
1287,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,caffeine,effect,effects adenosine_first antagonized methylxanthines caffeine_second theophylline.
1288,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,theophylline,effect,effects adenosine_first antagonized methylxanthines caffeine theophylline_second .
1289,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,presence methylxanthines_first larger doses adenosine_second may required adenosine may effective.
1290,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,presence methylxanthines_first larger doses adenosine may required adenosine_second may effective.
1291,Adenosine effects are potentiated by dipyridamole.,Adenosine,dipyridamole,effect,Adenosine_first effects potentiated dipyridamole_second .
1292,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.",adenosine,dipyridamole,effect,Thus smaller doses adenosine_first may effective presence dipyridamole_second .
1293,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.",adenosine,carbamazepine,effect,primary effect adenosine_first decrease conduction V node higher degrees heart block may produced presence carbamazepine_second .
1294,"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
",ADL 8-2698,morphine,effect,ADL 8-2698_first trans 3 4 dimethyl 4 (3 hydroxyphenyl) piperidine prevents gastrointestinal effects intravenous morphine_second without affecting analgesia.
1295,ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ,ADL-8-2698,opioid,effect,ADL-8-2698_first novel peripherally restricted opioid antagonist may selectively prevent opioid_second induced gastrointestinal effects without reversing analgesia.
1296,Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). ,Morphine,ADL 8-2698,effect,Morphine_first prolonged gastrointestinal transit time 69 103 minutes (P = .005); prevented ADL 8-2698_second (P = .004).
1297,We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.,ADL 8-2698,morphine,effect,conclude ADL 8-2698_first prevents morphine_second induced increases gastrointestinal transit time means selective peripheral opioid anitagonism without affecting central opioid analgesia.
1298,"Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).",cimetidine,isradipine,mechanism,Cimetidine: study healthy volunteers one week course cimetidine_first 400 mg b.i.d. single 5 mg dose isradipine_second sixth day showed increase isradipine mean peak plasma concentrations (36%) significant increase area curve (50%).
1299,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.,isradipine,cimetidine,advise,isradipine_first therapy initiated patient currently receiving cimetidine_second careful monitoring adverse reactions advised downward dose adjustment may required.
1300,"Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.",rifampicin,isradipine,mechanism,Rifampicin: study healthy volunteers six day course rifampicin_first 600 mg/day followed single 5 mg dose isradipine_second resulted reduction isradipine levels detectable limits.
1301,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.",rifampicin,isradipine,mechanism,rifampicin_first therapy required isradipine_second concentrations therapeutic effects likely markedly reduced abolished consequence increased metabolism higher clearance isradipine.
1302,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,beta blocker,effect,Fentanyl Anesthesia: Severe hypotension reported fentanyl_first anesthesia concomitant use beta blocker_second calcium channel blocker.
1303,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,calcium channel blocker,effect,Fentanyl Anesthesia: Severe hypotension reported fentanyl_first anesthesia concomitant use beta blocker calcium channel blocker_second .
1304,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",phenobarbital,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital_first rifampin rifabutin) would expected increase clearance efavirenz_second resulting lowered plasma concentrations.
1305,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifampin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital rifampin_first rifabutin) would expected increase clearance efavirenz_second resulting lowered plasma concentrations.
1306,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifabutin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital rifampin rifabutin_first ) would expected increase clearance efavirenz_second resulting lowered plasma concentrations.
1307,"In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.",SUSTIVA,clarithromycin,effect,uninfected volunteers 46% developed rash receiving SUSTIVA_first clarithromycin_second .
1308,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.,indinavir,SUSTIVA,mechanism,Increasing indinavir dose 1000 mg every 8 hours compensate increased indinavir_first metabolism due SUSTIVA_second .
1309,"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.",indinavir,SUSTIVA,mechanism,indinavir_first increased dose (1000 mg every 8 hours) given SUSTIVA_second (600 mg daily) indinavir AUC Cmin decreased average 33 46% 39 57% respectively compared indinavir (800 mg every 8 hours) given alone.
1310,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,lopinavir,SUSTIVA,advise,dose increase lopinavir_first /ritonavir 533/133 mg (4 capsules 6.5 mL) twice daily taken food recommended used combination SUSTIVA_second .
1311,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,ritonavir,SUSTIVA,advise,dose increase lopinavir/ritonavir_first 533/133 mg (4 capsules 6.5 mL) twice daily taken food recommended used combination SUSTIVA_second .
1312,"Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.",efavirenz,contraceptives,advise,potential interaction efavirenz_first oral contraceptives_second fully characterized reliable method barrier contraception used addition oral contraceptives.
1313,Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.,SUSTIVA,ritonavir,advise,Monitoring liver enzymes recommended SUSTIVA_first used combination ritonavir_second .
1314,Potential for reduction in anticonvulsant and/or efavirenz plasma levels;,anticonvulsant,efavirenz,mechanism,Potential reduction anticonvulsant_first and/or efavirenz_second plasma levels;
1315,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,itraconazole,mechanism,SUSTIVA_first potential decrease plasma concentrations itraconazole_second ketoconazole.
1316,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,ketoconazole,mechanism,SUSTIVA_first potential decrease plasma concentrations itraconazole ketoconazole_second .
1317,"Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.",Indinavir,amprenavir,mechanism,Indinavir_first steady state Cmax A.C. Cmin decreased 22% 38% 27% respectively concomitant amprenavir_second .
1318,"Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.",Saquinavir,amprenavir,mechanism,Saquinavir_first steady state Cmax A.C. Cmin increased 21% decreased 19% decreased 48% respectively concomitant amprenavir_second .
1319,"Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.",Nelfinavir,amprenavir,mechanism,Nelfinavir_first steady state Cmax A.C. Cmin increased 12% 15% 14% respectively concomitant amprenavir_second .
1320,Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.,amprenavir,methadone,effect,Methadone: Coadministration amprenavir_first methadone_second decrease plasma levels methadone.
1321,"Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",amprenavir,methadone,mechanism,Coadministration amprenavir_first methadone_second compared non matched historicalcontrol group resulted 30% 27% 25% decrease serum amprenavir AUC Cmax andCmin respectively.
1322,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,effect,Laboratory Tests: combination Amprenavir_first low dose ritonavir_second associated elevations cholesterol triglycerides SGOT (AST) SGPT (ALT) patients.
1323,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,advise,Appropriate laboratory testing considered prior initiating combination therapy Amprenavir_first ritonavir_second periodic intervals clinical signs symptoms hyperlipidemia elevated liver function tests occur therapy.
1324,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,Corticotropin_first may accentuate electrolyte loss associated diuretic_second therapy.
1325,"Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.",nifedipine,beta-blocking agents,effect,Beta adrenergic Blocking Agents: Experience 1400 patients non comparative clinical trial shown concomitant administration nifedipine_first beta-blocking agents_second usually well tolerated occasional literature reports suggesting combination may increase likelihood congestive heart failure severe hypotension exacerbation angina.
1326,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,int,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated digoxin levels possible interaction digoxin_first nifedipine_second recommended digoxin levels monitored initiating adjusting discontinuing nifedipine avoid possible digitalization.
1327,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated digoxin levels possible interaction digoxin nifedipine recommended digoxin_first levels monitored initiating adjusting discontinuing nifedipine_second avoid possible digitalization.
1328,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.,digoxin,digoxin,mechanism,Extended Release Tablets: Administration nifedipine digoxin_first increased digoxin_second levels 9 12 normal volunteers.
1329,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Since isolated reports patients elevated digoxin levels recommended digoxin_first levels monitored initiating adjusting discontinuing nifedipine_second avoid possible digitalization.
1330,Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).,quinidine,nifedipine,mechanism,Quinidine: Immediate Release Capsules: rare reports interaction quinidine_first nifedipine_second (with decreased plasma level quinidine).
1331,Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.,coumarin anticoagulants,nifedipine,effect,Coumarin Anticoagulants: rare reports increased prothrombin time patients taking coumarin anticoagulants_first nifedipine_second administered.
1332,Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.,cimetidine,nifedipine,mechanism,Cimetidine: study 6 healthy volunteers shown significant increase peak nifedipine plasma levels (80%) area curve (74%) 1 week course cimetidine_first 1000 mg per day nifedipine_second 40 mg per day.
1333,"If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.",nifedipine,cimetidine,advise,nifedipine_first therapy initiated patient currently receiving cimetidine_second cautious titration advised.
1334,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: Cholestyramine_first reported reduce intestinal absorption fat soluble vitamins_second ;
1335,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration thiazides_first vitamin D_second causes hypercalcemia.
1336,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D_first dosage must determined care patients undergoing treatment digitalis_second hypercalcemia patients may precipitate cardiac arrhythmias.
1337,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: Ketoconazole_first may inhibit synthetic catabolic enzymes vitamin D_second .
1338,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D,corticosteroids,effect,Corticosteroids: relationship functional antagonism exists vitamin D_first analogues promote calcium absorption corticosteroids_second inhibit calcium absorption.
1339,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,effect,Magnesium: Magnesium_first containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
1340,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,effect,Magnesium: Magnesium containing preparations (eg antacids_first ) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
1341,"In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.",diflunisal,indomethacin,mechanism,normal volunteers receiving indomethacin administration diflunisal_first decreased renal clearance significantly increased plasma levels indomethacin_second .
1342,"In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.",INDOCIN,diflunisal,effect,patients combined use INDOCIN_first diflunisal_second associated fatal gastrointestinal hemorrhage.
1343,"Therefore, diflunisal and INDOCIN should not be used concomitantly.",diflunisal,INDOCIN,advise,Therefore diflunisal_first INDOCIN_second used concomitantly.
1344,"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.",aspirin,indomethacin,mechanism,study normal volunteers found chronic concurrent administration 3.6 g aspirin_first per day decreases indomethacin_second blood levels approximately 20%.
1345,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",INDOCIN,NSAIDs,advise,concomitant use INDOCIN_first NSAIDs_second recommended due increased possibility gastrointestinal toxicity little increase efficacy.
1346,"However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.",INDOCIN,anticoagulant,advise,However additional drug including INDOCIN_first added treatment patients anticoagulant_second therapy patients observed alterations prothrombin time.
1347,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.",anticoagulants,INDOCIN,effect,post marketing experience bleeding reported patients concomitant treatment anticoagulants_first INDOCIN_second .
1348,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.,INDOCIN,anticoagulants,advise,Caution exercised INDOCIN_first anticoagulants_second administered concomitantly.
1349,"When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.",INDOCIN,probenecid,mechanism,INDOCIN_first given patients receiving probenecid_second plasma levels indomethacin likely increased.
1350,Caution should be used if INDOCIN is administered simultaneously with methotrexate.,INDOCIN,methotrexate,advise,Caution used INDOCIN_first administered simultaneously methotrexate_second .
1351,INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,INDOCIN,methotrexate,mechanism,INDOCIN_first reported decrease tubular secretion methotrexate_second potentiate toxicity.
1352,"Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",non-steroidal anti-inflammatory drugs,cyclosporine,effect,Administration non-steroidal anti-inflammatory drugs_first concomitantly cyclosporine_second associated increase cyclosporine induced toxicity possibly due decreased synthesis renal prostacyclin.
1353,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,NSAIDs_first used caution patients taking cyclosporine_second renal function carefully monitored.
1354,Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.,INDOCIN,lithium,mechanism,Capsules INDOCIN_first 50 mg t.i.d. produced clinically relevant elevation plasma lithium_second reduction renal lithium clearance psychiatric patients normal subjects steady state plasma lithium concentrations.
1355,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.",INDOCIN,lithium,advise,consequence INDOCIN_first lithium_second given concomitantly patient carefully observed signs lithium toxicity.
1356,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.,INDOCIN,digoxin,mechanism,INDOCIN_first given concomitantly digoxin_second reported increase serum concentration prolong half life digoxin.
1357,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.",INDOCIN,digoxin,advise,Therefore INDOCIN_first digoxin_second used concomitantly serum digoxin levels closely monitored.
1358,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,loop diuretics,effect,patients administration INDOCIN_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
1359,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,potassium-sparing diuretics,effect,patients administration INDOCIN_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium-sparing diuretics_second .
1360,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,thiazide diuretics,effect,patients administration INDOCIN_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
1361,It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.,triamterene,INDOCIN,effect,reported addition triamterene_first maintenance schedule INDOCIN_second resulted reversible acute renal failure two four healthy volunteers.
1362,INDOCIN and triamterene should not be administered together.,INDOCIN,triamterene,advise,INDOCIN_first triamterene_second administered together.
1363,The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.,INDOCIN,potassium-sparing diuretics,effect,potential effects INDOCIN_first potassium-sparing diuretics_second potassium kinetics renal function considered agents administered concurrently.
1364,"Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.",diuretics,INDOCIN,effect,effects concerning diuretics_first attributed least part mechanisms involving inhibition prostaglandin synthesis INDOCIN_second .
1365,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,non-steroidal antiinflammatory drugs,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents_first non-steroidal antiinflammatory drugs_second including INDOCIN reported.
1366,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,INDOCIN,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents_first non steroidal antiinflammatory drugs including INDOCIN_second reported.
1367,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,captopril,effect,INDOCIN_first reduce antihypertensive effects captopril_second losartan.
1368,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,losartan,effect,INDOCIN_first reduce antihypertensive effects captopril losartan_second .
1369,"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. ",antiretroviral drugs,antineoplastic drugs,advise,However careful attention must directed cross toxicity possible pharmacokinetic interactions antiretroviral antineoplastic drugs_f antiretroviral drugs_second .
1370,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",tamoxifen,anastrozole,advise,Based clinical pharmacokinetic results ATAC trial tamoxifen_first administered anastrozole_second (see CLINICAL PHARMACOLOGY Drug Interactions CLINICAL PHARMACOLOGY Clinical Studies Adjuvant Treatment Breast Cancer Postmenopausal Women subsections).
1371,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.,anastrozole,tamoxifen,mechanism,Co administration anastrozole_first tamoxifen_second resulted reduction anastrozole plasma levels 27% compared achieved anastrozole alone.
1372,Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.,Estrogen,ARIMIDEX,advise,Estrogen_first containing therapies used ARIMIDEX_second may diminish pharmacologic action.
1373,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",ciclesonide,ketoconazole,mechanism,another drug interaction study co administration orally inhaled ciclesonide_first oral ketoconazole_second potent inhibitor cytochrome P450 3A4 increased exposure (AUC) des ciclesonide approximately 3.6 fold steady state levels ciclesonide remained unchanged.
1374,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.",ketoconazole,ciclesonide,advise,Therefore ketoconazole_first administered caution intranasal ciclesonide_second .
1375,"Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.",doxylamine,CNS depressant drugs,effect,Potential drug interactions doxylamine include increased sedation doxylamine_first combined CNS depressant drugs_second .
1376,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,heparin,effect,Antihistamines_first may partially counteract anticoagulation effects heparin_second warfarin.
1377,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,warfarin,effect,Antihistamines_first may partially counteract anticoagulation effects heparin warfarin_second .
1378,Doxylamine may enhance the effects of epinephrine.,Doxylamine,epinephrine,effect,Doxylamine_first may enhance effects epinephrine_second .
1379,The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.,NSAIDs,ACE inhibitors,effect,use NSAIDs_first patients receiving ACE inhibitors_second may potentiate renal disease states.
1380,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration naproxen_first aspirin_second recommended naproxen displaced binding sites concomitant administration aspirin resulting lower plasma concentrations peak plasma levels.
1381,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration naproxen aspirin recommended naproxen_first displaced binding sites concomitant administration aspirin_second resulting lower plasma concentrations peak plasma levels.
1382,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,propranolol,effect,Naproxen_first NSAIDs reduce antihypertensive effect propranolol_second beta blockers.
1383,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,beta-blockers,effect,Naproxen_first NSAIDs reduce antihypertensive effect propranolol beta-blockers_second .
1384,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,propranolol,effect,Naproxen NSAIDs_first reduce antihypertensive effect propranolol_second beta blockers.
1385,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,beta-blockers,effect,Naproxen NSAIDs_first reduce antihypertensive effect propranolol beta-blockers_second .
1386,Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.,Probenecid,naproxen,mechanism,Probenecid_first given concurrently increases naproxen_second anion plasma levels extends plasma half life significantly.
1387,Caution should be used if naproxen is administered concomitantly with methotrexate.,naproxen,methotrexate,advise,Caution used naproxen_first administered concomitantly methotrexate_second .
1388,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",Naproxen,methotrexate,mechanism,Naproxen_first naproxen sodium NSAIDs reported reduce tubular secretion methotrexate_second animal model possibly increasing toxicity methotrexate.
1389,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",naproxen sodium,methotrexate,mechanism,Naproxen naproxen sodium_first NSAIDs reported reduce tubular secretion methotrexate_second animal model possibly increasing toxicity methotrexate.
1390,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",NSAIDs,methotrexate,mechanism,Naproxen naproxen sodium NSAIDs_first reported reduce tubular secretion methotrexate_second animal model possibly increasing toxicity methotrexate.
1391,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.",CEFOTAN,aminoglycoside,effect,CEFOTAN_first aminoglycoside_second used concomitantly renal function carefully monitored nephrotoxicity may potentiated.
1392,Colchicine is inhibited by acidifying agents.,Colchicine,acidifying agents,mechanism,Colchicine_first inhibited acidifying agents_second .
1393,The action of colchicine is potentiated by alkalinizing agents.,colchicine,alkalinizing agents,mechanism,action colchicine_first potentiated alkalinizing agents_second .
1394,Colchicine may increase sensitivity to the CNS depressants.,Colchicine,CNS depressants,effect,Colchicine_first may increase sensitivity CNS depressants_second .
1395,Response to sympathomimetic agents may be enhanced by colchicine.,sympathomimetic agents,colchicine,effect,Response sympathomimetic agents_first may enhanced colchicine_second .
1396,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,diazepam,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas picrotoxin_first (1 mg/kg) removes antiedematous action diazepam_second phenazepam phenibut amizyl reduces action phentolamine.
1397,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenazepam,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas picrotoxin_first (1 mg/kg) removes antiedematous action diazepam phenazepam_second phenibut amizyl reduces action phentolamine.
1398,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenibut,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas picrotoxin_first (1 mg/kg) removes antiedematous action diazepam phenazepam phenibut_second amizyl reduces action phentolamine.
1399,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,amizyl,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas picrotoxin_first (1 mg/kg) removes antiedematous action diazepam phenazepam phenibut amizyl_second reduces action phentolamine.
1400,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phentolamine,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas picrotoxin_first (1 mg/kg) removes antiedematous action diazepam phenazepam phenibut amizyl reduces action phentolamine_second .
1401,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.",Anagrelide,aspirin,effect,Anagrelide_first alone effect platelet aggregation slightly enhance inhibition platelet aggregation aspirin_second .
1402,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.",fluvoxamine,anagrelide,mechanism,known CYP1A2 inhibited several medicinal products including fluvoxamine_first medicinal products could theoretically adversely influence clearance anagrelide_second .
1403,Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.,Anagrelide,theophylline,mechanism,Anagrelide_first demonstrates limited inhibitory activity towards CYP1A2 may present theoretical potential interaction coadministered medicinal products sharing clearance mechanism e.g. theophylline_second .
1404,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",milrinone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone_first enoximone amrinone olprinone cilostazol may exacerbated anagrelide_second .
1405,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",enoximone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone_first amrinone olprinone cilostazol may exacerbated anagrelide_second .
1406,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",amrinone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone amrinone_first olprinone cilostazol may exacerbated anagrelide_second .
1407,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",olprinone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone amrinone olprinone_first cilostazol may exacerbated anagrelide_second .
1408,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",cilostazol,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone amrinone olprinone cilostazol_first may exacerbated anagrelide_second .
1409,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.",sucralfate,anagrelide,mechanism,single case report suggests sucralfate_first may interfere anagrelide_second absorption.
1410,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,non-depolarising muscle relaxant,effect,FLUOTHANE_first augments action non-depolarising muscle relaxant_second muscle relaxant effects aminoglycosides.
1411,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,aminoglycosides,effect,FLUOTHANE_first augments action non depolarising muscle relaxants muscle relaxant effects aminoglycosides_second .
1412,FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.,FLUOTHANE,tubocurarine,effect,FLUOTHANE_first may augment hypotension caused ganglionic blocking effect tubocurarine_second .
1413,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.,adrenaline,FLUOTHANE,advise,Caution exercised administration adrenaline_first patients anaesthetised FLUOTHANE_second arrhythmias may precipitated.
1414,"Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects",Accutane,vitamin A,effect,Vitamin A: relationship Accutane_first vitamin A_second patients advised taking vitamin supplements containing vitamin avoid additive toxic effects
1415,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,advise,Tetracyclines: Concomitant treatment Accutane_first tetracyclines_second avoided Accutane use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use tetracyclines
1416,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,effect,Tetracyclines: Concomitant treatment Accutane tetracyclines avoided Accutane_first use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use tetracyclines_second
1417,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.,progesterone,Accutane,effect,Micro dosed Progesterone Preparations: Micro dosed progesterone_first preparations (minipills contain estrogen) may inadequate method contraception Accutane_second therapy.
1418,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking,effect,Catecholamine depleting drugs (e.g. reserpine_first ) may additive effect given beta-blocking_second agents.
1419,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blockers,clonidine,advise,decided discontinue therapy patients receiving beta-blockers_first clonidine_second concurrently beta blocker discontinued slowly several days gradual withdrawal clonidine.
1420,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blocker,clonidine,advise,decided discontinue therapy patients receiving beta blockers clonidine concurrently beta-blocker_first discontinued slowly several days gradual withdrawal clonidine_second .
1421,"Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.",calcium antagonists,beta-adrenergic blocking agents,advise,Literature reports suggest oral calcium antagonists_first may used combination beta-adrenergic blocking agents_second heart function normal avoided patients impaired cardiac function.
1422,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.",beta-adrenergic blocking agents,calcium antagonist,effect,Hypotension AV conduction disturbances left ventricular failure reported patients receiving beta-adrenergic blocking agents_first oral calcium antagonist_second added treatment regimen.
1423,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",beta-blockers,epinephrine,effect,Risk Anaphylactic Reaction: Although known patients beta-blockers_first may refractory epinephrine_second treatment anaphylactic shock beta blockers addition interfere modulation allergic reaction lead increased severity and/or frequency attacks.
1424,The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.,guanfacine,CNS-depressant drug,effect,potential increased sedation guanfacine_first given CNS-depressant drug_second appreciated.
1425,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenobarbital,mechanism,administration guanfacine_first concomitantly known microsomal enzyme inducer (phenobarbital_second phenytoin) two patients renal impairment reportedly resulted significant reductions elimination half life plasma concentration.
1426,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenytoin,mechanism,administration guanfacine_first concomitantly known microsomal enzyme inducer (phenobarbital phenytoin_second ) two patients renal impairment reportedly resulted significant reductions elimination half life plasma concentration.
1427,TCAs decrease the hypotensive effect of guanfacine.,TCAs,guanfacine,effect,TCAs_first decrease hypotensive effect guanfacine_second .
1428,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",Noncardioselective beta-blockers,guanfacine,effect,Noncardioselective beta-blockers_first (nadolol porpranolol timolol) may exacerbate rebound hypertension guanfacine_second withdrawn.
1429,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",nadolol,guanfacine,effect,Noncardioselective beta blockers (nadolol_first porpranolol timolol) may exacerbate rebound hypertension guanfacine_second withdrawn.
1430,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",timolol,guanfacine,effect,Noncardioselective beta blockers (nadolol porpranolol timolol_first ) may exacerbate rebound hypertension guanfacine_second withdrawn.
1431,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",METH,SCH-23390,effect,Using situ hybridization observed METH_first caused rapid transient dose dependent increase arc mRNA level striatum cortex abolished pretreatment specific dopamine D1 receptor antagonist SCH-23390_second atypical neuroleptic clozapine.
1432,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg ranitidine_first q12h 3 days increased ceftibuten_second C max 23% ceftibuten AUC 16%.
1433,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg ranitidine_first q12h 3 days increased ceftibuten C max 23% ceftibuten_second AUC 16%.
1434,FLEXERIL may have life-threatening interactions with MAO inhibitors.,FLEXERIL,MAO inhibitors,int,FLEXERIL_first may life threatening interactions MAO inhibitors_second .
1435,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,alcohol,effect,FLEXERIL_first may enhance effects alcohol_second barbiturates CNS depressants.
1436,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,barbiturates,effect,FLEXERIL_first may enhance effects alcohol barbiturates_second CNS depressants.
1437,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,CNS depressants,effect,FLEXERIL_first may enhance effects alcohol barbiturates CNS depressants_second .
1438,Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.,Tricyclic antidepressants,guanethidine,effect,Tricyclic antidepressants_first may block antihypertensive action guanethidine_second similarly acting compounds.
1439,Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol,Tricyclic antidepressants,tramadol,effect,Tricyclic antidepressants_first may enhance seizure risk patients taking tramadol_second
1440,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents agents (ammonium chloride_first sodium acid phosphate etc.) increase concentration ionized species amphetamine_second molecule thereby increasing urinary excretion.
1441,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents agents (ammonium chloride sodium acid phosphate_first etc.) increase concentration ionized species amphetamine_second molecule thereby increasing urinary excretion.
1442,Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers Adrenergic blockers_first inhibited amphetamines_second .
1443,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,tricyclic antidepressants,effect,Antidepressants tricyclic Amphetamines_first may enhance activity tricyclic antidepressants_second sympathomimetic agents;
1444,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic Amphetamines_first may enhance activity tricyclic antidepressants sympathomimetic agents_second ;
1445,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,d-amphetamine_first desipramine_second protriptyline possibly tricyclics cause striking sustained increases concentration amphetamine brain;
1446,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,d-amphetamine_first desipramine protriptyline_second possibly tricyclics cause striking sustained increases concentration amphetamine brain;
1447,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,d-amphetamine_first desipramine protriptyline possibly tricyclics_second cause striking sustained increases concentration amphetamine brain;
1448,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors MAOI antidepressants_first well metabolite furazolidone slow amphetamine_second metabolism.
1449,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors MAOI antidepressants well metabolite furazolidone_first slow amphetamine_second metabolism.
1450,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: Amphetamines_first may counteract sedative effect antihistamines_second .
1451,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: Amphetamines_first may antagonize hypotensive effects antihypertensives_second .
1452,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: Chlorpromazine_first blocks dopamine norepinephrine receptors thus inhibiting central stimulant effects amphetamines_second used treat amphetamine poisoning.
1453,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: Amphetamines_first may delay intestinal absorption ethosuximide_second .
1454,"Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: Haloperidol_first blocks dopamine receptors thus inhibiting central stimulant effects amphetamines_second .
1455,Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: anorectic stimulatory effects amphetamines_first may inhibited lithium carbonate_second .
1456,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: Amphetamines_first potentiate analgesic effect meperidine_second .
1457,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.",amphetamines,methenamine,mechanism,Methenamine therapy Urinary excretion amphetamines_first increased efficacy reduced acidifying agents used methenamine_second therapy.
1458,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: Amphetamines_first enhance adrenergic effect norepinephrine_second .
1459,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: Amphetamines_first may delay intestinal absorption phenobarbital_second ;
1460,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: Amphetamines_first may delay intestinal absorption phenytoin_second ;
1461,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: cases propoxyphene_first overdosage amphetamine_second CNS stimulation potentiated fatal convulsions occur.
1462,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: Amphetamines_first inhibit hypotensive effect veratrum alkaloids_second .
1463,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",Intestinal adsorbents,Acarbose,mechanism,Intestinal adsorbents_first (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase pancreatin) may reduce effect Acarbose_second taken concomitantly.
1464,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",charcoal,Acarbose,mechanism,Intestinal adsorbents (e. g. charcoal_first ) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase pancreatin) may reduce effect Acarbose_second taken concomitantly.
1465,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",amylase,Acarbose,mechanism,Intestinal adsorbents (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase_first pancreatin) may reduce effect Acarbose_second taken concomitantly.
1466,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",pancreatin,Acarbose,mechanism,Intestinal adsorbents (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase pancreatin_first ) may reduce effect Acarbose_second taken concomitantly.
1467,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.",Acarbose,digoxin,mechanism,Acarbose_first shown change bioavailabillty digoxin_second co administered may require digoxin dose adjustment.
1468,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",metformin,Acarbose,mechanism,However peak plasma level metformin_first reduced approximately 20% taking Acarbose_second due slight delay absorption metformin.
1469,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",Acarbose,metformin,mechanism,However peak plasma level metformin reduced approximately 20% taking Acarbose_first due slight delay absorption metformin_second .
1470,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,carbachol,effect,Cyclopentolate_first may interfere anti glaucoma action carbachol_second pilocarpine;
1471,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,pilocarpine,effect,Cyclopentolate_first may interfere anti glaucoma action carbachol pilocarpine_second ;
1472,A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.,amiodarone,indinavir,mechanism,case report one patient taking amiodarone_first 200 mg indinavir_second 800 mg three times day resulted increases amiodarone concentrations 0.9 mg/L 1.3 mg/L.
1473,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.,amiodarone,protease inhibitor,advise,Monitoring amiodarone toxicity serial measurement amiodarone_first serum concentration concomitant protease inhibitor_second therapy considered.
1474,Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.,Histamine H2 antagonists,Cimetidine,mechanism,Histamine H2 antagonists_first : Cimetidine_second inhibits CYP3A4 increase serum amiodarone levels.
1475,"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.",amiodarone,digitalis,advise,administration oral amiodarone_first need digitalis_second therapy reviewed dose reduced approximately 50% discontinued.
1476,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",Nafazodone,Xanax,advise,Nafazodone_first fluvoxamine cimetidine (consider Xanax_second dose reduction).
1477,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",fluvoxamine,Xanax,advise,Nafazodone fluvoxamine_first cimetidine (consider Xanax_second dose reduction).
1478,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",cimetidine,Xanax,advise,Nafazodone fluvoxamine cimetidine_first (consider Xanax_second dose reduction).
1479,Concomitant use of calcium supplements and L-lysine may increase calcium absorption,calcium,L-lysine,mechanism,Concomitant use calcium_first supplements L-lysine_second may increase calcium absorption
1480,Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.,sympathomimetic amines,monoamine oxidase inhibitors,effect,Hypertensive crises resulted sympathomimetic amines_first used concomitantly within14 days following use monoamine oxidase inhibitors_second .
1481,DIDREX should not be used concomitantly with other CNS stimulants.,DIDREX,CNS stimulants,advise,DIDREX_first used concomitantly CNS stimulants_second .
1482,Amphetamines may decrease the hypotensive effect of antihypertensives.,Amphetamines,antihypertensives,effect,Amphetamines_first may decrease hypotensive effect antihypertensives_second .
1483,Amphetamines may enhance the effects of tricyclic antidepressants.,Amphetamines,tricyclic antidepressants,effect,Amphetamines_first may enhance effects tricyclic antidepressants_second .
1484,Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.,Urinary acidifying,amphetamines,mechanism,Urinary acidifying_first agents decrease blood levels increase excretion amphetamines_second .
1485,"In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.",labetalol HCl,tricyclic antidepressants,effect,one survey 2.3% patients taking labetalol HCl_first combination tricyclic antidepressants_second experienced tremor compared 0.7% reported occur labetalol HCl alone.
1486,Cimetidine has been shown to increase the bioavailability of labetalol HCl.,Cimetidine,labetalol HCl,mechanism,Cimetidine_first shown increase bioavailability labetalol HCl_second .
1487,Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.,halothane,labetalol HCl,effect,Synergism shown halothane_first anesthesia intravenously administered labetalol HCl_second .
1488,"During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.",labetalol HCl,halothane,effect,controlled hypotensive anesthesia using labetalol HCl_first association halothane_second high concentrations (3% above) halothane used degree hypotension increased possibility large reduction cardiac output increase central venous pressure.
1489,Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.,Labetalol HCl,nitroglycerin,effect,Labetalol HCl_first blunts reflex tachycardia produced nitroglycerin_second without preventing hypotensive effect.
1490,"If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.",labetalol HCl,nitroglycerin,effect,labetalol HCl_first used nitroglycerin_second patients angina pectoris additional antihypertensive effects may occur.
1491,Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.,labetalol,calcium antagonist,advise,Care taken labetalol_first used concomitantly calcium antagonist_second verapamil type.
1492,These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.,lead,alcohol,effect,results suggest exposure environmental lead_first may alter biological behavioral responsiveness animal alcohol_second .
1493,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants may produce severe prolonged hypertension.
1494,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second may produce severe prolonged hypertension.
1495,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants may produce severe prolonged hypertension.
1496,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second may produce severe prolonged hypertension.
1497,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,Phenothiazines_first butyrophenones may reduce reverse pressor effect epinephrine_second .
1498,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines butyrophenones_first may reduce reverse pressor effect epinephrine_second .
1499,Apraclonidine should not be used in patients receiving MAO inhibitors..,Apraclonidine,MAO inhibitors,advise,Apraclonidine_first used patients receiving MAO inhibitors_second ..
1500,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,CNS depressants,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants_second (alcohol barbiturates opiates sedatives anesthetics) considered.
1501,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,alcohol,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol_second barbiturates opiates sedatives anesthetics) considered.
1502,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,barbiturates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates_second opiates sedatives anesthetics) considered.
1503,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,opiates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates_second sedatives anesthetics) considered.
1504,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,sedatives,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives_second anesthetics) considered.
1505,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,anesthetics,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies IOPIDINE_first 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics_second ) considered.
1506,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.,Tricyclic antidepressants,clonidine,effect,Tricyclic antidepressants_first reported blunt hypotensive effect systemic clonidine_second .
1507,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.,clonidine,neuroleptic,effect,additive hypotensive effect reported combination systemic clonidine_first neuroleptic_second therapy.
1508,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,beta-blockers,advise,Since apraclonidine_first may reduce pulse blood pressure caution using drugs beta-blockers_second (ophthalmic systemic) antihypertensives cardiac glycosides advised.
1509,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,antihypertensives,advise,Since apraclonidine_first may reduce pulse blood pressure caution using drugs beta blockers (ophthalmic systemic) antihypertensives_second cardiac glycosides advised.
1510,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,cardiac glycosides,advise,Since apraclonidine_first may reduce pulse blood pressure caution using drugs beta blockers (ophthalmic systemic) antihypertensives cardiac glycosides_second advised.
1511,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip,anticoagulants of the coumarin type,effect,Bezalip Bezalip retard used time medicines substances following interactions must taken account: Bezalip_first Bezalip retard may enhance action anticoagulants coumarin type_second .
1512,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip retard,anticoagulants of the coumarin type,effect,Bezalip Bezalip retard used time medicines substances following interactions must taken account: Bezalip Bezalip retard_first may enhance action anticoagulants coumarin type_second .
1513,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,reason dose anticoagulant_first reduced 30 50% start treatment Bezalip_second Bezalip retard titrated according blood clotting parameters
1514,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,reason dose anticoagulant_first reduced 30 50% start treatment Bezalip Bezalip_second retard titrated according blood clotting parameters
1515,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip,effect,action sulphonylureas_first insulin may enhanced Bezalip_second Bezalip retard.
1516,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip retard,effect,action sulphonylureas_first insulin may enhanced Bezalip Bezalip retard_second .
1517,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip,effect,action sulphonylureas insulin_first may enhanced Bezalip_second Bezalip retard.
1518,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip retard,effect,action sulphonylureas insulin_first may enhanced Bezalip Bezalip retard_second .
1519,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.",immuno-suppressant,bezafibrate,effect,isolated cases pronounced though reversible impairment renal function (accompanied corresponding increase serum creatinine level) reported organ transplant patients receiving immuno-suppressant_first therapy concomitant bezafibrate_second .
1520,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,anion-exchange resins,advise,Bezalip_first Bezalip retard used concurrently anion-exchange resins_second (e.g. cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1521,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,cholestryramine,advise,Bezalip_first Bezalip retard used concurrently anion exchange resins (e.g. cholestryramine_second ) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1522,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,anion-exchange resins,advise,Bezalip Bezalip retard_first used concurrently anion-exchange resins_second (e.g. cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1523,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,cholestryramine,advise,Bezalip Bezalip retard_first used concurrently anion exchange resins (e.g. cholestryramine_second ) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1524,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip,advise,Perhexiline hydrogen maleate_first MAO inhibitors (with hepatotoxic potential) must administered together Bezalip_second Bezalip retard.
1525,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip retard,advise,Perhexiline hydrogen maleate_first MAO inhibitors (with hepatotoxic potential) must administered together Bezalip Bezalip retard_second .
1526,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip,advise,Perhexiline hydrogen maleate MAO-inhibitors_first (with hepatotoxic potential) must administered together Bezalip_second Bezalip retard.
1527,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip retard,advise,Perhexiline hydrogen maleate MAO-inhibitors_first (with hepatotoxic potential) must administered together Bezalip Bezalip retard_second .
1528,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitric oxide donor compounds,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds_first including sodium nitroprusside nitroglycerin may additive effect INOmax_second risk developing methemoglobinemia.
1529,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",sodium nitroprusside,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside_first nitroglycerin may additive effect INOmax_second risk developing methemoglobinemia.
1530,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitroglycerin,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside nitroglycerin_first may additive effect INOmax_second risk developing methemoglobinemia.
1531,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.,ketoconazole,budesonide,mechanism,Concomitant oral administration ketoconazole_first (a known inhibitor CYP3A4 activity liver intestinal mucosa) caused eight fold increase systemic exposure oral budesonide_second .
1532,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ketoconazole,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole_first intraconazole ritonavir indinavir saquinavir erythromycin etc.) indicated reduction budesonide_second dose considered.
1533,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",intraconazole,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole_first ritonavir indinavir saquinavir erythromycin etc.) indicated reduction budesonide_second dose considered.
1534,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ritonavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir_first indinavir saquinavir erythromycin etc.) indicated reduction budesonide_second dose considered.
1535,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",indinavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir_first saquinavir erythromycin etc.) indicated reduction budesonide_second dose considered.
1536,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",saquinavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir saquinavir_first erythromycin etc.) indicated reduction budesonide_second dose considered.
1537,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",erythromycin,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir saquinavir erythromycin_first etc.) indicated reduction budesonide_second dose considered.
1538,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,warfarin-type anticoagulants,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants_second phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1539,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin_second propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1540,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,propranolol,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol_second nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1541,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,nifedipine,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine_second chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1542,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,chlordiazepoxide,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide_second diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1543,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,diazepam,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam_second certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1544,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,tricyclic antidepressants,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants_second lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1545,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,lidocaine,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine_second theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1546,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline_second metronidazole thereby delaying elimination increasing blood levels drugs.
1547,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,metronidazole,mechanism,Tagamet_first apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole_second thereby delaying elimination increasing blood levels drugs.
1548,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.",anticoagulant,Tagamet,advise,therefore close monitoring prothrombin time recommended adjustment anticoagulant_first dose may necessary Tagamet_second administered concomitantly.
1549,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,mechanism,However crossover study healthy subjects receiving either Tagamet_first 300 mg q.i.d. 800 mg h.s. concomitantly 300 mg b.i.d. dosage theophylline_second (Theo Dur Key Pharmaceuticals Inc.) demonstrated less alteration steady state theophylline peak serum levels 800 mg h.s. regimen particularly subjects aged 54 years older.
1550,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,mechanism,However crossover study healthy subjects receiving either Tagamet_first 300 mg q.i.d. 800 mg h.s. concomitantly 300 mg b.i.d. dosage theophylline (Theo-Dur_second Key Pharmaceuticals Inc.) demonstrated less alteration steady state theophylline peak serum levels 800 mg h.s. regimen particularly subjects aged 54 years older.
1551,"Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.",ELLENCE,calcium channel blockers,advise,Concomitant use ELLENCE_first cardioactive compounds could cause heart failure (e.g. calcium channel blockers_second ) requires close monitoring cardiac function throughout treatment.
1552,Cimetidine increased the AUC of epirubicin by 50%.,Cimetidine,epirubicin,mechanism,Cimetidine_first increased AUC epirubicin_second 50%.
1553,Cimetidine treatment should be stopped during treatment with ELLENCE.,Cimetidine,ELLENCE,advise,Cimetidine_first treatment stopped treatment ELLENCE_second .
1554,MAO inhibitors prolong and intensify the effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors_first prolong intensify effects antihistamines_second .
1555,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,alcohol,effect,Concomitant use antihistamines_first alcohol_second tricyclic antidepressants barbiturates central nervous system depressants may additive effect.
1556,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,tricyclic antidepressants,effect,Concomitant use antihistamines_first alcohol tricyclic antidepressants_second barbiturates central nervous system depressants may additive effect.
1557,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,barbiturates,effect,Concomitant use antihistamines_first alcohol tricyclic antidepressants barbiturates_second central nervous system depressants may additive effect.
1558,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,central nervous system depressants,effect,Concomitant use antihistamines_first alcohol tricyclic antidepressants barbiturates central nervous system depressants_second may additive effect.
1559,"When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.",sympathomimetic drugs,monoamine oxidase inhibitors,effect,sympathomimetic drugs_first given patients receiving monoamine oxidase inhibitors_second hypertensive reactions including hypertensive crises may occur.
1560,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",methyldopa,sympathomimetics,effect,antihypertensive effects methyldopa_first mecamylamine reserpine veratrum alkaloids may reduced sympathomimetics_second .
1561,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",mecamylamine,sympathomimetics,effect,antihypertensive effects methyldopa mecamylamine_first reserpine veratrum alkaloids may reduced sympathomimetics_second .
1562,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",reserpine,sympathomimetics,effect,antihypertensive effects methyldopa mecamylamine reserpine_first veratrum alkaloids may reduced sympathomimetics_second .
1563,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",veratrum alkaloids,sympathomimetics,effect,antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids_first may reduced sympathomimetics_second .
1564,Beta-adrenergic blocking agents may also interact with sympathomimetics.,Beta-adrenergic blocking agents,sympathomimetics,int,Beta-adrenergic blocking agents_first may also interact sympathomimetics_second .
1565,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.,pseudoephedrine,digitalis,effect,Increased ectopic pacemaker activity occur pseudoephedrine_first used concomitantly digitalis_second .
1566,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",Antacids,pseudoephedrine,mechanism,Antacids_first increase rate absorption pseudoephedrine_second kaolin decreases it.
1567,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",pseudoephedrine,kaolin,mechanism,Antacids increase rate absorption pseudoephedrine_first kaolin_second decreases it.
1568,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,int,Dexbrompheniramine_first interact alcohol_second CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1569,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,int,Dexbrompheniramine_first interact alcohol CNS depressants_second (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1570,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,int,Dexbrompheniramine_first interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics_second medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1571,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,int,Dexbrompheniramine_first interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors_second (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1572,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).",TAXOL,cisplatin,effect,Phase trial using escalating doses TAXOL (110 200 mg/m2) cisplatin (50 75 mg/m2) given sequential infusions myelosuppression profound TAXOL_first given cisplatin_second alternate sequence (ie TAXOL cisplatin).
1573,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.,TAXOL,cisplatin,mechanism,Pharmacokinetic data patients demonstrated decrease paclitaxel clearance approximately 33% TAXOL_first administered following cisplatin_second .
1574,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.,paclitaxel,doxorubicin,mechanism,Reports literature suggest plasma levels doxorubicin (and active metabolite doxorubicinol) may increased paclitaxel_first doxorubicin_second used combination.
1575,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",cyclosporin,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg cyclosporin_first injection concentrate teniposide injection concentrate) treated TAXOL_second .
1576,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",teniposide,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg cyclosporin injection concentrate teniposide_first injection concentrate) treated TAXOL_second .
1577,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti-inflammatory agents_second azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1578,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,azoles,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles_second drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1579,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates_second sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1580,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides_second chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1581,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol_second probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1582,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid_second coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1583,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins_second monoamine oxidase inhibitors beta adrenergic blocking agents.
1584,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors_second beta adrenergic blocking agents.
1585,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,Immediate Extended Release Tablets hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents_second .
1586,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,int,potential interaction oral miconazole_first oral hypoglycemic agents_second leading severe hypoglycemia reported.
1587,The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.,fluconazole,glipizide,int,effect concomitant administration fluconazole_first glipizide_second demonstrated placebo controlled crossover study normal volunteers.
1588,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).,glipizide,fluconazole,mechanism,mean percentage increase glipizide_first AUC fluconazole_second administration 56.9% (range: 35 81).
1589,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",barbiturates,contraceptives,effect,Interactions may occur following: adrenocorticoids (cortisone like medicine) anticoagulants (blood thinners) carbamazepine corticotropin (barbiturates may decrease effects medicines) central nervous system (CNS) depressants (using medicines barbiturates may result increased CNS depressant effects) divalproex sodium valproic acid (using medicines barbiturates may change amount either medicine need take) oral contraceptives containing estrogens (barbiturates_first may decrease effectiveness oral contraceptives_second may need change different type birth control).
1590,ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE inhibitors Reports suggest NSAIDs_first may diminish antihypertensive effect ACE-inhibitors_second .
1591,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.,NSAIDs,ACE-inhibitors,advise,interaction given consideration patients taking NSAIDs_first concomitantly ACE-inhibitors_second .
1592,"Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.",Lodine,aspirin,mechanism,Aspirin: Lodine_first administered aspirin_second protein binding reduced although clearance free etodolac altered.
1593,"however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.",Lodine,aspirin,advise,however NSAIDs concomitant administration Lodine_first aspirin_second generally recommended potential increased adverse effects.
1594,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,cyclosporine,mechanism,Cyclosporine Digoxin Methotrexate Lodine_first like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine_second digoxin methotrexate increased toxicity.
1595,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,digoxin,mechanism,Cyclosporine Digoxin Methotrexate Lodine_first like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin_second methotrexate increased toxicity.
1596,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,methotrexate,mechanism,Cyclosporine Digoxin Methotrexate Lodine_first like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin methotrexate_second increased toxicity.
1597,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,cyclosporine,mechanism,Cyclosporine Digoxin Methotrexate Lodine like NSAIDs_first effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine_second digoxin methotrexate increased toxicity.
1598,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,digoxin,mechanism,Cyclosporine Digoxin Methotrexate Lodine like NSAIDs_first effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin_second methotrexate increased toxicity.
1599,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,methotrexate,mechanism,Cyclosporine Digoxin Methotrexate Lodine like NSAIDs_first effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin methotrexate_second increased toxicity.
1600,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,furosemide,effect,Nevertheless clinical studies well postmarketing observations shown Lodine_first reduce natriuretic effect furosemide_second thiazides patients.
1601,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,thiazides,effect,Nevertheless clinical studies well postmarketing observations shown Lodine_first reduce natriuretic effect furosemide thiazides_second patients.
1602,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: NSAIDs_first produced elevation plasma lithium_second levels reduction renal lithium clearance.
1603,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,effect,Thus NSAIDs_first lithium_second administered concurrently subjects observed carefully signs lithium toxicity.
1604,Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.,Phenylbutazone,etodolac,mechanism,Phenylbutazone: Phenylbutazone_first causes increase (by 80%) free fraction etodolac_second .
1605,"Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.",etodolac,phenylbutazone,advise,Although vivo studies done see etodolac_first clearance changed coadministration phenylbutazone_second recommended coadministered.
1606,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: effects warfarin_first NSAIDs_second GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone.
1607,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,Lodine,mechanism,Short term pharmacokinetic studies demonstrated concomitant administration warfarin_first Lodine_second (etodolac capsules tablets) results reduced protein binding warfarin change clearance free warfarin.
1608,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,etodolac,mechanism,Short term pharmacokinetic studies demonstrated concomitant administration warfarin_first Lodine (etodolac_second capsules tablets) results reduced protein binding warfarin change clearance free warfarin.
1609,"However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.",etodolac,warfarin,effect,However caution exercised spontaneous reports prolonged prothrombin times without bleeding etodolac_first treated patients receiving concomitant warfarin_second therapy.
1610,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.",aspirin,nizatidine,mechanism,patients given high doses (3900 mg) aspirin_first daily increases serum salicylate levels seen nizatidine_second 150 mg b.i.d. administered concurrently.
1611,Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ,ethanol,disulfiram,effect,Core temperature decreased rats dose dependent manner ethanol_first administered rats treated disulfiram_second 8 hours ethanol challenge.
1612,"Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ",Acetaminophen,theophylline,mechanism,Acetaminophen_first diminished binding theophylline_second human serum net change 5.7% (percentage increase free drug fraction [FDF] 11.0%) 662 micromol/L net change 7.1% (percentage increase FDF 13.7%) 1324 micromol/L.
1613,"Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ",Theophylline,acetaminophen,mechanism,Theophylline_first decreased binding acetaminophen_second net change 6.8% (percentage increase FDF 8.8%) 277.5 micromol/L;
1614,"Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ",Valproic acid,phenobarbital,mechanism,Valproic acid_first diminished binding phenobarbital_second net change 9.9% (percentage increase FDF 21.2%) 1732 micromol/L.
1615,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",acetaminophen,theophylline,effect,Coingestion acetaminophen_first theophylline_second phenobarbital acetaminophen valproic acid phenobarbital high toxic concentrations decreases binding target drug.
1616,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",phenobarbital,acetaminophen,effect,Coingestion acetaminophen theophylline phenobarbital_first acetaminophen_second valproic acid phenobarbital high toxic concentrations decreases binding target drug.
1617,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",valproic acid,phenobarbital,effect,Coingestion acetaminophen theophylline phenobarbital acetaminophen valproic acid_first phenobarbital_second high toxic concentrations decreases binding target drug.
1618,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,CNS depressants,effect,Additive CNS depression may occur antihistamines_first administered concomitantly CNS depressants_second including barbiturates tranquilizers alcohol.
1619,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,barbiturates,effect,Additive CNS depression may occur antihistamines_first administered concomitantly CNS depressants including barbiturates_second tranquilizers alcohol.
1620,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,tranquilizers,effect,Additive CNS depression may occur antihistamines_first administered concomitantly CNS depressants including barbiturates tranquilizers_second alcohol.
1621,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,alcohol,effect,Additive CNS depression may occur antihistamines_first administered concomitantly CNS depressants including barbiturates tranquilizers alcohol_second .
1622,Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.,antihistamines,CNS depressant drugs,advise,Patients receiving antihistamines_first advised concurrent use CNS depressant drugs_second .
1623,Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.,Monoamine oxidase (MAO) inhibitors,antihistamines,effect,Monoamine oxidase (MAO) inhibitors_first prolong intensify anticholinergic effects antihistamines_second .
1624,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,sympathomimetic,effect,Administration doxapram_first patients receiving sympathomimetic_second monoamine oxidase inhibiting drugs may result additive pressor effect .
1625,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,monoamine oxidase inhibiting drugs,effect,Administration doxapram_first patients receiving sympathomimetic monoamine oxidase inhibiting drugs_second may result additive pressor effect .
1626,"In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.",doxapram,muscle relaxant drugs,effect,patients received muscle relaxants doxapram_first may temporarily mask residual effects muscle relaxant drugs_second .
1627,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,ERGOMAR,triacetyloleandomycin,mechanism,effects ERGOMAR_first may potentiated triacetyloleandomycin_second inhibits metabolism ergotamine.
1628,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,triacetyloleandomycin,ergotamine,mechanism,effects ERGOMAR may potentiated triacetyloleandomycin_first inhibits metabolism ergotamine_second .
1629,The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.,ERGOMAR,vasoconstrictor drugs,effect,pressor effects ERGOMAR_first vasoconstrictor drugs_second combine cause dangerous hypertension.
1630,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",xanthine bronchodilators,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators_first (e.g. theophylline) ephedrine sympathomimetic bronchodilators_second reported.
1631,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",theophylline,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e.g. theophylline_first ) ephedrine sympathomimetic bronchodilators_second reported.
1632,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",ephedrine,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e.g. theophylline) ephedrine_first sympathomimetic bronchodilators_second reported.
1633,"Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",dyphylline,probenecid,mechanism,Concurrent administration dyphylline_first probenecid_second competes tubular secretion shown increase plasma half life dyphylline .
1634,"However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.",carbonic anhydrase inhibitors,salicylate,int,However patients treated oral carbonic anhydrase inhibitors_first rare instances drug interactions occurred high dose salicylate_second therapy.
1635,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.,levetiracetam,AEDs,mechanism,Effect AEDs Pediatric Patients 22% increase apparent total body clearance levetiracetam_first co administered enzyme inducing AEDs_second .
1636,"When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.",probenecid,ertapenem,mechanism,ertapenem co administered probenecid (500 mg p.o. every 6 hours) probenecid_first competes active tubular secretion reduces renal clearance ertapenem_second .
1637,"Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.",ertapenem,probenecid,mechanism,Based total ertapenem_first concentrations probenecid_second increased AUC 25% reduced plasma renal clearances 20% 35% respectively.
1638,"Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.",probenecid,ertapenem,advise,small effect half life coadministration probenecid_first extend half life ertapenem_second recommended.
1639,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",ketoconazole,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole_first itraconazole erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma bexarotene_second concentrations.
1640,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",itraconazole,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole itraconazole_first erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma bexarotene_second concentrations.
1641,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",erythromycin,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole itraconazole erythromycin_first gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma bexarotene_second concentrations.
1642,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",gemfibrozil,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole itraconazole erythromycin gemfibrozil_first grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma bexarotene_second concentrations.
1643,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",rifampin,bexarotene,mechanism,Furthermore rifampin_first phenytoin phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma bexarotene_second concentrations.
1644,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenytoin,bexarotene,mechanism,Furthermore rifampin phenytoin_first phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma bexarotene_second concentrations.
1645,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenobarbital,bexarotene,mechanism,Furthermore rifampin phenytoin phenobarbital_first inducers cytochrome P450 3A4 may cause reduction plasma bexarotene_second concentrations.
1646,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.",Targretin,gemfibrozil,mechanism,Concomitant administration Targretin_first capsules gemfibrozil_second resulted substantial increases plasma concentrations bexarotene probably least partially related cytochrome P450 3A4 inhibition gemfibrozil.
1647,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.,gemfibrozil,Targretin,advise,Concomitant administration gemfibrozil_first Targretin_second capsules recommended.
1648,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,effect,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine_first administered ondansetron_second concomitant use apomorphine drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1649,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,5HT3 antagonist class,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class_second (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1650,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class (including example ondansetron_second granisetron dolasetron palonosetron alosetron) contraindicated .
1651,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,granisetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class (including example ondansetron granisetron_second dolasetron palonosetron alosetron) contraindicated .
1652,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,dolasetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron_second palonosetron alosetron) contraindicated .
1653,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,palonosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron_second alosetron) contraindicated .
1654,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,alosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use apomorphine_first drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron alosetron_second ) contraindicated .
1655,"Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.",antihypertensive medications,vasodilators,effect,Antihypertensive Medications Vasodilators: following adverse events experienced commonly patients receiving concomitant antihypertensive medications_first vasodilators_second (n = 94) compared patients receiving concomitant drugs (n = 456): hypotension 10% vs 4% myocardial infarction 3% vs 1% serious pneumonia 5% vs 3% serious falls 9% vs 3% bone joint injuries 6% vs 2%.
1656,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",dopamine antagonists,metoclopramide,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists_first neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide_second may diminish effectiveness APOKYN.
1657,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",phenothiazines,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines_first butyrophenones thioxanthenes) metoclopramide may diminish effectiveness APOKYN_second .
1658,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",butyrophenones,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones_first thioxanthenes) metoclopramide may diminish effectiveness APOKYN_second .
1659,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",thioxanthenes,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes_first ) metoclopramide may diminish effectiveness APOKYN_second .
1660,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",metoclopramide,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide_first may diminish effectiveness APOKYN_second .
1661,"Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.",neuroleptics,dopamine agonists,advise,Patients major psychotic disorders treated neuroleptics_first treated dopamine agonists_second potential benefits outweigh risks.
1662,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants may produce severe prolonged hypertension.
1663,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second may produce severe prolonged hypertension.
1664,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants may produce severe prolonged hypertension.
1665,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second may produce severe prolonged hypertension.
1666,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,Phenothiazines_first butyrophenones may reduce reverse pressor effect epinephrine_second .
1667,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines butyrophenones_first may reduce reverse pressor effect epinephrine_second .
1668,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,centrally acting drugs,advise,Drug Drug Interactions Given primary CNS effects aripiprazole caution used ABILIFY_first taken combination centrally acting drugs_second alcohol.
1669,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,alcohol,advise,Drug Drug Interactions Given primary CNS effects aripiprazole caution used ABILIFY_first taken combination centrally acting drugs alcohol_second .
1670,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.",aripiprazole,antihypertensive agents,effect,1 adrenergic receptor antagonism aripiprazole_first potential enhance effect certain antihypertensive agents_second .
1671,"Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.",carbamazepine,aripiprazole,mechanism,Agents induce CYP3A4 (eg carbamazepine_first ) could cause increase aripiprazole_second clearance lower blood levels.
1672,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",ketoconazole,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole_first ) CYP2D6 (eg quinidine fluoxetine paroxetine) inhibit aripiprazole_second elimination cause increased blood levels.
1673,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",quinidine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine_first fluoxetine paroxetine) inhibit aripiprazole_second elimination cause increased blood levels.
1674,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",fluoxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine fluoxetine_first paroxetine) inhibit aripiprazole_second elimination cause increased blood levels.
1675,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",paroxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine fluoxetine paroxetine_first ) inhibit aripiprazole_second elimination cause increased blood levels.
1676,"Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",ketoconazole,aripiprazole,mechanism,Ketoconazole: Coadministration ketoconazole_first (200 mg/day 14 days) 15 mg single dose aripiprazole_second increased AUC aripiprazole active metabolite 63% 77% respectively.
1677,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.",ketoconazole,aripiprazole,advise,concomitant administration ketoconazole_first aripiprazole_second occurs aripiprazole dose reduced one half normal dose.
1678,"Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",aripiprazole,quinidine,mechanism,Quinidine: Coadministration 10 mg single dose aripiprazole_first quinidine_second (166 mg/day 13 days) potent inhibitor CYP2D6 increased AUC aripiprazole 112% decreased AUC active metabolite dehydroaripiprazole 35%.
1679,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.,quinidine,aripiprazole,advise,Aripiprazole dose reduced one half normal dose concomitant administration quinidine_first aripiprazole_second occurs.
1680,"Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",carbamazepine,aripiprazole,mechanism,Carbamazepine: Coadministration carbamazepine_first (200 mg BID) potent CYP3A4 inducer aripiprazole_second (30 mg QD) resulted approximate 70% decrease Cmax AUC values aripiprazole active metabolite dehydro aripiprazole.
1681,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.",carbamazepine,aripiprazole,advise,carbamazepine_first added aripiprazole_second therapy aripiprazole dose doubled.
1682,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.",carbamazepine,aripiprazole,advise,carbamazepine_first withdrawn combination therapy aripiprazole_second dose reduced.
1683,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY",alcohol,ABILIFY,advise,psychoactive medications patients advised avoid alcohol_first taking ABILIFY_second
1684,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,effect,Dexbrompheniramine_first interact alcohol_second CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1685,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,effect,Dexbrompheniramine_first interact alcohol CNS depressants_second (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1686,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,effect,Dexbrompheniramine_first interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics_second medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1687,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,effect,Dexbrompheniramine_first interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors_second (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1688,Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.,cholestyramine,vitamin K,mechanism,Cholestyramine Concomitant intake cholestyramine_first vitamin K_second may reduce absorption vitamin K.
1689,Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.,colestipol,vitamin K,mechanism,Colestipol Concomitant intake colestipol_first vitamin K_second may reduce absorption vitamin K.
1690,Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.,mineral oil,vitamin K,mechanism,Mineral Oil Concomitant intake mineral oil_first vitamin K_second may reduce absorption vitamin K.
1691,Orlistat-Orlistat may decrease the absorption of vitamin K.,Orlistat,vitamin K,mechanism,Orlistat Orlistat_first may decrease absorption vitamin K_second .
1692,Warfarin-Vitamin K can antagonize the effect of warfarin,Vitamin K,warfarin,effect,Warfarin Vitamin K_first antagonize effect warfarin_second
1693,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,rifabutin,mechanism,Amprenavir_first significantly increased area curve steady state (AUC(ss)) rifabutin_second 2.93 fold AUC(ss) 25 desacetylrifabutin 13.3 fold.
1694,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,25-O-desacetylrifabutin,mechanism,Amprenavir_first significantly increased area curve steady state (AUC(ss)) rifabutin 2.93 fold AUC(ss) 25-O-desacetylrifabutin_second 13.3 fold.
1695,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",Rifampin,amprenavir,mechanism,Rifampin_first significantly decreased AUC(ss) amprenavir_second 82% amprenavir effect rifampin pharmacokinetics.
1696,"Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. ",Amprenavir,rifabutin,effect,Amprenavir_first plus rifabutin_second poorly tolerated 5 11 subjects discontinued therapy.
1697,"Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. ",Rifampin,amprenavir,mechanism,Rifampin_first markedly increases metabolic clearance amprenavir_second coadministration contraindicated.
1698,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,rifabutin,mechanism,Amprenavir_first significantly decreases clearance rifabutin_second 25 desacetylrifabutin combination poorly tolerated.
1699,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,25-O-desacetylrifabutin,mechanism,Amprenavir_first significantly decreases clearance rifabutin 25-O-desacetylrifabutin_second combination poorly tolerated.
1700,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.,nisoldipine,cimetidine 400 mg,mechanism,30 45% increase AUC Cmax nisoldipine_first observed concomitant administration cimetidine 400 mg_second twice daily.
1701,Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,phenytoin,SULAR,mechanism,Coadministration phenytoin_first 40 mg SULAR_second tablets epileptic patients lowered nisoldipine plasma concentrations undetectable levels.
1702,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.,SULAR,phenytoin,advise,Coadministration SULAR_first phenytoin_second known CYP3A4 inducer avoided alternative antihypertensive therapy considered.
1703,Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.,Propranolol,nisoldipine,effect,Propranolol_first attenuated heart rate increase following administration immediate release nisoldipine_second .
1704,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.,SULAR,atenolol,effect,blood pressure effect SULAR_first tended greater patients atenolol_second patients antihypertensive therapy.
1705,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.",Quinidine,nisoldipine,mechanism,Quinidine_first 648 mg bid decreased bioavailability (AUC) nisoldipine_second 26% peak concentration.
1706,"The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.",nisoldipine,quinidine,mechanism,immediate release coat core formulation nisoldipine_first increased plasma quinidine_second concentrations 20%.
1707,"It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.",buspirone hydrochloride,MAO inhibitors,advise,recommended buspirone hydrochloride_first used concomitantly MAO inhibitors_second effects concomitant administration buspirone HCl psychotropic drugs studied concomitant use buspirone HCl CNS active drugs approached caution.
1708,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,trazodone hydrochloride,buspirone HCl,effect,one report suggesting concomitant use trazodone hydrochloride_first (Desyrel) buspirone HCl_second may caused 3 6 fold elevations SGPT (ALT) patients.
1709,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,Desyrel,buspirone HCl,effect,one report suggesting concomitant use trazodone hydrochloride (Desyrel_first ) buspirone HCl_second may caused 3 6 fold elevations SGPT (ALT) patients.
1710,"In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.",buspirone HCl,haloperidol,mechanism,study normal volunteers concomitant administration buspirone HCl_first haloperidol_second resulted increased serum haloperidol concentrations.
1711,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.",buspirone,warfarin,effect,However one report prolonged prothrombin time buspirone_first added regimen patient treated warfarin_second .
1712,"In vitro, buspirone may displace less firmly bound drugs like digoxin.",buspirone,digoxin,mechanism,vitro buspirone_first may displace less firmly bound drugs like digoxin_second .
1713,Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.,L-phenylalanine,non-selective MAO inhibitors,effect,Concomitant use L-phenylalanine_first non-selective MAO inhibitors_second may cause hypertension.
1714,Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.,L-phenylalanine,selegiline,effect,Selegiline L-phenylalanine_first selective MAO inhibitor selegiline_second may synergistic antidepressant activity used concomitantly.
1715,Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.,Neuroleptic Drugs,L-phenylalanine,effect,Neuroleptic Drugs_first L-phenylalanine_second may potentiate tardive dyskinesia side reactions neuroleptic drugs used concomitantly them.
1716,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,psychoactive drugs,advise,Nabilone_first administered caution patients taking psychoactive drugs_second CNS depressants including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1717,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,CNS depressants,advise,Nabilone_first administered caution patients taking psychoactive drugs CNS depressants_second including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1718,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,alcohol,advise,Nabilone_first administered caution patients taking psychoactive drugs CNS depressants including alcohol_second barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1719,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,barbiturates,advise,Nabilone_first administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates_second narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1720,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,narcotic analgesics,advise,Nabilone_first administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates narcotic analgesics_second history psychiatric disorder (including manic depressive illness schizophrenia).
1721,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,diazepam,effect,Nabilone_first shown additive CNS depressant effect given either diazepam_second secobarbitone sodium alcohol codeine.
1722,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,secobarbitone sodium,effect,Nabilone_first shown additive CNS depressant effect given either diazepam secobarbitone sodium_second alcohol codeine.
1723,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,alcohol,effect,Nabilone_first shown additive CNS depressant effect given either diazepam secobarbitone sodium alcohol_second codeine.
1724,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,codeine,effect,Nabilone_first shown additive CNS depressant effect given either diazepam secobarbitone sodium alcohol codeine_second .
1725,"Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac tromethamine,mechanism,Warfarin Digoxin Salicylate Heparin vitro binding warfarin_first plasma proteins slightly reduced ketorolac tromethamine_second (99.5% control vs 99.3%) ketorolac plasma concentrations reach 5 to10 g/mL.
1726,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.",salicylate,ketorolac,mechanism,vitro studies indicate therapeutic concentrations salicylate_first (300 g/mL) binding ketorolac_second reduced approximately 99.2% 97.5% representing potential twofold increase unbound ketorolac plasma levels.
1727,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.",TORADOL,anticoagulants,advise,Although results indicate significant interaction TORADOL warfarin heparin administration TORADOL_first patients taking anticoagulants_second done extremely cautiously patients closely monitored.
1728,Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,furosemide,effect,Furosemide: TORADOL_first IV/IM reduced diuretic response furosemide_second normovolemic healthy subjects approximately 20% (mean sodium urinary output decreased 17%).
1729,Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,probenecid,mechanism,Probenecid: Concomitant administration TORADOL_first ORAL probenecid_second resulted decreased clearance ketorolac significant increases ketorolac plasma levels (total AUC increased approximately threefold 5.4 17.8 g/h/mL) terminal half life increased approximately twofold 6.6 15.1 hours.
1730,"Therefore, concomitant use of TORADOL and probenecid is contraindicated.",TORADOL,probenecid,advise,Therefore concomitant use TORADOL_first probenecid_second contraindicated.
1731,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.",lithium,TORADOL,mechanism,effect TORADOL plasma lithium studied cases increased lithium_first plasma levels TORADOL_second therapy reported.
1732,"Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",methotrexate,NSAIDs,mechanism,Methotrexate: Concomitant administration methotrexate_first NSAIDs_second reported reduce clearance methotrexate enhancing toxicity methotrexate.
1733,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,antiepileptic drugs,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use TORADOL_first antiepileptic drugs_second (phenytoin carbamazepine).
1734,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,phenytoin,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use TORADOL_first antiepileptic drugs (phenytoin_second carbamazepine).
1735,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,carbamazepine,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use TORADOL_first antiepileptic drugs (phenytoin carbamazepine_second ).
1736,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,psychoactive drugs,effect,Psychoactive Drugs: Hallucinations reported TORADOL_first used patients taking psychoactive drugs_second (fluoxetine thiothixene alprazolam).
1737,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,fluoxetine,effect,Psychoactive Drugs: Hallucinations reported TORADOL_first used patients taking psychoactive drugs (fluoxetine_second thiothixene alprazolam).
1738,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,thiothixene,effect,Psychoactive Drugs: Hallucinations reported TORADOL_first used patients taking psychoactive drugs (fluoxetine thiothixene_second alprazolam).
1739,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,alprazolam,effect,Psychoactive Drugs: Hallucinations reported TORADOL_first used patients taking psychoactive drugs (fluoxetine thiothixene alprazolam_second ).
1740,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,ACE inhibitors,mechanism,Lithium Reversible increases serum lithium concentrations toxicity reported concomitant administration lithium_first ACE inhibitors_second angiotensin II receptor antagonists.
1741,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,angiotensin II receptor antagonists,mechanism,Lithium Reversible increases serum lithium concentrations toxicity reported concomitant administration lithium_first ACE inhibitors angiotensin II receptor antagonists_second .
1742,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",lithium,ATACAND,mechanism,increase serum lithium concentration reported concomitant administration lithium_first ATACAND_second careful monitoring serum lithium levels recommended concomitant use.
1743,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,alcohol,int,Benzthiazide_first may interact alcohol_second blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1744,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,blood thinner,int,Benzthiazide_first may interact alcohol blood thinner_second decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1745,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,decongestant drugs,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs_second (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1746,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,lithium,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium_second norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1747,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,norepinephrine,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine_second NSAIDs like Aleve Ibuprofen high blood pressure medications.
1748,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,NSAIDs,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs_second like Aleve Ibuprofen high blood pressure medications.
1749,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Aleve,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve_second Ibuprofen high blood pressure medications.
1750,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Ibuprofen,int,Benzthiazide_first may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen_second high blood pressure medications.
1751,"The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.",alcohol,bromocriptine mesylate,effect,risk using bromocriptine mesylate combination drugs systematically evaluated alcohol_first may potentiate side effects bromocriptine mesylate_second .
1752,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,dopamine antagonists,int,Bromocriptine mesylate_first may interact dopamine antagonists_second butyrophenones certain agents.
1753,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,butyrophenones,int,Bromocriptine mesylate_first may interact dopamine antagonists butyrophenones_second certain agents.
1754,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,phenothiazines,effect,Compounds categories result decreased efficacy bromocriptine mesylate_first : phenothiazines_second haloperidol metoclopramide pimozide.
1755,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,haloperidol,effect,Compounds categories result decreased efficacy bromocriptine mesylate_first : phenothiazines haloperidol_second metoclopramide pimozide.
1756,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,metoclopramide,effect,Compounds categories result decreased efficacy bromocriptine mesylate_first : phenothiazines haloperidol metoclopramide_second pimozide.
1757,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,pimozide,effect,Compounds categories result decreased efficacy bromocriptine mesylate_first : phenothiazines haloperidol metoclopramide pimozide_second .
1758,Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.,bromocriptine mesylate,ergot alkaloids,advise,Concomitant use bromocriptine mesylate_first ergot alkaloids_second recommended.
1759,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,coumarin-derivative anticoagulants,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking capecitabine_first concomitantly coumarin-derivative anticoagulants_second warfarin phenprocoumon.
1760,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,phenprocoumon,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking capecitabine_first concomitantly coumarin derivative anticoagulants warfarin phenprocoumon_second .
1761,Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).,coumarin-derivative anticoagulants,capecitabine,advise,Patients taking coumarin-derivative anticoagulants_first concomitantly capecitabine_second monitored regularly alterations coagulation parameters (PT INR).
1762,Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.,5-fluorouracil,leucovorin,mechanism,Leucovorin: concentration 5-fluorouracil_first increased toxicity may enhanced leucovorin_second .
1763,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.",leucovorin,fluorouracil,effect,Deaths severe enterocolitis diarrhea dehydration reported elderly patients receiving weekly leucovorin_first fluorouracil_second .
1764,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",Iodine,Carbimazole,effect,Iodine_first iodine excess may decrease effect Carbimazole_second iodine deficiency increase effect Carbimazole.
1765,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",iodine,Carbimazole,effect,Iodine iodine excess may decrease effect Carbimazole iodine_first deficiency increase effect Carbimazole_second .
1766,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digoxin,antithyroid agents,mechanism,Serum concentration digoxin_first digitoxin may increase patients take antithyroid agents_second .
1767,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digitoxin,antithyroid agents,mechanism,Serum concentration digoxin digitoxin_first may increase patients take antithyroid agents_second .
1768,"Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",Antithyroid agents,sodium iodide I131,effect,Antithyroid agents_first may decrease thyroidal uptake sodium iodide I131_second rebound uptake may occur 5 days sudden withdrawal Carbimazole.
1769,"Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.",buprenorphine,benzodiazepines,int,Based anecdotal reports may interaction buprenorphine_first benzodiazepines_second .
1770,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.,buprenorphine,benzodiazepines,effect,number reports post marketing experience coma death associated concomitant intravenous misuse buprenorphine_first benzodiazepines_second addicts.
1771,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,advise,SUBUTEX_first SUBOXONE prescribed caution patients benzodiazepines_second drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse.
1772,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBOXONE,benzodiazepines,advise,SUBUTEX SUBOXONE_first prescribed caution patients benzodiazepines_second drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse.
1773,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBOXONE,advise,Patients warned potential danger intravenous self administration benzodiazepines_first treatment SUBOXONE_second SUBUTEX.
1774,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBUTEX,advise,Patients warned potential danger intravenous self administration benzodiazepines_first treatment SUBOXONE SUBUTEX_second .
1775,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,cimetidine,mechanism,Blood levels hydrodolasetron increased 24% dolasetron_first coadministered cimetidine_second (nonselective inhibitor cytochrome P 450) 7 days decreased 28% coadministration rifampin (potent inducer cytochrome P 450) 7 days.
1776,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,rifampin,mechanism,Blood levels hydrodolasetron increased 24% dolasetron_first coadministered cimetidine (nonselective inhibitor cytochrome P 450) 7 days decreased 28% coadministration rifampin_second (potent inducer cytochrome P 450) 7 days.
1777,Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.,dolasetron mesylate,atenolol,mechanism,Clearance hydrodolasetron decreased 27% dolasetron mesylate_first administered intravenously concomitantly atenolol_second .
1778,Chlorprothixene may increase the plasma-level of concomitantly given lithium.,Chlorprothixene,lithium,mechanism,Chlorprothixene_first may increase plasma level concomitantly given lithium_second .
1779,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,advise,chlorprothixene_first given concomitantly opioids_second opioid dose reduced (by approx. 50%) chlorprothixene amplifies therapeutic actions side effects opioids massively.
1780,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,effect,chlorprothixene given concomitantly opioids opioid dose reduced (by approx. 50%) chlorprothixene_first amplifies therapeutic actions side effects opioids_second massively.
1781,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,tramadol,advise,Avoid concomitant use chlorprothixene_first tramadol_second (Ultram).
1782,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,Ultram,advise,Avoid concomitant use chlorprothixene_first tramadol (Ultram_second ).
1783,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,benzodiazepines,effect,Consider additive sedative effects confusional states emerge chlorprothixene_first given benzodiazepines_second barbituates.
1784,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,barbituates,effect,Consider additive sedative effects confusional states emerge chlorprothixene_first given benzodiazepines barbituates_second .
1785,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,anticholinergic drugs,advise,Exert particular caution combining chlorprothixene_first anticholinergic drugs_second (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1786,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,tricyclic antidepressants,advise,Exert particular caution combining chlorprothixene_first anticholinergic drugs (tricyclic antidepressants_second antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1787,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,antiparkinsonian agents,advise,Exert particular caution combining chlorprothixene_first anticholinergic drugs (tricyclic antidepressants antiparkinsonian agents_second ): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1788,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,antiepileptic drugs,mechanism,Use Conjunction Antiepileptic Drugs: addition Felbatol_first antiepileptic drugs_second (AEDs) affects steady state plasma concentrations AEDs.
1789,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,AEDs,mechanism,Use Conjunction Antiepileptic Drugs: addition Felbatol_first antiepileptic drugs (AEDs_second ) affects steady state plasma concentrations AEDs.
1790,Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.,Felbatol,phenytoin,mechanism,Specific Effects Felbatol Antiepileptic Drugs Phenytoin: Felbatol_first causes increase steady state phenytoin_second plasma concentrations.
1791,Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.,felbamate,phenytoin,mechanism,Increasing felbamate_first dose 1800 mg/day six subjects increased steady state phenytoin_second Cmin 25 7 micrograms/mL.
1792,"In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,advise,order maintain phenytoin levels limit adverse experiences achieve felbamate_first dose 3600 mg/day phenytoin_second dose reduction approximately 40% necessary eight 10 subjects.
1793,Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,Felbatol,carbamazepine,mechanism,Carbamazepine: Felbatol_first causes decrease steady state carbamazepine_second plasma concentrations increase steady state carbamazepine epoxide plasma concentration.
1794,"The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.",carbamazepine,felbamate,mechanism,carbamazepine_first steady state Cmin decreased 31% 5 1 micrograms/mL felbamate_second (3000 mg/day divided three doses) coadministered.
1795,Valproate: Felbatol  causes an increase in steady-state valproate concentrations.,Felbatol,valproate,mechanism,Valproate: Felbatol_first causes increase steady state valproate_second concentrations.
1796,Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.,felbamate,valproate,mechanism,Increasing felbamate_first dose 2400 mg/day increased steadystate valproate_second Cmin 96 25 micrograms/mL.
1797,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.",felbamate,phenobarbital,mechanism,Phenobarbital: Coadministration felbamate_first phenobarbital_second causes increase phenobarbital plasma concentrations 12 otherwise healthy male volunteers ingesting phenobarbital steady state trough (Cmin) phenobarbital concentration 14.2 micrograms/mL.
1798,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,Felbatol,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: Phenytoin_first causes approximate doubling clearance Felbatol_second (felbamate) steady state therefore addition phenytoin causes approximate 45% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1799,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,felbamate,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: Phenytoin_first causes approximate doubling clearance Felbatol (felbamate_second ) steady state therefore addition phenytoin causes approximate 45% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1800,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",phenytoin,Felbatol,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: Phenytoin causes approximate doubling clearance Felbatol (felbamate) steady state therefore addition phenytoin_first causes approximate 45% decrease steady state trough concentrations Felbatol_second compared dose Felbatol given monotherapy.
1801,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Carbamazepine,Felbatol,mechanism,Carbamazepine: Carbamazepine_first causes approximate 50% increase clearance Felbatol_second steady state therefore addition carbamazepine results approximate 40% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1802,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",carbamazepine,Felbatol,mechanism,Carbamazepine: Carbamazepine causes approximate 50% increase clearance Felbatol steady state therefore addition carbamazepine_first results approximate 40% decrease steady state trough concentrations Felbatol_second compared dose Felbatol given monotherapy.
1803,Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.,phenobarbital,felbamate,mechanism,Phenobarbital: appears phenobarbital_first may reduce plasma felbamate_second concentrations.
1804,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",Felbamate,gestodene,mechanism,Felbamate_first treatment resulted 42% decrease gestodene_second AUC 0 24 clinically relevant effect observed pharmacokinetic parameters ethinyl estradiol.
1805,Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.,Chirocaine,anesthetics,advise,Chirocaine_first used caution patients receiving local anesthetics_second agents structurally related amide type local anesthetics since toxic effects drugs could additive.
1806,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenytoin,mechanism,Although clinical studies conducted likely metabolism levobupivacaine_first may affected known CYP3A4 inducers (such phenytoin_second phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1807,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenobarbital,mechanism,Although clinical studies conducted likely metabolism levobupivacaine_first may affected known CYP3A4 inducers (such phenytoin phenobarbital_second rifampin) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1808,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,rifampin,mechanism,Although clinical studies conducted likely metabolism levobupivacaine_first may affected known CYP3A4 inducers (such phenytoin phenobarbital rifampin_second ) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1809,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,ketoconazole,mechanism,Although clinical studies conducted likely metabolism levobupivacaine_first may affected known CYP3A4 inducers (such phenytoin phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole_second ;
1810,Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.,Nicotinic acid,ganglionic blocking agents,effect,Interactions Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid_first may potentiate effects ganglionic blocking agents_second vasoactive drugs resulting postural hypotension.
1811,Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.,aspirin,nicotinic acid,mechanism,Aspirin: Concomitant aspirin_first may decrease metabolic clearance nicotinic acid_second .
1812,Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,irbesartan,aliskiren,mechanism,Co administration irbesartan_first reduced aliskiren_second Cmax 50% multiple dosing.
1813,Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,atorvastatin,aliskiren,mechanism,Co administration atorvastatin_first resulted 50% increase aliskiren_second Cmax AUC multiple dosing.
1814,Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,ketoconazole,aliskiren,mechanism,Ketoconazole: Co administration 200 mg twice daily ketoconazole_first aliskiren_second resulted approximate 80% increase plasma levels aliskiren.
1815,"Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,mechanism,Furosemide: aliskiren_first co administered furosemide_second AUC Cmax furosemide reduced 30% 50% respectively.
1816,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,morphine,effect,ibogaine_first 18 MC block morphine_second induced nicotine induced dopamine release nucleus accumbens;
1817,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,nicotine,effect,ibogaine_first 18 MC block morphine induced nicotine_second induced dopamine release nucleus accumbens;
1818,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,morphine,effect,ibogaine 18-MC_first block morphine_second induced nicotine induced dopamine release nucleus accumbens;
1819,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,nicotine,effect,ibogaine 18-MC_first block morphine induced nicotine_second induced dopamine release nucleus accumbens;
1820,only ibogaine enhances cocaine-induced increases in accumbal dopamine. ,ibogaine,cocaine,effect,ibogaine_first enhances cocaine_second induced increases accumbal dopamine.
1821,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",Ibogaine,morphine,effect,Ibogaine_first attenuates 18 MC potentiates acute locomotor effects morphine_second ;
1822,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",18-MC,morphine,effect,Ibogaine attenuates 18-MC_first potentiates acute locomotor effects morphine_second ;
1823,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,phenothiazines,effect,response Factrel_first may blunted phenothiazines_second dopamine antagonists cause rise prolactin.
1824,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,dopamine antagonists,effect,response Factrel_first may blunted phenothiazines dopamine antagonists_second cause rise prolactin.
1825,"Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.",diuretics,Lotensin,effect,Diuretics: Patients diuretics_first especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy Lotensin_second .
1826,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.,diuretic,Lotensin,advise,possibility hypotensive effects Lotensin minimized either discontinuing diuretic_first increasing salt intake prior initiation treatment Lotensin_second .
1827,Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.,Potassium-Sparing Diuretics,thiazide diuretics,effect,Potassium Supplements Potassium-Sparing Diuretics_first Lotensin attenuate potassium loss caused thiazide diuretics_second .
1828,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.,ACE inhibitors,lithium,mechanism,Lithium: Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors_first therapy lithium_second .
1829,"If a diuretic is also used, the risk of lithium toxicity may be increased.",diuretic,lithium,effect,diuretic_first also used risk lithium_second toxicity may increased.
1830,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",Benazepril,beta-adrenergic blockers,effect,Benazepril_first like ACE inhibitors less additive effects beta-adrenergic blockers_second presumably drugs lower blood pressure inhibiting parts renin angiotensin system
1831,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",ACE inhibitors,beta-adrenergic blockers,effect,Benazepril like ACE inhibitors_first less additive effects beta-adrenergic blockers_second presumably drugs lower blood pressure inhibiting parts renin angiotensin system
1832,Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ,fluoxetine,cisapride,mechanism,Coadministration fluoxetine_first significantly decreased cisapride_second plasma concentrations.
1833,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,Geocillin,probenecid,mechanism,Geocillin_first (carbenicillin indanyl sodium) blood levels may increased prolonged concurrent administration probenecid_second .
1834,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,carbenicillin indanyl sodium,probenecid,mechanism,Geocillin (carbenicillin indanyl sodium_first ) blood levels may increased prolonged concurrent administration probenecid_second .
1835,"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
",verapamil,bombesin,effect,Suppression verapamil_first bombesin_second enhanced peritoneal metastasis intestinal adenocarcinomas induced azoxymethane wistar rats.
1836,"Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. ",Verapamil,bombesin,effect,Verapamil_first also significantly decreased incidence lymphatic invasion adenocarcinomas enhanced bombesin_second .
1837,Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.,aspirin,valdecoxib,effect,Aspirin: Concomitant administration aspirin_first valdecoxib_second may result increased risk GI ulceration complications compared valdecoxib alone.
1838,ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE inhibitors:Reports suggest NSAIDs_first may diminish antihypertensive effect ACE-inhibitors_second .
1839,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.,BEXTRA,ACE-inhibitors,advise,interaction given consideration patients taking BEXTRA_first concomitantly ACE-inhibitors_second .
1840,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide_second thiazides patients.
1841,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide thiazides_second patients.
1842,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).,valdecoxib,phenytoin,mechanism,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) valdecoxib_first (40 mg BID 12 days) decreased 27% co administered multiple doses (300 mg QD 12 days) phenytoin_second (a CYP 3A4 inducer).
1843,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.,valdecoxib,phenytoin,advise,Patients already stabilized valdecoxib_first closely monitored loss symptom control phenytoin_second coadministration.
1844,"Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.",valdecoxib,dextromethorphan,mechanism,Coadministration valdecoxib_first (40 mg BID 7 days) resulted significant increase dextromethorphan_second plasma levels suggesting doses valdecoxib weak inhibitor 2D6.
1845,Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.,dextromethorphan,valdecoxib,mechanism,Even dextromethorphan_first plasma concentrations presence high doses valdecoxib_second almost 5 fold lower seen CYP 2D6 poor metabolizers suggesting dose adjustment necessary.
1846,Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.,Valdecoxib,lithium,mechanism,Lithium: Valdecoxib_first 40 mg BID 7 days produced significant decreases lithium_second serum clearance (25%) renal clearance (30%) 34% higher serum exposure compared lithium alone.
1847,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.,BEXTRA,lithium,advise,Lithium serum concentrations monitored closely initiating changing therapy BEXTRA_first patients receiving lithium_second .
1848,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,R-warfarin,mechanism,Valdecoxib_first caused statistically significant increase plasma exposures R-warfarin_second warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin.
1849,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,S-warfarin,mechanism,Valdecoxib_first caused statistically significant increase plasma exposures R warfarin S-warfarin_second (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin.
1850,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,warfarin,effect,Valdecoxib_first caused statistically significant increase plasma exposures R warfarin warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin_second .
1851,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.",BEXTRA,warfarin,advise,Anticoagulant therapy monitored particularly first weeks initiating therapy BEXTRA_first patients receiving warfarin_second similar agents.
1852,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,ketoconazole,mechanism,Concomitant single dose administration valdecoxib_first 20 mg multiple doses ketoconazole_second fluconazole produced significant increase exposure valdecoxib.
1853,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,fluconazole,mechanism,Concomitant single dose administration valdecoxib_first 20 mg multiple doses ketoconazole fluconazole_second produced significant increase exposure valdecoxib.
1854,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,fluconazole,mechanism,Plasma exposure (AUC) valdecoxib_first increased 62% coadministered fluconazole_second 38% coadministered ketoconazole.
1855,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,ketoconazole,mechanism,Plasma exposure (AUC) valdecoxib_first increased 62% coadministered fluconazole 38% coadministered ketoconazole_second .
1856,Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.,valdecoxib,glyburide,mechanism,Coadministration valdecoxib_first (40 mg BID (day 1) 40 mg QD (days 2 7)) glyburide_second (10 mg glyburide BID) resulted 21% increase glyburide AUC0 12 16% increase glyburide Cmax leading 16% decrease glucose AUC0 24.
1857,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.",glyburide,valdecoxib,advise,changes glucose concentrations valdecoxib coadministration within normal variability individual glucose concentrations near 70 mg/dL dose adjustment glyburide_first (5 mg QD 10 mg BID) valdecoxib_second coadministration (up 40 mg QD) indicated.
1858,Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.,valdecoxib,omeprazole,mechanism,Coadministration valdecoxib_first increased exposure omeprazole_second (AUC) 46%.
1859,"Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.",valdecoxib,Ortho-Novum,mechanism,Coadministration valdecoxib_first Ortho-Novum_second 1/35 increased exposure norethindrone ethinyl estradiol 20% 34% respectively.
1860,These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.,contraceptive,valdecoxib,advise,increased exposures norethindrone ethinyl estradiol taken consideration selecting oral contraceptive_first women taking valdecoxib_second .
1861,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.",diazepam,valdecoxib,mechanism,Plasma exposure diazepam_first (10 mg BID) increased 28% following administration valdecoxib_second (40 mg BID) 12 days plasma exposure valdecoxib (40 mg BID) substantially increased following administration diazepam (10 mg BID) 12 days.
1862,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.",valdecoxib,diazepam,effect,Although magnitude changes diazepam plasma exposure coadministered valdecoxib_first sufficient warrant dosage adjustments patients may experience enhanced sedative side effects caused increased exposure diazepam_second circumstance.
1863,"Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.",Clozapine,alcohol,effect,Given primary CNS effects Clozapine_first caution advised using concomitantly CNS active drugs alcohol_second .
1864,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,benzodiazepine,advise,Although established interaction Clozapine benzodiazepines psychotropics caution advised clozapine_first initiated patients taking benzodiazepine_second psychotropic drug.
1865,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,psychotropic drug,advise,Although established interaction Clozapine benzodiazepines psychotropics caution advised clozapine_first initiated patients taking benzodiazepine psychotropic drug_second .
1866,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,antihypertensive drugs,effect,Clozapine_first may potentiate hypotensive effects antihypertensive drugs_second anticholinergic effects atropine type drugs.
1867,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,atropine,effect,Clozapine_first may potentiate hypotensive effects antihypertensive drugs anticholinergic effects atropine_second type drugs.
1868,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",Phenytoin,Clozapine,mechanism,Phenytoin_first nicotine rifampin may decrease Clozapine_second plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1869,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",nicotine,Clozapine,mechanism,Phenytoin nicotine_first rifampin may decrease Clozapine_second plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1870,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",rifampin,Clozapine,mechanism,Phenytoin nicotine rifampin_first may decrease Clozapine_second plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1871,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",Cimetidine,Clozapine,mechanism,Cimetidine_first caffeine erythromycin may increase plasma levels Clozapine_second potentially resulting adverse effects.
1872,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",caffeine,Clozapine,mechanism,Cimetidine caffeine_first erythromycin may increase plasma levels Clozapine_second potentially resulting adverse effects.
1873,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",erythromycin,Clozapine,mechanism,Cimetidine caffeine erythromycin_first may increase plasma levels Clozapine_second potentially resulting adverse effects.
1874,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",Clozapine,carbamazepine,advise,Although concomitant use Clozapine_first carbamazepine_second recommended noted discontinuation concomitant carbamazepine administration may result increase Clozapine plasma levels.
1875,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",carbamazepine,Clozapine,mechanism,Although concomitant use Clozapine carbamazepine recommended noted discontinuation concomitant carbamazepine_first administration may result increase Clozapine_second plasma levels.
1876,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.,Paroxetine,clozapine,mechanism,Paroxetine_first produced minor changes levels clozapine_second metabolites.
1877,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,paroxetine,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations clozapine_first taken paroxetine_second fluoxetine sertraline.
1878,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,fluoxetine,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations clozapine_first taken paroxetine fluoxetine_second sertraline.
1879,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,sertraline,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations clozapine_first taken paroxetine fluoxetine sertraline_second .
1880,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.",Clozapine,fluvoxamine,advise,Therefore combined treatment approached caution patients monitored closely Clozapine_first combined drugs particularly fluvoxamine_second .
1881,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,antidepressants,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants_second phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1882,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,phenothiazines,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines_second carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1883,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,carbamazepine,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine_second Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1884,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,Type 1C antiarrhythmics,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics_second (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1885,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,propafenone,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone_second flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1886,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,flecainide,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide_second encainide) inhibit enzyme (e.g. quinidine) approached caution.
1887,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,encainide,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide_second ) inhibit enzyme (e.g. quinidine) approached caution.
1888,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,quinidine,advise,Therefore co administration clozapine_first drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine_second ) approached caution.
1889,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",quinolones,caffeine,mechanism,quinolones_first including ciprofloxacin also shown interfere metabolism caffeine_second .
1890,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",ciprofloxacin,caffeine,mechanism,quinolones including ciprofloxacin_first also shown interfere metabolism caffeine_second .
1891,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",quinolones,cyclosporine,effect,quinolones_first including ciprofloxacin associated transient elevations serum creatinine patients receiving cyclosporine_second concomitantly.
1892,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",ciprofloxacin,cyclosporine,effect,quinolones including ciprofloxacin_first associated transient elevations serum creatinine patients receiving cyclosporine_second concomitantly.
1893,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,sulfonylurea,effect,Glyburide: concomitant administration ciprofloxacin_first sulfonylurea_second glyburide rare occasions resulted severe hypoglycemia.
1894,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,glyburide,effect,Glyburide: concomitant administration ciprofloxacin_first sulfonylurea glyburide_second rare occasions resulted severe hypoglycemia.
1895,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.",methotrexate,ciprofloxacin,mechanism,Methotrexate Renal tubular transport methotrexate_first may inhibited concomitant administration ciprofloxacin_second potentially leading increased plasma levels methotrexate.
1896,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",methotrexate,ciprofloxacin,advise,Therefore patients methotrexate_first therapy carefully monitored concomitant ciprofloxacin_second therapy indicated.
1897,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,magnesium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium_second aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1898,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,aluminum,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum_second antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1899,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,antacids,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids_second sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1900,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,sucralfate,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate_second VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1901,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,VIDEX,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX_second chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1902,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,calcium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium_second iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1903,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,iron,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron_second zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1904,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,zinc,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone_first including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc_second may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1905,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,magnesium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium_second aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1906,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,aluminum,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum_second antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1907,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,antacids,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids_second sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1908,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,sucralfate,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate_second VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1909,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,VIDEX,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX_second chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1910,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,calcium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium_second iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1911,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,iron,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron_second zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1912,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,zinc,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc_second may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1913,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,ciprofloxacin,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including ciprofloxacin_first multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin_second resulting serum urine levels considerably lower desired.
1914,"This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.",ciprofloxacin,antacids,advise,time window different oral formulations ciprofloxacin_first usually administered 2 hours 6 hours antacids_second .
1915,Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.,phenytoin,ciprofloxacin,mechanism,Phenytoin: Altered serum levels phenytoin_first (increased decreased) reported patients receiving concomitant ciprofloxacin_second .
1916,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: Probenecid_first interferes renal tubular secretion ciprofloxacin_second produces increase level ciprofloxacin serum.
1917,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: Probenecid_first interferes renal tubular secretion ciprofloxacin produces increase level ciprofloxacin_second serum.
1918,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",quinolones,theophylline,mechanism,Theophylline: quinolones_first concurrent administration ciprofloxacin theophylline_second may lead elevated serum concentrations theophylline prolongation elimination half life.
1919,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",ciprofloxacin,theophylline,mechanism,Theophylline: quinolones concurrent administration ciprofloxacin_first theophylline_second may lead elevated serum concentrations theophylline prolongation elimination half life.
1920,Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.,Quinolones,warfarin,effect,Warfarin: Quinolones_first reported enhance effects oral anticoagulant warfarin_second derivatives.
1921,"Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",Bismuth subsalicylate,enoxacin,mechanism,Bismuth: Bismuth subsalicylate_first given concomitantly enoxacin_second 60 minutes following enoxacin administration decreased enoxacin bioavailability approximately 25%.
1922,"Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.",enoxacin,bismuth subsalicylate,advise,Thus concomitant administration enoxacin_first bismuth subsalicylate_second avoided.
1923,Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Caffeine: Enoxacin_first potent inhibitor cytochrome P 450 isozymes responsible metabolism methylxanthines_second .
1924,"In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",enoxacin,caffeine,mechanism,multiple dose study enoxacin_first caused dose related increase mean elimination half life caffeine_second thereby decreasing clearance caffeine 80% leading five fold increase AUC half life caffeine.
1925,Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.,caffeine,enoxacin,mechanism,Trough plasma enoxacin levels also 20% higher caffeine_first enoxacin_second administered concomitantly.
1926,Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.,caffeine,enoxacin,effect,Caffeine related adverse effects occurred patients consuming caffeine_first therapy enoxacin_second .
1927,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels cyclosporine reported concomitant use cyclosporine_first members quinolone class_second .
1928,Digoxin: Enoxacin may raise serum digoxin levels in some individuals.,Enoxacin,digoxin,mechanism,Digoxin: Enoxacin_first may raise serum digoxin_second levels individuals.
1929,"If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",enoxacin,digoxin,effect,signs symptoms suggestive digoxin toxicity occur enoxacin_first digoxin_second given concomitantly physicians advised obtain serum digoxin levels adjust digoxin doses appropriately.
1930,Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.,enoxacin,fenbufen,effect,Non steroidal anti inflammatory agents: Seizures reported patients taking enoxacin_first concomitantly nonsteroidal anti inflammatory drug fenbufen_second .
1931,or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.,zinc,quinolone,mechanism,multivitamins containing zinc_first may substantially interfere drug absorption result insufficient plasma tissue quinolone_second concentrations.
1932,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,aluminum hydroxide,enoxacin,mechanism,Antacids containing aluminum hydroxide_first magnesium hydroxide reduce oral absorption enoxacin_second 75%.
1933,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,magnesium hydroxide,enoxacin,mechanism,Antacids containing aluminum hydroxide magnesium hydroxide_first reduce oral absorption enoxacin_second 75%.
1934,The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.,enoxacin,ranitidine,mechanism,oral bioavailability enoxacin_first reduced 60% coadministration ranitidine_second .
1935,Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Theophylline: Enoxacin_first potent inhibitor cytochrome P 450 isozymes responsible metabolism methylxanthines_second .
1936,Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.,Enoxacin,theophylline,mechanism,Enoxacin_first interferes metabolism theophylline_second resulting 42% 74% dose related decrease theophylline clearance subsequent 260% 350% increase serum theophylline levels.
1937,Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.,theophylline,enoxacin,effect,Theophylline related adverse effects occurred patients theophylline_first enoxacin_second coadministered.
1938,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",Quinolones,R-warfarin,mechanism,Warfarin: Quinolones_first including enoxacin decrease clearance R-warfarin_second less active isomer racemic warfarin.
1939,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",enoxacin,R-warfarin,mechanism,Warfarin: Quinolones including enoxacin_first decrease clearance R-warfarin_second less active isomer racemic warfarin.
1940,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.",warfarin,enoxacin,advise,Nevertheless prothrombin time suitable coagulation test monitored warfarin_first derivatives enoxacin_second given concomitantly.
1941,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",calcium,Ibandronate,mechanism,Products containing calcium_first multivalent cations (such aluminum magnesium iron) likely interfere absorption Ibandronate_second .
1942,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",aluminum,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum_first magnesium iron) likely interfere absorption Ibandronate_second .
1943,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",magnesium,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum magnesium_first iron) likely interfere absorption Ibandronate_second .
1944,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",iron,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum magnesium iron_first ) likely interfere absorption Ibandronate_second .
1945,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,antacids,advise,Ibandronate_first taken least 60 minutes oral medications containing multivalent cations (including antacids_second supplements vitamins).
1946,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,vitamins,advise,Ibandronate_first taken least 60 minutes oral medications containing multivalent cations (including antacids supplements vitamins_second ).
1947,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",aspirin,Ibandronate,advise,However since aspirin NSAIDs bisphosphonates associated gastrointestinal irritation caution exercised concomitant use aspirin_first NSAIDs Ibandronate_second .
1948,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",NSAIDs,Ibandronate,advise,However since aspirin NSAIDs bisphosphonates associated gastrointestinal irritation caution exercised concomitant use aspirin NSAIDs_first Ibandronate_second .
1949,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,azathioprine,mechanism,Total body clearance Simulect_first reduced average 22% 51% azathioprine_second mycophenolate mofetil respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids.
1950,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,mycophenolate mofetil,mechanism,Total body clearance Simulect_first reduced average 22% 51% azathioprine mycophenolate mofetil_second respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids.
1951,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,central nervous system depressants,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants_second (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1952,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,alcohol,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol_second sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1953,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,sedatives,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives_second hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1954,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,hypnotics,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics_second opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1955,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,opioids,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids_second general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1956,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,anesthetics,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics_second barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1957,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,barbiturates,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates_second tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1958,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tricyclic antidepressants,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants_second phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1959,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,phenothiazines,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines_second tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1960,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tranquilizers,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers_second skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1961,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,skeletal muscle relaxants,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants_second antihistamines) may result additive central nervous system depressant effects.
1962,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,antihistamines,effect,Interactions CNS Agents: Concurrent use Levo-Dromoran_first central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines_second ) may result additive central nervous system depressant effects.
1963,"Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.",Levo-Dromoran,MAO inhibitors,advise,Although interaction MAO inhibitors Levo-Dromoran_first observed recommended use MAO inhibitors_second .
1964,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",Agonist/antagonist analgesics,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics_first (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1965,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pentazocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine_first nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1966,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",nalbuphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine_first butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1967,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",butorphanol,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol_first dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1968,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",dezocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine_first buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1969,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",buprenorphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine_first ) administered patient received receiving course therapy pure agonist opioid analgesic Levo-Dromoran_second .
1970,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pure agonist opioid analgesic,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic_first Levo-Dromoran_second .
1971,"In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
",prostaglandin F2alpha,oxytocin,int,vitro interaction prostaglandin F2alpha_first oxytocin_second placental vessels.
1972,PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. ,PGF2alpha,oxytocin,effect,PGF2alpha_first produced significantly increased vasoconstriction single administration oxytocin_second .
1973,There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.,PGF2alpha,oxytocin,effect,thus enhancement effect PGF2alpha_first upon reaction placental vessels oxytocin_second vitro.
1974,Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.,cinacalcet,amitriptyline,mechanism,Amitriptyline: Concurrent administration 25 mg 100 mg cinacalcet_first 50 mg amitriptyline_second increased amitriptyline exposure nortriptyline (active metabolite) exposure approximately 20% CYP2D6 extensive metabolizers.
1975,"Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.",ketoconazole,cinacalcet,mechanism,Co administration ketoconazole_first strong inhibitor CYP3A4 increased cinacalcet_second exposure following single 90 mg dose Sensipar 2.3 fold.
1976,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,ketoconazole,advise,Dose adjustment Sensipar_first may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. ketoconazole_second erythromycin itraconazole;
1977,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,erythromycin,advise,Dose adjustment Sensipar_first may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. ketoconazole erythromycin_second itraconazole;
1978,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,itraconazole,advise,Dose adjustment Sensipar_first may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. ketoconazole erythromycin itraconazole_second ;
1979,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",alcohol,ethchlorvynol,effect,depressasnts alcohol_first barbiturates MAOIs may enhance CNS depression administered ethchlorvynol_second .
1980,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",barbiturates,ethchlorvynol,effect,depressasnts alcohol barbiturates_first MAOIs may enhance CNS depression administered ethchlorvynol_second .
1981,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",MAOIs,ethchlorvynol,effect,depressasnts alcohol barbiturates MAOIs_first may enhance CNS depression administered ethchlorvynol_second .
1982,"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
",99mTc-methylene diphosphonate,gentamicin,effect,Therapeutic drug monitoring avoid iatrogenic alterations caused 99mTc-methylene diphosphonate_first (MDP) gentamicin_second interaction.
1983,"Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ",gentamicin,99mTc-MDP,mechanism,Due nephrotoxicity gentamicin_first may cause abnormal renal uptake seen 99mTc-MDP_second bone scintigraphy.
1984,"In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",cerivastatin sodium,cholestyramine,mechanism,first study concomitant administration 0.2 mg cerivastatin sodium_first 12 g cholestyramine_second resulted decreases 22% AUC 40% Cmax compared dosing cerivastatin sodium alone.
1985,"However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",cholestyramine,cerivastatin sodium,mechanism,However second study administration 12 g cholestyramine_first 1 hour evening meal 0.3 mg cerivastatin sodium_second approximately 4 hours evening meal resulted decrease cerivastatin AUC less 8% decrease Cmax 30% compared dosing cerivastatin sodium alone.
1986,"ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.",cerivastatin,erythromycin,mechanism,ERYTHROMYCIN: hypercholesterolemic patients steady state cerivastatin_first AUC Cmax increased approximately 50% 24% respectively 10 days co administration erythromycin_second known inhibitor cytochrome P450 3A4.
1987,Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).,allopurinol,VIDEX,mechanism,Allopurinol: AUC didanosine increased 4 fold allopurinol_first 300 mg/day coadministered single 200 mg dose VIDEX_second two patients renal impairment (CLcr=15 18 mL/min).
1988,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,antacids,VIDEX,effect,Antacids: Concomitant administration antacids_first containing magnesium aluminum VIDEX_second Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1989,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,magnesium,VIDEX,effect,Antacids: Concomitant administration antacids containing magnesium_first aluminum VIDEX_second Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1990,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,aluminum,VIDEX,effect,Antacids: Concomitant administration antacids containing magnesium aluminum_first VIDEX_second Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1991,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,ketoconazole,VIDEX,advise,Drugs Whose Absorption Affected Level Acidity Stomach: Drugs ketoconazole_first itraconazole administered least 2 hours prior dosing VIDEX_second .
1992,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,itraconazole,VIDEX,advise,Drugs Whose Absorption Affected Level Acidity Stomach: Drugs ketoconazole itraconazole_first administered least 2 hours prior dosing VIDEX_second .
1993,Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).,VIDEX,ganciclovir,mechanism,Ganciclovir: Administration VIDEX_first 2 hours prior concurrent oral ganciclovir_second associated 111 (114)% increase steady state AUC didanosine (n = 12).
1994,"A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",VIDEX,ganciclovir,mechanism,21 (17)% decrease steady state AUC ganciclovir observed VIDEX_first administered 2 hours prior ganciclovir_second two drugs administered simultaneously (n = 12).
1995,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",VIDEX,ciprofloxacin,advise,Quinolone Antibiotics: VIDEX_first administered least 2 hours 6 hours dosing ciprofloxacin_second plasma concentrations ciprofloxacin decreased administered antacids containing magnesium calcium aluminum.
1996,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,magnesium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations ciprofloxacin_first decreased administered antacids containing magnesium_second calcium aluminum.
1997,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,calcium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations ciprofloxacin_first decreased administered antacids containing magnesium calcium_second aluminum.
1998,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,aluminum,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations ciprofloxacin_first decreased administered antacids containing magnesium calcium aluminum_second .
1999,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.",ciprofloxacin,VIDEX,mechanism,eight HIV infected patients steady state AUC ciprofloxacin decreased average 26% (95% CI = 14% 37%) ciprofloxacin_first administered 2 hours prior marketed chewable/dispersible tablet formulation VIDEX_second .
2000,The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.,ciprofloxacin,didanosine,mechanism,AUC ciprofloxacin decreased average 15 fold 12 healthy subjects given ciprofloxacin_first didanosine_second placebo tablets concurrently.
2001,"In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",ciprofloxacin,didanosine,mechanism,single subject given one dose ciprofloxacin_first 2 hours dose didanosine_second placebo tablets greater 50% reduction AUC ciprofloxacin observed.
2002,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,magnesium,mechanism,Plasma concentrations quinolone antibiotics_first decreased administered antacids containing magnesium_second calcium aluminum.
2003,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,calcium,mechanism,Plasma concentrations quinolone antibiotics_first decreased administered antacids containing magnesium calcium_second aluminum.
2004,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,aluminum,mechanism,Plasma concentrations quinolone antibiotics_first decreased administered antacids containing magnesium calcium aluminum_second .
2005,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,delavirdine,VIDEX,mechanism,Interactions Antiretroviral Drugs: Significant decreases AUC delavirdine_first (20%) indinavir (84%) occurred following simultaneous administration agents VIDEX_second .
2006,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,indinavir,VIDEX,mechanism,Interactions Antiretroviral Drugs: Significant decreases AUC delavirdine (20%) indinavir_first (84%) occurred following simultaneous administration agents VIDEX_second .
2007,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",delavirdine,VIDEX,advise,avoid interaction delavirdine_first indinavir given 1 hour prior dosing VIDEX_second .
2008,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",indinavir,VIDEX,advise,avoid interaction delavirdine indinavir_first given 1 hour prior dosing VIDEX_second .
2009,The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.,SSRI,TCA,effect,extent SSRI_first TCA_second interactions may pose clinical problems depend degree inhibition pharmacokinetics SSRI involved.
2010,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.",TCAs,SSRIs,advise,Nevertheless caution indicated coadministration TCAs_first SSRIs_second also switching one class other.
2011,"Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.",amitriptyline HCl,anticholinergic,effect,Hyperpyrexia reported amitriptyline HCl_first administered anticholinergic_second agents neuroleptic drugs particularly hot weather.
2012,Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.,tricyclic antidepressants,anticholinergic,effect,Paralytic ileus may occur patients taking tricyclic antidepressants_first combination anticholinergic_second type drugs.
2013,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.",Cimetidine,tricyclic antidepressants,mechanism,Cimetidine_first reported reduce hepatic metabolism certain tricyclic antidepressants_second thereby delaying elimination increasing steady state concentrations drugs.
2014,Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.,tricyclic antidepressants,cimetidine,effect,Clinically significant effects reported tricyclic antidepressants_first used concomitantly cimetidine_second .
2015,"Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.",tricyclic antidepressants,cimetidine,mechanism,Increases plasma levels tricyclic antidepressants_first frequency severity side effects particularly anticholinergic reported cimetidine_second added drug regimen.
2016,Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.,tricyclic antidepressants,cimetidine,mechanism,Discontinuation cimetidine well controlled patients receiving tricyclic antidepressants_first cimetidine_second may decrease plasma levels efficacy antidepressants.
2017,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.,ethchlorvynol,amitriptyline HCl,effect,Transient delirium reported patients treated one gram ethchlorvynol_first 75 150 mg amitriptyline HCl_second .
2018,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,beta-blockers,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using beta-blockers_first digitalis concomitantly Tiazac_second .
2019,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,digitalis,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using beta blockers digitalis_first concomitantly Tiazac_second .
2020,Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.,diltiazem hydrochloride,propranolol,mechanism,Administration diltiazem hydrochloride_first concomitantly propranolol_second five normal volunteers resulted increased propranolol levels subjects bioavailability propranolol increased approximately 50%.
2021,"In vitro, propranolol appears to be displaced from its binding sites by diltiazem.",propranolol,diltiazem,mechanism,vitro propranolol_first appears displaced binding sites diltiazem_second .
2022,A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.,cimetidine,diltiazem,mechanism,study six healthy volunteers shown significant increase peak diltiazem plasma levels (58%) AUC (53%) 1 week course cimetidine_first 1200 mg/day single dose diltiazem_second 60mg.
2023,"The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.",cimetidine,diltiazem,mechanism,effect may mediated cimetidine_first known inhibition hepatic cytochrome P 450 enzyme system responsible first pass metabolism diltiazem_second .
2024,Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.,diltiazem,cimetidine,advise,Patients currently receiving diltiazem_first therapy carefully monitored change pharmacological effect initiating discontinuing therapy cimetidine_second .
2025,Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.,diltiazem hydrochloride,digoxin,mechanism,Administration diltiazem hydrochloride_first digoxin_second 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
2026,"Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",digoxin,diltiazem hydrochloride,advise,Since conflicting results regarding effect digoxin levels recommended digoxin_first levels monitored initiating adjusting discontinuing diltiazem hydrochloride_second therapy avoid possible digitalization.
2027,"The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.",anesthetics,calcium channel blockers,effect,depression cardiac contractility conductivity automaticity well vascular dilation associated anesthetics_first may potentiated calcium channel blockers_second .
2028,"When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.",anesthetics,calcium channel blockers,advise,used concomitantly anesthetics_first calcium channel blockers_second titrated carefully.
2029,A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.,diltiazem,cyclosporine,int,pharmacokinetic interaction diltiazem_first cyclosporine_second observed studies involving renal cardiac transplant patients.
2030,"In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.",cyclosporine,diltiazem,mechanism,renal cardiac transplant recipients reduction cyclosporine_first dose ranging 15% 48% necessary maintain cyclosporine trough concentrations similar seen prior addition diltiazem_second .
2031,"If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.",cyclosporine,diltiazem,advise,agents administered concurrently cyclosporine_first concentrations monitored especially diltiazem_second therapy initiated adjusted discontinued.
2032,"Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",diltiazem,carbamazepine,mechanism,Concomitant administration diltiazem_first carbamazepine_second reported result elevated serum levels carbamazepine (40% 72% increase) resulting toxicity cases.
2033,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,midazolam,mechanism,Studies showed diltiazem_first increased AUC midazolam_second triazolam 3 4 fold Cmax 2 fold compared placebo.
2034,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,triazolam,mechanism,Studies showed diltiazem_first increased AUC midazolam triazolam_second 3 4 fold Cmax 2 fold compared placebo.
2035,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,midazolam,diltiazem,mechanism,elimination half life midazolam_first triazolam also increased (1.5 2.5 fold) coadministration diltiazem_second .
2036,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,triazolam,diltiazem,mechanism,elimination half life midazolam triazolam_first also increased (1.5 2.5 fold) coadministration diltiazem_second .
2037,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,midazolam,effect,pharmacokinetic effects seen diltiazem_first coadministration result increased clinical effects (e.g. prolonged sodation)of midazolam_second triazolam.
2038,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,triazolam,effect,pharmacokinetic effects seen diltiazem_first coadministration result increased clinical effects (e.g. prolonged sodation)of midazolam triazolam_second .
2039,"In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",diltiazem,lovastatin,mechanism,ten subject study coadministration diltiazem_first (120 mg bid) lovastatin_second resulted 3 4 times increase mean lovastatin AUC Cmax vs. lovastatin alone;
2040,Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.,rifampin,diltiazem,mechanism,Coadministration rifampin_first diltiazem_second lowered diltiazem plasma concentrations undetectable levels.
2041,"Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",diltiazem,rifampin,advise,Coadministration diltiazem_first rifampin_second known CYP3A4 inducer avoided possible alternative therapy considered.
2042,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.,CRIXIVAN,atazanavir,advise,Combinations drugs studied coadministration CRIXIVAN_first atazanavir_second recommended.
2043,Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.,CRIXIVAN,delavirdine,advise,Dose reduction CRIXIVAN_first 600 mg every 8 hours considered taking delavirdine_second 400 mg three times day.
2044,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.,Indinavir,didanosine,advise,Indinavir_first didanosine_second formulations containing buffer administered least one hour apart empty stomach.
2045,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.,indinavir,efavirenz,mechanism,Increasing indinavir dose 1000 mg every 8 hours compensate increased indinavir_first metabolism due efavirenz_second .
2046,Indinavir concentrations may be decreased in the presence of nevirapine.,Indinavir,nevirapine,mechanism,Indinavir_first concentrations may decreased presence nevirapine_second .
2047,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.,indinavir,ritonavir,effect,Preliminary clinical data suggest incidence nephrolithiasis higher patients receiving indinavir_first combination ritonavir_second receiving CRIXIVAN 800 mg q8h.
2048,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.,antiarrhythmics,CRIXIVAN,advise,Caution warranted therapeutic concentration monitoring recommended antiarrhythmics_first coadministered CRIXIVAN_second .
2049,CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.,CRIXIVAN,indinavir,effect,CRIXIVAN_first may effective due decreased indinavir_second concentrations patients taking agents concomitantly.
2050,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",atorvastatin,CRIXIVAN,advise,Use lowest possible dose atorvastatin_first careful monitoring consider HMG CoA reductase inhibitors primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination CRIXIVAN_second .
2051,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",HMG-CoA reductase inhibitors,CRIXIVAN,advise,Use lowest possible dose atorvastatin careful monitoring consider HMG-CoA reductase inhibitors_first primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination CRIXIVAN_second .
2052,Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.,CRIXIVAN,itraconazole,advise,Dose reduction CRIXIVAN_first 600 mg every 8 hours recommended administering itraconazole_second concurrently.
2053,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.,rifabutin,CRIXIVAN,advise,Dose reduction rifabutin half standard dose dose increase CRIXIVAN 1000 mg (three 333 mg capsules) every 8 hours recommended rifabutin_first CRIXIVAN_second coadministered.
2054,Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.,Sildenafil,indinavir,advise,Sildenafil_first dose exceed maximum 25 mg 48 hour period patients receiving concomitant indinavir_second therapy.
2055,Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.,Tadalafil,indinavir,advise,Tadalafil_first dose exceed maximum 10 mg 72 hour period patients receiving concomitant indinavir_second therapy.
2056,Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.,Vardenafil,indinavir,advise,Vardenafil_first dose exceed maximum 2.5 mg 24 hour period patients receiving concomitant indinavir_second therapy.
2057,"Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",digoxin,conivaptan,mechanism,Digoxin: Coadministration digoxin_first P glycoprotein substrate oral conivaptan_second resulted reduction clearance increase digoxin Cmax AUC values.
2058,"Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.",digoxin,VAPRISOL,mechanism,Therefore digoxin_first administered VAPRISOL_second clinician alert possibility increases digoxin levels.
2059,There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.,etidronate,warfarin,effect,isolated reports patients experiencing increases prothrombin times etidronate_first added warfarin_second therapy.
2060,Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.,escitalopram,non-selective MAO inhibitor,advise,Wait 5 weeks stopping escitalopram_first starting non-selective MAO inhibitor_second .
2061,Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.,MAO inhibitor,escitalopram,advise,Wait 2 weeks stopping MAO inhibitor_first starting escitalopram_second .
2062,Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.,Erythromycin,theophylline,effect,Erythromycin_first use patients receiving high doses theophylline_second may associated increase serum theophylline levels potential theophylline toxicity.
2063,"In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.",theophylline,erythromycin,advise,case theophylline toxicity and/or elevated serum theophylline levels dose theophylline_first reduced patient receiving concomitant erythromycin_second therapy.
2064,Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Concomitant administration erythromycin_first digoxin_second reported result elevated digoxin serum levels.
2065,There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,reports increased anticoagulant effects erythromycin_first oral anticoagulants_second used concomitantly.
2066,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Concurrent use erythromycin_first ergotamine_second dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2067,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Concurrent use erythromycin_first ergotamine dihydroergotamine_second associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2068,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,triazolam,mechanism,Erythromycin_first reported decrease clearance triazolam_second midazolam thus may increase pharmacologic effect benzodiazepines.
2069,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,midazolam,mechanism,Erythromycin_first reported decrease clearance triazolam midazolam_second thus may increase pharmacologic effect benzodiazepines.
2070,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,benzodiazepines,effect,Erythromycin_first reported decrease clearance triazolam midazolam thus may increase pharmacologic effect benzodiazepines_second .
2071,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,carbamazepine,int,reports interactions erythromycin_first carbamazepine_second cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2072,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cyclosporine,int,reports interactions erythromycin_first carbamazepine cyclosporine_second tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2073,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,tacrolimus,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus_second hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2074,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,hexobarbital,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital_second phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2075,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,phenytoin,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin_second alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2076,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,alfentanil,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil_second cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2077,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cisapride,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride_second disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2078,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,disopyramide,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide_second lovastatin bromocriptine valproate terfenadine astemizole.
2079,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,lovastatin,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin_second bromocriptine valproate terfenadine astemizole.
2080,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,bromocriptine,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine_second valproate terfenadine astemizole.
2081,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,valproate,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate_second terfenadine astemizole.
2082,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,terfenadine,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine_second astemizole.
2083,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,astemizole,int,reports interactions erythromycin_first carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole_second .
2084,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,terfenadine,mechanism,Erythromycin_first reported significantly alter metabolism nonsedating antihistamines terfenadine_second astemizole taken concomitantly.
2085,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,astemizole,mechanism,Erythromycin_first reported significantly alter metabolism nonsedating antihistamines terfenadine astemizole_second taken concomitantly.
2086,"In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.",terfenadine,erythromycin,effect,addition deaths reported rarely concomitant administration terfenadine_first erythromycin_second .
2087,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",erythromycin,cisapride,effect,postmarketing reports drug interactions erythromycin_first coadministered cisapride_second resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism cisapride erythromycin.
2088,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",cisapride,erythromycin,mechanism,postmarketing reports drug interactions erythromycin coadministered cisapride resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism cisapride_first erythromycin_second .
2089,Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;,lovastatin,erythromycin,advise,Patients receiving concomitant lovastatin_first erythromycin_second carefully monitored;
2090,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ",neomycin,ACTH,effect,Studies rats shown neomycin_first administration attenuates certain types adrenocortical steroid dependent hypertension including ACTH_second hypertension.
2091,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,tetracyclines_first shown depress plasma prothrombin activity patients anticoagulant_second therapy may require downward adjustment anticoagulant dosage.
2092,"Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.",tetracycline class,penicillins,effect,Since bacteriostatic drugs tetracycline class_first antibiotics may interfere bactericidal action penicillins_second advisable administer drugs concomitantly.
2093,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent use tetracyclines_first oral contraceptives_second may render oral contraceptives less effective.
2094,Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.,warfarin,flutamide,effect,Increases prothrombin time noted patients receiving long term warfarin_first therapy flutamide_second initiated.
2095,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.",EULEXIN,warfarin,advise,Therefore close monitoring prothrombin time recommended adjustment anticoagulant dose may necessary EULEXIN_first Capsules administered concomitantly warfarin_second .
2096,"in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.",terfenadine,dirithromycin,mechanism,one man C max terfenadine 8.1 ng/mL terfenadine alone 7.2 ng/mL terfenadine_first plus dirithromycin_second .
2097,The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.,terfenadine,dirithromycin,effect,mean QT c interval (msec) 369 terfenadine alone 367 terfenadine_first plus dirithromycin_second .
2098,"Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.",erythromycin,terfenadine,int,Thus interaction observed erythromycin_first terfenadine_second expected dirithromycin.
2099,"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.",terfenadine,macrolide antibiotics,effect,Serious cardiac dysrhythmias resulting death occurred patients receiving terfenadine_first concomitantly macrolide antibiotics_second .
2100,"In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",macrolides,terfenadine,advise,addition macrolides_first contraindicated patients receiving terfenadine_second therapy pre existing cardiac abnormalities (arrhythmia bradycardia QT c interval prolongation ischemic heart disease congestive heart failure etc.) electrolyte disturbances.
2101,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,antacids,mechanism,Antacids H 2 receptor antagonists: dirithromycin_first administered immediately following antacids_second H 2 receptor antagonists absorption dirithromycin slightly enhanced.
2102,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,H 2 -receptor antagonists,mechanism,Antacids H 2 receptor antagonists: dirithromycin_first administered immediately following antacids H 2 -receptor antagonists_second absorption dirithromycin slightly enhanced.
2103,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,mechanism,Triazolam: Erythromycin_first reported decrease clearance triazolam_second thus may increase pharmacologic effect triazolam.
2104,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,effect,Triazolam: Erythromycin_first reported decrease clearance triazolam thus may increase pharmacologic effect triazolam_second .
2105,Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Digoxin: Concomitant administration erythromycin_first digoxin_second reported result elevated digoxin serum levels.
2106,Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,Anticoagulants: reports increased anticoagulant effects erythromycin_first oral anticoagulants_second used concomitantly.
2107,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Ergotamine: Concurrent use erythromycin_first ergotamine_second dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2108,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Ergotamine: Concurrent use erythromycin_first ergotamine dihydroergotamine_second associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2109,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,cyclosporine,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine_second hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2110,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,hexobarbital,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital_second carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2111,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,carbamazepine,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine_second alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2112,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,alfentanil,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil_second disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2113,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,disopyramide,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide_second phenytoin bromocriptine valproate astemizole lovastatin.
2114,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,phenytoin,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin_second bromocriptine valproate astemizole lovastatin.
2115,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,bromocriptine,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine_second valproate astemizole lovastatin.
2116,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,valproate,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate_second astemizole lovastatin.
2117,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,astemizole,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole_second lovastatin.
2118,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,lovastatin,int,drugs Drug interactions reported concomitant administration erythromycin_first medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin_second .
2119,"The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.",REVIA,disulfiram,effect,safety efficacy concomitant use REVIA_first disulfiram_second unknown concomitant use two potentially hepatotoxic medications ordinarily recommended unless probable benefits outweigh known risks.
2120,Lethargy and somnolence have been reported following doses of REVIA and thioridazine.,REVIA,thioridazine,effect,Lethargy somnolence reported following doses REVIA_first thioridazine_second .
2121,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid,effect,Patients taking REVIA_first may benefit opioid_second containing medicines cough cold preparations antidiarrheal preparations opioid analgesics.
2122,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid analgesics,effect,Patients taking REVIA_first may benefit opioid containing medicines cough cold preparations antidiarrheal preparations opioid analgesics_second .
2123,"In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.",REVIA,opioid,effect,emergency situation opioid analgesia must administered patient receiving REVIA_first amount opioid_second required may greater usual resulting respiratory depression may deeper prolonged.
2124,Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.,hydrochlorothiazide,anionic exchange resins,mechanism,Cholestyramine colestipol resins: Absorption hydrochlorothiazide_first impaired presence anionic exchange resins_second .
2125,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",cholestyramine,hydrochlorothiazide,mechanism,Single doses either cholestyramine_first colestipol resins bind hydrochlorothiazide_second reduce absorption gastrointestinal tract 85 43 percent respectively.
2126,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",colestipol,hydrochlorothiazide,mechanism,Single doses either cholestyramine colestipol_first resins bind hydrochlorothiazide_second reduce absorption gastrointestinal tract 85 43 percent respectively.
2127,Lithium: generally should not be given with diuretics.,Lithium,diuretics,advise,Lithium_first : generally given diuretics_second .
2128,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents_first reduce renal clearance lithium_second add high risk lithium toxicity.
2129,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,effect,Diuretic agents_first reduce renal clearance lithium add high risk lithium_second toxicity.
2130,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.,lithium,Hydrochlorothiazide,advise,Refer package insert lithium_first preparations use preparations Hydrochlorothiazide_second .
2131,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
2132,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium-sparing diuretics_second .
2133,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
2134,"Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore Hydrochlorothiazide_first non-steroidal anti-inflammatory agents_second used concomitantly patient observed closely determine desired effect diuretic obtained.
2135,"The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. ",trichlorfon,coumaphos,effect,treatment ewes intravenous (IV) injection trichlorfon_first insufficient produce significant inhibition erythrocyte acetylcholinesterase (AChE) activity appeared produce additive effects produced subsequent treatment 4 mg coumaphos_second /kg/day.
2136,"In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. ",phenobarbital sodium,coumaphos,effect,ewes given 40 mg phenobarbital sodium_first /kg 5 days intraperitoneally (IP) anticholinesterase effect 4 mg coumaphos_second /kg significantly reduced signs toxicity present.
2137,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycoside antibiotics_second .
2138,Sulfacetamide preparations are incompatible with silver preparations.,Sulfacetamide,silver,int,Sulfacetamide_first preparations incompatible silver_second preparations.
2139,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,vasodilators,effect,However iloprost_first potential increase hypotensive effect vasodilators_second antihypertensive agents.
2140,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,antihypertensive agents,effect,However iloprost_first potential increase hypotensive effect vasodilators antihypertensive agents_second .
2141,"Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.",iloprost,anticoagulants,effect,Since iloprost_first inhibits platelet function potential increased risk bleeding particularly patients maintained anticoagulants_second .
2142,RAPTIVA should not be used with other immunosuppressive drugs.,RAPTIVA,immunosuppressive drugs,advise,RAPTIVA_first used immunosuppressive drugs_second .
2143,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",Acellular vaccines,RAPTIVA,advise,Acellular live live attenuated Acellular vaccines_first administered RAPTIVA_second treatment.
2144,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live vaccines,RAPTIVA,advise,Acellular live live attenuated live vaccines_first administered RAPTIVA_second treatment.
2145,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live-attenuated vaccines,RAPTIVA,advise,Acellular live live-attenuated vaccines_first administered RAPTIVA_second treatment.
2146,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,fat-soluble vitamins,mechanism,Mineral oil_first interferes absorption fat-soluble vitamins_second including vitamin preparations.
2147,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,vitamin D preparations,mechanism,Mineral oil_first interferes absorption fat soluble vitamins including vitamin preparations_second .
2148,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.,thiazide diuretics,ergocalciferol,effect,Administration thiazide diuretics_first hypoparathyroid patients concurrently treated ergocalciferol_second may cause hypercalcemia.
2149,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,loop diuretics,advise,Netilmicin_first administered concomitantly potent loop diuretics_second furosemide ethacrynic acid potential ototoxicity enhanced combination.
2150,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,furosemide,advise,Netilmicin_first administered concomitantly potent loop diuretics furosemide_second ethacrynic acid potential ototoxicity enhanced combination.
2151,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,ethacrynic acid,advise,Netilmicin_first administered concomitantly potent loop diuretics furosemide ethacrynic acid_second potential ototoxicity enhanced combination.
2152,"When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.",amiloride,angiotensin-converting enzyme inhibitor,effect,amiloride_first HCl administered concomitantly angiotensin-converting enzyme inhibitor_second risk hyperkalemia may increased.
2153,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,Lithium_first generally given diuretics_second reduce renal clearance add high risk lithium toxicity.
2154,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
2155,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium-sparing diuretics_second .
2156,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
2157,"Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",MIDAMOR,non-steroidal anti-inflammatory agents,advise,Therefore MIDAMOR_first non-steroidal anti-inflammatory agents_second used concomitantly patient observed closely determine desired effect diuretic obtained.
2158,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,potassium-sparing diuretics,effect,Since indomethacin_first potassium-sparing diuretics_second including MIDAMOR may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently.
2159,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,MIDAMOR,effect,Since indomethacin_first potassium sparing diuretics including MIDAMOR_second may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently.
2160,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.",bumetanide,aminoglycoside antibiotics,advise,Drugs ototoxic potential: Especially presence impaired renal function use parenterally administered bumetanide_first patients aminoglycoside antibiotics_second also given avoided except life threatening conditions.
2161,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,Lithium: Lithium_first generally given diuretics_second (such bumetanide) reduce renal clearance add high risk lithium toxicity.
2162,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,bumetanide,advise,Lithium: Lithium_first generally given diuretics (such bumetanide_second ) reduce renal clearance add high risk lithium toxicity.
2163,- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.,probenecid,bumetanide,effect,Probenecid: Pretreatment probenecid_first reduces natriuresis hyperreninemia produced bumetanide_second .
2164,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.,probenecid,bumetanide,mechanism,antagonistic effect probenecid_first bumetanide_second natriuresis due direct action sodium excretion probably secondary inhibitory effect renal tubular secretion bumetanide.
2165,"Thus, probenecid should not be administered concurrently with bumetanide.",probenecid,bumetanide,advise,Thus probenecid_first administered concurrently bumetanide_second .
2166,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,mechanism,Indomethacin: Indomethacin_first blunts increases urine volume sodium excretion seen bumetanide_second treatment inhibits bumetanide induced increase plasma renin activity.
2167,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,effect,Indomethacin: Indomethacin_first blunts increases urine volume sodium excretion seen bumetanide treatment inhibits bumetanide_second induced increase plasma renin activity.
2168,"- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.",Bumetanide,antihypertensive drugs,effect,Antihypertensives: Bumetanide_first may potentiate effect various antihypertensive drugs_second necessitating reduction dosage drugs.
2169,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti-inflammatory agents_second drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2170,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates_second sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2171,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides_second chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2172,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol_second probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2173,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid_second coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2174,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins_second monoamine oxidase inhibitors beta adrenergic blocking agents.
2175,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors_second beta adrenergic blocking agents.
2176,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,hypoglycemic action sulfonylureas_first may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents_second .
2177,"A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.",glyburide,ciprofloxacin,int,possible interaction glyburide_first ciprofloxacin_second fluoroquinolone antibiotic reported resulting potentiation hypoglycemic action glyburide.
2178,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,effect,potential interaction oral miconazole_first oral hypoglycemic agents_second leading severe hypoglycemia reported.
2179,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.",anticoagulants,chlordiazepoxide,effect,Although clinical studies established cause effect relationship physicians aware variable effects blood coagulation reported rarely patients receiving oral anticoagulants_first chlordiazepoxide_second .
2180,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,amikacin,advise,Azlocillin_first administered concomitantly amikacin_second ciprofloxacin gentamicin netilmicin tobramycin.
2181,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,ciprofloxacin,advise,Azlocillin_first administered concomitantly amikacin ciprofloxacin_second gentamicin netilmicin tobramycin.
2182,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,gentamicin,advise,Azlocillin_first administered concomitantly amikacin ciprofloxacin gentamicin_second netilmicin tobramycin.
2183,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,netilmicin,advise,Azlocillin_first administered concomitantly amikacin ciprofloxacin gentamicin netilmicin_second tobramycin.
2184,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,tobramycin,advise,Azlocillin_first administered concomitantly amikacin ciprofloxacin gentamicin netilmicin tobramycin_second .
2185,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,didanosine,mechanism,Concurrent administration indinavir_first didanosine_second significantly reduces level exposure indinavir unclear soon didanosine administration indinavir may given safely.
2186,Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ,indinavir,didanosine,mechanism,Median gastric pH significantly higher indinavir_first taken didanosine_second administration;
2187,Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.,Indinavir,didanosine,advise,Indinavir_first may taken light meal 1 h following administration 400 mg didanosine_second .
2188,"Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.",vitamin B12,folic acid,int,Medications interfere folate utilization including: anticonvulsant medications (such phenytoin primidone) metformin (sometimes prescribed control blood sugar type 2 diabetes) sulfasalazine (used control inflammation associated Crohns disease ulcerative colitis) triamterene (a diuretic) Methotrexate concern interaction vitamin B12_first folic acid_second .
2189,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.",magnesium trisilicate,nitrofurantoin,mechanism,Antacids containing magnesium trisilicate_first administered concomitantly nitrofurantoin_second reduce rate extent absorption.
2190,The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.,nitrofurantoin,magnesium trisilicate,mechanism,mechanism interaction probably adsorption nitrofurantoin_first onto surface magnesium trisilicate_second .
2191,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",Uricosuric drugs,nitrofurantoin,mechanism,Uricosuric drugs_first probenecid sulfinpyrazone inhibit renal tubular secretion nitrofurantoin_second .
2192,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",probenecid,nitrofurantoin,mechanism,Uricosuric drugs probenecid_first sulfinpyrazone inhibit renal tubular secretion nitrofurantoin_second .
2193,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",sulfinpyrazone,nitrofurantoin,mechanism,Uricosuric drugs probenecid sulfinpyrazone_first inhibit renal tubular secretion nitrofurantoin_second .
2194,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",aminoglycosides,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides_first indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects PROLEUKIN_second may increase toxicity organ systems.
2195,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",indomethacin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin_first ) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects PROLEUKIN_second may increase toxicity organ systems.
2196,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",cytotoxic,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic_first chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects PROLEUKIN_second may increase toxicity organ systems.
2197,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",doxorubicin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin_first ) hepatotoxic (e.g. methotrexate asparaginase) effects PROLEUKIN_second may increase toxicity organ systems.
2198,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",methotrexate,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate_first asparaginase) effects PROLEUKIN_second may increase toxicity organ systems.
2199,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",asparaginase,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase_first ) effects PROLEUKIN_second may increase toxicity organ systems.
2200,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,antineoplastic agents,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose PROLEUKIN_first antineoplastic agents_second specifically dacarbazine cis platinum tamoxifen interferon alfa.
2201,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,dacarbazine,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose PROLEUKIN_first antineoplastic agents specifically dacarbazine_second cis platinum tamoxifen interferon alfa.
2202,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,cis-platinum,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose PROLEUKIN_first antineoplastic agents specifically dacarbazine cis-platinum_second tamoxifen interferon alfa.
2203,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,tamoxifen,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose PROLEUKIN_first antineoplastic agents specifically dacarbazine cis platinum tamoxifen_second interferon alfa.
2204,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,interferon-alfa,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose PROLEUKIN_first antineoplastic agents specifically dacarbazine cis platinum tamoxifen interferon-alfa_second .
2205,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.",PROLEUKIN,interferon-alfa,effect,Myocardial injury including myocardial infarction myocarditis ventricular hypokinesia severe rhabdomyolysis appear increased patients receiving PROLEUKIN_first interferon-alfa_second concurrently.
2206,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.",interferon-alfa,PROLEUKIN,effect,Exacerbation initial presentation number autoimmune inflammatory disorders observed following concurrent use interferon-alfa_first PROLEUKIN_second including crescentic IgA glomerulonephritis oculo bulbar myasthenia gravis inflammatory arthritis thyroiditis bullous pemphigoid Stevens Johnson syndrome.
2207,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",glucocorticoids,PROLEUKIN,effect,Although glucocorticoids_first shown reduce PROLEUKIN_second induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 Beta blockers antihypertensives may potentiate hypotension seen PROLEUKIN.
2208,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",Beta-blockers,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 Beta-blockers_first antihypertensives may potentiate hypotension seen PROLEUKIN_second .
2209,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",antihypertensives,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 Beta blockers antihypertensives_first may potentiate hypotension seen PROLEUKIN_second .
2210,"Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.",interleukin-2,radiographic iodinated contrast media,effect,Delayed Adverse Reactions Iodinated Contrast Media: review literature revealed 12.6% (range 11 28%) 501 patients treated various interleukin-2_first containing regimens subsequently administered radiographic iodinated contrast media_second experienced acute atypical adverse reactions.
2211,"Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.",Cevimeline,beta adrenergic antagonists,advise,Cevimeline_first administered caution patients taking beta adrenergic antagonists_second possibility conduction disturbances.
2212,PROSTIN E2 may augment the activity of other oxytocic drugs.,PROSTIN E2,oxytocic drugs,effect,PROSTIN E2_first may augment activity oxytocic drugs_second .
2213,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: Cholestyramine_first reported reduce intestinal absorption fat soluble vitamins_second ;
2214,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin_first phenobarbital affect plasma concentrations vitamin may reduce endogenous plasma levels calcitriol_second /ergocalcitriol accelerating metabolism.
2215,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin phenobarbital_first affect plasma concentrations vitamin may reduce endogenous plasma levels calcitriol_second /ergocalcitriol accelerating metabolism.
2216,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration thiazides_first vitamin D_second causes hypercalcemia.
2217,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D_first dosage must determined care patients undergoing treatment digitalis_second hypercalcemia patients may precipitate cardiac arrhythmias.
2218,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: Ketoconazole_first may inhibit synthetic catabolic enzymes vitamin D_second .
2219,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: relationship functional antagonism exists vitamin analogues_first promote calcium absorption corticosteroids_second inhibit calcium absorption.
2220,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: Magnesium_first containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
2221,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium containing preparations (eg antacids_first ) may cause hypermagnesemia therefore taken therapy vitamin D_second patients chronic renal dialysis.
2222,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",cholestyramine,thiazide diuretics,effect,May interact following: cholestyramine_first colestipol (use thiazide diuretics_second may prevent diuretic working properly;
2223,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",colestipol,thiazide diuretics,effect,May interact following: cholestyramine colestipol_first (use thiazide diuretics_second may prevent diuretic working properly;
2224,Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. ,antidepressant drugs,hypoglycemic agents,int,Treatment antidepressant drugs_first directly interfere blood glucose levels may interact hypoglycemic agents_second .
2225,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",CNS depressant drugs,INAPSINE,effect,CNS depressant drugs_first (e.g. barbiturates tranquilizers opioids general anesthetics) additive potentiating effects INAPSINE_second .
2226,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",barbiturates,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates_first tranquilizers opioids general anesthetics) additive potentiating effects INAPSINE_second .
2227,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",tranquilizers,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates tranquilizers_first opioids general anesthetics) additive potentiating effects INAPSINE_second .
2228,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",opioids,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates tranquilizers opioids_first general anesthetics) additive potentiating effects INAPSINE_second .
2229,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",anesthetics,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates tranquilizers opioids general anesthetics_first ) additive potentiating effects INAPSINE_second .
2230,"Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.",INAPSINE,CNS depressant drugs,advise,Following administration INAPSINE_first dose CNS depressant drugs_second reduced.
2231,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. ",pentazocine,tripelennamine,effect,Twelve strains Staphylococcus aureus (a frequent cause infection heroin pentazocine_first tripelennamine_second addicts) completely inhibited drug combination.
2232,"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. ",tripelennamine,pentazocine,effect,Dose response curves (derived results using tablets well pure powders) showed tripelennamine_first responsible inhibitory activity partially antagonized pentazocine_second .
2233,"Interaction of ketamine and halothane in rats.
",ketamine,halothane,int,Interaction ketamine_first halothane_second rats.
2234,"However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. ",halothane,ketamine,mechanism,However halothane_first anesthetic requirement (i.e. MAC) depressed dose dependent fashion much 56% 1 2 hours much 14% 5 6 hours injection ketamine_second 50 mg/kg im.
2235,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ,ketamine,halothane,mechanism,half life ketamine_first plasma brain longer presence halothane_second ketamine given alone.
2236,It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.,ketamine,halothane,effect,concluded ketamine_first short acting drug concomitant use halothane_second would expected prolong duration action central nervous system.
2237,Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.,Isoproterenol hydrochloride,epinephrine,advise,Isoproterenol hydrochloride_first injection epinephrine_second administered simultaneously drugs direct cardiac stimulants combined effects may induce serious arrhythmias.
2238,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,anesthetics,advise,ISUPREL_first used caution potent inhalational anesthetics_second halothane employed potential sensitize myocardium effects sympathomimetic amines.
2239,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,halothane,advise,ISUPREL_first used caution potent inhalational anesthetics halothane_second employed potential sensitize myocardium effects sympathomimetic amines.
2240,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,phenytoin,effect,effectiveness progestin_first pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin_second carbamazepine barbiturates antituberculosis drug rifampin.
2241,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,carbamazepine,effect,effectiveness progestin_first pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin carbamazepine_second barbiturates antituberculosis drug rifampin.
2242,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,barbiturates,effect,effectiveness progestin_first pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin carbamazepine barbiturates_second antituberculosis drug rifampin.
2243,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,rifampin,effect,effectiveness progestin_first pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin carbamazepine barbiturates antituberculosis drug rifampin_second .
2244,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,calcium carbonate,mechanism,Concomitant administration FACTIVE_first calcium carbonate_second cimetidine omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2245,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,cimetidine,mechanism,Concomitant administration FACTIVE_first calcium carbonate cimetidine_second omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2246,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,omeprazole,mechanism,Concomitant administration FACTIVE_first calcium carbonate cimetidine omeprazole_second estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2247,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,estrogen,mechanism,Concomitant administration FACTIVE_first calcium carbonate cimetidine omeprazole estrogen_second /progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2248,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,progesterone,mechanism,Concomitant administration FACTIVE_first calcium carbonate cimetidine omeprazole estrogen/progesterone_second oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2249,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,contraceptive,mechanism,Concomitant administration FACTIVE_first calcium carbonate cimetidine omeprazole estrogen/progesterone oral contraceptive_second produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2250,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.,FACTIVE,probenecid,mechanism,Concomitant administration FACTIVE_first probenecid_second resulted 45% increase systemic exposure gemifloxacin.
2251,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolones,warfarin,effect,However quinolones_first reported enhance anticoagulant effects warfarin_second derivatives patients prothrombin time suitable coagulation test closely monitored quinolone antimicrobial administered concomitantly warfarin derivatives.
2252,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance anticoagulant effects warfarin derivatives patients prothrombin time suitable coagulation test closely monitored quinolone antimicrobial_first administered concomitantly warfarin_second derivatives.
2253,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,aluminum,mechanism,absorption oral gemifloxacin_first significantly reduced concomitant administration antacid containing aluminum_second magnesium.
2254,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,magnesium,mechanism,absorption oral gemifloxacin_first significantly reduced concomitant administration antacid containing aluminum magnesium_second .
2255,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Magnesium,FACTIVE,advise,Magnesium_first and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2256,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",aluminum,FACTIVE,advise,Magnesium and/or aluminum_first containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2257,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",ferrous sulfate,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate_first (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2258,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",iron,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron_first ) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2259,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",multivitamin preparations,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations_first containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2260,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",zinc,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc_first metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2261,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Videx,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx_first (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2262,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",didanosine,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine_first ) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours FACTIVE_second .
2263,Sucralfate should not be taken within 2 hours of FACTIVE.,Sucralfate,FACTIVE,advise,Sucralfate_first taken within 2 hours FACTIVE_second .
2264,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Steroids,edetate calcium disodium,effect,Steroids_first enhance renal toxicity edetate calcium disodium_second animals. 7 Edetate calcium disodium interferes action zinc insulin preparations chelating zinc. 7
2265,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Edetate calcium disodium,zinc insulin,mechanism,Steroids enhance renal toxicity edetate calcium disodium animals. 7 Edetate calcium disodium_first interferes action zinc insulin_second preparations chelating zinc. 7
2266,(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.),thiazide diuretics,digitalis,effect,(Concurrent use thiazide diuretics_first may enhance possibility digitalis_second toxicity associated hypokalemia.)
2267,"for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;",hypoglycemic medications,thiazide diuretic,advise,adult onset diabetics dosage adjustment hypoglycemic medications_first may necessary thiazide diuretic_second therapy;
2268,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,loop diuretics,effect,(In patients steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
2269,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,potassium sparing diuretics,effect,(In patients steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium sparing diuretics_second .
2270,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,thiazide diuretics,effect,(In patients steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
2271,"Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)",hydroflumethiazide,nonsteroidal anti-inflammatory agents,advise,Therefore hydroflumethiazide_first nonsteroidal anti-inflammatory agents_second used concomitantly patient observed closely determine desired effect diuretic obtained.)
2272,(Thiazides may decrease arterial responsiveness to norepinephrine.,Thiazides,norepinephrine,effect,(Thiazides_first may decrease arterial responsiveness norepinephrine_second .
2273,(Thiazide drugs may increase the responsiveness to tubocurarine.),Thiazide drugs,tubocurarine,effect,(Thiazide drugs_first may increase responsiveness tubocurarine_second .)
2274,"Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.",HMG-CoA reductase inhibitors,Fentanyl,advise,Experience co administration HMG CoA reductase inhibitors Fentanyl patients limited therefore consideration given temporarily suspending use HMG-CoA reductase inhibitors_first patients receiving Fentanyl_second .
2275,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,acetaminophen,effect,Acetaminophen methotrexate L-methionine_first may decrease hepatic toxicity acetaminophen_second overdosage taking methotrexate.
2276,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,methotrexate,effect,Acetaminophen methotrexate L-methionine_first may decrease hepatic toxicity acetaminophen overdosage taking methotrexate_second .
2277,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.,Methionine,gentamicin,effect,Gentamicin Methionine_first may protect ototoxic effects gentamicin_second .
2278,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.",BETAGAN,epinephrine,effect,Although BETAGAN used alone little effect pupil size mydriasis resulting concomitant therapy BETAGAN_first epinephrine_second may occur.
2279,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended beta-blocker_first administered patients receiving catecholamine depleting drugs reserpine_second possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension.
2280,"Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.",beta-adrenergic blocking agents,calcium antagonists,advise,Patients receiving beta-adrenergic blocking agents_first along either oral intravenous calcium antagonists_second monitored possible atrioventricular conduction disturbances left ventricular failure hypotension.
2281,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,digitalis,effect,concomitant use beta-adrenergic blocking agents_first digitalis_second calcium antagonists may additive effects prolonging atrioventricular conduction time.
2282,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,calcium antagonist,effect,concomitant use beta-adrenergic blocking agents_first digitalis calcium antagonist_second may additive effects prolonging atrioventricular conduction time.
2283,Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.,Phenothiazine-related compounds,beta-adrenergic blocking agents,mechanism,Phenothiazine-related compounds_first beta-adrenergic blocking agents_second may additive hypotensite effects due inhibition metabolism.
2284,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.,warfarin,IRESSA,effect,International Normalized Ratio (INR) elevations and/or bleeding events reported patients taking warfarin_first IRESSA_second therapy.
2285,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole_first itraconazole) decrease gefitinib_second metabolism increase gefitinib plasma concentrations.
2286,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole_first itraconazole) decrease gefitinib metabolism increase gefitinib_second plasma concentrations.
2287,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole itraconazole_first ) decrease gefitinib_second metabolism increase gefitinib plasma concentrations.
2288,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole itraconazole_first ) decrease gefitinib metabolism increase gefitinib_second plasma concentrations.
2289,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,histamine H2-receptor antagonists,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2-receptor antagonists_first ranitidine cimetidine) may reduce plasma concentrations IRESSA_second therefore potentially may reduce efficacy.
2290,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,ranitidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2 receptor antagonists ranitidine_first cimetidine) may reduce plasma concentrations IRESSA_second therefore potentially may reduce efficacy.
2291,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,cimetidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2 receptor antagonists ranitidine cimetidine_first ) may reduce plasma concentrations IRESSA_second therefore potentially may reduce efficacy.
2292,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.",IRESSA,vinorelbine,effect,Phase II clinical trial data IRESSA vinorelbine used concomitantly indicate IRESSA_first may exacerbate neutropenic effect vinorelbine_second .
2293,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.",loxapine,lorazepam,effect,rare reports significant respiratory depression stupor and/or hypotension concomitant use loxapine_first lorazepam_second .
2294,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,ketoconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering Gleevec_first inhibitors CYP3A4 family (e.g. ketoconazole_second itraconazole erythromycin clarithromycin).
2295,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,itraconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering Gleevec_first inhibitors CYP3A4 family (e.g. ketoconazole itraconazole_second erythromycin clarithromycin).
2296,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,erythromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering Gleevec_first inhibitors CYP3A4 family (e.g. ketoconazole itraconazole erythromycin_second clarithromycin).
2297,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,clarithromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering Gleevec_first inhibitors CYP3A4 family (e.g. ketoconazole itraconazole erythromycin clarithromycin_second ).
2298,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).,Gleevec,ketoconazole,mechanism,significant increase exposure imatinib Gleevec_first coadministered ketoconazole_second (CYP3A4 inhibitor).
2299,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,mechanism,Pretreatment healthy volunteers multiple doses rifampin_first followed single dose Gleevec_second increased Gleevec oral dose clearance 3.8 fold significantly (p 0.05) decreased mean cmax AUC(0 8).
2300,"Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",Gleevec,simvastatin,mechanism,Drugs may plasma concentration altered Gleevec Gleevec_first increases mean cmax AUC simvastatin_second (CYP3A4 substrate) 2 3.5 fold respectively suggesting inhibition CYP3A4 Gleevec.
2301,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,cyclosporine,advise,Particular caution recommended administering Gleevec_first CYP3A4 substrates narrow therapeutic window (e.g. cyclosporine_second pimozide).
2302,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,pimozide,advise,Particular caution recommended administering Gleevec_first CYP3A4 substrates narrow therapeutic window (e.g. cyclosporine pimozide_second ).
2303,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,benzodiazepines,mechanism,Gleevec_first increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo benzodiazepines_second dihydropyridine calcium channel blockers certain HMG CoA reductase inhibitors etc.).
2304,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,dihydropyridine calcium channel blockers,mechanism,Gleevec_first increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo benzodiazepines dihydropyridine calcium channel blockers_second certain HMG CoA reductase inhibitors etc.).
2305,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,HMG-CoA reductase inhibitors,mechanism,Gleevec_first increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo benzodiazepines dihydropyridine calcium channel blockers certain HMG-CoA reductase inhibitors_second etc.).
2306,Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.,acetaminophen,Gleevec,mechanism,Systemic exposure acetaminophen_first expected increased coadministered Gleevec_second .
2307,A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.,FOSCAVIR,pentamidine,int,possible drug interaction FOSCAVIR_first intravenous pentamidine_second described.
2308,Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;,FOSCAVIR,pentamidine,effect,Concomitant treatment four patients United Kingdom FOSCAVIR_first intravenous pentamidine_second may caused hypocalcemia;
2309,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,aminoglycosides,advise,foscarnets tendency cause renal impairment use FOSCAVIR_first avoided combination potentially nephrotoxic drugs aminoglycosides_second amphotericin B intravenous pentamidine unless potential benefits outweigh risks patient.
2310,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,amphotericin B,advise,foscarnets tendency cause renal impairment use FOSCAVIR_first avoided combination potentially nephrotoxic drugs aminoglycosides amphotericin B_second intravenous pentamidine unless potential benefits outweigh risks patient.
2311,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,pentamidine,advise,foscarnets tendency cause renal impairment use FOSCAVIR_first avoided combination potentially nephrotoxic drugs aminoglycosides amphotericin B intravenous pentamidine_second unless potential benefits outweigh risks patient.
2312,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergotamine,naratriptan,advise,theoretical basis effects may additive use ergotamine_first containing ergot type medications (like dihydroergotamine methysergide) naratriptan_second within 24 hours contraindicated.
2313,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergot-type medications,naratriptan,advise,theoretical basis effects may additive use ergotamine containing ergot-type medications_first (like dihydroergotamine methysergide) naratriptan_second within 24 hours contraindicated.
2314,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",dihydroergotamine,naratriptan,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine_first methysergide) naratriptan_second within 24 hours contraindicated.
2315,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",methysergide,naratriptan,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine methysergide_first ) naratriptan_second within 24 hours contraindicated.
2316,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.",naratriptan,5-HT1 agonists,advise,vasospastic effects may additive coadministration naratriptan_first 5-HT1 agonists_second within 24 hours recommended.
2317,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",naratriptan,SSRI,advise,concomitant treatment naratriptan_first SSRI_second clinically warranted appropriate observation patient advised.
2318,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,fluconazole,int,Clinical studies celecoxib_first identified potentially significant interactions fluconazole_second lithium.
2319,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,lithium,int,Clinical studies celecoxib_first identified potentially significant interactions fluconazole lithium_second .
2320,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,furosemide,int,Experience nonsteroidal anti-inflammatory drugs_first (NSAIDs) suggests potential interactions furosemide_second ACE inhibitors.
2321,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,ACE inhibitors,int,Experience nonsteroidal anti-inflammatory drugs_first (NSAIDs) suggests potential interactions furosemide ACE inhibitors_second .
2322,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,furosemide,int,Experience nonsteroidal anti inflammatory drugs (NSAIDs_first ) suggests potential interactions furosemide_second ACE inhibitors.
2323,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,ACE inhibitors,int,Experience nonsteroidal anti inflammatory drugs (NSAIDs_first ) suggests potential interactions furosemide ACE inhibitors_second .
2324,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest NSAIDs_first may diminish antihypertensive effect Angiotensin Converting Enzyme (ACE) inhibitors_second .
2325,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.,CELEBREX,ACE-inhibitors,advise,interaction given consideration patients taking CELEBREX_first concomitantly ACE-inhibitors_second .
2326,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide_second thiazides patients.
2327,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide thiazides_second patients.
2328,Aspirin: CELEBREX can be used with low dose aspirin.,CELEBREX,aspirin,advise,Aspirin: CELEBREX_first used low dose aspirin_second .
2329,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.",aspirin,CELEBREX,effect,However concomitant administration aspirin_first CELEBREX_second may result increased rate GI ulceration complications compared use CELEBREX alone.
2330,Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.,fluconazole,celecoxib,mechanism,Fluconazole: Concomitant administration fluconazole_first 200 mg QD resulted two fold increase celecoxib_second plasma concentration.
2331,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).,celecoxib,fluconazole,mechanism,increase due inhibition celecoxib_first metabolism via P450 2C9 fluconazole_second (see CLINICAL PHARMACOLOGY Pharmacokinetics: Metabolism).
2332,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.,CELEBREX,fluconazole,advise,CELEBREX_first introduced lowest recommended dose patients receiving fluconazole_second .
2333,"Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.",lithium,CELEBREX,mechanism,Lithium: study conducted healthy subjects mean steady state lithium plasma levels increased approximately 17% subjects receiving lithium_first 450 mg BID CELEBREX_second 200 mg BID compared subjects receiving lithium alone.
2334,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.,lithium,CELEBREX,advise,Patients lithium_first treatment closely monitored CELEBREX_second introduced withdrawn.
2335,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.",CELEBREX,warfarin,advise,However caution used administering CELEBREX_first warfarin_second since patients increased risk bleeding complications.
2336,Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.,L-histidine,medroxyprogesterone acetate,effect,Medroxyprogesterone Acetate L-histidine_first observed enhance (in tissue culture) effect medroxyprogesterone acetate_second reducing number human breast cancer cells phase.
2337,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H1 blockers,effect,H1 H2 Blockers Although reported L-histidine_first via metabolism histamine might decrease efficacy H1 H2 H1 blockers_second .
2338,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H2 blockers,effect,H1 H2 Blockers Although reported L-histidine_first via metabolism histamine might decrease efficacy H1 H2 blockers_second .
2339,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,EGF,effect,Dexamethasone_first retinyl acetate similarly inhibit stimulate EGF_second insulin induced proliferation prostatic epithelium.
2340,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,insulin,effect,Dexamethasone_first retinyl acetate similarly inhibit stimulate EGF insulin_second induced proliferation prostatic epithelium.
2341,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,EGF,effect,Dexamethasone retinyl acetate_first similarly inhibit stimulate EGF_second insulin induced proliferation prostatic epithelium.
2342,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,insulin,effect,Dexamethasone retinyl acetate_first similarly inhibit stimulate EGF insulin_second induced proliferation prostatic epithelium.
2343,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,EGF,effect,Although neither dexamethasone_first retinyl acetate affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF_second insulin.
2344,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,insulin,effect,Although neither dexamethasone_first retinyl acetate affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF insulin_second .
2345,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,EGF,effect,Although neither dexamethasone retinyl acetate_first affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF_second insulin.
2346,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,insulin,effect,Although neither dexamethasone retinyl acetate_first affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF insulin_second .
2347,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,Dexamethasone,EGF,effect,Dexamethasone_first 10( 10) retinyl acetate 3 X 10( 9) inhibits proliferation stimulated EGF_second .
2348,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,retinyl acetate,EGF,effect,Dexamethasone 10( 10) retinyl acetate_first 3 X 10( 9) inhibits proliferation stimulated EGF_second .
2349,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,dexamethasone,EGF,effect,Higher concentrations dexamethasone_first (10( 8) 10( 6) M) retinyl acetate (3 X 10( 8) 10( 7) M) enhance mitogenic activity EGF_second .
2350,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,retinyl acetate,EGF,effect,Higher concentrations dexamethasone (10( 8) 10( 6) M) retinyl acetate_first (3 X 10( 8) 10( 7) M) enhance mitogenic activity EGF_second .
2351,"However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. ",retinyl acetate,insulin,effect,However retinyl acetate_first stimulated significantly inhibit proliferation presence insulin_second .
2352,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,insulin,effect,results suggest dexamethasone_first retinyl acetate possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin_second EGF.
2353,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,EGF,effect,results suggest dexamethasone_first retinyl acetate possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin EGF_second .
2354,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,insulin,effect,results suggest dexamethasone retinyl acetate_first possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin_second EGF.
2355,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,EGF,effect,results suggest dexamethasone retinyl acetate_first possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin EGF_second .
2356,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,insulin,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids_first retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin_second EGF.
2357,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,EGF,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids_first retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin EGF_second .
2358,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,insulin,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids retinoids_first may regulate proliferation prostate epithelium dose dependent modification activity insulin_second EGF.
2359,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,EGF,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids retinoids_first may regulate proliferation prostate epithelium dose dependent modification activity insulin EGF_second .
2360,"An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ",perchlorate,pertechnetate,mechanism,intravenous injection perchlorate_first given later also produces complete immediately beginning depletion pertechnetate_second already accumulated thyroid within period 195 min 99m TcO 4 injection corresponding increase blood levels.
2361,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,theophylline,mechanism,However systemic administration quinolones_first shown elevate plasma concentrations theophylline_second interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2362,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,caffeine,mechanism,However systemic administration quinolones_first shown elevate plasma concentrations theophylline interfere metabolism caffeine_second enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2363,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,warfarin,effect,However systemic administration quinolones_first shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant warfarin_second derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2364,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,cyclosporine,effect,However systemic administration quinolones_first shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine_second concomitantly.
2365,Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.,Erythromycin,vardenafil,mechanism,Erythromycin_first (500 mg t.i.d) produced 4 fold increase vardenafil_second AUC 3 fold increase Cmax co administered Vardenafil 5 mg healthy volunteers.
2366,It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.,Vardenafil,erythromycin,advise,recommended exceed single 5 mg dose Vardenafil_first 24 hour period used combination erythromycin_second .
2367,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.,Ketoconazole,vardenafil,mechanism,Ketoconazole_first (200 mg daily) produced 10 fold increase vardenafil_second AUC 4 fold increase Cmax co administered Vardenafil (5 mg) healthy volunteers.
2368,A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.,Vardenafil,ketoconazole,advise,5 mg Vardenafil_first dose exceeded used combination 200 mg daily ketoconazole_second .
2369,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.",Vardenafil,ketoconazole,advise,Since higher doses ketoconazole (400 mg daily) may result higher increases Cmax AUC single 2.5 mg dose Vardenafil_first exceeded 24 hour period used combination ketoconazole_second 400 mg daily.
2370,"HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.",Indinavir,Vardenafil,mechanism,HIV Protease Inhibitors: Indinavir_first (800 mg t.i.d.) co administered Vardenafil_second 10 mg resulted 16 fold increase vardenafil AUC 7 fold increase vardenafil Cmax 2 fold increase vardenafil half life.
2371,It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.,Vardenafil,indinavir,advise,recommended exceed single 2.5 mg Vardenafil_first dose 24 hour period used combination indinavir_second .
2372,Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.,Ritonavir,Vardenafil,mechanism,Ritonavir_first (600 mg b.i.d.) co administered Vardenafil_second 5 mg resulted 49 fold increase vardenafil AUC 13 fold increase vardenafil Cmax.
2373,"The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",vardenafil,ritonavir,mechanism,interaction consequence blocking hepatic metabolism vardenafil_first ritonavir_second highly potent CYP3A4 inhibitor also inhibits CYP2C9.
2374,Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.,Ritonavir,vardenafil,mechanism,Ritonavir_first significantly prolonged half life vardenafil_second 26 hours.
2375,"Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.",Vardenafil,ritonavir,advise,Consequently recommended exceed single 2.5 mg Vardenafil_first dose 72 hour period used combination ritonavir_second .
2376,"In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",nitrates,vardenafil,mechanism,vivo studies: Nitrates: blood pressure lowering effects sublingual nitrates_first (0.4 mg) taken 1 4 hours vardenafil_second increases heart rate taken 1 4 8 hours potentiated 20 mg dose Vardenafil healthy middle aged subjects.
2377,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.",Vardenafil,nitrates,advise,Potentiation hypotensive effects nitrates patients ischemic heart disease evaluated concomitant use Vardenafil_first nitrates_second contraindicated.
2378,"In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.",nifedipine,Vardenafil,effect,patients whose hypertension controlled nifedipine_first Vardenafil_second 20 mg produced mean additional supine systolic/diastolic blood pressure reductions 6/5 mm Hg compared placebo.
2379,"Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.",Vardenafil,terazosin,effect,Alpha blockers: Vardenafil_first 10 20 mg given healthy volunteers either simultaneously 6 hours 10 mg dose terazosin_second significant hypotension developed substantial number subjects.
2380,"With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,simultaneous dosing Vardenafil_first 10 mg terazosin_second 10 mg 6 8 subjects experienced standing systolic blood pressure less 85 mm Hg.
2381,"With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,simultaneous dosing Vardenafil_first 20 mg terazosin_second 10 mg 2 9 subjects experienced standing systolic blood pressure less 85 mm Hg.
2382,"When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",Vardenafil,terazosin,effect,Vardenafil_first dosing separated terazosin_second 10 mg 6 hours 7 28 subjects received 20 mg Vardenafil experienced decrease standing systolic blood pressure 85 mm Hg.
2383,"In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.",Vardenafil,tamsulosin,effect,similar study tamsulosin healthy volunteers 1 24 subjects dosed Vardenafil_first 20 mg tamsulosin_second 0.4 mg separated 6 hours experienced standing systolic blood pressure 85 mm Hg.
2384,Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.,Vardenafil,tamsulosin,effect,Two 16 subjects dosed simultaneously Vardenafil_first 10 mg tamsulosin_second 0.4 mg experienced standing systolic blood pressure 85 mm Hg.
2385,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.",Vardenafil,alpha-blocker,advise,Based data Vardenafil_first used patients alpha-blocker_second therapy.
2386,"Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.",Vardenafil,ritonavir,mechanism,Ritonavir indinavir: Upon concomitant administration 5 mg Vardenafil_first 600 mg BID ritonavir_second Cmax AUC ritonavir reduced approximately 20%.
2387,"Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",Vardenafil,indinavir,mechanism,Upon administration 10 mg Vardenafil_first 800 mg TID indinavir_second Cmax AUC indinavir reduced 40% 30% respectively.
2388,"High-dose cisplatin with sodium thiosulfate protection.
",cisplatin,sodium thiosulfate,effect,High dose cisplatin_first sodium thiosulfate_second protection.
2389,Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. ,Sodium thiosulfate,cisplatin,effect,Sodium thiosulfate_first neutralizing agent cisplatin_second protects renal damage.
2390,This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.,thiosulfate,cisplatin,mechanism,study demonstrates concurrent administration thiosulfate_first permits least twofold increase dose total exposure cisplatin_second .
2391,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",b-lactam antibiotics,probenecid,mechanism,Probenecid: b-lactam antibiotics_first renal excretion loracarbef inhibited probenecid_second resulted approximate 80% increase AUC loracarbef.
2392,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",loracarbef,probenecid,mechanism,Probenecid: b lactam antibiotics renal excretion loracarbef_first inhibited probenecid_second resulted approximate 80% increase AUC loracarbef.
2393,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.,anticoagulants,thyroid,advise,Patients stabilized oral anticoagulants_first found require thyroid_second replacement therapy watched closely thyroid started.
2394,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T4,mechanism,Cholestyramine: Cholestyramine_first binds T4_second T3 intestine thus impairing absorption thyroid hormones.
2395,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T3,mechanism,Cholestyramine: Cholestyramine_first binds T4 T3_second intestine thus impairing absorption thyroid hormones.
2396,"Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.",cholestyramine,thyroid hormones,advise,Therefore 4 5 hours elapse administration cholestyramine_first thyroid hormones_second .
2397,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.",levothyroxine,estrogens,mechanism,patient nonfunctioning thyroid gland receiving thyroid replacement therapy free levothyroxine_first may decreased estrogens_second started thus increasing thyroid requirements.
2398,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,estrogens,advise,Therefore patients without functioning thyroid_first gland thyroid replacement therapy may need increase thyroid dose estrogens_second estrogen containing oral contraceptives given.
2399,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,contraceptives,advise,Therefore patients without functioning thyroid_first gland thyroid replacement therapy may need increase thyroid dose estrogens estrogen containing oral contraceptives_second given.
2400,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,imipramine,effect,Tricyclic Antidepressants: Use thyroid products_first imipramine_second tricyclic antidepressants may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed.
2401,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,tricyclic antidepressants,effect,Tricyclic Antidepressants: Use thyroid products_first imipramine tricyclic antidepressants_second may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed.
2402,Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.,Thyroid preparations,digitalis,effect,Digitalis: Thyroid preparations_first may potentiate toxic effects digitalis_second .
2403,"Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.",thyroid preparation,anesthetic,effect,Ketamine: administered patients thyroid preparation_first parenteral anesthetic_second may cause hypertension tachycardia.
2404,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,epinephrine,effect,Vasopressors: Thyroxine_first increases adrenergic effect catecholamines epinephrine_second norepinephrine.
2405,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,norepinephrine,effect,Vasopressors: Thyroxine_first increases adrenergic effect catecholamines epinephrine norepinephrine_second .
2406,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.,antacids,lactulose,mechanism,Results preliminary studies humans rats suggest nonabsorbable antacids_first given concurrently lactulose_second may inhibit desired lactulose induced drop colonic pH.
2407,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.,Digitalis,Bretylium Tosylate,effect,Digitalis_first toxicity may aggravated initial release norepinephrine caused Bretylium Tosylate_second Injection.
2408,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,catecholamines,Bretylium Tosylate,effect,pressor effects catecholamines_first dopamine norepinephrine enhanced Bretylium Tosylate_second .
2409,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,dopamine,Bretylium Tosylate,effect,pressor effects catecholamines dopamine_first norepinephrine enhanced Bretylium Tosylate_second .
2410,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,norepinephrine,Bretylium Tosylate,effect,pressor effects catecholamines dopamine norepinephrine_first enhanced Bretylium Tosylate_second .
2411,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,long-acting nitrates,advise,Sildenafil_first contraindicated patients using long-acting nitrates_second may need use short acting nitrates combination may cause sharp fall blood pressure.
2412,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,short-acting nitrates,advise,Sildenafil_first contraindicated patients using long acting nitrates may need use short-acting nitrates_second combination may cause sharp fall blood pressure.
2413,"Interaction of clindamycin and gentamicin in vitro.
",clindamycin,gentamicin,int,Interaction clindamycin_first gentamicin_second vitro.
2414,Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ,clindamycin,gentamicin,effect,Combinations clindamycin_first gentamicin_second indifferent 29 strains synergistic 33 strains.
2415,Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ,clindamycin,gentamicin,effect,Combinations clindamycin_first gentamicin_second indifferent 16 synergistic 11 resistant strains.
2416,These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; ,ethanol,acetaldehyde,effect,results suggest hepatoxicity ethanol_first alcoholic beverages enhanced interaction congeners acetaldehyde_second ;
2417,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,muscle relaxants,effect,Isoflurane_first potentiates muscle relaxant effect muscle relaxants_second notably nondepolarizing muscle relaxants MAC (minimum alveolar concentration) reduced concomitant administration N 2O.
2418,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,nondepolarizing muscle relaxants,effect,Isoflurane_first potentiates muscle relaxant effect muscle relaxants notably nondepolarizing muscle relaxants_second MAC (minimum alveolar concentration) reduced concomitant administration N 2O.
2419,Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.,MAO inhibitors,dopamine HCl,advise,Patients treated MAO inhibitors_first within two three weeks prior administration dopamine HCl_second receive initial doses dopamine HCl greater one tenth (1/10) usual dose.
2420,Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.,dopamine HCl,diuretic agents,effect,Concurrent administration low dose dopamine HCl_first diuretic agents_second may produce additive potentiating effect urine flow.
2421,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,beta-adrenergic blocking agents,effect,Cardiac effects dopamine_first antagonized beta-adrenergic blocking agents_second propranolol metoprolol.
2422,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,propranolol,effect,Cardiac effects dopamine_first antagonized beta adrenergic blocking agents propranolol_second metoprolol.
2423,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,metoprolol,effect,Cardiac effects dopamine_first antagonized beta adrenergic blocking agents propranolol metoprolol_second .
2424,The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.,dopamine HCl,alpha-adrenergic blocking agents,effect,peripheral vasoconstriction caused high doses dopamine HCl_first antagonized alpha-adrenergic blocking agents_second .
2425,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,Butyrophenones,dopamine,effect,Butyrophenones_first (such haloperidol) phenothiazines suppress dopamine_second rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2426,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,haloperidol,dopamine,effect,Butyrophenones (such haloperidol_first ) phenothiazines suppress dopamine_second rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2427,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,phenothiazines,dopamine,effect,Butyrophenones (such haloperidol) phenothiazines_first suppress dopamine_second rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2428,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,catecholamines,effect,Cyclopropane_first halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines_second dopamine.
2429,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,dopamine,effect,Cyclopropane_first halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines dopamine_second .
2430,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,catecholamines,effect,Cyclopropane halogenated hydrocarbon anesthetics_first increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines_second dopamine.
2431,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,dopamine,effect,Cyclopropane halogenated hydrocarbon anesthetics_first increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines dopamine_second .
2432,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,cyclopropane,advise,Therefore EXTREME CAUTION exercised administering dopamine HCl_first patients receiving cyclopropane_second halogenated hydrocarbon anesthetics.
2433,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,halogenated hydrocarbon anesthetics,advise,Therefore EXTREME CAUTION exercised administering dopamine HCl_first patients receiving cyclopropane halogenated hydrocarbon anesthetics_second .
2434,It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.,dopamine,propranolol,effect,reported results studies animals indicate dopamine_first induced ventricular arrhythmias anesthesia reversed propranolol_second .
2435,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",vasopressor,oxytocic drugs,effect,concomitant use vasopressor_first vasoconstricting agents (such ergonovine) oxytocic drugs_second may result severe hypertension.
2436,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",ergonovine,oxytocic drugs,effect,concomitant use vasopressors vasoconstricting agents (such ergonovine_first ) oxytocic drugs_second may result severe hypertension.
2437,Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.,phenytoin,dopamine HCl,effect,Administration phenytoin_first patients receiving dopamine HCl_second reported lead hypotension bradycardia.
2438,"It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.",dopamine HCl,phenytoin,advise,suggested patients receiving dopamine HCl_first alternatives phenytoin_second used anticonvulsant therapy needed.
2439,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,narcotic analgesics,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics_second meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2440,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,meperidine,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine_second phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2441,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,phenothiazines,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines_second antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2442,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antipsychotics,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics_second tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2443,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,tricyclic antidepressants,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants_second certain antiarrhythmics quinidine salts antihistamines.
2444,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antiarrhythmics,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics_second quinidine salts antihistamines.
2445,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,quinidine,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine_second salts antihistamines.
2446,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antihistamines,effect,Drug Interactions: central anticholinergic_first syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines_second .
2447,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,narcotic analgesics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics_second meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2448,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,meperidine,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine_second phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2449,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,phenothiazines,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines_second antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2450,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antipsychotics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics_second tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2451,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,tricyclic antidepressants,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants_second certain antiarrhythmics quinidine salts antihistamines.
2452,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antiarrhythmics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics_second quinidine salts antihistamines.
2453,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,quinidine,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine_second salts antihistamines.
2454,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antihistamines,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents AKINETON_first administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines_second .
2455,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ritonavir,mechanism,concomitant use transdermal fentanyl_first ritonavir_second potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2456,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ketoconazole,mechanism,concomitant use transdermal fentanyl_first ritonavir potent 3A4 inhibitors ketoconazole_second itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2457,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,itraconazole,mechanism,concomitant use transdermal fentanyl_first ritonavir potent 3A4 inhibitors ketoconazole itraconazole_second troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2458,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,troleandomycin,mechanism,concomitant use transdermal fentanyl_first ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin_second clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2459,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,clarithromycin,mechanism,concomitant use transdermal fentanyl_first ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin_second nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2460,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,nelfinavir,mechanism,concomitant use transdermal fentanyl_first ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin nelfinavir_second nefazadone may result increase fentanyl plasma concentrations.
2461,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,mechanism,concomitant use CYP3A4 inhibitors diltiazem_first erythromycin transdermal fentanyl_second may also result increase fentanyl plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression.
2462,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,mechanism,concomitant use CYP3A4 inhibitors diltiazem erythromycin_first transdermal fentanyl_second may also result increase fentanyl plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression.
2463,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,central nervous system depressants,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants_second including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2464,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,opioids,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids_second sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2465,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,sedatives,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives_second hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2466,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,hypnotics,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics_second tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2467,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,tranquilizers,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers_second (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2468,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,benzodiazepines,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines_second ) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2469,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,anesthetics,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics_second phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2470,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,phenothiazines,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines_second skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2471,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,skeletal muscle relaxants,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants_second alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2472,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,alcohol,effect,Central Nervous System Depressants: concomitant use DURAGESIC_first (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol_second may cause respiratory depression hypotension profound sedation potentially result coma death.
2473,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,central nervous system depressants,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants_second including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2474,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,opioids,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids_second sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2475,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,sedatives,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives_second hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2476,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,hypnotics,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics_second tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2477,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,tranquilizers,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers_second (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2478,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,benzodiazepines,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines_second ) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2479,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,anesthetics,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics_second phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2480,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,phenothiazines,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines_second skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2481,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,skeletal muscle relaxants,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants_second alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2482,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,alcohol,effect,Central Nervous System Depressants: concomitant use DURAGESIC (fentanyl_first transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol_second may cause respiratory depression hypotension profound sedation potentially result coma death.
2483,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,DURAGESIC,MAOI,advise,MAO Inhibitors: DURAGESIC_first recommended use patients received MAOI_second within 14 days severe unpredictable potentiation MAO inhibitors reported opioid analgesics
2484,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,MAO inhibitors,opioid analgesics,advise,MAO Inhibitors: DURAGESIC recommended use patients received MAOI within 14 days severe unpredictable potentiation MAO inhibitors_first reported opioid analgesics_second
2485,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,coumarin anticoagulant,mechanism,vitro studies shown CASODEX_first displace coumarin anticoagulant_second warfarin protein binding sites.
2486,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,warfarin,mechanism,vitro studies shown CASODEX_first displace coumarin anticoagulants warfarin_second protein binding sites.
2487,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,coumarin anticoagulants,advise,recommended CASODEX_first started patients already receiving coumarin anticoagulants_second prothrombin times closely monitored adjustment anticoagulant dose may necessary.
2488,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,anticoagulant,advise,recommended CASODEX_first started patients already receiving coumarin anticoagulants prothrombin times closely monitored adjustment anticoagulant_second dose may necessary.
2489,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,tricyclic antidepressants,effect,administration local anesthetic solutions_first containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second phenothiazines may produce severe prolonged hypotension hypertension.
2490,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,phenothiazines,effect,administration local anesthetic solutions_first containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines_second may produce severe prolonged hypotension hypertension.
2491,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension.
2492,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second phenothiazines may produce severe prolonged hypotension hypertension.
2493,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,phenothiazines,effect,administration local anesthetic solutions containing epinephrine_first norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines_second may produce severe prolonged hypotension hypertension.
2494,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors_second tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension.
2495,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors tricyclic antidepressants_second phenothiazines may produce severe prolonged hypotension hypertension.
2496,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,phenothiazines,effect,administration local anesthetic solutions containing epinephrine norepinephrine_first patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines_second may produce severe prolonged hypotension hypertension.
2497,"Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.",vasopressor drugs,ergot-type oxytocic drugs,effect,Concurrent administration vasopressor drugs_first (for treatment hypotension related obstetric blocks) ergot-type oxytocic drugs_second may cause severe persistent hypertension cerebrovascular accidents.
2498,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.",chloroprocaine,sulfonamide drug,advise,Therefore chloroprocaine_first used condition sulfonamide drug_second employed.
2499,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;",Anticholinergic agents,digoxin,mechanism,Anticholinergic agents_first may affect gastrointestinal absorption various drugs slowly dissolving dosage forms digoxin_second ;
2500,"Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.",Anticholinergic drugs,metoclopramide,mechanism,Anticholinergic drugs_first may antagonize effects drugs alter gastrointestinal motility metoclopramide_second .
2501,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.",antacids,anticholinergic agents,mechanism,antacids_first may interfere absorption anticholinergic agents_second simultaneous use drugs avoided.
2502,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).",ENBREL,anakinra,effect,study patients active RA treated 24 weeks concurrent ENBREL_first anakinra_second therapy 7% rate serious infections observed higher observed ENBREL alone (0%).
2503,Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).,ENBREL,anakinra,effect,Two percent patients treated concurrently ENBREL_first anakinra_second developed neutropenia (ANC 1 x 109/L).
2504,"Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.",sulfasalazine,ENBREL,effect,Patients clinical study established therapy sulfasalazine_first ENBREL_second added noted develop mild decrease mean neutrophil counts comparison groups treated either ENBREL CI sulfasalazine alone.
2505,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,nabumetone,warfarin,advise,Caution exercised administering nabumetone_first warfarin_second since interactions seen NSAIDs.
2506,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,warfarin,NSAIDs,int,Caution exercised administering nabumetone warfarin_first since interactions seen NSAIDs_second .
2507,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,KRM-1648,effect,combined ofloxacin_first KRM-1648_second exhibited strong synergistic activity additive effects observed combination rifampicin (or rifabutin) ofloxacin.
2508,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifampicin,ofloxacin,effect,combined ofloxacin KRM 1648 exhibited strong synergistic activity additive effects observed combination rifampicin_first (or rifabutin) ofloxacin_second .
2509,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifabutin,ofloxacin,effect,combined ofloxacin KRM 1648 exhibited strong synergistic activity additive effects observed combination rifampicin (or rifabutin_first ) ofloxacin_second .
2510,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,central nervous system depressants,effect,Concurrent use butorphanol_first central nervous system depressants_second (e.g. alcohol barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects.
2511,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,alcohol,effect,Concurrent use butorphanol_first central nervous system depressants (e.g. alcohol_second barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects.
2512,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,barbiturates,effect,Concurrent use butorphanol_first central nervous system depressants (e.g. alcohol barbiturates_second tranquilizers antihistamines) may result increased central nervous system depressant effects.
2513,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,tranquilizers,effect,Concurrent use butorphanol_first central nervous system depressants (e.g. alcohol barbiturates tranquilizers_second antihistamines) may result increased central nervous system depressant effects.
2514,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,antihistamines,effect,Concurrent use butorphanol_first central nervous system depressants (e.g. alcohol barbiturates tranquilizers antihistamines_second ) may result increased central nervous system depressant effects.
2515,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.",STADOL NS,sumatriptan,mechanism,However another study healthy volunteers pharmacokinetics butorphanol significantly altered (29% decrease AUC 38% decrease Cmax) 1 mg dose STADOL NS_first administered 1 minute 20 mg dose sumatriptan_second nasal spray.
2516,"When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,mechanism,STADOL NS_first administered 30 minutes sumatriptan_second nasal spray AUC butorphanol increased 11% Cmax decreased 18%.
2517,"These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,effect,results suggest analgesic effect STADOL NS_first may diminished administered shortly sumatriptan_second nasal spray 30 minutes reduction effect minimal.
2518,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",butorphanol,erythromycin,advise,known effects butorphanol_first altered concomitant medications affect hepatic metabolism drugs (erythromycin_second etc.) physicians alert possibility smaller initial dose longer intervals doses may needed.
2519,"Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.",STADOL NS,nasal vasoconstrictor,effect,Therefore slower onset anticipated STADOL NS_first administered concomitantly immediately following nasal vasoconstrictor_second .
2520,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalapril,effect,Hypotension: Patients Diuretic Therapy: Patients diuretics_first especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy enalapril_second enalaprilat.
2521,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalaprilat,effect,Hypotension: Patients Diuretic Therapy: Patients diuretics_first especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy enalapril enalaprilat_second .
2522,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalapril,diuretic,effect,possibility hypotensive effects enalapril_first enalaprilat minimized either discontinuing diuretic_second increasing salt intake prior initiation treatment enalapril enalaprilat.
2523,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalaprilat,diuretic,effect,possibility hypotensive effects enalapril enalaprilat_first minimized either discontinuing diuretic_second increasing salt intake prior initiation treatment enalapril enalaprilat.
2524,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: antihypertensive effect enalapril_first enalapril IV augmented antihypertensive agents_second cause renin release (e.g. diuretics).
2525,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: antihypertensive effect enalapril_first enalapril IV augmented antihypertensive agents cause renin release (e.g. diuretics_second ).
2526,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: antihypertensive effect enalapril enalapril_first IV augmented antihypertensive agents_second cause renin release (e.g. diuretics).
2527,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: antihypertensive effect enalapril enalapril_first IV augmented antihypertensive agents cause renin release (e.g. diuretics_second ).
2528,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.",nonsteroidal anti-inflammatory drugs,enalapril,effect,Non steroidal Anti inflammatory Agents: patients compromised renal function treated nonsteroidal anti-inflammatory drugs_first co administration enalapril_second may result deterioration renal function.
2529,"However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.",NSAIDs,ACE inhibitors,effect,However reports suggest NSAIDs_first may diminish antihypertensive effect ACE inhibitors_second .
2530,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking NSAIDs_first concomitantly ACE inhibitors_second .
2531,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,Enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: Enalapril_first enalapril IV attenuate potassium loss caused thiazide-type diuretics_second .
2532,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: Enalapril enalapril_first IV attenuate potassium loss caused thiazide-type diuretics_second .
2533,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: Lithium toxicity reported patients receiving lithium_first concomitantly drugs cause elimination sodium including ACE inhibitors_second .
2534,It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.,enalapril,lithium,advise,recommended serum lithium levels monitored frequently enalapril_first administered concomitantly lithium_second .
2535,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,Colchicine,vitamin B12,mechanism,Colchicine_first para aminosalicylic acid heavy alcohol intake longer 2 weeks may produce malabsorption vitamin B12_second .
2536,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,para-aminosalicylic acid,vitamin B12,mechanism,Colchicine para-aminosalicylic acid_first heavy alcohol intake longer 2 weeks may produce malabsorption vitamin B12_second .
2537,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,alcohol,vitamin B12,mechanism,Colchicine para aminosalicylic acid heavy alcohol_first intake longer 2 weeks may produce malabsorption vitamin B12_second .
2538,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,probenecid,effect,Uricosuric Agents: Aspirin_first may decrease effects probenecid_second sulfinpyrazone phenylbutazone.
2539,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,sulfinpyrazone,effect,Uricosuric Agents: Aspirin_first may decrease effects probenecid sulfinpyrazone_second phenylbutazone.
2540,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,phenylbutazone,effect,Uricosuric Agents: Aspirin_first may decrease effects probenecid sulfinpyrazone phenylbutazone_second .
2541,Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.,Alcohol,aspirin,effect,Alcohol_first : synergistic effect aspirin_second causing gastrointestinal bleeding.
2542,Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.,Corticosteroids,aspirin,effect,Corticosteroids_first : Concomitant administration aspirin_second may increase risk gastrointestinal ulceration may reduce serum salicylate levels.
2543,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",Pyrazolone Derivatives,aspirin,effect,Pyrazolone Derivatives_first (phenylbutazone oxyphenbutazone possibly dipyrone): Concomitant administration aspirin_second may increase risk gastrointestinal ulceration.
2544,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",phenylbutazone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone_first oxyphenbutazone possibly dipyrone): Concomitant administration aspirin_second may increase risk gastrointestinal ulceration.
2545,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",oxyphenbutazone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone_first possibly dipyrone): Concomitant administration aspirin_second may increase risk gastrointestinal ulceration.
2546,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",dipyrone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone possibly dipyrone_first ): Concomitant administration aspirin_second may increase risk gastrointestinal ulceration.
2547,Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.,Aspirin,nonsteroidal anti-inflammatory,advise,Nonsteroidal Antiinflammatory Agents: Aspirin_first contraindicated patients hypersensitive nonsteroidal anti-inflammatory_second agents.
2548,Phenobarbital: Decreases aspirin effectiveness by enzyme induction.,Phenobarbital,aspirin,mechanism,Phenobarbital_first : Decreases aspirin_second effectiveness enzyme induction.
2549,Phenytoin: Serum phenytoin levels may be increased by aspirin.,phenytoin,aspirin,effect,Phenytoin: Serum phenytoin_first levels may increased aspirin_second .
2550,Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.,Propranolol,aspirins,effect,Propranolol_first : May decrease aspirins_second anti inflammatory action competing receptors.
2551,"Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.",Aspirin,antacids,advise,Antacids: Enteric Coated Aspirin_first given concurrently antacids_second since increase pH stomach may effect enteric coating tablets.
2552,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ketoconazole,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole_second itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2553,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,itraconazole,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole_second erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2554,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,erythromycin,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin_second clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2555,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,clarithromycin,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin_second ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2556,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ritonavir,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir_second atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2557,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,atazanavir,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir_second indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2558,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,indinavir,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir_second nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2559,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nefazodone,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone_second nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2560,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nelfinavir,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir_second saquinavir telithromycin) may increase exposure dasatinib avoided.
2561,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,saquinavir,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir_second telithromycin) may increase exposure dasatinib avoided.
2562,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,telithromycin,mechanism,Concomitant use SPRYCEL_first drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin_second ) may increase exposure dasatinib avoided.
2563,Simultaneous administration of SPRYCEL with antacids should be avoided.,SPRYCEL,antacids,advise,Simultaneous administration SPRYCEL_first antacids_second avoided.
2564,"If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.",antacid,SPRYCEL,advise,antacid_first therapy needed antacid dose administered least 2 hours prior 2 hours dose SPRYCEL_second .
2565,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",H2 blockers,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers_first proton pump inhibitors (eg famotidine omeprazole) likely reduce dasatinib_second exposure.
2566,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",proton pump inhibitors,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers proton pump inhibitors_first (eg famotidine omeprazole) likely reduce dasatinib_second exposure.
2567,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",famotidine,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine_first omeprazole) likely reduce dasatinib_second exposure.
2568,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",omeprazole,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine omeprazole_first ) likely reduce dasatinib_second exposure.
2569,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,H2 blockers,SPRYCEL,advise,concomitant use H2 blockers_first proton pump inhibitors SPRYCEL_second recommended.
2570,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,proton pump inhibitors,SPRYCEL,advise,concomitant use H2 blockers proton pump inhibitors_first SPRYCEL_second recommended.
2571,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,H2 blockers,SPRYCEL,advise,use antacids considered place H2 blockers_first proton pump inhibitors patients receiving SPRYCEL_second therapy.
2572,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,proton pump inhibitors,SPRYCEL,advise,use antacids considered place H2 blockers proton pump inhibitors_first patients receiving SPRYCEL_second therapy.
2573,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",alfentanil,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil_first astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2574,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",astemizole,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole_first terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2575,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",terfenadine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine_first cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2576,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cisapride,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride_first cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2577,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cyclosporine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine_first fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2578,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",fentanyl,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl_first pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2579,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",pimozide,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide_first quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2580,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",quinidine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine_first sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2581,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",sirolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus_first tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2582,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",tacrolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus_first ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2583,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergot alkaloids,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids_first (ergotamine dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2584,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine_first dihydroergotamine) administered caution patients receiving SPRYCEL_second .
2585,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",dihydroergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine_first ) administered caution patients receiving SPRYCEL_second .
2586,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",interferon beta-1a,TYSABRI,mechanism,multiple dosing interferon beta-1a_first (AVONEX 30 mcg IM weekly) reduced TYSABRI_second clearance approximately 30%.
2587,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",AVONEX,TYSABRI,mechanism,multiple dosing interferon beta 1a (AVONEX_first 30 mcg IM weekly) reduced TYSABRI_second clearance approximately 30%.
2588,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.",terfenadine,Itraconazole,mechanism,Coadministration terfenadine_first Itraconazole_second led elevated plasma concentrations terfenadine resulting rare instances life threatening cardiac dysrhythmias one death.
2589,"Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.",ketoconazole,astemizole,mechanism,Another oral azole antifungal ketoconazole_first inhibits metabolism astemizole_second resulting elevated plasma concentrations astemizole active metabolite desmethylastermizole may prolong QT intervals.
2590,"In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.",itraconazole,astemizole,mechanism,vitro data suggest itraconazole_first compared ketoconazole less pronounced effect biotransformation system responsible metabolism astemizole_second .
2591,"Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.",astemizole,itraconazole,advise,Based chemical resemblance itraconazole ketoconazole coadministration astemizole_first itraconazole_second contraindicated.
2592,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral ketoconazole_first potently inhibits metabolism cisapride_second resulting eight fold increase mean AUC cisapride.
2593,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral ketoconazole_first cisapride_second result prolongation QT interval ECG.
2594,In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;,itraconazole,cisapride,mechanism,vitro data suggest itraconazole_first also markedly inhibits biotransformation system mainly responsible metabolism cisapride_second ;
2595,therefore concomitant administration of Itraconazole with cisapride is contraindicated.,Itraconazole,cisapride,advise,therefore concomitant administration Itraconazole_first cisapride_second contraindicated.
2596,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,midazolam,mechanism,Coadministration Itraconazole_first oral midazolam_second triazolam resulted elevated plasma concentrations latter two drugs.
2597,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,triazolam,mechanism,Coadministration Itraconazole_first oral midazolam triazolam_second resulted elevated plasma concentrations latter two drugs.
2598,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,cyclosporine,mechanism,Coadministration Itraconazole_first cyclosporine_second tacrolimus digoxin led increased plasma concentrations latter three drugs.
2599,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,tacrolimus,mechanism,Coadministration Itraconazole_first cyclosporine tacrolimus_second digoxin led increased plasma concentrations latter three drugs.
2600,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,digoxin,mechanism,Coadministration Itraconazole_first cyclosporine tacrolimus digoxin_second led increased plasma concentrations latter three drugs.
2601,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",Cyclosporine,Itraconazole,advise,Cyclosporine_first tacrolimus digoxin concentrations monitored initiation Itraconazole_second therapy frequently thereafter dose three drug products adjusted appropriately.
2602,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",tacrolimus,Itraconazole,advise,Cyclosporine tacrolimus_first digoxin concentrations monitored initiation Itraconazole_second therapy frequently thereafter dose three drug products adjusted appropriately.
2603,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",digoxin,Itraconazole,advise,Cyclosporine tacrolimus digoxin_first concentrations monitored initiation Itraconazole_second therapy frequently thereafter dose three drug products adjusted appropriately.
2604,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,immunosuppressive drugs,effect,Rhabdomyolysis observed patients receiving HMG-CoA reductase inhibitors_first administered alone (at recommended dosages) concomitantly immunosuppressive drugs_second including cyclosporine.
2605,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,cyclosporine,effect,Rhabdomyolysis observed patients receiving HMG-CoA reductase inhibitors_first administered alone (at recommended dosages) concomitantly immunosuppressive drugs including cyclosporine_second .
2606,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,phenytoin,mechanism,Itraconazole_first coadministered phenytoin_second rifampin H2antagonists reduced plasma concentrations itraconazole reported.
2607,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,rifampin,mechanism,Itraconazole_first coadministered phenytoin rifampin_second H2antagonists reduced plasma concentrations itraconazole reported.
2608,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;",Itraconazole,phenytoin,mechanism,Although studies conducted concomitant administration Itraconazole_first phenytoin_second may alter metabolism phenytoin;
2609,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.",phenytoin,Itraconazole,advise,therefore plasma concentrations phenytoin_first also monitored given concurrently Itraconazole_second .
2610,It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.,Itraconazole,coumarin,effect,reported Itraconazole_first enhances anticoagulant effect coumarin_second like drugs.
2611,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.",Itraconazole,coumarin,advise,Therefore prothrombin time carefully monitored patients receiving Itraconazole_first coumarin_second like drugs simultaneously.
2612,Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.,azole antifungal agents,isoniazid,mechanism,Plasma concentrations azole antifungal agents_first reduced given concurrently isoniazid_second .
2613,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.,Itraconazole,isoniazid,advise,Itraconazole plasma concentrations monitored Itraconazole_first isoniazid_second coadministered.
2614,Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.,azole antifungal agents,hypoglycemic agents,effect,Severe hypoglycemia reported patients concomitantly receiving azole antifungal agents_first oral hypoglycemic agents_second .
2615,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.,Itraconazole,hypoglycemic agents,advise,Blood glucose concentrations carefully monitored Itraconazole_first oral hypoglycemic agents_second coadministered.
2616,Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.,Itraconazole,quinidine,effect,Tinnitus decreased hearing reported patients concomitantly receiving Itraconazole_first quinidine_second .
2617,Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.,Itraconazole,dihydropyridine calcium channel blockers,effect,Edema reported patients concomitantly receiving Itraconazole_first dihydropyridine calcium channel blockers_second .
2618,"Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ",Cytochalasin D,carbachol,effect,Cytochalasin D_first 10 microM preferentially blocked secretory effect carbachol_second synergism cAMP whereas effect histamine cAMP stimulated acid secretion within 15 min.
2619,Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. ,Cytochalasin D,carbachol,effect,Cytochalasin D_first inhibited carbachol_second stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due release Ca(2+) store.
2620,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,Tetracycline_first bacteriostatic antibiotic may antagonize bactercidal effect penicillin_second concurrent use drugs avoided.
2621,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",clarithromycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show clarithromycin_first erythromycin troleandomycin markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2622,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",erythromycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show clarithromycin erythromycin_first troleandomycin markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2623,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",troleandomycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show clarithromycin erythromycin troleandomycin_first markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2624,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",anticholinergic compounds,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds_first belladonna alkaloids dicyclomine would expected compromise beneficial effects cisapride_second .
2625,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",belladonna alkaloids,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids_first dicyclomine would expected compromise beneficial effects cisapride_second .
2626,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",dicyclomine,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids dicyclomine_first would expected compromise beneficial effects cisapride_second .
2627,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.",cisapride,anticoagulant,advise,advisable check coagulation time within first days start discontinuation cisapride_first therapy appropriate adjustment anticoagulant_second dose necessary.
2628,"Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,mechanism,Antidepressants: vitro data indicate nefazodone_first inhibits metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2629,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",fluconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate fluconazole_first itraconazole oral ketoconazole markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2630,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",itraconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate fluconazole itraconazole_first oral ketoconazole markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2631,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",ketoconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate fluconazole itraconazole oral ketoconazole_first markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2632,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.",ketoconazole,cisapride,mechanism,Human pharmacokinetic data indicate oral ketoconazole_first markedly inhibits metabolism cisapride_second resulting mean eight fold increase AUC cisapride.
2633,A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.,cisapride,ketoconazole,effect,study 14 normal male female volunteers suggests coadministration cisapride_first ketoconazole_second result prolongation QT interval ECG.
2634,"H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.",Cimetidine,cisapride,mechanism,H2 Receptor Antagonists: Cimetidine_first coadministration leads increased peak plasma concentration AUC cisapride_second effect cisapride absorption coadministered ranitidine.
2635,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,cimetidine,cisapride,mechanism,gastrointestinal absorption cimetidine_first ranitidine accelerated coadministered cisapride_second .
2636,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,ranitidine,cisapride,mechanism,gastrointestinal absorption cimetidine ranitidine_first accelerated coadministered cisapride_second .
2637,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,indinavir,cisapride,mechanism,Protease Inhibitors: vitro data indicate indinavir_first ritonavir markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2638,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,mechanism,Protease Inhibitors: vitro data indicate indinavir ritonavir_first markedly inhibit metabolism cisapride_second result increase plasma cisapride levels prolongation QT interval ECG.
2639,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,antiarrhythmics,advise,Cisapride_first used concomitantly drugs known prolong QT interval: certain antiarrhythmics_second including Class IA (such quinidine procainamide) Class III (such sotalol);
2640,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,quinidine,advise,Cisapride_first used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine_second procainamide) Class III (such sotalol);
2641,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,procainamide,advise,Cisapride_first used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine procainamide_second ) Class III (such sotalol);
2642,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,sotalol,advise,Cisapride_first used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine procainamide) Class III (such sotalol_second );
2643,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,antidepressants,int,Chlorotrianisene_first may interact antidepressants_second aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2644,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,aspirin,int,Chlorotrianisene_first may interact antidepressants aspirin_second barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2645,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,barbiturates,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates_second bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2646,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,bromocriptine,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine_second calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2647,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,calcium,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium_second supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2648,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticosteroids,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids_second corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2649,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticotropin,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin_second cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2650,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,cyclosporine,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine_second dantrolene nicotine somatropin tamoxifen warfarin.
2651,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,dantrolene,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene_second nicotine somatropin tamoxifen warfarin.
2652,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,nicotine,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine_second somatropin tamoxifen warfarin.
2653,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,somatropin,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin_second tamoxifen warfarin.
2654,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,tamoxifen,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen_second warfarin.
2655,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,warfarin,int,Chlorotrianisene_first may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin_second .
2656,"Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ",estradiol,noradrenaline,effect,Aortic rings intact endothelium high dose (4 mg/kg/day) estradiol_first group supersensitive noradrenaline_second compared vehicle low dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/ 0.09 7.30+/ 0.11 7.35+/ 0.04 respectively).
2657,"Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ",estradiol,noradrenaline,effect,Endothelium intact aortic rings high estradiol_first rats supersensitive noradrenaline_second compared vehicle progesterone progesterone + high estradiol treated rats (pD2 values = 7.77+/ 0.12 7.21+/ 0.13 6.93+/ 0.04 7.22+/ 0.18 respectively).
2658,"In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.",central nervous system depressants,heroin,effect,combination central nervous system depressants_first heroin_second may still kill even experienced users particularly tolerance drug reduced strength usual dose increased.
2659,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,central nervous system depressants,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants_second including alcohol benzodiazepines diazepam (Valium) rising degree methadone.
2660,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,alcohol,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants including alcohol_second benzodiazepines diazepam (Valium) rising degree methadone.
2661,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,benzodiazepines,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines_second diazepam (Valium) rising degree methadone.
2662,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,diazepam,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam_second (Valium) rising degree methadone.
2663,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,Valium,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium_second ) rising degree methadone.
2664,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,methadone,effect,Toxicology studies heroin_first related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium) rising degree methadone_second .
2665,Cocaine sometimes proves to be fatal when used in combination with heroin.,Cocaine,heroin,effect,Cocaine_first sometimes proves fatal used combination heroin_second .
2666,"however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ",nitrate,sildenafil,effect,however patients moderate severe cardiovascular disease taking nitrate_first therapy increased risk potentially serious cardiovascular adverse effects sildenafil_second therapy.
2667,It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ,MPTP,pargyline,effect,observed MPTP_first induced long lasting depletions striatal dopamine concentrations neurotoxic effect could prevented pargyline_second pretreatment.
2668,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,amphetamine,effect,MPTP_first induced neuronal damage produced tolerance disruptive effects amphetamine_second supersensitivity disruptive effects apomorphine rats responding schedule controlled paradigm.
2669,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,apomorphine,effect,MPTP_first induced neuronal damage produced tolerance disruptive effects amphetamine supersensitivity disruptive effects apomorphine_second rats responding schedule controlled paradigm.
2670,"Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. ",Methamphetamine,pargyline,effect,Methamphetamine_first like MPTP produced depletions striatal dopamine actions potentiated pargyline_second pretreatment.
2671,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,Cholestytamine,thiazide diuretics,mechanism,Cholestyramine colestipol resins: Cholestytamine_first colestipol resins potential binding thiazide diuretics_second reducing diuretic absorption gastrointestinal tract
2672,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,colestipol,thiazide diuretics,mechanism,Cholestyramine colestipol resins: Cholestytamine colestipol_first resins potential binding thiazide diuretics_second reducing diuretic absorption gastrointestinal tract
2673,- Lithium: Generally should not be given with diuretics.,Lithium,diuretics,advise,Lithium_first : Generally given diuretics_second .
2674,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents_first reduce renal clearance lithium_second add high risk lithium toxicity.
2675,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents_first reduce renal clearance lithium add high risk lithium_second toxicity.
2676,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide,lithium,chlorothiazide,advise,Refer package insert lithium_first preparations use preparations chlorothiazide_second
2677,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
2678,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium-sparing diuretics_second .
2679,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration non-steroidal anti-inflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
2680,"Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained",chlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore chlorothiazide_first non-steroidal anti-inflammatory agents_second used concomitantly patient observed closely determine desired effect diuretic obtained
2681,Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.,antidiabetic agents,VELCADE,advise,Patients oral antidiabetic agents_first receiving VELCADE_second treatment may require close monitoring blood glucose levels adjustment dose antidiabetic medication.
2682,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,tricyclic antidepressants,effect,Antihistamines_first may enhance effects tricyclic antidepressants_second barbiturates alcohol CNS depressants.
2683,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,barbiturates,effect,Antihistamines_first may enhance effects tricyclic antidepressants barbiturates_second alcohol CNS depressants.
2684,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,alcohol,effect,Antihistamines_first may enhance effects tricyclic antidepressants barbiturates alcohol_second CNS depressants.
2685,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,CNS depressants,effect,Antihistamines_first may enhance effects tricyclic antidepressants barbiturates alcohol CNS depressants_second .
2686,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors_first prolong intensify anticholinergic effects antihistamines_second .
2687,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,reserpine,effect,Sympathomimetic amines_first may reduce antihypertensive effects reserpine_second veratrum alkaloids methyldopa mecamylamine.
2688,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,veratrum alkaloids,effect,Sympathomimetic amines_first may reduce antihypertensive effects reserpine veratrum alkaloids_second methyldopa mecamylamine.
2689,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,methyldopa,effect,Sympathomimetic amines_first may reduce antihypertensive effects reserpine veratrum alkaloids methyldopa_second mecamylamine.
2690,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,mecamylamine,effect,Sympathomimetic amines_first may reduce antihypertensive effects reserpine veratrum alkaloids methyldopa mecamylamine_second .
2691,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,MAO inhibitors,effect,Effects sympathomimetics_first increased MAO inhibitors_second beta adrenergic blockers.
2692,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,beta adrenergic blockers,effect,Effects sympathomimetics_first increased MAO inhibitors beta adrenergic blockers_second .
2693,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.",halofantrine,Mefloquine,advise,danger potentially fatal prolongation QTc interval halofantrine_first must given simultaneously subsequent Mefloquine_second .
2694,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinine,effect,Concomitant administration Mefloquine_first related compounds (eg quinine_second quinidine chloroquine) may produce electrocardiographic abnormalities increase risk convulsions.
2695,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinidine,effect,Concomitant administration Mefloquine_first related compounds (eg quinine quinidine_second chloroquine) may produce electrocardiographic abnormalities increase risk convulsions.
2696,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,chloroquine,effect,Concomitant administration Mefloquine_first related compounds (eg quinine quinidine chloroquine_second ) may produce electrocardiographic abnormalities increase risk convulsions.
2697,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,anti-arrhythmic,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic_second beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2698,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,beta-adrenergic blocking agents,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta-adrenergic blocking agents_second calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2699,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,calcium channel blockers,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers_second antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2700,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,antihistamines,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines_second H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2701,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,H1-blocking agents,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents_second tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2702,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,tricyclic antidepressants,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants_second phenothiazines) might also contribute prolongation QTc interval.
2703,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,phenothiazines,effect,appears clinically relevant interaction kind Mefloquine_first although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants phenothiazines_second ) might also contribute prolongation QTc interval.
2704,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",anticonvulsant,Mefloquine,effect,patients taking anticonvulsant_first (eg valproic acid carbamazepine phenobarbital phenytoin) concomitant use Mefloquine_second may reduce seizure control lowering plasma levels anticonvulsant.
2705,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",valproic acid,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid_first carbamazepine phenobarbital phenytoin) concomitant use Mefloquine_second may reduce seizure control lowering plasma levels anticonvulsant.
2706,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",carbamazepine,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid carbamazepine_first phenobarbital phenytoin) concomitant use Mefloquine_second may reduce seizure control lowering plasma levels anticonvulsant.
2707,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenobarbital,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid carbamazepine phenobarbital_first phenytoin) concomitant use Mefloquine_second may reduce seizure control lowering plasma levels anticonvulsant.
2708,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenytoin,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid carbamazepine phenobarbital phenytoin_first ) concomitant use Mefloquine_second may reduce seizure control lowering plasma levels anticonvulsant.
2709,"When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.",Mefloquine,live typhoid vaccines,effect,Mefloquine_first taken concurrently oral live typhoid vaccines_second attenuation immunization cannot excluded.
2710,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.",Mefloquine,anticoagulants,advise,Nevertheless effects Mefloquine_first travelers receiving comedication particularly diabetics patients using anticoagulants_second checked departure.
2711,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,mechanism,Lithium_first generally given diuretics_second reduce renal clearance add high risk lithium toxicity.
2712,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,aminoglycoside,effect,EDECRIN_first may increase ototoxic potential drugs aminoglycoside_second cephalosporin antibiotics.
2713,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,cephalosporin antibiotics,effect,EDECRIN_first may increase ototoxic potential drugs aminoglycoside cephalosporin antibiotics_second .
2714,"A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;",ethacrynic acid,warfarin,mechanism,number drugs including ethacrynic acid_first shown displace warfarin_second plasma protein;
2715,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,loop diuretics,effect,patients administration non- steroidal antiinflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide loop diuretics_second .
2716,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,potassium- sparing diuretics,effect,patients administration non- steroidal antiinflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide potassium- sparing diuretics_second .
2717,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,thiazide diuretics,effect,patients administration non- steroidal antiinflammatory agent_first reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics_second .
2718,"Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",EDECRIN,non- steroidal anti- inflammatory agents,effect,Therefore EDECRIN_first non- steroidal anti- inflammatory agents_second used concomitantly patient observed closely determine desired effect diuretic obtained.
2719,"Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.",L-tyrosine,MAO inhibitors,effect,Non selective MAO inhibitors including tranylcypromine sulfate phenelzine sulfate pargyline HC1: Concomitant use L-tyrosine_first non selective MAO inhibitors_second may cause hypertension.
2720,"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ",thiabendazole,melarsoprol,effect,Among risk factors studied two appear increase risk ARE: prescription thiabendazole_first treat strongyloidiasis melarsoprol_second cure bad general clinical conditions patients.
2721,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,cimetidine,advise,Based adult data lower doses caffeine_first may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine_second ketoconazole) higher caffeine doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital phenytoin).
2722,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,ketoconazole,advise,Based adult data lower doses caffeine_first may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine ketoconazole_second ) higher caffeine doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital phenytoin).
2723,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenobarbital,advise,Based adult data lower doses caffeine may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine ketoconazole) higher caffeine_first doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital_second phenytoin).
2724,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenytoin,advise,Based adult data lower doses caffeine may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine ketoconazole) higher caffeine_first doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital phenytoin_second ).
2725,Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,effect,Caffeine_first administered concurrently ketoprofen_second reduced urine volume 4 healthy volunteers.
2726,The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.,nevirapine,warfarin,int,vitro interaction nevirapine_first antithrombotic agent warfarin_second complex.
2727,"When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.",warfarin,nevirapine,advise,warfarin_first co administered nevirapine_second anticoagulation levels monitored frequently.
2728,Clarithromycin exposure was significantly decreased by nevirapine;,Clarithromycin,nevirapine,mechanism,Clarithromycin_first exposure significantly decreased nevirapine_second ;
2729,"Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.",contraceptives,nevirapine,advise,Oral contraceptives_first hormonalmethods birth control usedas sole method contraception inwomen taking nevirapine_second since nevirapinemay lower plasma levels thesemedications.
2730,Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.,Nevirapine,ketoconazole,advise,Nevirapine_first ketoconazole_second beadministered concomitantly becausedecreases ketoconazole plasmaconcentrations may reduce efficacy drug.
2731,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,lopinavir,nevirapine,advise,dose increase lopinavir_first /ritonavir 533/133 mg twice daily food isrecommended combination nevirapine_second .
2732,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,ritonavir,nevirapine,advise,dose increase lopinavir/ritonavir_first 533/133 mg twice daily food isrecommended combination nevirapine_second .
2733,Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.,Methadone,nevirapine,advise,Methadone levels may decreased; increased dosages may required prevent symptoms opiate withdrawal. Methadone_first maintained patients beginning nevirapine_second therapy monitored forevidence withdrawal methadone dose adjusted accordingly.
2734,Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.,Nevirapine,rifampin,advise,Nevirapine_first rifampin_second beadministered concomitantly becausedecreases nevirapine plasmaconcentrations may reduce efficacy ofthe drug.
2735,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.",nevirapine,methadone,effect,aBased reports narcotic withdrawal syndrome patients treated nevirapine_first methadone_second concurrently evidence decreased plasma concentrations methadone.
2736,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",ketamine,ouabain,effect,comparison digitalis tolerance dogs anesthetized ketamine_first Innovar Vet pentobarbital dosage ouabain_second needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2737,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",Innovar Vet,ouabain,effect,comparison digitalis tolerance dogs anesthetized ketamine Innovar Vet_first pentobarbital dosage ouabain_second needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2738,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",pentobarbital,ouabain,effect,comparison digitalis tolerance dogs anesthetized ketamine Innovar Vet pentobarbital_first dosage ouabain_second needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2739,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,Innovar,effect,Ventricular tachycardia induced ouabain_first generally converted sinus rhythm following administration Innovar_second ketamine droperidol administration fentayl alone pentobarbital.
2740,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,ketamine,effect,Ventricular tachycardia induced ouabain_first generally converted sinus rhythm following administration Innovar ketamine_second droperidol administration fentayl alone pentobarbital.
2741,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,droperidol,effect,Ventricular tachycardia induced ouabain_first generally converted sinus rhythm following administration Innovar ketamine droperidol_second administration fentayl alone pentobarbital.
2742,"Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.",ketoconazole,lapatinib,mechanism,Ketoconazole: healthy subjects receiving ketoconazole_first CYP3A4 inhibitor 200 mg twice daily 7 days systemic exposure (AUC) lapatinib_second increased approximately 3.6 fold control half life increased 1.7 fold control.
2743,"Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.",carbamazepine,lapatinib,mechanism,Carbamazepine: healthy subjects receiving CYP3A4 inducer carbamazepine_first 100 mg twice daily 3 days 200 mg twice daily 17 days systemic exposure (AUC) lapatinib_second decreased approximately 72%.
2744,MAO inhibitors should be used with caution in patients receiving hydralazine.,MAO inhibitors,hydralazine,advise,MAO inhibitors_first used caution patients receiving hydralazine_second .
2745,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,diazoxide,effect,potent parental antihypertensive drugs_first diazoxide_second used combination hydralazine patients continuously observed several hours excessive fall blood pressure.
2746,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,hydralazine,effect,potent parental antihypertensive drugs_first diazoxide used combination hydralazine_second patients continuously observed several hours excessive fall blood pressure.
2747,Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.,diazoxide,hydralazine,effect,Profound hypotensive episodes may occur diazoxide_first infection hydralazine_second used concomitantly.
2748,Propranolol increases hydralazines serum concentrations.,Propranolol,hydralazine,mechanism,Propranolol_first increases hydralazine_second serum concentrations.
2749,NSAIDs may decrease the hemodynamic effects of hydralazine;,NSAIDs,hydralazine,effect,NSAIDs_first may decrease hemodynamic effects hydralazine_second ;
2750,Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.,carbamazepine,SUPRAX,mechanism,Carbamazepine: Elevated carbamazepine_first levels reported postmarketing experience SUPRAX_second administered concomitantly.
2751,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Warfarin,cefixime,effect,Warfarin_first Anticoagulants: Increased prothrombin time without clinical bleeding reported cefixime_second administered concomitantly.
2752,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Anticoagulants,cefixime,effect,Warfarin Anticoagulants_first : Increased prothrombin time without clinical bleeding reported cefixime_second administered concomitantly.
2753,Cimetidine: Cimetidine increases nicardipine HCl plasma levels.,Cimetidine,nicardipine HCl,mechanism,Cimetidine: Cimetidine_first increases nicardipine HCl_second plasma levels.
2754,Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.,calcium blockers,digitalis preparations,mechanism,Digoxin: calcium blockers_first may increase concentration digitalis preparations_second blood.
2755,"Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.",digoxin,nicardipine HCl,advise,Nicardipine HCl usually alter plasma levels digoxin however serum digoxin_first levels evaluated concomitant therapy nicardipine HCl_second initiated.
2756,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.",cyclosporine,nicardipine,advise,Plasma concentrations cyclosporine_first therefore closely monitored dosage reduced accordingly patients treated nicardipine_second .
2757,Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.,proton pump inhibitors,warfarin,effect,Patients treated proton pump inhibitors_first warfarin_second concomitantly may need monitored increases INR prothrombin time.
2758,"Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.",esomeprazole,diazepam,mechanism,Coadministration esomeprazole_first 30 mg diazepam_second CYP2C19 substrate resulted 45% decrease clearance diazepam.
2759,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,ketoconazole,mechanism,Therefore esomeprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole_second iron salts digoxin).
2760,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,iron,mechanism,Therefore esomeprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole iron_second salts digoxin).
2761,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,digoxin,mechanism,Therefore esomeprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole iron salts digoxin_second ).
2762,Concomitant administration of clarithromycin with pimozide is contraindicated.,clarithromycin,pimozide,advise,Concomitant administration clarithromycin_first pimozide_second contraindicated.
2763,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,advise,Aspirin: Concomitant administration diclofenac_first aspirin_second recommended diclofenac displaced binding sites concomitant administration aspirin resulting lower plasma concentrations peak plasma levels AUC values.
2764,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,mechanism,Aspirin: Concomitant administration diclofenac aspirin recommended diclofenac_first displaced binding sites concomitant administration aspirin_second resulting lower plasma concentrations peak plasma levels AUC values.
2765,"Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.",diclofenac,NSAIDs,advise,Anticoagulants: studies shown diclofenac_first interact anticoagulants warfarin type caution exercised nonetheless since interactions seen NSAIDs_second .
2766,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",NSAIDs,warfarin,advise,prostaglandins play important role hemostasis NSAIDs affect platelet function well concurrent therapy NSAIDs_first including diclofenac warfarin_second requires close monitoring patients certain change anticoagulant dosage required.
2767,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",diclofenac,warfarin,advise,prostaglandins play important role hemostasis NSAIDs affect platelet function well concurrent therapy NSAIDs including diclofenac_first warfarin_second requires close monitoring patients certain change anticoagulant dosage required.
2768,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,digoxin,mechanism,Ingestion diclofenac_first may increase serum concentrations digoxin_second methotrexate increase cyclosporine nephrotoxicity.
2769,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,methotrexate,mechanism,Ingestion diclofenac_first may increase serum concentrations digoxin methotrexate_second increase cyclosporine nephrotoxicity.
2770,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,cyclosporine,effect,Ingestion diclofenac_first may increase serum concentrations digoxin methotrexate increase cyclosporine_second nephrotoxicity.
2771,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,digoxin,effect,Patients begin taking diclofenac_first increase diclofenac dose NSAID taking digoxin_second methotrexate cyclosporine may develop toxicity characteristics drugs.
2772,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,methotrexate,effect,Patients begin taking diclofenac_first increase diclofenac dose NSAID taking digoxin methotrexate_second cyclosporine may develop toxicity characteristics drugs.
2773,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,cyclosporine,effect,Patients begin taking diclofenac_first increase diclofenac dose NSAID taking digoxin methotrexate cyclosporine_second may develop toxicity characteristics drugs.
2774,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,digoxin,effect,Patients begin taking diclofenac increase diclofenac dose NSAID_first taking digoxin_second methotrexate cyclosporine may develop toxicity characteristics drugs.
2775,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,methotrexate,effect,Patients begin taking diclofenac increase diclofenac dose NSAID_first taking digoxin methotrexate_second cyclosporine may develop toxicity characteristics drugs.
2776,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,cyclosporine,effect,Patients begin taking diclofenac increase diclofenac dose NSAID_first taking digoxin methotrexate cyclosporine_second may develop toxicity characteristics drugs.
2777,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: Diclofenac_first decreases lithium_second renal clearance increases lithium plasma levels.
2778,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: Diclofenac_first decreases lithium renal clearance increases lithium_second plasma levels.
2779,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.",diclofenac,lithium,effect,patients taking diclofenac_first lithium_second concomitantly lithium toxicity may develop.
2780,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",insulin,diclofenac,effect,rare reports however marketing experiences changes effects insulin_first oral hypoglycemic agents presence diclofenac_second necessitated changes doses agents.
2781,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",hypoglycemic agents,diclofenac,effect,rare reports however marketing experiences changes effects insulin oral hypoglycemic agents_first presence diclofenac_second necessitated changes doses agents.
2782,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,insulin,effect,direct causal relationship established physicians consider possibility diclofenac_first may alter diabetic patient response insulin_second oral hypoglycemic agents.
2783,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,hypoglycemic agents,effect,direct causal relationship established physicians consider possibility diclofenac_first may alter diabetic patient response insulin oral hypoglycemic agents_second .
2784,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,Diclofenac,diuretics,effect,Diuretics: Diclofenac_first NSAIDs inhibit activity diuretics_second .
2785,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,NSAIDs,diuretics,effect,Diuretics: Diclofenac NSAIDs_first inhibit activity diuretics_second .
2786,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.,phenobarbital,diclofenac,effect,Phenobarbital toxicity reported occurred patient chronic phenobarbital_first treatment following initiation diclofenac_second therapy.
2787,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,salicylic acid,mechanism,Protein Binding vitro diclofenac_first interferes minimally protein binding salicylic acid_second (20% decrease binding) tolbutamide prednisolone (10% decrease binding) warfarin.
2788,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,tolbutamide,mechanism,Protein Binding vitro diclofenac_first interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide_second prednisolone (10% decrease binding) warfarin.
2789,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,prednisolone,mechanism,Protein Binding vitro diclofenac_first interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide prednisolone_second (10% decrease binding) warfarin.
2790,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,warfarin,mechanism,Protein Binding vitro diclofenac_first interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide prednisolone (10% decrease binding) warfarin_second .
2791,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.,aminoglycosides,MAXIPIME,advise,Renal function monitored carefully high doses aminoglycosides_first administered MAXIPIME_second increased potential nephrotoxicity ototoxicity aminoglycoside antibiotics.
2792,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration cephalosporins_first potent diuretics_second furosemide.
2793,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration cephalosporins_first potent diuretics furosemide_second .
2794,Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.,Potassium-depleting diuretics,digitalis,effect,Potassium-depleting diuretics_first major contributing factor digitalis_second toxicity.
2795,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",Quinidine,digoxin,mechanism,Quinidine_first verapamil amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2796,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",verapamil,digoxin,mechanism,Quinidine verapamil_first amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2797,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",amiodarone,digoxin,mechanism,Quinidine verapamil amiodarone_first propafenone indomethacin itraconazole alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2798,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",propafenone,digoxin,mechanism,Quinidine verapamil amiodarone propafenone_first indomethacin itraconazole alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2799,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",indomethacin,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin_first itraconazole alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2800,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",itraconazole,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole_first alprazolam spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2801,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",alprazolam,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole alprazolam_first spironolactone raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2802,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",spironolactone,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole alprazolam spironolactone_first raise serum digoxin_second concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2803,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",Erythromycin,digoxin,mechanism,Erythromycin_first clarithromycin (and possibly macrolide antibiotics) tetracycline may increase digoxin_second absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2804,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",clarithromycin,digoxin,mechanism,Erythromycin clarithromycin_first (and possibly macrolide antibiotics) tetracycline may increase digoxin_second absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2805,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",macrolide antibiotics,digoxin,mechanism,Erythromycin clarithromycin (and possibly macrolide antibiotics_first ) tetracycline may increase digoxin_second absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2806,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",tetracycline,digoxin,mechanism,Erythromycin clarithromycin (and possibly macrolide antibiotics) tetracycline_first may increase digoxin_second absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2807,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",Propantheline,digoxin,mechanism,Propantheline_first diphenoxylate decreasing gut motility may increase digoxin_second absorption.
2808,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",diphenoxylate,digoxin,mechanism,Propantheline diphenoxylate_first decreasing gut motility may increase digoxin_second absorption.
2809,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",Antacids,digoxin,mechanism,Antacids_first kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2810,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",kaolin,digoxin,mechanism,Antacids kaolin_first pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2811,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",sulfasalazine,digoxin,mechanism,Antacids kaolin pectin sulfasalazine_first neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2812,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",neomycin,digoxin,mechanism,Antacids kaolin pectin sulfasalazine neomycin_first cholestyramine certain anticancer drugs metoclopramide may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2813,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",cholestyramine,digoxin,mechanism,Antacids kaolin pectin sulfasalazine neomycin cholestyramine_first certain anticancer drugs metoclopramide may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2814,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",metoclopramide,digoxin,mechanism,Antacids kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide_first may interfere intestinal digoxin_second absorption resulting unexpectedly low serum concentrations.
2815,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",Rifampin,digoxin,mechanism,Rifampin_first may decrease serum digoxin_second concentration especially patients renal dysfunction increasing non renal clearance digoxin.
2816,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.",Thyroid,digoxin,advise,Thyroid_first administration digitalized hypothyroid patient may increase dose requirement digoxin_second .
2817,Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.,digoxin,sympathomimetics,effect,Concomitant use digoxin_first sympathomimetics_second increases risk cardiac arrhythmias.
2818,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",beta-adrenergic blockers,digoxin,effect,Although beta-adrenergic blockers_first calcium channel blockers digoxin_second may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block.
2819,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",calcium channel blockers,digoxin,effect,Although beta adrenergic blockers calcium channel blockers_first digoxin_second may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block.
2820,"In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",theophylline,cetirizine,mechanism,multiple dose study theophylline_first (400 mg daily 3 days) cetirizine_second (20 mg daily 3 days) 16% decrease clearance cetirizine observed.
2821,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;,cetirizine,theophylline,mechanism,small decrease clearance cetirizine_first caused 400 mg dose theophylline_second ;
2822,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.,dapsone,Lamprene,effect,Preliminary data suggest dapsone_first may inhibit anti inflammatory activity Lamprene_second confirmed.
2823,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.",dapsone,clofazimine,advise,leprosy associated inflammatory reactions develop patients treated dapsone_first clofazimine_second still advisable continue treatment drugs.
2824,Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ,Diazepam,morphine,effect,Diazepam_first doses 0.25 mg/kg 2.5 mg/kg injected morphine_second found decrease antinociceptive effect morphine.
2825,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,metamizol,effect,Similarly diazepam_first decreased antinociceptive effect metamizol_second (only tail flick test) indomethacin.
2826,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,indomethacin,effect,Similarly diazepam_first decreased antinociceptive effect metamizol (only tail flick test) indomethacin_second .
2827,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,morphine,effect,Midazolam_first used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect morphine_second metamizol (only tail flick test) indomethacin.
2828,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,metamizol,effect,Midazolam_first used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect morphine metamizol_second (only tail flick test) indomethacin.
2829,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,indomethacin,effect,Midazolam_first used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect morphine metamizol (only tail flick test) indomethacin_second .
2830,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).,piperazine,phenothiazine,effect,Phenothiazines Taking piperazine_first phenothiazine_second together may increase risk convulsions (seizures).
2831,"Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.",piperazine,pyrantel,effect,Pyrantel (e.g. Antiminth) Taking piperazine_first pyrantel_second together may decrease effects piperazine.
2832,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,alcohol,effect,Diphenhydramine hydrochloride_first additive effects alcohol_second CNS depressants (hypnotics sedatives tranquilizers etc).
2833,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,CNS depressants,effect,Diphenhydramine hydrochloride_first additive effects alcohol CNS depressants_second (hypnotics sedatives tranquilizers etc).
2834,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,hypnotics,effect,Diphenhydramine hydrochloride_first additive effects alcohol CNS depressants (hypnotics_second sedatives tranquilizers etc).
2835,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,sedatives,effect,Diphenhydramine hydrochloride_first additive effects alcohol CNS depressants (hypnotics sedatives_second tranquilizers etc).
2836,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,tranquilizers,effect,Diphenhydramine hydrochloride_first additive effects alcohol CNS depressants (hypnotics sedatives tranquilizers_second etc).
2837,MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors_first prolong intensify anticholinergic (drying) effects antihistamines_second .
2838,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.,anticoagulants,Atromid-S,advise,Caution exercised anticoagulants_first given conjunction Atromid-S_second .
2839,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,phenytoin,mechanism,Atromid-S_first may displace acidic drugs phenytoin_second tolbutamide binding sites.
2840,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,tolbutamide,mechanism,Atromid-S_first may displace acidic drugs phenytoin tolbutamide_second binding sites.
2841,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.,tolbutamide,Atromid-S,effect,hypoglycemic effect tolbutamide_first reported increase Atromid-S_second given concurrently.
2842,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.,fibrate,lovastatin,effect,Fulminant rhabdomyolysis seen early three weeks initiation combined therapy another fibrate_first lovastatin_second may seen several months.
2843,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.",lovastatin,fibrate,effect,reasons felt subjects unsatisfactory lipid response either drug alone possible benefits combined therapy lovastatin_first fibrate_second outweigh risks severe myopathy rhabdomyolysis acute renal failure.
2844,"Therefore, the combined use of lovastatin with fibrates should generally be avoided.",lovastatin,fibrates,advise,Therefore combined use lovastatin_first fibrates_second generally avoided.
2845,Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.,PEGASYS,theophylline,mechanism,Treatment PEGASYS_first weekly 4 weeks healthy subjects associated inhibition P450 1A2 25% increase theophylline_second AUC.
2846,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.,theophylline,PEGASYS,advise,Theophylline serum levels monitored appropriate dose adjustments considered patients given theophylline_first PEGASYS_second .
2847,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.,COPEGUS,didanosine,advise,Nucleoside Analogues Didanosine Co administration COPEGUS_first didanosine_second recommended.
2848,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,stavudine,effect,Stavudine Zidovudine Ribavirin_first antagonize vitro antiviral activity stavudine_second zidovudine HIV.
2849,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,zidovudine,effect,Stavudine Zidovudine Ribavirin_first antagonize vitro antiviral activity stavudine zidovudine_second HIV.
2850,"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
",simvastatin,clarithromycin,effect,Rhabdomyolysis secondary drug interaction simvastatin_first clarithromycin_second .
2851,"DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ",Clarithromycin,simvastatin,mechanism,DISCUSSION: Clarithromycin_first potent inhibitor CYP3A4 major enzyme responsible simvastatin_second metabolism.
2852,The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ,macrolide antibiotics,hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,effect,concomitant administration macrolide antibiotics_first hydroxymethylglutaryl coenzyme (HMG-CoA) reductase inhibitors_second resulted previous reports rhabdomyolysis.
2853,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,atorvastatin,mechanism,CONCLUSIONS: Macrolide antibiotics_first inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin_second cerivastatin lovastatin simvastatin).
2854,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,cerivastatin,mechanism,CONCLUSIONS: Macrolide antibiotics_first inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin cerivastatin_second lovastatin simvastatin).
2855,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,lovastatin,mechanism,CONCLUSIONS: Macrolide antibiotics_first inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin cerivastatin lovastatin_second simvastatin).
2856,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,simvastatin,mechanism,CONCLUSIONS: Macrolide antibiotics_first inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin cerivastatin lovastatin simvastatin_second ).
2857,"The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.",CAMPTOSAR,antineoplastic agents,effect,adverse effects CAMPTOSAR_first myelosuppression diarrhea would expected exacerbated antineoplastic agents_second similar adverse effects.
2858,"Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.",CAMPTOSAR,dexamethasone,effect,Lymphocytopenia reported patients receiving CAMPTOSAR_first possible administration dexamethasone_second antiemetic prophylaxis may enhanced likelihood effect.
2859,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).",prochlorperazine,CAMPTOSAR,effect,incidence akathisia clinical trials weekly dosage schedule greater (8.5% 4/47 patients) prochlorperazine_first administered day CAMPTOSAR_second drugs given separate days (1.3% 1/80 patients).
2860,"It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.",laxative,CAMPTOSAR,effect,would expected laxative_first use therapy CAMPTOSAR_second would worsen incidence severity diarrhea studied.
2861,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.",diuretics,CAMPTOSAR,effect,view potential risk dehydration secondary vomiting and/or diarrhea induced CAMPTOSAR physician may wish withhold diuretics_first dosing CAMPTOSAR_second certainly periods active vomiting diarrhea.
2862,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",etanercept,anakinra,effect,Concurrent administration etanercept_first (another TNF blocking agent) anakinra_second (an interleukin 1 antagonist) associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
2863,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,TNFa-blocking agents,anakinra,effect,TNFa-blocking agents_first (including REMICADE) used combination anakinra_second may also result similar toxicities.
2864,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,REMICADE,anakinra,effect,TNFa blocking agents (including REMICADE_first ) used combination anakinra_second may also result similar toxicities.
2865,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).",dorzolamide,carbonic anhydrase inhibitors,effect,Although acid base electrolyte disturbances reported clinical trials dorzolamide_first disturbances reported oral carbonic anhydrase inhibitors_second instances resulted drug interactions (e.g. toxicity associated high dose salicylate therapy).
2866,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,mercaptopurine,mechanism,Mercaptopurine/Azathioprine: Allopurinol_first inhibits enzymatic oxidation mercaptopurine_second azathioprine 6 thiouric acid.
2867,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,azathioprine,mechanism,Mercaptopurine/Azathioprine: Allopurinol_first inhibits enzymatic oxidation mercaptopurine azathioprine_second 6 thiouric acid.
2868,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,mercaptopurine,advise,patients receiving mercaptopurine (Purinethol) azathioprine (Imuran) concomitant administration 300 600 mg allopurinol_first per day require reduction dose approximately one third one fourth usual dose mercaptopurine_second azathioprine.
2869,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,azathioprine,advise,patients receiving mercaptopurine (Purinethol) azathioprine (Imuran) concomitant administration 300 600 mg allopurinol_first per day require reduction dose approximately one third one fourth usual dose mercaptopurine azathioprine_second .
2870,"Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.",allopurinol,dicumarol,mechanism,Dicumarol: reported allopurinol_first prolongs half life anticoagulant dicumarol_second .
2871,"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.",uricosuric agents,oxipurinol,mechanism,Uricosuric Agents: Since excretion oxipurinol similar urate uricosuric agents_first increase excretion urate also likely increase excretion oxipurinol_second thus lower degree inhibition xanthine oxidase.
2872,The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.,uricosuric agents,allopurinol,mechanism,concomitant administration uricosuric agents_first allopurinol_second associated decrease excretion oxypurines (hypoxanthine xanthine) increase urinary uric acid excretion compared observed allopurinol alone.
2873,Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.,allopurinol,thiazide diuretics,effect,Thiazide Diuretics: reports concomitant use allopurinol_first thiazide diuretics_second may contribute enhancement allopurinol toxicity patients reviewed attempt establish cause effect relationship mechanism causation.
2874,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..",thiazide diuretics,allopurinol,advise,Although causal mechanism cause effect relationship established current evidence suggests renal function monitored patients thiazide diuretics_first allopurinol_second even absence renal failure dosage levels even conservatively adjusted patients combined therapy diminished renal function detected..
2875,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,ampicillin,allopurinol,effect,Ampicillin/Amoxicillin: increase frequency skin rash reported among patients receiving ampicillin_first amoxicillin concurrently allopurinol_second compared patients receiving drugs.
2876,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,amoxicillin,allopurinol,effect,Ampicillin/Amoxicillin: increase frequency skin rash reported among patients receiving ampicillin amoxicillin_first concurrently allopurinol_second compared patients receiving drugs.
2877,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cyclophosphamide,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression cyclophosphamide_first cytotoxic agents reported among patients neoplastic disease except leukemia presence allopurinol_second .
2878,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cytotoxic agents,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression cyclophosphamide cytotoxic agents_first reported among patients neoplastic disease except leukemia presence allopurinol_second .
2879,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",Chlorpropamide,allopurinol,mechanism,Chlorpropamide: Chlorpropamide_first plasma half life may prolonged allopurinol_second since allopurinol chlorpropamide may compete excretion renal tubule.
2880,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",allopurinol,chlorpropamide,mechanism,Chlorpropamide: Chlorpropamides plasma half life may prolonged allopurinol since allopurinol_first chlorpropamide_second may compete excretion renal tubule.
2881,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.,allopurinol,chlorpropamide,effect,risk hypoglycemia secondary mechanism may increased allopurinol_first chlorpropamide_second given concomitantly presence renal insufficiency.
2882,Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.,cyclosporine,allopurinol sodium,mechanism,Cyclosporin: Reports indicate cyclosporine_first levels may increased concomitant treatment allopurinol sodium_second injection.
2883,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",Catecholamine-depleting drugs,beta-blocking agents,effect,Catecholamine-depleting drugs_first reserpine may additive effect given beta-blocking agents_second .
2884,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agents,effect,Catecholamine depleting drugs reserpine_first may additive effect given beta-blocking agents_second .
2885,"Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",acebutolol,catecholamine depletors,advise,Patients treated acebutolol_first plus catecholamine depletors_second therefore observed closely evidence marked bradycardia hypotension may present vertigo syncope/presyncope orthostatic changes blood pressure without compensatory tachycardia.
2886,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.",beta-adrenergic antagonists,alpha-adrenergic stimulants,effect,Exaggerated hypertensive responses reported combined use beta-adrenergic antagonists_first alpha-adrenergic stimulants_second including contained proprietary cold remedies vasoconstrictive nasal drops.
2887,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.,beta-adrenoceptor blocking agents,nonsteroidal anti-inflammatory drugs,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents_first nonsteroidal anti-inflammatory drugs_second reported.
2888,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.",antibiotics,anticholinesterase,advise,antibiotics_first used myasthenic patient definitely indicated careful adjustment made adjunctive anticholinesterase_second dosage.
2889,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,cocaine,norepinephrine,effect,uptake inhibitors cocaine_first desipramine (3 mumol/liter) potentiated positive inotropic effects norepinephrine_second nonfailing myocardium (p < 0.05) functional class IV myocardium.
2890,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,desipramine,norepinephrine,effect,uptake inhibitors cocaine desipramine_first (3 mumol/liter) potentiated positive inotropic effects norepinephrine_second nonfailing myocardium (p < 0.05) functional class IV myocardium.
2891,Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.,Betaseron,antipyrine,mechanism,Betaseron_first administration three cancer patients dose range 0.025 mg 2.2 mg led dose dependent inhibition antipyrine_second elimination.14 effect alternate day administration 0.25 mg Betaseron drug metabolism MS patients unknown.
2892,Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.,piperacillin,aminoglycoside,effect,Aminoglycosides: mixing piperacillin_first aminoglycoside_second vitro result substantial inactivation aminoglycoside.
2893,"Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.",piperacillin,vecuronium,effect,Vecuronium: used perioperative period piperacillin_first implicated prolongation neuromuscular blockade vecuronium_second .
2894,"In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.",piperacillin,vecuronium,effect,one controlled clinical study ureidopenicillins including piperacillin_first reported prolong action vecuronium_second .
2895,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.",non-depolarizing muscle relaxants,piperacillin,effect,Due similar mechanism action expected neuromuscular blockade produced non-depolarizing muscle relaxants_first could prolonged presence piperacillin_second .
2896,Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.,probenecid,PIPRACIL,mechanism,Probenecid: oral combination probenecid_first intramuscular injection PIPRACIL_second produces increase piperacillin peak serum level 30%.
2897,Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.,Piperacillin sodium,methotrexate,mechanism,Methotrexate: Piperacillin sodium_first may reduce excretion methotrexate_second .
2898,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,alcohol,effect,Ethopropazine_first may interact alcohol_second CNS depressants causing increased sedative effects.
2899,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,CNS depressants,effect,Ethopropazine_first may interact alcohol CNS depressants_second causing increased sedative effects.
2900,"Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.",Ethopropazine,chlorpromazine,mechanism,Ethopropazine_first interact chlorpromazine_second increasing metabolism chlorpromazine.
2901,"Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.",reserpine,beta blocking agents,effect,Catecholamine depleting drugs e.g. reserpine_first may additive effect given beta blocking agents_second .
2902,"BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.",BREVIBLOC,warfarin,mechanism,BREVIBLOC_first concentrations equivocally higher given warfarin_second likely clinically important.
2903,"When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.",digoxin,BREVIBLOC,mechanism,digoxin_first BREVIBLOC_second concomitantly administered intravenously normal volunteers 10 20% increase digoxin blood levels time points.
2904,"When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.",BREVIBLOC,morphine,mechanism,intravenous morphine BREVIBLOC concomitantly administered normal subjects effect morphine blood levels seen BREVIBLOC_first steady state blood levels increased 46% presence morphine_second .
2905,"The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.",succinylcholine,BREVIBLOC,effect,onset neuromuscular blockade succinylcholine_first unaffected BREVIBLOC_second duration neuromuscular blockade prolonged 5 minutes 8 minutes.
2906,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,digoxin,advise,Although interactions observed studies appear major clinical importance BREVIBLOC_first titrated caution patients treated concurrently digoxin_second morphine succinylcholine warfarin.
2907,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,morphine,advise,Although interactions observed studies appear major clinical importance BREVIBLOC_first titrated caution patients treated concurrently digoxin morphine_second succinylcholine warfarin.
2908,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,succinylcholine,advise,Although interactions observed studies appear major clinical importance BREVIBLOC_first titrated caution patients treated concurrently digoxin morphine succinylcholine_second warfarin.
2909,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,warfarin,advise,Although interactions observed studies appear major clinical importance BREVIBLOC_first titrated caution patients treated concurrently digoxin morphine succinylcholine warfarin_second .
2910,Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.,BREVIBLOC,verapamil,advise,Caution exercised considering use BREVIBLOC_first verapamil_second patients depressed myocardial function.
2911,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,dopamine,advise,Additionally BREVIBLOC_first used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine_second epinephrine norepinephrine danger blocking cardiac contractility systemic vascular resistance high.
2912,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,epinephrine,advise,Additionally BREVIBLOC_first used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine epinephrine_second norepinephrine danger blocking cardiac contractility systemic vascular resistance high.
2913,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,norepinephrine,advise,Additionally BREVIBLOC_first used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine epinephrine norepinephrine_second danger blocking cardiac contractility systemic vascular resistance high.
2914,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,enkephalins,effect,Interaction antinociceptive effect neurotensin_first enkephalins_second tuftsin.
2915,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,tuftsin,effect,Interaction antinociceptive effect neurotensin_first enkephalins tuftsin_second .
2916,It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ,neurotensin,enkephalins,effect,shown neurotensin_first antagonized evidently antinociceptive effect enkephalins_second analogue.
2917,"On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ",neurotensin,tuftsin,effect,contrary neurotensin_first tuftsin_second agonists induction analgesia.
2918,It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.,neurotensin,tuftsin,effect,concluded neurotensin_first modulates opposite way function enkephalinergic neurons central action tuftsin_second .
2919,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,succinylcholine,int,Possible drug interactions HUMORSOL_first succinylcholine_second anticholinesterase agents.
2920,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,anticholinesterase agents,int,Possible drug interactions HUMORSOL_first succinylcholine anticholinesterase agents_second .
2921,"When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.",idoxuridine,boric acid,advise,using idoxuridine_first especially important health care professional know using following: Eye product containing boric acid_second .
2922,Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.,Boric acid,idoxuridine,mechanism,Boric acid_first may interact idoxuridine_second preparation causing gritty substance form may interact preservative idoxuridine preparation causing toxic effect eye.
2923,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.,nelfinavir,azithromycin,effect,Co administration nelfinavir_first steady state single dose azithromycin_second (2 x 600 mg tablets) results increased azithromycin serum concentrations.
2924,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",azithromycin,nelfinavir,advise,Although dose adjustment azithromycin_first recommended administered combination nelfinavir_second close monitoring known side effects azithromycin liver enzyme abnormalities hearing impairment warranted.
2925,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.",azithromycin,warfarin,advise,However prudent medical practice dictates careful monitoring prothrombin time patients treated azithromycin_first warfarin_second concomitantly.
2926,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.,macrolides,warfarin,effect,Concurrent use macrolides_first warfarin_second clinical practice associated increased anticoagulant effects.
2927,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,atorvastatin,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin_second carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2928,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,carbamazepine,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine_second cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2929,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,cetirizine,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine_second didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2930,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,didanosine,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine_second efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2931,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,efavirenz,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz_second fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2932,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,fluconazole,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole_second indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2933,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,indinavir,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir_second midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2934,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,midazolam,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam_second rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2935,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,rifabutin,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin_second sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2936,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sildenafil,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil_second theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2937,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,theophylline,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline_second (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2938,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,triazolam,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam_second trimethoprim/sulfamethoxazole zidovudine.
2939,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,trimethoprim,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim_second /sulfamethoxazole zidovudine.
2940,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sulfamethoxazole,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole_second zidovudine.
2941,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,zidovudine,mechanism,used therapeutic doses azithromycin_first modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine_second .
2942,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,efavirenz,azithromycin,mechanism,Co administration efavirenz_first fluconazole modest effect pharmacokinetics azithromycin_second .
2943,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,fluconazole,azithromycin,mechanism,Co administration efavirenz fluconazole_first modest effect pharmacokinetics azithromycin_second .
2944,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.,probenecid,acyclovir,mechanism,Co administration probenecid_first acyclovir_second shown increase mean half life area concentration time curve.
2945,"Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.",Rifampin,losartan,mechanism,Rifampin_first inducer drug metabolism decreased concentrations losartan_second active metabolite.
2946,"Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.",Fluconazole,losartan,mechanism,Fluconazole_first inhibitor P450 2C9 decreased active metabolite concentration increased losartan_second concentration.
2947,"As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin",losartan,indomethacin,effect,antihypertensive agents antihypertensive effect losartan_first may blunted non steroidal anti inflammatory drug indomethacin_second
2948,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",Probenecid,cephalosporins,mechanism,Probenecid_first may decrease renal tubular secretion cephalosporins_second used concurrently resulting increased prolonged cephalosporin blood levels.
2949,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Sucralfate,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate_first antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes lomefloxacin_second interfere bioavailability.
2950,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",magnesium,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium_first aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes lomefloxacin_second interfere bioavailability.
2951,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",aluminum,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum_first well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes lomefloxacin_second interfere bioavailability.
2952,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Videx,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx_first (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes lomefloxacin_second interfere bioavailability.
2953,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",didanosine,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx (didanosine_first ) chewable/buffered tablets pediatric powder oral solution form chelation complexes lomefloxacin_second interfere bioavailability.
2954,Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).,Sucralfate,lomefloxacin,mechanism,Sucralfate_first administered 2 hours lomefloxacin_second resulted slower absorption (mean C max decreased 30% mean max increased 1 hour) lesser extent absorption (mean AUC decreased approximately 25%).
2955,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",Magnesium,lomefloxacin,mechanism,Magnesium_first aluminum containing antacids administered concomitantly lomefloxacin_second significantly decreased bioavailability (48%) lomefloxacin.
2956,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",aluminum,lomefloxacin,mechanism,Magnesium aluminum_first containing antacids administered concomitantly lomefloxacin_second significantly decreased bioavailability (48%) lomefloxacin.
2957,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",antacids,lomefloxacin,mechanism,Magnesium aluminum containing antacids_first administered concomitantly lomefloxacin_second significantly decreased bioavailability (48%) lomefloxacin.
2958,Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;,antacid,lomefloxacin,mechanism,Separating doses antacid_first lomefloxacin_second minimizes decrease bioavailability;
2959,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.",quinolones,caffeine,mechanism,quinolones_first demonstrated moderate marked interference metabolism caffeine_second resulting reduced clearance prolongation plasma half life increase symptoms accompany high levels caffeine.
2960,Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.,Cimetidine,quinolones,mechanism,Cimetidine: Cimetidine_first demonstrated interfere elimination quinolones_second .
2961,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels cyclosporine reported concomitant use cyclosporine_first members quinolone class_second .
2962,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,anticoagulant,effect,Warfarin: Quinolones_first may enhance effects oral anticoagulant_second warfarin derivatives.
2963,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,warfarin,effect,Warfarin: Quinolones_first may enhance effects oral anticoagulant warfarin_second derivatives.
2964,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,S(-) warfarin,mechanism,Aprepitant_first shown induce metabolism S(-) warfarin_second tolbutamide metabolized CYP2C9.
2965,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,tolbutamide,mechanism,Aprepitant_first shown induce metabolism S( ) warfarin tolbutamide_second metabolized CYP2C9.
2966,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,mechanism,Coadministration Aprepitant_first drugs drugs known metabolized CYP2C9 phenytoin_second may result lower plasma concentrations drugs.
2967,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: Aprepitant_first given regimen 125mg dexamethasone_second coadministered orally 20 mg Day 1 Aprepitant given 80 mg/day dexamethasone coadministered orally 8 mg Days 2 5 increased AUC dexamethasone CYP3A4 substrate 2.2 fold Days 1 5.
2968,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: Aprepitant given regimen 125mg dexamethasone coadministered orally 20 mg Day 1 Aprepitant_first given 80 mg/day dexamethasone_second coadministered orally 8 mg Days 2 5 increased AUC dexamethasone CYP3A4 substrate 2.2 fold Days 1 5.
2969,"The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",dexamethasone,Aprepitant,advise,oral dexamethasone_first doses reduced approximately 50% coadministered Aprepitant_second achieve exposures dexamethasone similar obtained given without Aprepitant.
2970,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.,dexamethasone,Aprepitant,mechanism,daily dose dexamethasone_first administered clinical studies Aprepitant_second reflects approximate 50% reduction dose dexamethasone.
2971,"Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",Aprepitant,methylprednisolone,mechanism,Aprepitant_first given regimen 125 mg Day 1 80 mg/day Days 2 3 increased AUC methylprednisolone_second CYP3A4 substrate 1.34 fold Day 1 2.5 fold Day 3 methylprednisolone coadministered intravenously 125 mg Day 1 orally 40 mg Days 2 3.
2972,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,IV methylprednisolone_first dose reduced approximately 25% oral methylprednisolone dose reduced approximately 50% coadministered Aprepitant_second achieve exposures methylprednisolone similar obtained given without Aprepitant.
2973,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,IV methylprednisolone dose reduced approximately 25% oral methylprednisolone_first dose reduced approximately 50% coadministered Aprepitant_second achieve exposures methylprednisolone similar obtained given without Aprepitant.
2974,"Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",S(-)warfarin,Aprepitant,mechanism,Although effect Aprepitant plasma AUC R(+) S( ) warfarin determined Day 3 34% decrease S(-)warfarin_first (a CYP2C9 substrate) trough concentration accompanied 14% decrease prothrombin time (reported International Normalized Ratio INR) 5 days completion dosing Aprepitant_second .
2975,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.",warfarin,Aprepitant,advise,patients chronic warfarin_first therapy prothrombin time (INR) closely monitored 2 week period particularly 7 10 days following initiation 3 day regimen Aprepitant_second chemotherapy cycle.
2976,"Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",tolbutamide,Aprepitant,mechanism,Tolbutamide: Aprepitant given 125 mg Day 1 80 mg/day Days 2 3 decreased AUC tolbutamide (a CYP2C9 substrate) 23% Day 4 28% Day 8 15% Day 15 single dose tolbutamide_first 500 mg admini stered orally prior administration 3 day regimen Aprepitant_second Days 4 8 15.
2977,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,ethinyl estradiol,mechanism,Oral contraceptives: Aprepitant_first given daily 14 days 100 mg capsule oral contraceptive containing 35 mcg ethinyl estradiol_second 1 mg norethindrone decreased AUC ethinyl estradiol 43% decreased AUC norethindrone 8%;
2978,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,norethindrone,mechanism,Oral contraceptives: Aprepitant_first given daily 14 days 100 mg capsule oral contraceptive containing 35 mcg ethinyl estradiol 1 mg norethindrone_second decreased AUC ethinyl estradiol 43% decreased AUC norethindrone 8%;
2979,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.",contraceptives,Aprepitant,effect,therefore efficacy oral contraceptives_first administration Aprepitant_second may reduced.
2980,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.",Aprepitant,contraceptives,advise,Although 3 day regimen Aprepitant_first given concomitantly oral contraceptives_second studied alternative back methods contraception used.
2981,"Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",Aprepitant,midazolam,mechanism,Midazolam: Aprepitant_first increased AUC midazolam_second sensitive CYP3A4 substrate 2.3 fold Day 1 3.3 fold Day 5 single oral dose midazolam 2 mg coadministered Day 1 Day 5 regimen Aprepitant 125 mg Day 1 80 mg/day Days 2 5.
2982,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",midazolam,Aprepitant,advise,potential effects increased plasma concentrations midazolam_first benzodiazepines metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents Aprepitant_second .
2983,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",benzodiazepines,Aprepitant,advise,potential effects increased plasma concentrations midazolam benzodiazepines_first metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents Aprepitant_second .
2984,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",alprazolam,Aprepitant,advise,potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 (alprazolam_first triazolam) considered coadministering agents Aprepitant_second .
2985,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",triazolam,Aprepitant,advise,potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 (alprazolam triazolam_first ) considered coadministering agents Aprepitant_second .
2986,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,Aprepitant_first increased AUC midazolam_second 25% Day 4 decreased AUC midazolam 19% Day 8 relative dosing Aprepitant Days 1 3.
2987,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,Aprepitant_first increased AUC midazolam 25% Day 4 decreased AUC midazolam_second 19% Day 8 relative dosing Aprepitant Days 1 3.
2988,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ketoconazole,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole_second itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2989,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,itraconazole,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole_second nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2990,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nefazodone,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone_second troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2991,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,troleandomycin,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin_second clarithromycin ritonavir nelfinavir) approached caution.
2992,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,clarithromycin,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin clarithromycin_second ritonavir nelfinavir) approached caution.
2993,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ritonavir,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir_second nelfinavir) approached caution.
2994,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nelfinavir,advise,Consequently concomitant administration Aprepitant_first strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir_second ) approached caution.
2995,"Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.",diltiazem,aprepitant,advise,moderate CYP3A4 inhibitors (e.g. diltiazem_first ) result 2 fold increase plasma concentrations aprepitant_second concomitant administration also approached caution.
2996,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,rifampin,mechanism,therefore coadministration Aprepitant_first drugs strongly induce CYP3A4 activity (e.g. rifampin_second carbamazepine phenytoin) may result reduced plasma concentrations aprepitant may result decreased efficacy Aprepitant.
2997,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,phenytoin,mechanism,therefore coadministration Aprepitant_first drugs strongly induce CYP3A4 activity (e.g. rifampin carbamazepine phenytoin_second ) may result reduced plasma concentrations aprepitant may result decreased efficacy Aprepitant.
2998,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,aprepitant,mechanism,therefore coadministration Aprepitant_first drugs strongly induce CYP3A4 activity (e.g. rifampin carbamazepine phenytoin) may result reduced plasma concentrations aprepitant_second may result decreased efficacy Aprepitant.
2999,"Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",Aprepitant,ketoconazole,mechanism,Ketoconazole: single 125 mg dose Aprepitant_first administered Day5 10 day regimen 400 mg/day ketoconazole_second strong CYP3A4 inhibitor AUC aprepitant increased approximately 5 fold mean terminal half life aprepitant increased approximately 3 fold.
3000,"Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",Aprepitant,rifampin,mechanism,Rifampin: single 375 mg dose Aprepitant_first administered Day9 14 day regimen 600 mg/day rifampin_second strong CYP3A4 inducer AUC aprepitant decreased approximately 11 fold mean terminal half life decreased approximately 3 fold.
3001,"Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",aprepitant,diltiazem,mechanism,Diltiazem: patients mild moderate hypertension administration aprepitant_first daily tablet formulation comparable 230 mg capsule formulation diltiazem_second 120 mg 3 times daily 5 days resulted 2 fold increase aprepitant AUC simultaneous 1.7 fold increase diltiazem AUC.
3002,"Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",aprepitant,paroxetine,mechanism,Paroxetine: Coadministration daily doses aprepitant_first tablet formulation comparable 85 mg 170 mg capsule formulation paroxetine_second 20 mg daily resulted decrease AUC approximately 25% Cmax approximately 20% aprepitant paroxetine.
3003,"Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. ",Cholestyramine,fluvastatin,mechanism,Cholestyramine_first anionic binding resin considerable effect lowering rate extent fluvastatin_second bioavailability.
3004,"Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. ",cholestyramine,fluvastatin,effect,Although effect noted even cholestyramine_first given 4 hours prior fluvastatin_second regimen result diminished efficacy.
3005,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,tetracyclines_first shown depress plasma prothrombin activity patients anticoagulant_second therapy may require downward adjustment anticoagulant dosage.
3006,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.",tetracyclines,penicillin,advise,Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving tetracyclines_first conjunction penicillin_second .
3007,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,aluminum,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum_second calcium magnesium iron containing preparations.
3008,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,calcium,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium_second magnesium iron containing preparations.
3009,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,magnesium,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium magnesium_second iron containing preparations.
3010,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,iron,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium magnesium iron_second containing preparations.
3011,Absorption of tetracycline is impaired by bismuth subsalicylate.,tetracycline,bismuth subsalicylate,mechanism,Absorption tetracycline_first impaired bismuth subsalicylate_second .
3012,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",Barbiturates,doxycycline,mechanism,Barbiturates_first carbamazepine phenytoin decrease half life doxycycline_second .
3013,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",carbamazepine,doxycycline,mechanism,Barbiturates carbamazepine_first phenytoin decrease half life doxycycline_second .
3014,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",phenytoin,doxycycline,mechanism,Barbiturates carbamazepine phenytoin_first decrease half life doxycycline_second .
3015,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,Penthrane,effect,concurrent use tetracycline_first Penthrane_second (methoxyflurane) reported result fatal renal toxicity.
3016,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,methoxyflurane,effect,concurrent use tetracycline_first Penthrane (methoxyflurane_second ) reported result fatal renal toxicity.
3017,Concurrent use of tetracycline may render oral contraceptives less effective.,tetracycline,contraceptives,effect,Concurrent use tetracycline_first may render oral contraceptives_second less effective.
3018,Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ,Etofibrate,heparin,effect,Etofibrate_first elicited 62% enhancement post heparin_second lipolytic activity 100% increase 3H triglyceride fractional clearance rate compared placebo treatment.
3019,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",narcotic analgesics,hydrocodone,effect,Patients receiving narcotic analgesics_first antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly hydrocodone_second acetaminophen tablets may exhibit additive CNS depression.
3020,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antipsychotics,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics_first antianxiety agents CNS depressants (including alcohol) concomitantly hydrocodone_second acetaminophen tablets may exhibit additive CNS depression.
3021,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antianxiety agents,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents_first CNS depressants (including alcohol) concomitantly hydrocodone_second acetaminophen tablets may exhibit additive CNS depression.
3022,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",CNS depressants,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants_first (including alcohol) concomitantly hydrocodone_second acetaminophen tablets may exhibit additive CNS depression.
3023,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",alcohol,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including alcohol_first ) concomitantly hydrocodone_second acetaminophen tablets may exhibit additive CNS depression.
3024,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,MAO inhibitors,hydrocodone,effect,use MAO inhibitors_first tricyclic antidepressants hydrocodone_second preparations may increase effect either antidepressant hydrocodone.
3025,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,tricyclic antidepressants,hydrocodone,effect,use MAO inhibitors tricyclic antidepressants_first hydrocodone_second preparations may increase effect either antidepressant hydrocodone.
3026,The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.,anticholinergics,hydrocodone,effect,concurrent use anticholinergics_first hydrocodone_second may produce paralytic ileus.
3027,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine_first containing ergot type medications (like dihydroergotamine methysergide) FROVA_second within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3028,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergot-type medications,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing ergot-type medications_first (like dihydroergotamine methysergide) FROVA_second within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3029,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing ergot type medications (like dihydroergotamine_first methysergide) FROVA_second within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3030,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",methysergide,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing ergot type medications (like dihydroergotamine methysergide_first ) FROVA_second within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3031,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",Selective serotonin reuptake inhibitors,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors_first (SSRIs) (e.g. fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3032,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs_first ) (e.g. fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3033,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine_first fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3034,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine fluvoxamine_first paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3035,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine fluvoxamine paroxetine_first sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3036,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine fluvoxamine paroxetine sertraline_first ) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists_second .
3037,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",frovatriptan,SSRI,advise,concomitant treatment frovatriptan_first SSRI_second clinically warranted appropriate observation patient advised.
3038,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",decongestants,tricyclic antidepressants,advise,Avoid use preparations decongestants_first local anesthetics contain sympathomimetic amine (e.g. epinephrine norepinephrine) since reported tricyclic antidepressants_second potentiate effects catecholamines.
3039,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",anesthetics,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics_first contain sympathomimetic amine (e.g. epinephrine norepinephrine) since reported tricyclic antidepressants_second potentiate effects catecholamines.
3040,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",sympathomimetic amine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine_first (e.g. epinephrine norepinephrine) since reported tricyclic antidepressants_second potentiate effects catecholamines.
3041,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",epinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e.g. epinephrine_first norepinephrine) since reported tricyclic antidepressants_second potentiate effects catecholamines.
3042,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",norepinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e.g. epinephrine norepinephrine_first ) since reported tricyclic antidepressants_second potentiate effects catecholamines.
3043,Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.,Imipramine hydrochloride,CNS depressant drugs,effect,Imipramine hydrochloride_first may potentiate effects CNS depressant drugs_second .
3044,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,cimetidine,mechanism,plasma concentration imipramine_first may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine_second fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates phenytoin) adjustment dosage imipramine may therefore necessary.
3045,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,fluoxetine,mechanism,plasma concentration imipramine_first may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine fluoxetine_second ) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates phenytoin) adjustment dosage imipramine may therefore necessary.
3046,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,barbiturates,mechanism,plasma concentration imipramine_first may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates_second phenytoin) adjustment dosage imipramine may therefore necessary.
3047,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,phenytoin,mechanism,plasma concentration imipramine_first may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates phenytoin_second ) adjustment dosage imipramine may therefore necessary.
3048,"The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.",SSRI,TCA,int,extent SSRI_first TCA_second interactions may pose clinical problems depend degree inhibition pharmacokinetics SSRI involved.
3049,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,Antacids,chloroquine,mechanism,Antacids kaolin: Antacids_first kaolin reduce absorption chloroquine_second ;
3050,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,kaolin,chloroquine,mechanism,Antacids kaolin: Antacids kaolin_first reduce absorption chloroquine_second ;
3051,"Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.",Cimetidine,chloroquine,mechanism,Cimetidine: Cimetidine_first inhibit metabolism chloroquine_second increasing plasma level.
3052,"Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.",chloroquine,ampicillin,mechanism,Ampicillin: study healthy volunteers chloroquine_first significantly reduced bioavailability ampicillin_second .
3053,"Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.",chloroquine,cyclosporin,mechanism,Cyclosporin: introduction chloroquine_first (oral form) sudden increase serum cyclosporin_second level reported.
3054,The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.,aspirin,fenoprofen,mechanism,coadministration aspirin_first decreases biologic half life fenoprofen_second increase metabolic clearance results greater amount hydroxylated fenoprofen urine.
3055,"Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.",fenoprofen,aspirin,mechanism,Although mechanism interaction fenoprofen_first aspirin_second totally known enzyme induction displacement fenoprofen plasma albumin binding sites possibilities.
3056,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",aspirin,Nalfon,mechanism,Nalfon shown produce additional effect beyond obtained aspirin alone aspirin_first increases rate excretion Nalfon_second concomitant use Nalfon salicylates recommended.
3057,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",Nalfon,salicylates,advise,Nalfon shown produce additional effect beyond obtained aspirin alone aspirin increases rate excretion Nalfon concomitant use Nalfon_first salicylates_second recommended.
3058,"Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.",phenobarbital,fenoprofen,mechanism,Chronic administration phenobarbital_first known enzyme inducer may associated decrease plasma half life fenoprofen_second .
3059,"When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.",phenobarbital,Nalfon,advise,phenobarbital_first added withdrawn treatment dosage adjustment Nalfon_second may required.
3060,"In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.",coumarin-type anticoagulants,Nalfon,effect,patients receiving coumarin-type anticoagulants_first addition Nalfon_second therapy could prolong prothrombin time.
3061,Patients treated with Nalfon may be resistant to the effects of loop diuretics.,Nalfon,loop diuretics,effect,Patients treated Nalfon_first may resistant effects loop diuretics_second .
3062,"In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.",Nalfon,steroid,advise,patients receiving Nalfon_first steroid_second concomitantly reduction steroid dosage gradual order avoid possible complications sudden steroid withdrawal.
3063,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,verapamil,mechanism,WelChol_first decreased Cmax AUC sustained release verapamil_second (Calan SR ) approximately 31% 11% respectively.
3064,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,Calan SR,mechanism,WelChol_first decreased Cmax AUC sustained release verapamil (Calan SR_second ) approximately 31% 11% respectively.
3065,"Clinical implications of warfarin interactions with five sedatives.
",warfarin,sedatives,int,Clinical implications warfarin_first interactions five sedatives_second .
3066,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,Barbiturates,coumarin drugs,advise,Barbiturates_first glutethimide administered patients receiving coumarin drugs_second .
3067,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,glutethimide,coumarin drugs,advise,Barbiturates glutethimide_first administered patients receiving coumarin drugs_second .
3068,"Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ",Chloral hydrate,anticoagulant agents,int,Chloral hydrate_first methaqualone interact pharmacologically orally administered anticoagulant agents_second effect clinically significant.
3069,"Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ",methaqualone,anticoagulant agents,int,Chloral hydrate methaqualone_first interact pharmacologically orally administered anticoagulant agents_second effect clinically significant.
3070,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DIAMOX_first modifies phenytoin_second metabolism increased serum levels phenytoin.
3071,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DIAMOX_first modifies phenytoin metabolism increased serum levels phenytoin_second .
3072,"By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.",DIAMOX,primidone,mechanism,decreasing gastrointestinal absorption primidone DIAMOX_first may decrease serum concentrations primidone_second metabolites consequent possible decrease anticonvulsant effect.
3073,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.",DIAMOX,primidone,advise,Caution advised beginning discontinuing changing dose DIAMOX_first patients receiving primidone_second .
3074,Acetazolamide may increase the effects of other folic acid antagonists.,Acetazolamide,folic acid antagonists,effect,Acetazolamide_first may increase effects folic acid antagonists_second .
3075,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.,Acetazolamide,amphetamine,mechanism,Acetazolamide_first decreases urinary excretion amphetamine_second may enhance magnitude duration effect.
3076,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.,Acetazolamide,quinidine,mechanism,Acetazolamide_first reduces urinary excretion quinidine_second may enhance effect.
3077,Acetazolamide may prevent the urinary antiseptic effect of methenamine.,Acetazolamide,methenamine,effect,Acetazolamide_first may prevent urinary antiseptic effect methenamine_second .
3078,Acetazolamide increases lithium excretion and the lithium may be decreased.,Acetazolamide,lithium,mechanism,Acetazolamide_first increases lithium_second excretion lithium may decreased.
3079,Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.,Acetazolamide,sodium bicarbonate,effect,Acetazolamide_first sodium bicarbonate_second used concurrently increases risk renal calculus formation.
3080,Acetazolamide may elevate cyclosporine levels.,Acetazolamide,cyclosporine,mechanism,Acetazolamide_first may elevate cyclosporine_second levels.
3081,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,ketoconazole,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised PLETAL_first coadministered inhibitors C.P.A. ketoconazole_second erythromycin inhibitors CYP2C19 omeprazole.
3082,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,erythromycin,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised PLETAL_first coadministered inhibitors C.P.A. ketoconazole erythromycin_second inhibitors CYP2C19 omeprazole.
3083,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,omeprazole,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised PLETAL_first coadministered inhibitors C.P.A. ketoconazole erythromycin inhibitors CYP2C19 omeprazole_second .
3084,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,omeprazole,cilostazol,mechanism,Pharmacokinetic studies demonstrated omeprazole_first erythromycin significantly increased systemic exposure cilostazol_second and/or major metabolites.
3085,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,erythromycin,cilostazol,mechanism,Pharmacokinetic studies demonstrated omeprazole erythromycin_first significantly increased systemic exposure cilostazol_second and/or major metabolites.
3086,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..",cilostazol,diltiazem,mechanism,Population pharmacokinetic studies showed higher concentrations cilostazol_first among patients concurrently treated diltiazem_second inhibitor C.P.A..
3087,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,hexobarbital,effect,Animal experience indicates clorazepate dipotassium_first prolongs sleeping time hexobarbital_second ethyl alcohol increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition.
3088,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,ethyl alcohol,effect,Animal experience indicates clorazepate dipotassium_first prolongs sleeping time hexobarbital ethyl alcohol_second increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition.
3089,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,chlorpromazine,effect,Animal experience indicates clorazepate dipotassium_first prolongs sleeping time hexobarbital ethyl alcohol increases inhibitory effects chlorpromazine_second exhibit monoamine oxidase inhibition.
3090,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,barbiturates,effect,actions benzodiazepines_first may potentiated barbiturates_second narcotics phenothiazines monoamine oxidase inhibitors antidepressants.
3091,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,narcotics,effect,actions benzodiazepines_first may potentiated barbiturates narcotics_second phenothiazines monoamine oxidase inhibitors antidepressants.
3092,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,phenothiazines,effect,actions benzodiazepines_first may potentiated barbiturates narcotics phenothiazines_second monoamine oxidase inhibitors antidepressants.
3093,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,monoamine oxidase inhibitors,effect,actions benzodiazepines_first may potentiated barbiturates narcotics phenothiazines monoamine oxidase inhibitors_second antidepressants.
3094,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,antidepressants,effect,actions benzodiazepines_first may potentiated barbiturates narcotics phenothiazines monoamine oxidase inhibitors antidepressants_second .
3095,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,aminoglycoside antibiotics,effect,Nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycoside antibiotics_second potent diuretics furosemide.
3096,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycoside antibiotics potent diuretics_second furosemide.
3097,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration cephalosporins_first aminoglycoside antibiotics potent diuretics furosemide_second .
3098,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,beta-lactam antibiotics,effect,Chloramphenicol_first shown antagonistic beta-lactam antibiotics_second including ceftazidime based vitro studies time kill curves enteric gram negative bacilli.
3099,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,ceftazidime,effect,Chloramphenicol_first shown antagonistic beta lactam antibiotics including ceftazidime_second based vitro studies time kill curves enteric gram negative bacilli.
3100,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",anakinra,TNF-blocking agent,effect,Anakinra: Concurrent administration anakinra_first (an interleukin 1 antagonist) another TNF-blocking agent_second associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
3101,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",interleukin-1 antagonist,TNF-blocking agent,effect,Anakinra: Concurrent administration anakinra (an interleukin-1 antagonist_first ) another TNF-blocking agent_second associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
3102,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,TNF-blocking agents,effect,Therefore combination anakinra_first TNF-blocking agents_second including HUMIRA may also result n similar toxicities.
3103,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,HUMIRA,effect,Therefore combination anakinra_first TNF blocking agents including HUMIRA_second may also result n similar toxicities.
3104,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,antiparkinsonian drug,effect,concurrent use two drugs anticholinergic activity antipsychotic drug_first (eg chlorpromazine) antiparkinsonian drug_second (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3105,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,trihexyphenidyl,effect,concurrent use two drugs anticholinergic activity antipsychotic drug_first (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl_second ) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3106,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug_first (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant_second (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3107,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug_first (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline_second ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3108,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,antiparkinsonian drug,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine_first ) antiparkinsonian drug_second (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3109,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,trihexyphenidyl,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine_first ) antiparkinsonian drug (eg trihexyphenidyl_second ) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3110,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine_first ) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant_second (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3111,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine_first ) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline_second ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3112,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug_first (eg trihexyphenidyl) and/or tricyclic antidepressant_second (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3113,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug_first (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline_second ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3114,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl_first ) and/or tricyclic antidepressant_second (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3115,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl_first ) and/or tricyclic antidepressant (eg amitriptyline_second ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3116,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",Isoflurane,NUROMAX,mechanism,Isoflurane_first enflurane halothane decrease ED50 NUROMAX_second 30% 45%.
3117,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",enflurane,NUROMAX,mechanism,Isoflurane enflurane_first halothane decrease ED50 NUROMAX_second 30% 45%.
3118,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",halothane,NUROMAX,mechanism,Isoflurane enflurane halothane_first decrease ED50 NUROMAX_second 30% 45%.
3119,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,antibiotics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics_second (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3120,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,aminoglycosides,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides_second tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3121,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,tetracyclines,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines_second bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3122,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,bacitracin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin_second polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3123,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,polymyxins,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins_second lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3124,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lincomycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin_second clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3125,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,clindamycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin_second colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3126,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,colistin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin_second sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3127,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,sodium colistimethate,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate_second ) magnesium salts lithium local anesthetics procainamide quinidine.
3128,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,magnesium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium_second salts lithium local anesthetics procainamide quinidine.
3129,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lithium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium_second local anesthetics procainamide quinidine.
3130,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,anesthetics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics_second procainamide quinidine.
3131,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,procainamide,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide_second quinidine.
3132,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,quinidine,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents NUROMAX_first include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine_second .
3133,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,phenytoin,effect,nondepolarizing neuromuscular blocking agents_first time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving phenytoin_second carbamazepine.
3134,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,carbamazepine,effect,nondepolarizing neuromuscular blocking agents_first time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving phenytoin carbamazepine_second .
3135,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,phenytoin,effect,nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced NUROMAX_first lengthened duration block shortened patients receiving phenytoin_second carbamazepine.
3136,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,carbamazepine,effect,nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced NUROMAX_first lengthened duration block shortened patients receiving phenytoin carbamazepine_second .
3137,Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.,anticonvulsant agents,cisplatin,mechanism,Plasma levels anticonvulsant agents_first may become subtherapeutic cisplatin_second therapy.
3138,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",quinidine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine_first fluoxetine paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer carvedilol_second .
3139,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",fluoxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine fluoxetine_first paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer carvedilol_second .
3140,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",paroxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine fluoxetine paroxetine_first propafenone) studied drugs would expected increase blood levels R(+) enantiomer carvedilol_second .
3141,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",propafenone,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine fluoxetine paroxetine propafenone_first ) studied drugs would expected increase blood levels R(+) enantiomer carvedilol_second .
3142,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,reserpine,effect,Catecholamine depleting Agents: Patients taking agents b-blocking properties_first drug deplete catecholamines (e.g. reserpine_second monoamine oxidase inhibitors) observed closely signs hypotension and/or severe bradycardia.
3143,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,monoamine oxidase inhibitors,effect,Catecholamine depleting Agents: Patients taking agents b-blocking properties_first drug deplete catecholamines (e.g. reserpine monoamine oxidase inhibitors_second ) observed closely signs hypotension and/or severe bradycardia.
3144,Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.,clonidine,agents with b-blocking properties,effect,Clonidine: Concomitant administration clonidine_first agents b-blocking properties_second may potentiate blood pressure heart rate lowering effects.
3145,"When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.",agents with b-blocking properties,clonidine,advise,concomitant treatment agents b-blocking properties_first clonidine_second terminated b blocking agent discontinued first.
3146,Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.,cyclosporine,carvedilol,mechanism,Cyclosporine: Modest increases mean trough cyclosporine_first concentrations observed following initiation carvedilol_second treatment 21 renal transplant patients suffering chronic vascular rejection.
3147,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",cyclosporine,carvedilol,advise,Due wide interindividual variability dose adjustment required recommended cyclosporine_first concentrations monitored closely initiation carvedilol_second therapy dose cyclosporine adjusted appropriate.
3148,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",carvedilol,cyclosporine,advise,Due wide interindividual variability dose adjustment required recommended cyclosporine concentrations monitored closely initiation carvedilol_first therapy dose cyclosporine_second adjusted appropriate.
3149,Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.,digoxin,carvedilol,mechanism,Digoxin: Digoxin concentrations increased 15% digoxin_first carvedilol_second administered concomitantly.
3150,Both digoxin and COREG slow AV conduction.,digoxin,COREG,effect,digoxin_first COREG_second slow AV conduction.
3151,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.",digoxin,COREG,advise,Therefore increased monitoring digoxin_first recommended initiating adjusting discontinuing COREG_second .
3152,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.,Rifampin,carvedilol,mechanism,Inducers Inhibitors Hepatic Metabolism: Rifampin_first reduced plasma concentrations carvedilol_second 70%.
3153,Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.,COREG,diltiazem,effect,Calcium Channel Blockers: Isolated cases conduction disturbance (rarely hemodynamic compromise) observed COREG_first co administered diltiazem_second .
3154,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,verapamil,advise,agents b blocking properties COREG_first administered orally calcium channel blockers verapamil_second diltiazem type recommended ECG blood pressure monitored.
3155,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,diltiazem,advise,agents b blocking properties COREG_first administered orally calcium channel blockers verapamil diltiazem_second type recommended ECG blood pressure monitored.
3156,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,insulin,effect,Insulin Oral Hypoglycemics: Agents b-blocking properties_first may enhance blood sugar reducing effect insulin_second oral hypoglycemics.
3157,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,hypoglycemics,effect,Insulin Oral Hypoglycemics: Agents b-blocking properties_first may enhance blood sugar reducing effect insulin oral hypoglycemics_second .
3158,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.,baclofen,morphine,effect,Interactions attributed combined use baclofen_first injection epidural morphine_second include hypotension dyspnea.
3159,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,calcium channel blockers,advise,recommended combination intravenous dantrolene sodium_first calcium channel blockers_second verapamil used together management malignant hyperthermia crisis relevance findings humans established.
3160,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,verapamil,advise,recommended combination intravenous dantrolene sodium_first calcium channel blockers verapamil_second used together management malignant hyperthermia crisis relevance findings humans established.
3161,Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.,dantrolene,vecuronium,effect,Administration dantrolene_first may potentiate vecuronium_second induced neuromuscular block.
3162,The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.,nitroglycerin,vasodilators,effect,vasodilating effects nitroglycerin_first may additive vasodilators_second .
3163,Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.,calcium channel blockers,nitrates,effect,Marked symptomatic orthostatic hypotension reported calcium channel blockers_first organic nitrates_second used combination.
3164,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,serotoninergic agents,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents_second (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3165,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluoxetine,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine_second fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3166,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluvoxamine,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine_second paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3167,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,paroxetine,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine_second sertraline venlafaxine) reports serious sometimes fatal reactions.
3168,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,sertraline,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline_second venlafaxine) reports serious sometimes fatal reactions.
3169,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,venlafaxine,effect,patients receiving nonselective monoamine oxidase inhibitors_first (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine_second ) reports serious sometimes fatal reactions.
3170,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,serotoninergic agents,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents_second (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3171,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluoxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine_second fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3172,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluvoxamine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine_second paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3173,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,paroxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine_second sertraline venlafaxine) reports serious sometimes fatal reactions.
3174,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,sertraline,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline_second venlafaxine) reports serious sometimes fatal reactions.
3175,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,venlafaxine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs_first ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine_second ) reports serious sometimes fatal reactions.
3176,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,serotoninergic agents,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents_second (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3177,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluoxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents (e.g. fluoxetine_second fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3178,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluvoxamine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine_second paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3179,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,paroxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine_second sertraline venlafaxine) reports serious sometimes fatal reactions.
3180,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,sertraline,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline_second venlafaxine) reports serious sometimes fatal reactions.
3181,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,venlafaxine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. selegiline hydrochloride_first ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine_second ) reports serious sometimes fatal reactions.
3182,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.",dexfenfluramine,MAO inhibitor,advise,dexfenfluramine serotonin releaser reuptake inhibitor dexfenfluramine_first used concomitantly MAO inhibitor_second .
3183,At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.,MAO inhibitor,dexfenfluramine,advise,least 14 days elapse discontinuation MAO inhibitor_first initiation treatment dexfenfluramine_second .
3184,At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.,dexfenfluramine,MAO inhibitor,advise,least 3 weeks elapse discontinuation dexfenfluramine_first initiation treatment MAO inhibitor_second .
3185,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,Imitrex,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors_first (SSRIs) agents migraine therapy Imitrex_second (sumatriptan succinate) dihydroergotamine.
3186,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,sumatriptan succinate,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors_first (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate_second ) dihydroergotamine.
3187,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,dihydroergotamine,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors_first (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) dihydroergotamine_second .
3188,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,Imitrex,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs_first ) agents migraine therapy Imitrex_second (sumatriptan succinate) dihydroergotamine.
3189,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,sumatriptan succinate,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs_first ) agents migraine therapy Imitrex (sumatriptan succinate_second ) dihydroergotamine.
3190,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,dihydroergotamine,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs_first ) agents migraine therapy Imitrex (sumatriptan succinate) dihydroergotamine_second .
3191,Dexfenfluramine should not be administered with other serotoninergic agents.,Dexfenfluramine,serotoninergic agents,advise,Dexfenfluramine_first administered serotoninergic agents_second .
3192,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",Itraconazole,busulfan,mechanism,Itraconazole_first decreases busulfan_second clearance 25% may produce AUCs 1500 min patients.
3193,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,mechanism,Phenytoin_first increases clearance busulfan_second 15% possibly due induction glutathione transferase.
3194,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.",BUSULFEX,phenytoin,mechanism,Since pharmacokinetics BUSULFEX_first studied patients treated phenytoin_second clearance BUSULFEX recommended dose may lower exposure (AUC) higher patients treated phenytoin.
3195,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.",acetaminophen,BUSULFEX,mechanism,busulfan eliminated body via conjugation glutathione use acetaminophen_first prior ( 72 hours) concurrent BUSULFEX_second may result reduced busulfan clearance based upon known property acetaminophen decrease glutathione levels blood tissues.
3196,Trecator has been found to temporarily raise serum concentrations of isoniazid.,Trecator,isoniazid,mechanism,Trecator_first found temporarily raise serum concentrations isoniazid_second .
3197,Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.,Trecator,antituberculous drugs,effect,Trecator_first may potentiate adverse effects antituberculous drugs_second administered concomitantly.
3198,"In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.",ethionamide,cycloserine,effect,particular convulsions reported ethionamide_first administered cycloserine_second special care taken treatment regimen includes drugs.
3199,"Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).",danazol,lovastatin,effect,Danazol: risk myopathy/rhabdomyolysis increased concomitant administration danazol_first particularly higher doses lovastatin_second (see WARNINGS Myopathy/Rhabdomyolysis).
3200,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",amiodarone,HMG-CoA reductase inhibitor class,effect,Amiodarone Verapamil: risk myopathy/rhabdomyolysis increased either amiodarone_first verapamil used concomitantly closely related member HMG-CoA reductase inhibitor class_second (see WARNINGS Myopathy/Rhabdomyolysis).
3201,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",verapamil,HMG-CoA reductase inhibitor class,effect,Amiodarone Verapamil: risk myopathy/rhabdomyolysis increased either amiodarone verapamil_first used concomitantly closely related member HMG-CoA reductase inhibitor class_second (see WARNINGS Myopathy/Rhabdomyolysis).
3202,"However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.",HMG-CoA reductase inhibitor,warfarin,effect,However another HMG-CoA reductase inhibitor_first found produce less two second increase prothrombin time healthy volunteers receiving low doses warfarin_second .
3203,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.",coumarin anticoagulant,lovastatin,effect,Also bleeding and/or increased prothrombin time reported patients taking coumarin anticoagulant_first concomitantly lovastatin_second .
3204,"It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",anticoagulants,lovastatin,advise,recommended patients taking anticoagulants_first prothrombin time determined starting lovastatin_second frequently enough early therapy insure significant alteration prothrombin time occurs.
